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ABSTRACT
This thesis tested the hypothesis that cytomegalovirus (CMV) may initiate 
or enhance chronic rejection of liver grafts. A polymerase chain reaction 
(PGR) test was developed and used to monitor 33 liver transplant patients 
for active CMV infection (Chapters 2 and 3). The incidence of urine PCR 
positivity and prolonged active CMV infection were risk factors for 
chronic rejection (Chapter 4).
Matching and mismatching of HLA alleles between donor and recipient 
was not shown to be a risk factor for chronic rejection. However, HLA 
class I matching was associated with (clearance of active CMV (Chapter 4).
Recipients with the TNF-2 promoter allele (associated with enhanced 
expression of TNF) were at increased risk of chronic rejection. 
Furthermore, active CMV infection and the TNF-2 promoter allele were 
shown to act synergistically as risk factors for chronic rejection (Chapter 4).
In addition, two or more episodes of acute rejection or a pre transplant 
diagnosis of primary biliary cirrhosis (PEG) were shown tu be risk factors 
for chronic rejection (Chapter 4).
CMV was also studied in the context of humoral immunity and chronic 
rejection (Chapter 5). Western blotting of hepatic artery and bile duct tissue 
(sites of rejection mediated damage) showed that post transplant IgA 
antibody to a 44 kD bile duct protein was associated with development of 
active CMV infection but was not associated with chronic rejection. 
However, pre transplant IgA antibodies to 94 and 39 kD bile duct proteins 
or IgG antibodies to 160 and 85 kD hepatic artery proteins were associated 
with an increased risk of chronic rejection.
CMV was identified in bile duct epithelial cells  ^ vascular endothelial cells, 
hepatocytes and mononuclear cells of liver grafts by in situ hybridisation 
(Chapter 6). Active CMV infection of the graft, especially epithelial cells, 
was associated with chronic rejection.
Finally, human herpesvirus 6 (HHV-6) was not detected in serum, whole 
blood or liver graft tissue by PCR and was not an important pathogen after 
liver transplantation.
ii
Acknowledgements
I acknowledge and thank Dr Graeme Alexander (Director of Studies) for 
providing superb advice and direction over the past three years, for 
patience during times of 'technical crisis' and for encouragement and 
support. Similarly, the advice of Dr Tim Wreghitt (Second Supervisor) 
has been crucial to this thesis.
I also gratefully acknowledge Dr Jane Collier, Mr Avi Soin and Mr Giles 
Toogood for provision of clinical data. Dr Nick Coleman and Miss Alison 
Warn for provision of liver sections and protocols for in situ  
hybridisation. Dr Craig Taylor and Miss Sheila Smith for provision of 
protocols for HLA typing and TNF allele PCR and advice on the 
interpretation of HLA data. Dr Brian Thompson and Mrs Chen Huang for 
provision of reagents and protocols for HHV-6 detection and Dr Jim Gray 
for provision of reagents and protocols for detection of CMV by DEAFF 
and culture. I am indebted to other colleagues who are acknowledged 
throughout this thesis.
I acknowledge the financial support provided by the Anglia and Oxford 
Health Authority.
The encouragement provided by my colleagues in Dr Alexander's 
laboratory is also greatly appreciated; this 'dream team' comprises Simona 
Caronia, Shaun Greer, Lesley Ramsay and Shim Wong.
Finally, I thank my fiancee, family and friends for their support.
j i i
DECLARATION
The work presented in this thesis was conducted by the author, unless 
otherwise acknowledged.
Signed
Paul Evans
IV
CONTENTS
Page
fLE i
pTRACT i i
CKNOWLEDGEMENTS ü i
icLARATION iv
j)NTENTS V
STOFHGURES xv
I
5T OF TABLES xix
ap ter 1 Introduction 1
■
!
A Historical Account of Cytomegalovirus 2
Cytomegalovirus is a M ember of the Human Herpesviridae 4
Members 4
Prevalence 5
Infection of Immunocompetent Individuals 5
Infection of Immunosuppressed Individuals 6
Virology and Biology of Cytomegalovirus 6 .
Genes 6
Latent Infection 9
Lytic Infection 11 ‘
Imm ediate Early Genes 11
Early (E) Genes 12
Late Genes ' 12
Effect of CMV Infection on Cell Protein Contents 12
CMV Encodes a Protein with Homology to the MHC Molecule 14
Im m unity and Cytomegalovirus 14
Cellular Responses . . 1 4
Cytotoxic T Lymphocytes (CDS +) 14
.1.2 CD4 + T-Lymphocytes - 16
.2 Huinoral Immunity 16
1 ' . . ;
? Liver T ransplantation and Cytomegalovirus (CMV) 18
5.1 Im m unosuppression Facilitates Active CMV Infection 18
5.2 Sources of CMV 18
.^3 CMV Disease, after Liver Transplantation 19
Targeting Antiviral Treatment After Liver Transplantation 19
Liver Transplantation at Addenbrooke's NHS Trust 21
Prim ary Disease ' '  21
Patient and Graft Survival 23
Causes of Graft Loss 23
CMV Disease Among Liver Transplant Patients at Addenbrooke’s NÎEiS Trust 24
Bone M arrow Transplantation (BMT) and Cytomegalovirus (CMV) 24
Obliteration of Cellular Immunity Facilitates Active CMV Infection 24
Sources of CMV , ' 25
Timing * 25
l"
CMV Disease after Bone Marrow Transplantation 26
Targetting Antiviral Treatment After Bone M arrow Transplantation 26
Graft Versus Host Disease (GVHD) 27
Acute GVHD 27
Chronic GVHD 28
Allogeneic Bone M arrow Transplantation at Addenbrooke’s NHS Trust 28
Prim ary Disease 29
Post-Transplant M ortality 30
Diagnosis of Active CMV Infection 31
Conventional Tests 31
Dot -Blot Hybridisation and Polymerase Chain Reaction (PCR) ? 32
Testing of Urine . . .  32
Polymerase Chain Reaction (PCR) Testing of Blood 32
PCR Positivity and Disease 33
Chronic Rejection after Liver Transplantation: A role for CMV? 33
Histopathology of Liver Allograft Rejection 33
Acute Rqectioii ' • . 33
Chronic Rqectibn 34
Risk Factors for Chronic Rejection after Liver Transplantation 35
A Comprehensive Study 35
The Effect of HLA Matching upon Chronic rejection: Suggested Links with CMV 
and Autoimmune disease 36
The Importance of Tissue Invasion by CMV 38
Are Antibodies a Risk Factor for Rejection of Liver Allografts? 40
Are Primary Autoimmune Disorders a Risk for Chronic Rejection ? 41
v i
O ther Allografts 42
HLA M atching Benefits Renal and Cardiac Transplantation 42
CMV is a Risk Factor for Rejection After Renal and Cardiac Transplantation 42
CMV Infection of Graft Tissue After Renal or Cardiac Transplzmtation 43
AUoreactive and Autoreactive Antibodies and Rejection after Renal and Cardiac Transplantation 46 
Does CMV have a Caused Relationship with Rejection? 49
Mechanisms of Rejection 50
HLA O a ^  n  Matching May Facilitate Presentation of Foreign MHC or CMV Peptides 50
H ypothesis 50
Evidence 50
CMV and HLA Regulation 51
I
H ypothesis 51
Evidence 51
AUoreactive CeUular Immune Responses may be Augmented by CMV 53
CMV Upregulates Inflammatory Markers 54
Tumour Necrosis Factor-a (TNF-a), CMV and Chronic Rejection of Liver Grafts 55
CMV Infection Modulates Autoantibody Production 56
CMV and Autoantibody Production 56
CMV âild Autoantibudy Production After Transplantation 57
Cross-Reactive Antibodies '  ^ gg
Rqection m ay be Modulated by Autoantibodies Associated with PSC, PBC and AIH 58
Prim ary Sclerosing Cholangitis (PSC) 58
Prim ary Biliary Cirrhosis (PBC) 59
Autoimm une Hepatitis (AIH) 59
.0 H um an Herpesvirus 6 (HHV-6) and Transplantation 60
0.1 Discovery of a New Herpesvirus 60
0.2 Biology and Virology of HHV-6 60
0.3 Interaction Between HHV-6 and CMV 61
0.4 HHV-6 Infection After Transplantation 62
0.4.1 HHV-6 and l iv e r  Transplantation 62
0.4.2 HHV-6 and Bone M arrow Transplantation . 63
Outline of Thesis and Hypotheses . 65
OveraU Hypothesis for Thesis 65.
Hypotheses for Chapters 2 And 3 65
Hypotheses for Chapter 4 65
Hypotheses for Chapter 5 66
vii
LJ.5 Hypotheses for Chapter 6 66
11.6 Hypothesis for Chapter 7 66
lapter 2 Development Of A Sensitive A nd Specific Test For Cytomegalovirus: Dot-Blot
H ybridisation And The Polymerase Chain Reaction 67
Introduction 68
jZ M aterials and M ethods 69
2.1 Dot-blot Hybridisation 69
,  I  ■
2.1.1 Plasmid Gifts 69
jZ.1.2 Construction of Plasmid pT7/T3-IE.PCR and pT7/T3-IE.PCRDel 70
p.1.3 Plasmid Amplification and Harvesting 80
2.1.4 A 983 base pair (bp) Probe Derived From PCR Amplification 81
2.1.5 Probe Labelling and Purification 82
: I  -
12.1.6 Dot blotting ■ . 82
|2.1;7 H ybridisation '  83
2.1.8 Visualisation of Hybridisation 83
2.1.9 Hum an and Herpesvirus DNA Controls 84
'  I
I 2.2 Polymerase Chain Reaction (PCR) ' 84
2.2.1 Urine Sample Preparation -   84
2.2.2 Serum Sample Preparation 85
2.2.3 PCR Amplification of Sample DNA 85
2.2.4 Non Competitive Quantitive PCR 86
2.3 Detection of Early Antigen Fluorescent Foci (DEAFF) . 88
p.4 Isolation of CMV by Cell Culture
|2.5 Collection and Processing of Clinical Samples
Patients and Testing of Clinical Samples 89
Results 91
Optimising Dot-blot Hybridisation 91
False Positives Using a Digoxigenin (DIG) Labelled Probe 91
Specificity of ^^-L abelled  CMV DNA Prubes 93
S ensitiv ity  101
Dot Blot Hybridisation of Clinical Samples 104
Latent Virus Was Not Detected by Dot Blot Hybridisation 104
Comparison of Dot Blot Hybridisation w ith Culture and DEAFF Testing 104
Optimising Polymerase Chain Reaction (PCR) Amplification of CMV DNA in Serum and Urine 105 
S ensitiv ity  106
viii
88
89
i 3.3.2 Specificity 106
1
p.3.3 Optimisation of Urine Sample Preparation 109
p.3.4 Optimisation of Serum Sample Preparation . 109
p.4 Comparison of PCR with Culture and DEAFF Tests H I
3.4.1 Comparison of Urine PCR with Culture and DEAFF Testing H I
p.3.4 Comparison of PCR of CMV DNA from Serum with Culture and DEAFF Testing of Buffy Coat 112
3.5 Q uantitative and Semi-Quantitative PCR 113
4  Discussion H 5
4.1 Conclusions 115
4.2 Digoxigenin Labelling and Dot-blot Hybridisation of Urine 116
4.3 Contamination of Probes with Rcoli Nucleic Acids 117
4.4 Hybridisation of CMV DNA Probes with H um an DNA 117
4.5 Dot-blot Hybridisation Using a PCR Derived Probe 118
4.6 Optimisation of Polymerase Chain Reaction (PCR) Amplification of CMV DNA from Serum
and Urine 119
4.7 Comparison of PCR with DEAFF and Culture Testing of CMV 120
4.8 Q uantitative zmd Semi-Quantitative PCR 122
hapter 3 Qualitative and Quantitative Polymerase Chain Reaction (PCR) Testing for
Cytomegalovirus DNA in Serum may allow Prediction of Symptomatic CMV Infection 124
Introduction 125
2 Patients, M aterials and M ethods 126
2.1 Liver and  Bone M arrow Transplant Recipients and Collection of Clinical Sétmples 126
2.2 Laboratory Tests 126
2.2.1 Testing by PCR, DEAFF and Culture 126
2.2.2 Serological Testing of Donor and Recipient 126
2.3 Clinical Data 127
2.4 Analysis of Results 127
3 Results 128
3.1 CMV Disease after Liver Transplantation 128
3.1.1 The Study Group 128
3.1.2 Prediction of CMV Infection arid Disease from CMV Antibody Status 129
3.1.3 Is Qualitative Polymerase Chain Reaction (PCR) Testing of CMV DNA a Clinically
Useful Test ? 130
3.1.4 Is Semi-Quantitative Polymerase Chain Reaction (PCR) Testing of CMV DNA a
ix
Clinically Useful Test ? 134
.2 CMV Disease After Allogeneic Bone M arrow Transplantation 138
.2.1 The Study Group 138
.2.2 CMV Infection and Disease 139
.2.3 Active CMV Infection and Acute Graft Versus Host Disease 140
.3 Case studies 141
Discussion 148
:.l Conclusions 148
.1.1 Liver Transplant Recipients 148
.1.2 Bone M arrow Transplant Recipients , 148
.2 ■ Incidence of Active CMV Infection and Disease 149
1.3 CMV Serology Identified Patients at Risk of Active CMV Infection 149
1.4 Qualitative PCR and Prediction of CMV Disease 151
1.5 Semi-Quantitative PCR and Prediction of CMV Disease 152
1.6 PCR Positivity May Occur before the Onset of Symptoms 154
I
t.7 Active CMV Infection and Bone Marrow Transplantation 154
lapter 4 Risk Factors for Chronic Rejection of Liver Grafts Including Cytomegalovirus 159
J
Introduction   160
Patients, M aterials and M ethods 162
1 P atien ts 162
^.2 Sample Collection 163
L3 Virological Data 163
p.4 H um an Leukocyte Antigen (HLA) Allele Typing 163
L5 Tumour Necrosis Factor (TNF) Promoter Allele Typing 164
L6 Clinical Data 165
1.7 Results Analysis 165
Results ~  ^ 167
Cytomegalovirus as a Risk Factor for Chronic Rejection 167
•1.1 CMV-Related Risk Factors for Chronic Rejection 167
.1.2 Early Active CMV Infection after Re transplantation for Chronic Rejection 168
2 H um an Leukocyte Antigen (HLA) Alleles and Chronic Rejection 169
3.2.1 The Effect of HLA M atching/ Mismatching upon Chronic Rejection 169
3.2.2 HLA Allele Combinations and ChronicRejection. 170
3.3 The Effect of HLA Matching on the Duration of Active CMV Infection 171
A  Other Risk Factors for Chronic Rejection of Liver Grafts 172
5 Cytomegalovirus and the TNF-2 Allele: Risk Factors for Chronic Rejection 173
,5,1 The TNF-2 Allele and Chronic Rejection 173
.5.2 Active CMV Infection and the TNF-2 Promoter Allele May Sjmergise as Risk Factors for
Chronic Rejection 174
5.3 Active CMV Infection and the TNF-2 Allele 175
Discussion - 176
.1 Conclusions 176
.2 Prolonged Active CMV Infection m ay be a Risk Factor for Chronic Rejection 177
.3 CMV Antibody Status and Chronic Rejection 180
|.4 The Effect of HLA M atching/ Mismatching upon the Incidence of Chronic Rejection 181
I
.5 Recipients with the TNF-2 Promoter Allele May be at a Greater Risk of Developing
Chronic Rejection 183
.6 Recurrent Acute Rejection May be a Risk Factor for Chronic Rejection 185
.7 Pretransplant Diagnosis of Primary Biliary Cirrhosis (PBC) may be a Risk Factor for
Chronic Rejection 187
.8 Lack of Correlation Between Chronic Rejection and Sex, Age or CMV Antibody Mismatch 188
.9 Retransplantation was Not Shown to be a Risk Factor for Chronic Rejection 188
Lapter 5 The Relationship Between Chronic Rejection of Liver Grafts, Active Cytomegalovirus
Infection and Humoral Immune Responses to Bile Duct And Hepatic Artery 189
Introduction 190
Patients, M aterials and M ethods 192
t.l Selection of 38 Liver Tréinsplant Recipients ' 192
|.2 Western Blotting 194
L2.1 Protein Extraction and Quantitation 194
1.2.2, SDS-Polyacrylamide Gel Electrophoresis and Blotting 194
1.2.3 Detection of Serum Antibodies 195
1.2.4 Investigation of Cross-Reactivity 196
1.3 Phase I 196
|.4 Phase II 201
1.5 Crossreactivity Between Antibodies Generated to CMV and Cellular Proteins 201
Results 202
.1 Coomassie Stain of W estern-blotted Tissue * 202
.2 Phase I: Analysis of Antibodies to a Pcir\el of Various Tissues 203
x i
^2.1 Pretransplant and Posttransplant Sera Contained Numerous Antibodies to Bile Duct and
Hepatic A rtery Proteins 203
.2.2 Reactive Antibodies and Liver Disease 2(B
.2.3 IgA and Bile Duct Analysis 206
.2.4 IgG and Hepatic Artery Analysis 208
.2.5 Summary for Phase I 210
.3 Phase II 211
.3.1 IgA Antibodies to Bile Duct Tissue 211
.3.2 IgG Antibodies to Hepatic Artery Tissue 221
.4 Lack of Cross-Reactivity Between Cellular Antigens and CMV-Specific Antibodies 228
Discussion ! 231
Ll Conclusions 231
i.2 Humoral Immunity and Chronic Rejection 232
i.2.1 Two Antibodies to Bile Duct were Associated with Chronic Rejection 232
.2.2 Two Antibodies to Hepatic Artery were Associated with .Chronic Rejection 234
.2.3 C ausality  236
.3 . Active CMV Infection, Hum oral Immunity and Chronic Rejection 237
l.4 Antibodies and Pretransplant Diagnosis of PBC or PSC 237
:.5 Antigens of Interest d id  Not Cross-React with Polyclonal Antibodies to CMV 240
lapter 6 Cytomegalovirus Actively Infects Bile Duct Epithelial Cells and Vascular
Endothelial Cells of Liver Grafts Lost to Chronic Rejection 241
Introduction 242
J Patients, M aterials and M ethods 245
Ll Patients 245
I .
L2 Preparation of Slides 246
:.3 Immunohistochemistry 247
L4 In Situ Hybridisation (ISH) 248
Ls CMV Antibody Status and Active CMV Infection 251
6 HLA Typing 251[
Results 252
.1 Raw Data 252
.2 Cells Shown to H arbour Active CMV Infection 252
.3 In Situ Hybridisation Detection of CMV Occurred via DNA: DNA Hybridisation 252
1.4 Specificity of In Situ Hybridisation to CMV DNA 252
xii
Distribution of CMV Positive Cells Amongst Liver Transplant Recipients According to CMV 
Antibody Status and Active CMV Infection 253
Distribution of CMV Positive Cells Amongst Liver Transplant Recipients w ith the 
Development of Chronic Rejection 256
j7 HLA M atching/ M ismatching Between Recipient and Donor and Active CMV Infection of
the G raft 258
8 The Significance of Active CMV Infection of Liver Graft Epithelial or Endothelial Cells 259
9 Cases 261
Discussion 274
1 Conclusions 274
|2 In Situ Hybridisation (ISH) was a Specific and Sensitive Test i 275
Detection of Active CMV Infection of the Graft, CMV Antibody Status and Active CMV Infection as 
Detected by Viral Surveillance of Serum an d /o r Buffy Coat an d /o r Urine. 276
4 Active CMV Infection of the Liver Graft and Chronic Rejection 278
5 Persistence Active CMV Infection, Cellular Immunity and Chronic Rejection 279
5.1 Detection of Active CMV Infection in BUe Duct Epithelial Cells and Hepatic Artery
Endothelial Cells 279
5.2 Persistence of Active CMV Infection in the Graft and Complete Mismatching of HLA Class
I Alleles 281
5.3 Persistence of Active CMV Infection in the Graft, Matching of HLA DR Alleles and
Chronic Rejection 281
6 Active CMV Infection m ay Initiate Ischaemia 282
7 Lytic Infection of Endothelial or Epithelial Cells 284
Chronically Rejected Liver Grafts may Facilitate Active CMV Infection 284
apter 7 H um an H erpesvirus - 6 (HHV-6) is Not an Important Pathogen after
Liver T ransplantation 286
Introduction 287
Patients, M aterials and M ethods 288
1 Patients 288
2 Clinical Specimens 288
2.1 Serum Séimples 288
2.2 Whole Blood Samples 289
2.3 Tissue Samples . 289
2.4 Collection and Storage of Samples 290
3 DNA Extraction from Clinical Specimens 290
xiii
3.1 Serum and Whole Blood 290
3.2 Formalin Fixed, Paraffin Embedded Tissue 290
,4 Polymerase Chain Reaction (PCR) 291
4.1 PCR of HHV-6 DNA 291
4.2 PCR of CMV DNA 292
4.3 PCR of Cellular DNA 292
5 Southern blotting 292
Results 293
1 Sensitivity of the PCR Test for HHV-6 DNA 293
2 Serum Samples 294
2.2 PCR for CMV DNA (Control Reaction) 294
2.1 PCR for HHV-6 DNA 294
[3 Whole Blood Samples 294
.3.1 PCR for Cellular DNA (Control Reaction) 294
.3.2 PCR for HHV-6 DNA 294
.4 Liver Tissue Samples 295
4.1 PCR for Cellular DNA (Control Reaction) 295
4.2 PCR for HHV-6 DNA 295
5 - Antiviral Treatment or Prophylaxis for Liver Transplant Recipients 295
Discussion 297
.1 Conclusions 297
2 Controls for HHV-6 PCR . 297
3 Antivirals and Active HHV-6 Infection 298
4 HHV-6 W as Not Found in Liver Grafts Lost to Chronic Rejection 300
AFTER 8 H N A L DISCUSSION 301
Conclusions 302
Diagnosis of Active CMV Infection 305
1 Recommendations 305
2 Recent Developments 306
Cytomegalovirus and Chronic Rejection of Liver Grafts 308
1 Models 308
2 Recent Developments 313
pen d ix l Clinical Details of Liver Transplant Recipients 314
pendix 2 . Clinical Details of Bone Marrow Transplant Recipients 327
pendix 3 In  Situ Hybridisation (ISH) and Immimocytochemistry for Active CMV 331
ferences 333
xiv
List of Figures Page
gure 1.1 Structure of the CMV genome g
gure 12 Schematic of the CMV virion 13
g u rel3  Types and proportions of primary disease in 235 liver allograft recipients at Addenbrooke's NHS Trust 22
gure 1.4 Causes of graft loss for the last 50 re-transplanted patients at Addenbrooke's NHS Trust 2 3
gure 15 Types and proportions of primary disease in 58 bone marrow allograft recipients at Addenbrooke’s
NHS Trust .29
! • . 
gure 15 Causes of death for 34 bone marrow transplant patients at Addenbrooke’s NHS Trust 30
gure 1.7 A hepatocyte permissive to active CMV infection identified by immunohistochemistry 39
[gure 1.8 Occlusion of a hepatic artery due to chronic rejection 45
[gure 1.9 Atherc»clerotic coronary artery  ^ 45 .
Lgure 2.1 Target DNA primers and oligonucleotide sequence used to amplify a 293 bp region of die CMV
immediate early gene 1 71
Construction of a 50 bp deleted version of the wild type target sequence for use in quantitative 
PCR experiments 73
Non-specific hybridisation of a digoxigenin labelled CMV DNA probe with dot-blotted urine using 
colourimetric detection 91
Dot-blotted urine interacted directly with the colourimetric substrates NBT and X-phos but not with 
lumigei 92
^^-labelled IE gene DNA probe hybridised with dot-blotted DNA from CMV negative urine 94
CMV Hind HI D fragment hybridised to human DNA and E. coli DNA under conditions of very high 9 5
stringency
The Hind III D fragment of CMV DNA can be restricted by Eco R1 into four fragments 96
XV
^ure 2.8 Inclusion of E. coli and calf thymus DNA into prehybridisatioh and hybridisation solutions reduced
hybridisation of CMV probe gL to human and E. coli DNA 99
aUre 2.9 A CMV DNA probe (IE1.983) that was amplified by PCR did not hybridise to human or E. coli DNA 100
pre 2.10 Optimising sample treatment for dot-blot hybridisation of CMV DNA in urine 103
p r e  2.11 Single round PCR of CMV target DNA gave a sensitivity of 561 copies 106
p r e  2.12 Southern hybridisation confirms the identity of a 293 bp PCR product ' 108
pne 2.13 • The Qiamp blood kit enabled extraction of amplifiable DNA from serum .110
ktue 2.14 Semi-quantitative PCR for CMV in three bone marrow transplant recipients 113f
gure 2.15 Quantitative PCR for CMV in three bone marrow transplant redpients 114
p r e  3.1 Ccise 1: Liver transplant recipient 142
gure 32 Case 2: Liver transplant recipient 143
p r e  33 Case 2: Liver transplant recipient - -- - 144-
gure 3.4 Case 4: Bone marrow transplant recipient 145
gure 33 Case 5: Bone marrow transplant recipient 146
gure 3.6 Case 6: Bone marrow transplant recipient ■ j  147
gure 5.1 Example of a plot analysed in phase I 200
gure 52 Coomassie stain of Western blotted proteins extracted from bile duct, hepatic artery, liver and fibroblasts 202
gure 53 Examples of Western blots of bile duct tissue after application of transplant patients sera 204
' 5.4 Examples of Western blots of hepatic artery tissue after application of transplant patients sera 205
gure 53 The proportion of sera from patients that developed chronic rejection (CR) and controls (non-CR) that
contained IgA antibodies to a 94kD antigen in 'chronically rejected, CMV infected bile duct' 206
x v i
gure 5.6 Proportion of sera from patimts that developed chronic rejection (CR) and controls (non-CR) that
contained IgA antibodies to a 39kD antigen in ’chronically rqected, CMV infected bile duct’ 207
gurç 5,7 Proportion of sera from patients that developed active CMV infection (CMV) and controls that
contained 1 ^  antibodies to a 44kD antigen in chronically rejected, CMV infected bile duct’ 207
gure 5.8 Proportion of sera from patients that developed chronic rejection (CR) and controls (non-CR) that
contained IgG antibodies to a 160 kD antigen in chronically rejected hepatic artery' 208
gure 5.9 Proportion of sera from patients that developed chronic rejection (CR) and controls (non-CR) that
contained IgG antibodies to an 85 kD antigen in chronically rqected hepatic artery' 209
[gure 5.10 Autoantigens present in hepatic arter)| do not cross react with antibodies raised to CMV proteins 229
gure 6.1 Cross-sections of normal and chronically rejected portal tracts 244
lgure 62 Portal tract showing the characteristic histopathology of chronic rejection: stained for CMV DNA by
in situ hybridisation (patient 1). 263
gure 63 Active CMV infection of bile duct epithelial cells shown by in situ hybridisation (patient 1) 264
gure 6.4 Active CMV infection of bile duct epithelial cells shown by in situ hybridisation (patient 1) 264
lgure 63 Active cmv infection of bile duct epithelial cells shown by in situ hybridisation and aggregation of
mononuclear cells (patient 1) 265
lgure 6.6 Active CMV infection of portal vein endothelial cells and mononuclear cells shown by in situ
hybridisation (patient 8) 266
gure 6.7 Active CMV infection of a portal vein endothelial cell shown by in situ hybridisation (patient 8) 267
igure 6.8 Active CMV infection of two mononuclear cells in close proximity to a portal vein shown by in situ
hybridisation (patient 8) 267
gure 6.9 Hepatic artery occluded by foamy macrophages: stained for CMV DNA by in situ hybridisation (patient 12) 269
gure 6.10 Active CMV infection of bile duct epithelial cells shown by in situ hybridisation (patient 12) 270
gure 6.11 Active CMV infection of bile duct epithelial cells shown by in situ hybridisation (patient 12) 270
x v ii
gure 6.12 Active CMV infection of büe duct epithelium shown by immunohistochemistry (patient 29) 272
gure 6.13 Bile duct epiüielium shown by immunohistochemistry (patient 29) 272
gure 6.14 Active CMV infection of a hepatic artery endothelial cell shown by in situ hybridisation (patient 29) 273
igure 7.1 Detection of 30 copies of HHV-6 DNA after PCR and southern blotting 293
lei 1 CMV initiates or augments cellular rqection 308
lei 2 Cellular rejection initiates or augments opportunistic active CMV infection 310
XVlll
11 List of Tables
Page
1 able 1.1 Proteins identified as targets for antibody production in CMV antibody positive recipients 17
able 2.1 Combinations of treatments compared in order to optimise CMV DNA preparation before hybridisation 102
able 2.2 Comparison of dot blot hybridisation with culture and DEAFF tests 105
able 2.3 Urine testing for CMV by DEAFF or culture was compared with PCR 111
able 24 Buffy coat testing for CMV by DEAFF or culture was compared with PCR testing of serum 112
able 3.1 Incidence of active CMV infection and disease in relation to CMV mtibody status in liver transplant 
for 111 liver graft recipients
129
able 3.2 Correlation of clinical findings with qualitative PCR of serum and urine and with urine DEAFF in 
liver transplant recipients
131
able 3.3 Sensitivity, specificity and predictive value of serum and urine PCR and urine DEAFF in relation to 
episodes of CMV disease 131
able 3.4 Correlation of viral load with the presence or absence of CMV disease during episodes of active CMV 135
able 3.5 Correlation of cumulative viral load with the presence or absence of CMV disease during episodes 
of active CMV infection in liver transplant recipients 137
able 3.6 Incidence of CMV infection and disease in relation to CMV serology in bone marrow transplant recipients 139
able 4M Summary of studies of C\4V as a risk factor for chronic rejection of liver grafts 160
able 4.2a CMV as a risk factor for chronic rejection of liver grafts 167
able 42b Early active CMV infection occurred after re transplantation for chronic rejection 168
able 4.3 The effect of HLA matching/ mismatching upon chronic rejection . 169
able 4.4 The effect of HLA allele combinations on the incidence of chronic rejection 170
ble 4.5 The effect of HLA matching on the duration of active CMV infection
xix
171
able 4.6 Other, possible risk factors for chronic rqection of liver grafts
able 4.7
able 4.8
able 4.9
able 5.2
ible 5.4
ible 5.6
ble 5.8
ble 5.9 .
Distribution of TNF-1 and TNF-2 promoter allele genotypes with the incidence of chronic rejection in 
132 liver graft recipients
/
Distribution of the TNF-2 promoter allele and active CMV infection with chronic rejection for 
111 liver graft recipients
) - 
Distribution of TNF-1 and TNF-2 promoter allele genotypes with the incidence of active CMV infection
Patients studied in Chapter 5
Distribution of sera containing IgA antibodies to a 94kD antigen present in chronically rqected, CMV 
infected bile duct (CR/ CMV bile duct) or normal bile duct
Distribution of sera containing IgA antibodies to a 39 kD antigen present in chronicaUy rejected, CMV 
infected bile duct (CR/ CMV bile duct) or normal' bile duct
Distribution of sera containing IgA antibodi^ to a 44 kD antigen present in chronically rejected, CMV 
infected bile duct (CR/ CMV bile duct) or normal bile duct
Distribution of sera containing IgA antibodies to a 134 kD antigen present in chronically rejected, CMV 
infected bile duct (CR/ CMV bile duct) or normal" bile duct
Distribution of sera containing IgA antibodies to a 44 kD antigen present in chronically rejected, CMV 
infected bile duct (CR/ CMV bile duct) or "normal" bile duct
Distribution of sera containing IgG antibodies to a 160 kD antigen present in "chronically rejected" 
hepatic artery (CR hepatic artery) or "normal" hepatic artery
172
173
174
175
193
212
>ble5.3 Presence (+) or absence (-) of IgA antibodies to a 94kD antigen present in various bile duct tissues
(CR/CMV, CR, Tx or normal) for sera from six patients that developed chronic rejection 213
214
absence (-) of IgA antibodies to a 39 kD antigen present in various bile duct tissues 
 ^ CR, Tx or normal) for sera from six patients that developed chronic rejec tion . 215
216
218
219
222
ble 5.10 Presence (+) or absence (-) of IgG antibodies to a 160kD antigen present in various hepatic artery tissues
(CR, Tx or normal) for sera from six patients that developed chronic rejection 223
XX
ble 5.11 Distribution of sera containing IgG antibodies to an 85 kD antigen present in ’chronically rejected'
hepatic artery (CR hepatic artery) or normal' hepatic artery 224
ble 5.12 Presence (+) or absence (-) of IgG antibodies to an 85 kD antigen present in various hepatic artery <
tissues (CR, Tx or normal) for sera from  six patients that developed chronic rejection 225
Ï 6.1 Distribution of CMV positive cells am on^t 29 liver transplant recipients according to CMV
antibody status and active CMV infection 254
; 6.2 Distribution of CMV-positive cells amongst liver graft recipients 257
■J
: 6.3 Distribution of mismatched HLA alleles for liver transplant recipients with or without active CMV
infection of the graft as detected by in situ hybridisation 258
6.4 Patients harbouring active CMV in epithelial and endothelial cells 260
7.1 Distribution of liver transplant recipients according to CMV antibody status and treatment with
ganciclovir 295
>pendix3 In situ hybridisation and immunohistochemistry for active CMV 331
XXI
CHAPTER 1
INTRODUCTION
1.1 A Historical Account of Cytomegalovirus
'Protozoan like' cells were initially observed in the kidney of a newborn 
child in 1881 by Ribbert (1). Similarly, Jesionek and Kiolemenoglou (1904) 
(2) published a case report describing large (20-30|im diameter) cells found 
in kidney, lung and liver of an eight month old fetus; intranuclear 
inclusions were observed in these cells.
The cells described in these early case reports of congenital disease 
displayed the hallmarks of CMV infection; indeed, an infectious agent was 
thought to be responsible but initially this was thought to be an 
amoebiform protozoan. Smith and Weidman (1910) (3) proposed the 
name Entamoeba mortinatalium.
In the 1920's a viral aetiology was suspected. Goodpasture and Talbot 
(1921) (4) described a six week old infant; cells found in kidney, lung and 
liver were described and termed "cytomegalic" for the first time. This 
paper was also a milestone in the history of cytomegalovirus because the 
authors proposed that the intranuclear inclusions seen were similar to 
those seen after varicella infection and doubted protozoan involvement.
Von Glahn and Pappenheimer (1925) (5) also proposed a viral aetiology 
and suggested membership of the herpesvirus group; analogies were made 
between 'cytomegalic inclusions' and inclusions associated with herpes 
zoster and herpes simplex.
Survival of an infected neonate was reported by Margileth (1955) (6). 
Clinical symptoms at birth included hepatosplenomegaly, haemolytic
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anaemia, thrombocytopaenia and microcephaly. In addition, a diagnosis of 
cytomegalic inclusion disease was confirmed after detection of cytomegalic 
cells in urine (the first reported method of,laboratory diagnosis).
Isolation of this suspected virus was achieved after the advent of cell 
culture in the 1950's. Smith (1956) (7) described isolation from samples of 
salivary gland and kidney, taken from infants with cytomegalic inclusion 
disease. Viral particles replicated in human uterine cell cultures.
In addition, two groups isolated CMV by accident. Rowe et al (1956) (8) and 
Weller et al (1957) (9) were attempting to isolate adenovirus and 
Toxoplasma gondii respectively. Inclusions in cell cultures of human 
adenoid tissue (8) and skin-muscle tissue (9) were reminiscent of those 
seen after cytomegalic inclusion disease.
In modem times, the study of cytomegalovirus (CMV) has changed focus 
dramatically; immunosuppressed individuals i.e. organ transplant 
recipients receiving immunosuppressive drugs and patients with acquired 
immime-deficiency syndrome (AIDS) are new populations at risk of 
severe CMV disease.
The advent of molecular biology has provided powerful tools which have 
enabled a better understanding of the biology of CMV.
1.2 Cytomegalovirus is a Member of the 
Human Herpesviridae
1.2.1 Members
The human herpesviridae group consists of eight DNA viruses namely 
herpes simplex virus type 1 (HSV 1), herpes simplex virus type 2 (HSV 2), 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus 
(VZV), human herpesvirus 6 (HHV 6), HHV 7 and HHV 8. The 
molecular and biological characteristics of the latter two recently described 
viruses are poorly understood.
The heipesviruses share a number of characteristics that justify their 
grouping. The genomes are large (over 100 Kb), double-stranded, linear 
DNA molecules. The genomes are complex; HSV and CMV genomes 
encode 72 and 208 open reading frames respectively (10, 12). The genetic 
material is contained within an icosahedral shaped capsid which is 
surrounded by an amorphous proteinaceous tegument and finally, a lipid 
membrane envelope (10). Ah overall molecular weight of 10^ Daltons is 
similar for all human herpesviruses (11).
In addition, a number of homologies between DNA and protein sequences 
have been found throughout the human herpesviruses (10, 13, 14, 15, 16).
Herpesviridae have been delineated into 3 sub-groups on the basis of 
tropism: alpha (a), beta (P) and gamma (y)-herpesviridae (17). a -  
herpesviridae include HSV-1, HSV-2 and VZV and are neurotropic 
whereas P-herpesviridae, which include CMV, and y-herpesviridae, which 
include EBV, are lymphotropic. Members of each sub-group also have 
similar genome structures and other biological characteristics (10, 17).
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1.2.2 Prevalence
Herpes viruses are prevalent; in Britain 50-60% and over 90% of the adult 
population are chronic carriers of CMV and EBV respectively (18, 19). The 
prevalence of the herpes simplex viruses (HSV) varies worldwide, 
depending upon socioeconomic factors, approaching 100% in some 
populations (20). Similarly, HHV-6 is highly prevalent and infection rates 
between 50-95% have been described (33).
s.
The serbprevalance of CMV antibodies increases with age; in a Swedish 
population seroprevalance increased from 19% (age 1-3 months) to 53% 
(age over 50 years) (76). Seroconversion rate, which is a reflection of 
infection rate, peaked between 6 months and 5 years.
1.2.3 Infection of Immunocompetent Individuals
Upon primary infection an individual may display a spectrum of well 
recognised symptoms, e.g. infectious mononucleosis (EBV), oro-facial or 
genital lesions (HSV 1). H owever, herpesviruses often infect 
asymptomatically or give rise to unrecognised symptoms. Primary 
infections with CMV, EBV or HSV in healthy individuals are rarely 
symptomatic, or symptoms are not recognised (85) but less than 4% of 
VZV primary infections in children are inapparent (21).
After primary infection, herpesviruses persist latently in a restricted 
population of host cells. Reactivation of the latent population occurs 
sporadically and this may lead to a symptomatic infection, but in a healthy 
individual viral replication is often ablated efficiently by specific cellular 
and humoral immune responses (see section 1.4). Thus a large proportion
of reactivation infections are asymptomatic, e.g. 50% of HSV-1; 
reactivations have been'shown to not manifest clinically (22).
1.2.4 Infection of Immimosuppressed Individuals
In an immunosuppressed individual, viral replication is not suppressed if 
T cell immunity is impaired; this may lead to severe symptomatic 
infection. High risk groups for symptomatic herpesvirus infection include 
neonates (80, 81), patients with AIDS (82, 83, 84, 90) and transplant 
recipients.
EBV is ah important pathogen after liver (23, 24), bone marrow (27, 30), 
renal (25, 26) and cardiac (38,29) transplantation. Similarly, active VZV and 
HSV infections have been recorded after bone marrow transplantation 
((31, 32, 33, 34; VZV), (32, 33, 34; HSV)) or liver transplantation ((32; HSV), 
(34, 35; VZV)).
The importance of CMV infection in transplant patients is covered in 
sections 1.5,1.6,1.8 and 1.9.
1.3 Virology and Biology of Cytomegalovirus
1.3.1 Genes
Cytomegalovirus (CMV) (strain AD169) was sequenced by Chee et al (1990) 
(12). This large and complex genome is present as a Hnear, double stranded 
molecule within the cell nucleus; it is 230 Kb in size and encodes 208 open 
reading frames.
The genome comprises a long unique sequence (UL) and a short unique 
sequence (US); each is flanked by inverted repeats (IR). The unique
\
sequences can invert during replication to produce 1 of 4 possible isomers 
(59).
Homology has been found between CMV DNA and human DNA and/or 
DNA from other herpesviruses. This is shown diagramatically in figure 
1.1.
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1.3.2 Latent Infection
The ability to establish latent infection is a characteristic shared by all 
herpesviridae.
Herpes simplex virus (HSV) latently infects neural ganglia; in thi^ state, 
HSV produces a transcript known as LAT (latency associated transcript). 
LAT is not translated but is thought to be important in maintaining a 
latent state (36). Epstein Barr virus latently infects epithelial cells (37) and 
B-lymphocytes (38).
Historically, epidemiological evidence from the study of seroconversion 
after blood transfusion suggested that blood cells were a site of latency for 
CMV (39, 40). However, demonstration of latent CMV in monocytes has 
only recently been achieved after implementing an extremely sensitive 
detection technique i.e. nested PCR (41). Furthermore, bone marrow 
progenitors of the monocyte/macrophage lineage have been shown to 
harbour latent CMV (42).
The epidemiology of CMV infection after solid organ transplantation
strongly suggests that the donated organ harbours latent CMV (43).
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Attempts t o . isolate CMV from the tissue of healthy CMV antibody 
positive individuals has been unrewarding. However, in a recent report 
murine CMV (mCMV) was found to be tropic to endothelial cells of lung, 
liver and spleen (44). Here, in situ-FCR technology was used which  
allowed highly sensitive detection of mCMV whilst preserving cellular 
architecture and therefore allowing identification of latently infected cells. 
This finding has not been reported for human CMV.
Lungs are. an important site of pathology during active CMV infection 
(109) and it has been suggested that alveolar macrophages harbour latent 
CMV (45). Balthesen et al (1993) (45) infected BALB/c mice with 10  ^ pfu 
murine CMV (mCMV), 1 day after birth. In surviving mice (60%), 
replicating virus was found in salivary glands for up to 6 weeks after 
infection. Latency was established after this time; replicating virus was not 
cultured from salivary gland, lung or spleen at 1 year post-infection. 
However, PCR amplification demonstrated latent mCMV in lung and 
spleen.
Latency in lung tissue has not been properly investigated for human 
CMV; Fajac et al (1994) (46) could not detect latent CMV in 
bronchoalveolar lavage from healthy CMV antibody positive individuals 
after PCR. The authors conceded that this may be due to lack of 
sensitivity; latent CMV was also undetected in blood mononuclear cells 
which have been shown to be a latent site by others (41,42).
To date, a 'latency associated transcript' has not been found for CMV. 
Studies conducted in the Department of Medicine, University of 
Cambridge by Dr. ' Sinclair demonstrated that host-factors are important. 
Specifically, this group showed that monocytes (cell line THP 1) were non- 
permissive for productive CMV infection because the major immediate 
promoter-enhancer (12) was repressed (also see below). Immediate early 
expression was restored in vitro after differentiation of monocytes into 
macrophages (48). In a model system, non-permissive tetracardnoma (T2) 
cells were differentiated after addition of retinoic acid; YYl (a host 
transcription factor) was lost from regulatory elements positioned within 
and upstream of the major immediate early promoter-enhancer and this
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the transcriptional cascade that leads to viral replication (49).
1.3.3 Lytic Infection
A 'cascade' of transcription occurs after the initiation of lytic infection. 
CMV genes have been designated immediate early (IE), early (E) or late (L) 
according to the time of transcription initiation.
1.3.3.1 Inunediate Early Genes
Immediate early (IE) genes 1 and 2 are both controlled by the major 
immediate early promoter. Both are transcribed immediately after and 
throughout infection (50). Cyclohexamide (translation inhibitor) does not 
prevent IE gene transcription which probably occurs using host cell RNA 
polymerase (51).
Immediate early mRNA is translated in the cytoplasm; IE proteins are 
trarisported into the nucleus where they function as transcription factors 
(52).
IE 1 positively auto-regulates IE 1 and 2 gene transcription whereas IE 2 
negatively auto-regulates IE 1 and 2 gene transcription (53). Both lEl and IE 
2 proteins upregulate a number of ceUular genes; Hagemeier et al (1992) 
(54) showed upregulation of c-fos, c-myc and hsp-70 independently by both 
IE proteins. Jault et al (1995) (366) have shown upregulation of p53, cyclin E 
cmd the retinoblastoma gene product by CMV infection of fibroblasts.
IE genes are also vital for transcriptional activation of the early (E) and late 
(L) genes (55).
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1.3.3.2 Early (E) Genes
Early genes are transcribed 2-24 hours after infection; generally, these genes 
are not structural but encode a number, of enzymes crucial to assembly of 
intact virions. Early gene products include DNA polymerase (140kD) and 
DNA binding proteins (52 and 140kD) (52). Other gene products have been 
predicted from DNA sequence analysis including a DNase, helicase, deoxy- 
UTPase, uradl-DNA glycosylase and helicase-primase (56).
1.3.3.3 Late Genes
Late gene and early gene transcripts are produced simultaneously; 
how ever, late gene transcripts are retained in the nucleus until viral D N A  
synthesis is initiated at 12 hours post-infection (57). Therefore, late gene 
products appear after 24 hours; the mechanism of retention is unclear.
Late genes (L) are predominantly structural; their function within the 
virion is shown in figure 1.2.
1.3.4 Effect of CMV Infection on Cell Protein Contents 
CMV infection leads to production of CMV proteins and altered host cell 
protein synthesis. This leads to an altered immune response which has 
important implications for the study of the relationship between CMV 
and allograft rejection. For example, humoral or cellular responses to 
CMV proteins or upregulated auto-antigens may occur (see sections 1.3.3.1 
and 1.4).
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Figure 1.2
Schematic of the CMV virion: an icosahedral structure
Nucleocaps id
Major nucleocapsid protein150 kO (90% whole nucleocapsid) 
gp34 34 kD
gp28 28 kD
Matrix
1
Lower matrix protein (pp65) 65 kD
Upper matrix protein 71 kD
Basic phosphoprotein 150 kD
E n v e lo p e
D ouble lipid bilayer with g lycoproteins
gB 55/92 kD complex 
gH 86 kD
gC II 50/>200 kD complex 
gp48 48 kD
CMV genom e
Linear 230 Kb molecule
1.3.5 CMV Encodes a Protein w ith H om ology to the MHC
Molecule
Beck and Barrell (1988) (60) performed DNA sequence analysis upon the 
human CMV gene H301. From a predicted protein sequence it was shown 
that the H301 gene product has 20% homology with the HLA class I gene. 
The P2 microglobulin (P2"na) binding site is a loop of 6 amino acids present 
in the A-3 domain of class I; in the CMV homologue 4 /6  amino acids were 
shown to be conserved: In addition, the CMV homologue was shown to 
contain a conserved region of 23 hydrophobic amino acid residues 
responsible for spanning the cell membrane.
CMV proteins were shown to bind p2 -m in vitro by Grundy et al 1987 (61); 
two proteins (36 and 65 kD) were identified. Beck and Barrell (1988) (60) 
speculate that, depending upon the extent of glycosylation, the H301 gene 
product may assume a molecular weight of 65kD in vivo.
CMV virions were found coated with p2 -m in vivo by McKeating et al 
1987 (62). Here, the authors suggested that CMV virions exchange their 
surface bound P2 -m for class I associated P2 -m to facilitate cell entry after 
class I/P 2-m/CMV complex endocytosis.
1.4 Immunity and Cytomegalovirus
1.4.1 Cellular Responses
1.4.1.1 Cytotoxic T Lymphocytes (CD8 +)
Autologous antigen presenting cells and T-lymphocytes can be combined 
to investigate MHC restricted T-lymphocyte responses; lysis of target cells 
is measured by ^^Cr release. This system was used by Borysiewicz et al 
(1983) (63); bulk cultures of peripheral blood mononuclear cells from
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healthy CMV antibody positive individuals contained cytotoxic 
lymphocytes (CTL) (CD8 +) that responded specifically to CMV antigens. In 
a subsequent paper, Borysiewicz et al (1988) (64) used limiting dilution 
assay to investigate the proportion of CTL precursors having specificity 
against IE-1 and gB proteins expressed in vaccinia-vectors in autologous 
fibroblasts; 20 - 60% clones recognised IE-1 whereas less than 4% recognised 
gB.
In contrast, Gilbert et al (1993) (367) studied MHC restricted presentation of 
CMV proteins after active CMV infection of fibroblasts (as opposed to
I
vaccinia construct expression of individual CMV proteins) and found that 
the proportion of IE protein specific T-lymphocytes (after stimulation of 
peripheral blood mononuclear cells with CMV infected fibroblasts) was 
low.
This was due to inefficient presentation of IE peptides by CMV infected 
fibroblasts; T-lymphocytes with specificity to pp65, gB and IE led to specific 
lysis of 51%, 25% and 2% of CMV infected target cells respectively. It was 
proposed that this mechanism allows CMV to escape detection of IE 
protein. Further reports showed that MHC class I heavy chain/IE peptide 
complexes were rendered unstable (253) by the activity of early genes 
(252).
McLaughlin-T ay lor et al (1994) (430) have shown that pp65 is a common 
target for CD8+ class I MHC restricted cytotoxic lymphocyte activity 
amongst latently infected individuals. Studies of transplant patients by 
one group suggest that cellular responses to CMV after transplantation 
may protect against CMV disease (65, 66). Quinnan et al (1982) (65) studied 
58 bone marrow transplant recipients; 43 developed CMV infection
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including 28 cases of CMV pneumonitis. All 18 patients that survived 
developed CMV-specific cellular responses (9 CTL and 9 natural killer cells 
(NK)) whereas only 2 of 10 patients that died developed an NK and none 
developed a CTL response. However, cellular responses were not 
developed by patients without CMV disease suggesting that other 
immune factors are involved. In addition, Grundy et al (1987) (67) suggest 
that CMV pneumonitis is immunopathogenic (see section 1.6.6.4).
1.4.1.2 CD4 + T-Lymphocytes
Fewer studies have focused on the role of CD4+ T-lymphocytes. These
.1
cells were (collected from CMV antibody positive individuals and were 
shown to be cytotoxic towards autologous monocytes (which express MHC 
class n) expressing CMV protein (Lindsay 1986) (68). Cytotoxic CD4+ T- 
lymphocytes have also been shown for mCMV. Shanley et al (1987) (377) 
performed adoptive transfer of CD4+ and CD8+ T-lymphocytes from mice 
which were latently infected with mCMV into naive, homozygous nude 
mice (deficient in mature lymphocytes) before infection with mCMV (21 
days later); only transfer of CD4+ T-lymphocytes suppressed viral 
replication. Furthermore, Geier SA (1995) (378) found reduced CD4+ T- 
lymphocyte counts to be an important prognostic factor for active CMV 
infection in patients with AIDS.
Interferon-y production production by CMV specific CD4+ T cells has also 
been shown (431, 432). Waldmah et al (1993) (431) suggested that such IFN- 
y  production may lead to proliferation of alloreactive T cells in addition, to 
CMV specific T cells and suggest that CMV may contribute to graft 
rejection indirectly.
1.4.2 Humoral Immunity
Antibodies reactive with specific CMV proteins have been found in CMV 
antibody positive individuals; target proteins are listed in table 1.1.
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Table 1.1
Proteins Identified as targets for antibody production in CMV ar#(pdy positive individuals. ;
NAME MOLECULAR
WEIGHT
VIRION
LOCATION
REFERENCE
DNA-binding protein 52 KDa NA Gergely etal 1988 (7)
DNA-binding protein 35 KDa NA Gergely et al 1988 (7)
Structural Protein 28 KDa Capsid Re et al 1985 (8)
Lower matrix protein 64 kDa Matrix Forman et al 1985 (9)
Basic phosphoprotein 150 KDa . Matrix Landini et al 1986 (10) .
Glycoprotein gC II , 527 >200 KDa Envelope Liuetal 1988 (11)
Glycoprotein gB 9 2 /5 5  KDa Envelope Liuetal 1988 (11)
Glycoprotein gH 86 KDa Envelope ' Liuetal 1988(11)
*
^Commercial antigenaemia assays contain antibody-conjugates that are 
directed to the 65 kD lower matrix protein (379).
Antibodies reactive with CMV glycoproteins have been shown to be 
neutralising in vitro but this has not been shown in vivo  (74). The 
presence of CMV-reactive antibodies in transplant recipients does not 
necessarily prevent infection but may reduce the severity of CMV disease 
(75).
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1.5 Liver Transplantation and 
Cytomegalovirus (CMV)
1.5.1 Immunosuppression Facilitates Active CMV Infection
Liver transplantation is the treatment of choice for most end-stage liver 
diseases. Immunosuppressive drugs minimise the incidence of rejection 
by reducing the recipients ability to mount a cellular immune response 
against the graft, e.g. cyclosporine abrogates the transcription of cytokine 
mRNA in activated lymphocytes. When first introduced, cyclosporine-A 
improved renal graft survival rates at one year by 20% (101). However, it 
has been shown by Converse et al 1983 (97) that cyclosporine reduces the 
response of cytotoxic lymphocytes to CMV infected fibroblasts iri vitro.
Active CMV infection may occur readily in this setting; infection rates of 
up to 60% have been reported in some series (93, 94,43,96, 97, 98, 99).
1.5.2 -Sources of CMV
Primary infections may cause severe disease and in some cases may be 
fatal; latent virus may be acquired from donor tissue (43) and/or  
transfused blood (100).
Recipients that have previously encountered CMV also host active CMV 
infection after immunosuppression; however, such secondary infections 
generally cause less disease than primary infections (93, 94, 43, 96, 98, 99). 
Secondary infection may occur as a reactivation  of recipient virus or 
reinfection with a different strain originating from the donated organ.
Sutherland et al 1992 (43) showed that, for 120 liver transplant recipients, 
88% of primary infections (n=18) were symptomatic compared to only 55%
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of reinfections and reactivations (n=77). In addition, symptomatic primary 
infections were more severe; manifestations included CMV hepatitis, 
gastrointestinal complications and thrombocytopenia. Eight per cent of 
transplants between CMV antibody negative donor and recipients were 
complicated post-transplant by CMV infection; this was presumed to be 
due to transmission from transfused blood. Other reports have confirmed 
the relatively low importance of CMV transmission by blood products in 
this setting (93, 98, 99). Furthermore, some CMV antibody negative 
individuals harbour CMV DNA in monocytes, which have been shown to 
be a site of latency (102); therefore, the 8% rate of transmission via blood
I . '
products (43) may be an overestimate.
1.5.3 CMV Disease after Liver Transplantation
Symptomatic CMV infection after liver transplantation usually occurs in 
the first few months and may manifest as fever, malaise, arthralgias, 
leukopenia, thrombocytopenia, hepatitis, interstitial pneum onitis, 
enteritis, chorioretinitis and disseminated disease (99).
Often the only symptom evident is fever (99) which is also a symptom of 
acute rejection. Rejection is treated by increasing immunosuppression 
whereas CMV infection is treated by lowering immunosuppression 
and/or administration of anti-viral drugs. Therefore, specific diagnosis of 
active CMV infection is crucial (see section 1.7).
1.5.4 Targeting Antiviral Treatment After Liver Transplantation
A number of antiviral treatments are currently used including  
administration of acyclovir, ganciclovir, foscarnet and immune globulin. 
Acyclovir is a nucleoside analogue that is highly effective against HSV 
which encodes the enzyme (thymidine kinase) responsible for converting
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acyclovir into its active form (acyclovir triphosphate) which is a potent 
inhibitor of HSV DNA polymerase activity (85); acyclovir is less effective 
against CMV (85) which does not encode thymidine kinase.
However, both the nucleoside analogue ganciclovir and the drug foscarnet 
(phosphonoformic acid) reduce the activity of CMV DNA polymerase (103, 
380). The active, triphosphate form of ganciclovir is thought to be 
produced after the activity of a number of cellular kinases that are 
upregulated after CMV infection (85). True prophylactic administration of 
intravenous ganciclovir (5 m g/kg/day) is more effective than high-dose 
oral prophylaxis of acyclovir (800 m g/k g /d ay) and can prevent CMV 
disease in liver transplant recipients (104, 105). However, this regime is 
undesirable because ganciclovir is myelotoxic; in addition, intravenous 
adm inistration of ganciclovir or foscarnet requires prolonged  
hospitalisation. Oral ganciclovir has recently become available and is 
likely to be effective in reducing the impact of CMV disease
CMV antibody negative bone marrow (261) and liver (96) transplant 
recipients have been shown to be at less risk of CMV disease after 
prophylaxis w ith high titre CMV immune globulin; however, this 
preparation is costly, requires intravenous administration and is probably 
inferior to antivirals (Alexander GJM; personal communication).
Targetting of individuals at risk of developing CMV disease for pre­
emptive ganciclovir treatment (given when asymptomatic CMV infection 
is detected) is an attractive alternative because patients at no risk are 
spared urmecessary treatment. The incidence of CMV disease is reduced 
when this policy is employed but not eliminated (106, 107). Elimination
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may be possible if^a highly sensitive laboratory test is used so that pre­
emptive treatment can be given earlier (see section 1.7).
1.5.5 Liver Transplantation at Addenbrooke's NHS Trust 
The success of liver transplantation, measured in terms of patient and 
graft survival, has improved since programmes were first initiated. The 
population of patients transplanted and the frequency and causes of graft 
and patient loss vary between centres. Therefore, initial diagnoses and 
survival statistics of the patients transplanted during the period of this 
study need to be stated in order to make worthwhile comparisons with 
previous reports from this and other centres.
During the period of study (the past 4 years), 235 patients have undergone 
liver transplantation at Addenbrooke's Hospital. These patients had a 
male: female ratio of 1.06 and à median age 38 (range 7- 67).
1.5.5.1 Primary Disease
Liver transplantation was used to treat patients presenting with a variety 
of disorders as shown in figure 1.3.
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Figure 1.3 Types and proportions of primary disease i 
allograft recipients at Addenbrooke's NHS Trust
in 235 liver
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1.5.5.2 Patient and Graft Survival
The five-year actuarial survival rate for patients is now  approaching 75%; 
currently, the re-transplantation rate is 9.8%.
1.5.5.3 Causes of Graft Loss
Fifty patients were re-transplanted over the past 4 years; the causes of these 
graft losses are distributed as show n in figure 1.4.
Figure 1.4 Causes of graft loss for the last 50 re-transplanted patients at 
A ddenbrooke's N H S Trust
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20/1%
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2 0 %
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H  Chronic rejection
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H  Hepatic artery 
thrombosis
[ ]  Portal vein thrombosis
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H  Acute rejection
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Chronic rejection w as the largest single cause of graft loss am ong these  
patients (38%).
1.5.5.4 C M V  D ise a se  A m o n g  L iver T ra n sp la n t P a tien ts  at
A ddenbrooke's N H S Trust
O ver the p ast four years, 8.6% of liver transp lant recip ien ts at 
A ddenbrooke's N H S Trust had CMV disease.  This w as clinically defined  
after  o b se r v a tio n  o f fev er , m a la ise , a r th ra lg ia s , le u k o p e n ia ,  
th ro m b o c y to p e n ia , h e p a tit is , in ter stit ia l p n e u m o n it is , en te r it is ,  
chorioretin itis or d issem inated  disease and the association w ith  active  
CMV infection w as confirmed by laboratory testing.
1.6 Bone Marrow Transplantation (BMT) 
and Cytomegalovirus (CMV)
1.6.1 O bliteration of Cellular Im m unity Facilitates A ctive CMV Infection
A llogeneic bone m arrow transplantation (BMT) and volunteer unrelated  
donor (VUD) BMT occur w hen  bone marrow is transplanted from HLA  
identical sib lings and HLA identical unrelated ind ividuals respectively; 
both are used to treat leukaemia. Pre-transplant conditioning is required to 
provide 'marrow space' for donor stem  cells, to eradicate the recipients 
cellular im m unity and therefore avoid  graft rejection and to eradicate 
m arrow  m align an cy  (108). This is ach ieved  by a com bin ation  of 
cyclop hospham ide, anti-thym ocyte globulin  (ATG), cyclosporin  a n d /o r  
total body irradiation (TBI). Cellular responses are com pletely ablated and 
subsequent CMV disease is com m on and often severe.
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M eyers et al (109) found a 50% incidence of sym ptom atic infection CMV 
and a 10-30% incidence of CM V-m ediated interstitial pn eu m onitis (of 
w hich 80% of cases proved fatal).
1.6.2 Sources of CMV
In the early period of bone marrow transplantation, severe and fatal CMV 
disease occurred after transm ission of CMV by CMV antibody positive  
blood and blood products. More recently, CMV antibody negative blood  
products have been provided. This has affected the incidence of CMV 
infection o f CMV antibody negative recipients. D e W itte et al 1990 (110) 
fo llow ed  this regim e and found the incidence of active CMV infection to 
be 86% and 0% in CMV antibody positive and CMV antibody negative  
rec ip ien ts resp ective ly ; 50% of th ose w ith  active CM V in fec tio n  
experienced CMV disease.  Similarly, Sullivan et al 1990 (111) found that 
only 2% of CMV antibody negative recipients are infected post-transplant.
CMV antibody p ositive  recipients are therefore at a h igh  risk of CMV  
infection and disease (in contrast, donor CMV antibody positiv ity  confers 
the h ighest risk of subsequent active CMV infection and disease after liver 
transplantation). CMV can be transmitted w ith  the transplanted marrow  
(112, 113) but it is believed  that reconstitution of the donor im m une  
system  (which is prim ed for a response to CMV) m ediates protection.
1.6.3 T im in g
A ctive CMV infection, tested by blood and urine culture, appears during a 
relatively  discrete tim e period; m edian tim es of initial detection  vary  
betw een centres from day 35 (114) to day 59 (115).
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1.6.4 CM V D isease after Bone Marrow Transplantation
CMV d i se a s e  in this transplant population  includes fever, athralgia, 
m alaise, interstitial pneum onitis (see section 1.6.6.4), enteritis, hepatitis 
and graft suppression  (throm bocytopenia and neutropenia) (116). The 
association  betw een CMV and graft-versus-host d isease is d iscussed  in 
detail later (see section 1.6.6).
1.6.5 T a r g e tt in g  A n t iv ir a l  T re a tm en t A fte r  B o n e  M a rro w  
T ransplantation
A  num ber of antiviral preparations are available (see section  1.5.4); 
ganciclovir is the m ost efficient inhibitor of CMV replication studied  to 
date.
Survival am ong bone marrow transplant patients w ith  CMV pneum onia  
treated w ith  ganciclovir after the onset of clinical sym ptom s is low  (10%) 
and relapses are com m on (108). True prophylactic adm inistration of full 
doses o f ganciclovir from the tim e of transplantation, to all allogeneic  
bone m arrow transplant patients w ithout regard to clinical sym ptom s or 
laboratory  d ia g n o sis  of active  CMV in fection , can p rev en t the  
d e v e lo p m e n t o f CM V p n eu m o n itis  (109). H o w ev er , g a n c ic lo v ir  
prophylaxis in this guise is undesirable because com m on adverse effects of 
ganciclovir include neutropenia and throm bocytopenia (119).
A num ber of reports suggest that a com prom ise position can be clinically  
advantageous; early, pre-em ptive treatment w ith  ganciclovir, before the 
developm ent of clinical sym ptom s, im proves survival and reduces CMV 
d i sease  (120, 121). In addition, low  doses of ganciclovir, used  in this 
m anner, are effective; this m inim ises hospitalisation and toxicity.
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To exploit this approach an early diagnosis of active CMV infection, before 
the on set of clinical sym ptom s, is essential to a llow  early, low -d ose  
ganciclovir prophylactic treatment to be targetted to ind ividuals at high  
risk of develop ing CMV pneum onitis.
1.6.6 Graft Versus Host Disease (GVHD) after Allogeneic Bone Marrow 
Transplantation
Risk factors for the developm ent of GVHD were listed by Billingham 1966 
(122). The transfusion of im m unocom petent cells from donor to recipient; 
T -lym phocytes are im portant and the number transfused is associated  
w ith  d isease severity  (123). A ntigenic differences b etw een  donor and  
recipient and recipient im m unosuppression are also required.
Thus, a patient undergoing allogeneic bone marrow transplantation is at 
h igh  risk of d ev e lo p in g  GVHD. A link has been p rop osed  betw een  
cytom egalovirus infection and GVHD (see Chapter 3).
1.6.6.1 Acute GVHD
A cu te  G VH D after a llogeneic  bone m arrow transplantation  has an 
incidence of 10-80% and is responsible for severe m orbidity and mortality  
(124). D am age to the epithelium  of gut, liver and skin is initiated after T- 
lym p hocyte  infiltration (125). A s the disease progresses the degree of 
inflam m ation increases and a com plex array of cytokines are produced  
(126). Tum our necrosis factor a  (TNF-a) production is im portant and 
m ediates necrosis w ithout the necessity of cell-cell interaction (127).
R isk factors for the d ev e lo p m en t of acute G V H D  in clu d e  HLA  
m ism atch ing, donor leukocyte infusion, recipient im m unosup pression , 
sex m ism atching and possibly donor herpesvirus serology (124).
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1.6.6.2 Chronic GVHD
The incidence of chronic graft versus host disease (GVHD) after HLA- 
identical sibling transplantation is approxim ately 50% (128).
The m echanism  of epithelial cell dam age is similar to that of acute disease; 
epithelial cells are infiltrated by donor CD8+ T-lym phocytes. Cellular and 
hum oral im m unity are directed towards undefined recipient antigens and 
this is associated w ith  severe im m unodeficiency; this relationship has not 
been investigated  fu lly  but m ay occur because of exhaustion of factors 
required to m ount T-lym phocyte activation. Infection in this setting is 
often severe and m ay be fatal (129).
Risk factors are preceding acute GVHD, recipient age and adm inistration  
of donor buffy coat cells w ith marrow (129).
1.6.7 A llo g en e ic  Bone Marrow Transplantation at A ddenbrooke's N H S  
Trust: Data from the Past Five Years
Initial d iagnoses and survival statistics of the patients transplanted during 
the period of this study need to be stated in order to make w orthw hile 
com parisons w ith  previous reports other centres.
Over the past five years, 58 bone marrow allografts have been performed  
at Addenbrooke's NH S Trust; 48 transplants were from HLA-identical 
siblings and 10 were from HLA-identical unrelated donors. This group  
com prised 28 m ale and 30 female recipients and had a m edian age 36.5 
years (range 16-53 years).
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1.6.7.1 Primary D isease,
BMT w as used to treat patients w ith a variety of blood m alignacies (see 
figure 1.5).
Figure 1.5 Types and proportions of primary disease in 58 bone marrow 
allograft recipients at Addenbrooke's NHS Trust.
29&%
9%
2 2 %
28%
28%
■  Acute myeloid 
leukaemia
H  Chronic myeloid 
leukaemia
I  Acute lymphocytic 
leukaemia
n  myeloma
H  Myelodysplastic 
syndrome
H  Non-Hodgkins 
lymphoma
H  Paroxysmal nocturnal 
haemaglobinuria
29
1.6.7.2 Post-Transplant Mortality
A total of 41% (24/58) recipients have survived to date; mortality rates 
among sibling and unrelated-donor transplants are 50% (24/48) and 100% 
(10/10) respectively.
Causes of mortality are distributed as shown in figure 1.6.
Figure 1.6 Causes of death for 34 bone marrow transplant patients at 
Addenbrooke's NHS Trust
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Infection accounted for 24% (8/34) deaths; CMV pneum onitis accounted  
for 2 /8  cases of fatal infectious disease (see section 1.8.4). Chronic GVHD  
was responsible for 15% deaths (see section 1.8.4).
Cases of acute GVHD were not fatal but were associated w ith considerable 
morbidity (see section 1.8.4). Of the 58 patients allografted, 41% (24/58) 
experienced acute GVHD; moderate to severe (grade 3) and severe (grade 4) 
disease occurred in 19% (11/58) patients.
1.7 Diagnosis of Active CMV Infection
Pre-em ptive ganciclovir treatment (see sections 1.5.4 and 1.6.5) requires a 
laboratory test o f high specificity and sensitivity, w ith  the ability to predict 
the subsequent developm ent of CMV disease.
1.7.1 Conventional Tests
A number of m ethods are available for the diagnosis of CMV infection. 
Serological diagnosis depends on the appearance of specific IgM antibodies 
or a four fold increase in IgG titre (189). Such antibodies usually  appear 
tw o to four w eeks after the onset of CMV replication; serological diagnosis 
is, therefore, of lim ited  use in relation to prom pt antiviral treatment. 
Furthermore, antibody responses m ay be delayed in transplant patients 
due to im m unosuppression. CMV m ay be isolated from buff y coat, urine 
and other specim ens and cultured in hum an fibroblast cells. This m ethod  
is regarded as the gold standard w ith  respect to specificity and sensitivity  
but cytopathic changes occur too late to influence treatment. The detection  
of early antigen  fluorescent foci (DEAFF) is a w id e ly  used  detection  
m ethod (190). The DEAFF test is perform ed by centrifugal inoculation of 
CMV from various clinical sam ples onto hum an fibroblasts, incubation
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for 24 hours and then application of fluorescein labelled im m ediate early 
a n d /or  early CMV m onoclonal antibodies to the cells. This rapid test may 
be com pleted w ith in  24-48 hours and its specificity and sensitiv ity  are 
alm ost comparable w ith  that of virus isolation. A problem encountered by  
both culture and the DEAFF test is that of reliability; a significant number 
of culture and DEAFF tests on blood and urine sam ples fail to give a result 
because o f toxic effects of the specim en  on the cells or m icrobial 
contam ination .
1.7.2 Dot -Blot Hybridisation and Polymerase Chain Reaction (PCR)
1.7.2.1 Testing of Urine
Transplant patients w ith  CMV infection usually  excrete CMV in urine. 
D ot-blot hyb rid isation  and the polym erase chain reaction (PCR) are 
potentially  valuable tests in this field  but major problem s have been  
experienced w ith  hybridisation specificity (157, 158, 159) and urine PCR 
inhibitors (160, 161, 162, 163,164) respectively.
Kidd et al (1993) (160) reported testing of urine by PCR, culture and DEAFF 
in a m ixed population  of organ transplant recipients and patients w ith  
AIDS. PCR w as m ost sensitive and detected active CMV infection earlier 
than culture or DEAFF (by 22 and 10 days respectively). PCR positivity was 
significantly associated w ith  CMV disease.
1.7.2.2 Polymerase Chain Reaction (PCR) Testing of Blood
A num ber of reports su ggest that b lood PCR p ositiv ity  has a better 
correlation w ith  CMV d i se a s e  than urine p ositiv ity  (160) after liver  
transplantation. Furthermore, PCR testing of blood has been show n to be
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more sensitive than conventional cell culture (CCC) (166, 167, 160, 168, 169, 
160,170) and DEAFF (165, 171,166, 164,160,162,170).
1.7.2.3 PCR Positivity and D isease
PCR p ositiv ity  does not necessarily correlate w ith sym ptom atic infection. 
Cerna 1991 (166) reported that, for 14 heart transplant recipients, blood  
PCR positiv ity  in the absence of positive DEAFF or isolation results w as  
not associated w ith CMV disease.
H ow ever, quantitation o f CMV D N A  levels m ay determ ine a threshold  
above w hich  sym ptom atic infection is likely. G em a 1991 (166) found such  
a th resh o ld  of v iraem ia in  14 heart transplant rec ip ien ts u s in g  
conventional cell culture.
Attem pts have been m ade to measure CMV load in clinical sam ples using  
sem i-quantitative and quantitative PCR (180, 181, 182, 183). The latter is 
typically perform ed by am plifying exogenous controls, of know n quantity, 
alongside sam ples or by lim iting dilution.
1.8 Chronic Rejection after Liver
Transplantation: A role for CMV?
1.8.1 H istopathology of Liver A llograft Rejection
1.8.1.1 Acute Rejection
The incidence of acute rejection in liver allograft recipients is 70% (191). 
Snover et al 1984 (192) defined the follow ing criteria for the diagnosis of 
acute rejection based on portal tract histology :
33
1. Inflam m atory in filtration  of portal tract in v o lv in g  lym p h ocytes, 
m onocytes, plasm a cells, neutrophils and eosinophils.
2. Inflam m atory dam age to sm all and m edium  sized bile ducts involving  
m on onuclear and polym orphonuclear cells; dam age to the b iliary  
epithelium  m ay occur.
3. V en o u s  e n d o th e lia l in fla m m a tio n  in v o lv in g  su b e n d o th e lia l  
inflam m ation in severe cases.
Parenchym al lesions m ay also occur and include lym phocytic infiltration, 
cholestasis, hepatocyte ballooning and hepatocyte necrosis. Parenchym al 
in volvem en t is caused by direct im m une m ediated injury or ischaem ia
(191.193).
H istological studies suggest that the sites of initial dam age are the bile duct 
e n d o th e liu m  an d  e p ith e liu m  (193). In fla m m a to ry  in f iltr a te s  
predom inantly consist of T-lym phocytes; CD4+ cells predom inate before 
clonal expansion of the CD8+ fraction leads to a high ratio CD8+ : CD4+
(191.193).
1.8.1.2 Chronic Rejection
The in cid en ce o f chronic rejection after liver transplantation  varies  
betw een  5-20%. In m ost cases the initial time of onset is 3-6 m onths.
H ubscher 1991 (191) defined tw o criteria for the d iagnosis of chronic 
rejection;
1. V anishing bile duct syndrom e (VBDS)
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2. Obliterative vasculopathy of small and m edium  sized arteries
VBDS is a progressive disorder w hich cannot be treated and leads to graft 
loss. Initial inflam m ation of portal tracts, associated w ith bile duct dam age, 
is h isto logically  sim ilar to that seen in acute rejection. H ow ever, initial 
inflam m ation m ay be unnoticed. Infiltrates com prise predom inantly T- 
ly m p h o cy tes  p lu s natural killer cells and n eu trop h ils . Portal tract 
in flam m ation  precedes progressive loss of b ile ducts, w h ich  is not a 
feature of acute rejection (191, 193).
Arteries are also involved; endothelial dam age leads to infiltration of the 
intim a by foam y m acrophages and occlusion of the lum en. Subsequent 
ischaem ia, together w ith  direct im m une dam age, leads to hepatocyte  
necrosis and interstitial fibrosis (191, 193). In som e cases, vascular disease  
precedes VBDS.
1.8.2 R isk Factors for Chronic Rejection after Liver Transplantation
1.8.2.1 A C om prehensive Study
To date, the m ost com prehensive study was perform ed by Cardinas et al 
(1995) (210); 423 consecutive primary liver transplants w ere analysed
(chronic rejection inciden ce 5.2%). Risk factors w ere pre-transplant 
diagnosis of primary biliary cirrhosis (PBC) (relative risk 10.6; p=0.006) or 
autoim m une hepatitis (relative risk 6.7; p<0.05), recipient age < 30 years 
(relative risk 3.8; p=0.015), acute rejection ep isode(s) (relative risk 3.6; 
p=0.03) and transplantation from a m ale donor into a fem ale recipient 
(relative risk 3.03; p=0.04). CMV antibody mismatch (donor CMV antibody  
p ositive : recipient CMV antibody negative) was also positively  associated
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w ith  chronic rejection (relative risk 3.5; p=0.015). In contrast to other 
reports (see below ), human leukocyte antigen (HLA) m ism atch at the A, B 
or DR loci, d iagnosis of primary sclerosing cholangitis pretransplant and 
sym ptom atic CMV infection were not associated w ith chronic rejection.
1.8.2.2 The E ffect o f HLA M atch ing u p on  C hronic rejection:
Su ggested  Links w ith  CMV and A utoim m une disease.
R eports of an association  b etw een  HLA m a tch in g /m ism a tch in g  and  
chronic rejection have been conflicting.
A  stud y by the Kings College group (243) investigated 62 liver transplant 
recip ien ts, 14 (23%) of w hom  d evelop ed  chronic rejection. HLA DR  
m atching of 1 or 2 loci (relative risk 2.5; p<0.025) and zero HLA A,B 
m atching (6.2; p<0.05) were independently associated w ith the incidence of 
chronic rejection. The authors suggest that m atched DR HLA present 
foreign A,B HLA peptides and facilitate M HC-restricted interaction and 
subsequent im m une-m ediated dam age.
This group confirm ed these findings in a second study (224) of 101 liver 
transp lan t p atien ts (17% chronic rejection). C hronic rejection  w as  
p ositive ly  associated w ith  HLA DR m atching (relative risk 9.4; p<0.002) 
and HLA A and B mism atching (3.1; p<0.05). In addition, chronic rejection 
w as associated w ith  active CMV infection (7.5; p<0.005). A  1-2 HLA DR 
m atch com bined w ith  CMV disease com prised the highest relative risk 
for rejection suggesting  synergy. The authors suggest that MHC class II 
restricted presentation of foreign HLA A,B and viral peptides leads to 
chronic rejection.
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Interestingly, the recent report from the Birmingham group (210) did not 
find such  a correlation betw een  active CMV infection  and chronic  
rejection. It is possib le that the introduction of ganciclovir, subsequent to 
the Kings C ollege report, is responsible for this conflict; 33% and 8% of 
patients suffered sym ptom atic CMV infection respectively in these tw o  
studies .
The findings of the Kings College group differ w ith  those of the Pittsburgh  
group. M arkus et al (1988) (240) studied 507 liver allograft recipients and  
found that, although HLA-DR m atching w as associated w ith reduced graft 
survival (p=0.054), m ism atching of this locus w as associated w ith  chronic 
rejection (p=0.007). These authors suggest that DR m atching facilitates the 
recurrence o f autoim m une d iseases such as prim ary biliary cirrhosis 
(PBC), primary sclerosing cholangitis (PSC) and alcoholic cirrhosis.
Subsequently, the Pittsburgh group (225) studied  a series of 399 liver  
transplants having a 7% incidence of CMV hepatitis and an 8% incidence  
of chronic rejection. The incidence of chronic rejection w as associated  
positively  w ith  the incidence of CMV hepatitis (24% versus 6%; p=0.0007). 
In ad d ition , chronic rejection occurred earlier in the CMV hepatitis  
positive group (m edian 60 versus 245 days; p=0.07). Furtherm ore, the 
incidence of CMV hepatitis was higher in HLA-DR matched transplants in 
both CMV antibody negative (44% versus 14%; p=0.07) and CMV antibody  
positive (12% versus 2%; p=0.006) recipients. H ow ever, DR m atching per 
se w as not associated w ith the incidence of chronic rejection. The authors 
propose that the im m unopathology of CMV hepatitis is m ediated  by  
M HC-restricted presentation of CMV peptides and is associated w ith  the 
developm ent of chronic rejection.
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It is difficult to consolidate these reports. The Birmingham group (210) 
found no relationship betw een HLA m ism atching and the incidence of 
chronic rejection but failed to score for HLA matches; therefore, this paper 
cannot be com pared directly w ith  the Kings C ollege papers (243, 224). 
Functional relevance is important w hen scoring m atches or m ism atches 
e.g. HLA m olecules w ith  antigenic dissim ilarity m ay be able to present 
similar peptides if peptide binding grooves are identical.
The effects of HLA upon chronic rejection m ay be 'dualistic'. For one HLA  
a lle le  it is n ot in co n ceivab le  that m atch in g  for M H C -restricted  
p resentation  and m ism atch ing for antigenic variability  can both  be 
associated positively  w ith chronic rejection.
Such dualism  of a single HLA allele may have been dem onstrated by the 
Pittsburgh group (see above). Here, DR m atching is associated w ith  CMV 
hepatitis and graft loss but not w ith  chronic rejection. DR m ism atching  
and CMV hep atitis  are associated  w ith  chronic rejection. If m ore  
transplants w ere studied then a direct link betw een DR m atching and  
chronic rejection may emerge.
1.8.2.3 The Importance of T issue Invasion by CMV
1.8.2.3.1 P ersistent CM V In fection  in  C hronically  R ejected  Liver
Allografts
This question was addressed by the Kings College group after describing  
the link betw een active CMV infection and chronic rejection. Arnold et al 
1992 (284) used in s itu  hybridisation to screen serial liver biopsies taken 
from patients w ith VBDS or uncom plicated CMV hepatitis. CMV D N A  
w as found in the hepatocytes of all patients w ith CMV hepatitis and 10/12
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of those w ith  VBDS. The latter group w ere persistently CMV positive  
until the graft w as lost whereas the CMV hepatitis group cleared CMV 
from hepatocytes (p<0.0005). CMV was not found in the principal sites of 
dam age (see section 1.8.1 ) i.e. bile ducts and arterioles. H ow ever, CMV 
infection of hepatocytes may indirectly cause or prom ote dam age of these 
tissues, for exam ple by m ediating clonal expansion  of allospecific  T- 
lym p h ocytes (see section  1.9.3) or by affecting lym p hok in e a n d /o r  
ad h esion  m olecu le  lev e ls  (see section  1.9.4). A n actively  in fected , 
im m unostained, bi-nucleate hepatocyte is show n in figure 1.7 (see Chapter 
6).
F ig u r e  1 .7  A  H e p a t o c y t e  P e r m is s iv e  to  A c t iv e  C M V  I n f e c t i o n  I d e n t i f i e d  
b y  I m m u n o h i s t o c h e m i s t r y  ( o r ig in a l  m a g n i f i c a t i o n  x 2 0 0 ; a r r o w  i n d i c a t e s  
p o s i t i v e  c e ll) .
CMV infection of liver graft endothelial or epithelial cells has not been  
p rev io u sly  reported . H ow ever, Patterson et al (1988) (381) described  
d ev e lo p m en t o f necrotic skin lesions in a liver transplant recipient;
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vascular endothelial cells and epithelial cells were cytom egalic and active 
CMV infection w as confirmed by in situ hybridisation (see also Chapter 6).
1.8.2.3.2 Endothelial and Epithelial C ells are Perm issive to A ctive  
CMV Infection In v i t r o
CMV infects 5-10% of endothelial cells in vitro  (249); these cells have been  
im plicated in chronic renal, heart and liver rejection (see section 1.8.3.2).
CMV also infects 5% cultured tubular epithelial cells (217, 250) w hich  are 
involved  in acute renal rejection. Epithelial cells are perm issive to CMV 
replication (250).
Chronic rejection-mediated dam age is associated w ith fibrosis. It has been  
show n in vi tro  that fibroblasts are perm issive to CMV infection and 
replication (282).
1.8.2.4 Are A n tib o d ie s  a R isk  Factor for R ejec tio n  o f Liver
Allografts?
Liver grafts are considered to be relatively refractory to the presence of 
alloreactive lym phocytotoxic antibodies pretransplant (289, 290, 291, 292, 
293) and posttransplant (287) w hen compared to studies of renal transplant 
recipients (see sections 1.8.3.3.2 and 1.8.3.3.3). Gordon et al (295) presented  
data from 337 primary liver transplants; the incidence of retransplantation  
after rejection w as similar for the 'positive crossmatch' group (n=38) and 
controls (11.3% versus 12.4%).
40
H ow ever, other groups have presented data suggesting a link (293, 294, 
286). Batts et al (1988) (293) used a more sensitive detection technique  
(antihum an globu lin-com plem ent dependent cytotoxicity assay (AHG- 
CDC)) and found a higher incidence of crossm atching (31%; 1 6 /5 2 ). 
Chronic rejection w as associated w ith pretransplant crossm atch positivity  
(83% (5 /6 ) versus 24% (11/46); p<0.004).
In another study (294), the authors speculated that the previously observed  
insignificance of crossmatching occurred because IgM antibody (detected in 
conventional CDC) did not play a role in chronic rejection. Therefore, IgM  
w as e lim in a ted  in this stu d y  after treating serum  sam p les w ith  
dithiothreitol. Significantly higher incidences of graft failure and cellular 
rejection (chronic and acute) were found in a group of IgG crossm atch  
p o s it iv e  p a tien ts  (n=26) com pared  to controls (n=52). H o w ev er , 
crossm atching did not influence the incidence of chronic rejection per se.
1 .8 .2 .5  A r e  P r i m a r y  A u t o i m m u n e  D i s o r d e r s  a  R i s k  f o r  C h r o n i c
R e j e c t i o n  ?
M ost centres report su ccessfu l liver transp lantation  after prim ary  
sclerosing cholangitis (PSC) (194, 195, 196), primary biliary cirrhosis (PBC) 
(197, 198, 199) and autoim m une hepatitis (AIH). C irculating antibodies 
have been  associated  w ith  these autoim m une hepatic d isorders (see  
section 1.9.6); successful outcom e after transplantation suggests that other 
factors are important.
H ow ever, recurrence of PBC (200, 201, 202), PSC (203) and AIH (204) may 
occur after transplantation. Some reports contend that PBC (197, 210) and 
PSC (203, 205, 206) are linked w ith liver allograft chronic rejection.
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1.8.3 Other Allografts
1 .8 .3 .1  H L A  M a t c h i n g  B e n e f i t s  R e n a l  a n d  C a r d ia c  T r a n s p l a n t a t i o n
The benefits of HLA m atching upon outcom e have been docum ented for 
renal and cardiac transplantation (232, 233, 234, 235, 207).
Morris et al (1993) (207) studied 148 renal transplant recipients w hose grafts 
w ere op tim ally  m atched for H LA-A, -B, and -DR. M ism atching w as  
sign ifican tly  associated w ith  an increased incidence of acute rejection  
episodes (p<0.005) and reduced graft survival (p<0.03).
1 .8 .3 .2  C M V  is  a  R i s k  F a c to r  f o r  R e je c t io n  A f t e r  R e n a l  a n d  C a r d ia c
T  r a n s p l a n t a t i o n
Data from a number of papers suggests a link betw een CMV infection and 
rejection of renal (207, 211, 214, 217, 218, 219), cardiac (228, 222), lung (209) 
and intestinal (208) allografts.
The findings of Von W illebrand (1986) (214) are com pelling; in a series of 
237 renal allograft transplants the incidence of CMV disease, d iagnosed by 
culture and clinical sym ptom s, w as 6%. The incidence of rejection w as 
sign ifican tly  higher in patients w ith  CMV d i se a s e  (86% versus 17%; 
p<0.001) and rejection episodes w ere concom itant w ith  the d iagnosis of 
CMV disease.
The largest study of cardiac allografts was performed by Gratton et al (1989) 
(228, 229). In 389 heart transplant recipients the incidence of active CMV 
infection w as 30% (91/301). U pon com parison of those w ith  active CMV 
in fection  w ith  those w ith  no evidence of active CMV infection it w as  
sh ow n  that the former group had a significantly higher incidence of acute
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rejection, rate of acute rejection (ep isod es/ 100 days post transplant), death  
rate from atherosclerosis at five years post-transplant and correspondingly, 
a significantly low er overall survival rate at five years post-transplant.
1 .8 .3 .3  C M V  I n f e c t i o n  o f  G r a f t  T i s s u e  A f t e r  R e n a l  o r  C a r d i a c
T r a n s p l a n t a t i o n
The endothelium  provides a barrier betw een the graft and the recipient's 
im m une system . CMV infection of endothelial cells m ay be an im portant 
initiator or m odulator of graft rejection; CMV has been show n to be tropic 
for renal and cardiac graft endothelial cells (382, 383, 384, 385, 386). In 
addition, it has recently been show n that murine endothelial cells harbour 
latent m urine CMV (44).
R e n a l  G r a f t s
Payton D et al (1987) (383) described a renal transplant recipient w ith  CMV 
infection (observed after light m icroscopy) of glom erular and peritubular 
endothelia l cells and tubular epithelial cells. A ctive CMV infection  of 
derm al vascu lar end oth elia l cells has been described for one renal 
transplant recip ient (382). Furtherm ore, actively in fected , circulating  
endothelial cells have been described after renal transplantation (387); the 
authors suggest that CMV uses these cells as a vehicle for dissem ination.
Cardiac  Graf ts
Atherosclerosis is a vascular disease that has been linked to CMV infection  
and is accelerated after heart transplantation (388). This association is of 
particular im portance because chronic rejection of liver grafts is often  
initiated by hepatic artery occlusion (191, 193; see figure 1.8) and histology  
is sim ilar to that seen for atherosclerotic coronary arteries (figure 1.9 
(A lexander GJM; unpublished observations)).
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O cclusion of the lum en after intimai thickening is characteristic of both  
atherosclerotic untransplanted coronary arteries and chronically rejected, 
tran sp lan ted  h ep atic  arteries (see figu res 1.8 and 1.9 overleaf). 
Furtherm ore, intim ai thickening involves proliferation of m acrophages 
in both diseases; the processes leading to proliferation of these cells may be 
sim ilar.
H endrix et al (1989) (389) detected CMV by PCR in femoral or abdominal 
arterial sam ples from  non-transplanted , atherosclerotic patien ts and  
norm al controls; a greater proportion of atherosclerotic patients tested  
positive (90% (40/44) versus 53% (18/34)). Furthermore, it has been show n  
that a significantly higher proportion of non-transplanted, atherosclerotic 
patients were CMV antibody positive compared to controls (382).
CMV D N A  has been detected in endothelia l cells, lym p hocytes and 
sm ooth m uscle cells of coronary arteries after cardiac transplantation; 6 /1 9  
grafts were positive after in situ hybridisation (385).
H erp esv iru s in vo lvem en t w ith  atherosclerosis has been  proven  in a 
chicken m odel. Fabricant et al (1983) (392) found that chickens developed  
atherosclerosis after infection w ith Mareks disease virus (MDV) and that 
disease w as accelerated after feeding w ith cholesterol; uninfected animals 
did not develop atherosclerosis.
In a rev iew  article, M elnick et al (1995) (388) h y p o th es ise s  that 
ath erosclerosis is in itiated  after C M V -m ediated en d oth elia l dam age. 
Exposed sm ooth m uscle cells are dam aged and subsequently proliferate; 
this leads to intim ai thickening and lum en occlusion.
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Figure 1.8 Occlusion of a Hepatic Artery Due to Chronic Rejection
Figure 1.8 shows a cross section of a medium sized hepatic artery from a liver graft that was 
explanted after chronic rejection. A subintimal aggregation of foam cells (macrophages) led 
to com plete occlusion of the lumen. Intima (I), foam cells (F). Magnification x 200.
Figure 1.9 Atherosclerotic Coronary Artery
I •
..•V
Figure 1.9 shows an un transplanted, atherosclerotic coronary artery (proximal, right). The 
intima (I) is thickened by an atherosclerotic plaque (A) containing macrophages, calcium 
and lipid which is capped by a proliferation of smooth muscle cells (SM). The lumen (L) is 
occluded. Magnification x 400. Photograph kindly provided by Professor Peter Weissberg.
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1 .8 .3 .4  A l lo r e a c t iv e  a n d  A u to r e a c t iv e  A n t i b o d i e s  a n d  R e je c t io n  a f t e r
R e n a l  a n d  C a r d ia c  T r a n s p l a n t a t i o n
1 .8 .3 .4 .1  P r e f o r m e d  A l l o r e a c t i v e  L y m p h o c y t o t o x i c  A n t i b o d i e s  a n d  
H y p e r a c u t e  R e je c t io n
The presence of preform ed alloreactive lym phocytotoxic antibodies in  
renal graft recipients has been show n to elicit hyperacute rejection (296, 
297, 298) w hich  occurs w ith in  m inutes after restoration of b lood flow . 
Such antibodies are alloreactive and are directed against hum an leukocyte 
antigens (HLA). Cells expressing HLA in vivo are targetted; graft cells have 
been  sh o w n  to express class I and, to a lesser extent, class II MHC  
m olecules (see section 1.9).
Patel and Terasaki 1969 (297) published the results of a multi-centre study  
of 248 renal transplant recipients. Pre-transplant serum  from  each  
recipient w as assayed for antibody against a panel of lym phocytes from 10- 
40 in d iv id u a ls  as w ell as graft donor lym p hocytes. The presence of 
preform ed lym phocytotoxic antibodies w as associated w ith  hyperacute  
rejection (43% (3 4 /80  grafts versus 2% (4/168); p=0.001); this correlation 
w as stronger w hen  donor specific antibodies w ere present i.e. a positive  
crossmatch w as seen (80% (24/30 grafts) versus 4.1% (8/195); p<0.001).
1 .8 .3 .4 .2  A l lo r e a c t iv e  L y m p h o c y to to x ic  A n t i b o d i e s  P o s t - t r a n s p l a n t
The d ev e lo p m en t of a lloreactive lym p h ocyto tox ic  an tib od ies p o st­
transplant is also associated unfavourably w ith outcom e (300, 301, 302, 303, 
304, 305). Halloran et al 1992 (302) tested serially taken serum sam ples from 
64 renal transplant recipients against a panel of lym p h ocytes. The 
d ev e lo p m en t o f lym phocytotoxic antibodies w as associated  w ith  an
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increased incidence of rejection (100% (13/13) versus 41% (21/51); p<0.005) 
and graft loss (38% (5/13) versus 4% (2/51); p<0.002). The authors suggest 
that rejection of renal grafts m ay be m ediated by cellular or antibody  
responses and contrast the histopathology of each.
A n tib od y  p rod u ction  during rejection ep iso d es w as th ou gh t to be 
artefactual by McCarty et al 1984 (306) after screening 42 renal transplant 
rec ip ien ts  for p o st-tran sp lan t p ro d u ctio n  of a u to -a n tib o d ies  and  
lym phocytotoxic antibodies. Antibody responses were associated w ith graft 
lo ss b u t not w ith  the occurrence of rejection ep isod es; the authors 
proposed  that antibodies w ere form ed after rejection-m ediated dam age  
and subsequent exposure of im m unogens.
1.8.3.4.3 N on-Lym phocytotoxic A ntibodies
R e n a l  t r a n s p l a n t a t i o n
A  num ber o f reports have docum ented the association b etw een  graft 
rejection and non-lym phocytotoxic antibodies (305, 306, 307, 308, 309, 310, 
311).
Soulillo et al 1981 (305) investigated the specificities of im m unoglobulins  
deposited  in rejected renal allografts. Im m unoglobulin w as only found in 
grafts rem oved after severe acute rejection (62% IgG positive) or chronic 
rejection (75% IgG positive). A proportion of eluted  antibodies w ere  
lym phocytotoxic. Im m unohistochem ical application of eluates to normal 
k id n e y  sec tio n s  sh o w ed  that g lom eru lar  and tubular b a sem en t  
m em branes and D N A  were also targets.
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Sim ilarly, M cPhaul et al 1981 (307) found that 35 rejected renal grafts 
contained antibodies directed specifically to renal structures. In addition, 
antibodies bound to sm ooth m uscle and endothelium  cells. Som e anti­
sm ooth m uscle antibodies were also lym phocytotoxic.
Other reports also docum ent a correlation betw een poor graft function and 
the occurrence of anti-endothelial cell antibodies pre- (312) and p ost­
transplant (308).
C a r d i a c  T r a n s p l a n ta t i o n
The effect of pre-transplant antibodies upon the outcom e of cardiac grafts 
w as investigated by Latif et al 1995 (309). Pre- and post-transplant sera from  
129 heart transplant recipients w as screened by polyacry lam id e gel 
electrophoresis (PAGE) and W estern blotting against normal heart tissue. 
Low am ounts of anti-heart IgG and IgM and were found in 48% and 45% 
of recipients respectively. In addition, 22.5% of recipients harboured large 
am ounts of anti-heart IgM and these recipients experienced more rejection 
ep iso d e s  (p=0.001). A  num ber of im m unogens w ere characterised; 
tropom ysin  (35kD), actin (42kD), heat shock protein-60 (HSP-60; 60kD), 
HSP-70 (70kD) and m yosin (200kD).
After injection of LEW rats w ith  DA rat heart hom ogenate a m ixture of 
auto- and allo-antibodies w ere ind uced  (311). A u to-an tib od ies w ere  
directed against heart-specific targets whereas allo-antibodies, studied after 
pre-absorbtion w ith  LEW heart hom ogenate, reacted specifica lly  w ith  
donor sp leen  cells (presum ably against MHC antigens) and donor heart 
antigens.
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1.8.4 D oes CM V have a Causal R elationship w ith Rejection?
A lth ough  sign ifican t associations b etw een  rejection even ts and CMV 
antibody status m ay be found it is difficult to establish whether CMV has a 
causal relationship w ith  rejection.
A number of authors have hypothesised that active CMV infection occurs 
as a result of further im m unosuppressive treatment for rejection episodes  
(219, 220, 221, 222, 234). Burd et al (1994) (219) found, in 135 paediatric renal 
transplant recipients, that treatment for acute rejection w as a risk factor for 
the developm ent of CMV disease.
In contrast, Pouteil-N oble et al (1993) (218) have elegantly  sh ow n  that 
active CMV infection can be a risk factor for subsequent rejection. Of 242 
renal transplant recipients, 157 patients (65%) develop ed  active CMV 
infection w hereas 85 patients (35%) rem ained CMV free. In a retrospective 
analysis, each  CM V-free recipient w as paired w ith  a CMV infected  
ind iv idual to create 85 pairs. For each pair, the occurrence of rejection  
episodes after the time of diagnosis of CMV infection (in the CMV infected  
individual) w as noted for both individuals. Rejection after CMV diagnosis 
occurred in  45% (38/85) of CMV infected individuals and 10.6% (9 /85) of 
CMV free individuals (p<0.0001).
A ckerm ann 1988 (212) published the results of a policy  to graft CMV 
antibody negative recipients on ly  w ith  k idneys from  CMV negative  
donors; graft loss (0% versus 2.5%; p=0.016) and mortality (0% versus 3.7%; 
p=0.002) w ere reduced compared to historical controls. This is evidence for 
the hyp othesis that CMV initiates or enhances the rejection process in 
renal grafts.
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1.9 Mechanisms of Rejection
1.9.1 HLA Class II M atching M ay Facilitate Presentation of Foreign MHC  
or CMV Peptides
1.9.1.1 H ypothesis
Som e authors have hypothesised  that HLA m atching, in the context of 
liver transplantation, plays a dualistic role.
Markus (1988) (240) suggest that DR matching facilitates the recurrence of 
autoim m une diseases such as prim ary biliary cirrhosis (PBC), prim ary  
sclerosing cholangitis (PSC) and alcoholic cirrhosis.
Other authors propose that HLA m atching eliminates non-M HC restricted 
cellular im m une injury (242) but facilitates MHC restricted presentation of 
graft antigens. MHC restricted presentation of Y chrom osom e specific  
(210), m ism atched HLA class I (224, 243) or CMV antigens (224) m ay occur 
(see section 1.8.2).
1.9.1.2 Evidence
There is ev id en ce to support the hypothesis that m atching facilitates 
M HC-restricted presentation of graft antigens. Fung et al 1986 (244) and 
M arkus et al (1987) (245) have both dem onstrated that lym p h ocytes  
directed  against specific HLA antigens infiltrate liver grafts during  
rejection episodes.
M HC-restricted lym phocytes directed against specific CMV antigens have 
been docum ented (Quinnan et al 1981 (246); class I restriction, Lindsay et al
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1986 (68) and Gehrz et al 1987 (248); class II restriction); infiltration of such  
cells during rejection episodes has not been shown.
In contrast, W aldm an et al (1992) (262) suggested that CMV protein IE 2 
m ay be able to present peptides to T-lym phocytes. T-cell proliferation in  
the p resen ce  o f a llo g en e ic  en d o th e lia l ce lls  w as d em on stra ted . 
Proliferation of CD4+ T-lym phocytes (CMV antibody positive donor) w as 
sign ifican tly  enhanced w h en  target cells w ere CMV infected . M HC- 
restricted presentation of CMV antigens w as im possible because target cells 
w ere allogeneic; the authors speculated that sequence hom ology betw een  
CMV IE-2 protein and the HLA DR p chain, reported by Fujinami et al 
(1988) (263) m ay be important.
1 .9 .2  C M V  a n d  H L A  R e g u l a t i o n
1 .9 .2 .1  H y p o th e s i s
CMV infection regulates expression of graft HLA w hich in turn m odulates 
rejection processes.
1 .9 .2 .2  E v id e n c e
C M V  U p r e g u l a t e s  H L A  C l a s s  I  E x p r e s s io n  in E p i t h e l i a l ,  E n d o t h e l i a l  a n d  
S m o o t h  M u s c l e  Ce l ls .
The effect of CMV upon ep ithelia l and endothelia l cells is of great 
im portance because these cells are the sites of initial rejection-m ediated  
dam age (see sections 1.8.1 and 1.8.2.3.2).
CMV infection has been show n to increase the surface levels of class I 
M HC m o lecu le s . Van D orp 1993 (249) and 1989 (250) u sed  a 
radioim m unoassay to dem onstrate augm entation of HLA class I surface
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le v e ls  for p roxim al tubular ep ith elia l cells and hum an um b ilica l 
endothelia l (HUVE) cells in vitro;  5% and 10% of these cells becam e  
infected respectively and class I expression initially increased 24 hours 
post-infection, peaking 48-72 hours post-infection. CMV infection had no 
effect upon surface expression of HLA class II but did not render cells 
refractory to class II upregulation by interferon (IFN)-y. The upregulation  
of class I expression w as not cytokine m ediated; supernatants from CMV 
infected cell cultures had no effect on class I or II expression therefore 
excluding the effect of virus induced cytokines.
In contrast, H osepud 1991 (251) w as unable to show  HLA upregulation in 
CMV infected HUVE or hum an aortic endothelial cells (infectivity 10%) 
but d id  show  class I upregulation in hum an aortic sm ooth m uscle cells 
(in fectiv ity  100%). Flow cytom etry w as perform ed after application of 
m onoclonal antibodies to HLA class I or II; it is possible that this assay w as  
not as sensitive as the radioim m unoassay used by Van Dorp et al 1989 
(249) and 1993 (250).
C M V  D o w n r e g u l a t e s  H L A  Class  I  Express io n  in F ib r o b la s t s  
It is possible that the effect of CMV infection upon HLA expression is cell- 
type specific; other workers have dem onstrated CM V-mediated HLA class 
I dow nregulation in fibroblasts. Del Val et al 1992 (252) and Beersma et al 
1993 (253), w orking w ith murine and hum an CMV respectively, show  that 
a CMV early gene is responsible for blocking HLA class I transport from  
the endoplasm ic reticulum and thus reducing surface expression. Class II 
expression w as unaltered and was induced by IFN-y.
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H L A  Surface  E x p r e s s io n  in v i v o  D u r i n g  A c t i v e  C M V  I n fec t ion  
Von W illebrand et al 1986 (214) (see section 1.8.3.2) suggested  that CMV 
upregulation  of HLA class II is an im portant factor during renal graft 
rejection. Im m unohistochem istry for class II HLA m olecules show ed that 
the expression of HLA class II upon endothelial and tubular cells occurred 
subsequent to active CMV infection.
Several reports of HLA class II upregulation in rats infected w ith  rat CMV 
support the findings of Von W illebrand et al 1986 (214) (Ustinov et al 1994 
a (254) and b (255), Lemstrom et al 1995 (256). U stinov et al 1994 a (254) and 
b (255) stud ied  the effects of rat CMV in untransplanted anim als thus 
elim inating the possible effects of rejection. HLA class II upregulation w as 
seen  in cells w hich  are targets for im m une m ediated dam age during  
rejection i.e. k idney vascular endothelium , tubular cells and glom eruli, 
liver vascu lar en d o th e liu m  and parenchym a and heart cap illary  
en d o th e liu m .
1.9.3 A lloreactive C ellular Im m une R esponses m ay be A ugm ented  by  
CMV
G rundy and Shearer 1984 (257) describe the effect of primary infection of 
m urine CMV (Sm ith strain) upon alloreactive T -lym phocytes in non- 
transplanted m ice. Initially, the response w as d im in ished  fo llow in g  
infection (days 2-4) but rose and was greatly enhanced from days 7-13.
Bulk cultures of lym phocytes from endom yocardial b iopsy specim ens, 
taken from heart transplant recipients, w ere tested for alloreactivity by  
O uw ehand et al (1994) (258). A significantly greater proportion of biopsy- 
derived  cultures taken from patients w ith  active CMV infection , had  
alloreactive activity (88% (74/84) versus 74% (173/234); p=0.01). The
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authors su g g est that HLA m olecu le  a n d /o r  adh esion  m olecu le  (see 
sections 1.9.2 and 1.9.4) upregulation by CMV caused this phenom enum . 
Other possib ilities exist, e.g. IFN-y production by CD4+ cells directed  
against MHC-restricted CMV targets could cause clonal expansion of CD8+ 
cells to MHC-restricted or -unrestricted allogeneic targets.
1 .9 .4  C M V  U p r e g u l a t e s  I n f l a m m a to r y  M a r k e r s
CMV disease  is associated w ith  enhanced levels of lym phokines in serum  
and tissue. Elevated serum levels of IL-2 (264), IL-6 (370, 434), IL-8 (371, 
433) and T N F-a (399) have been docum ented during ep isodes of active 
CMV infection after transplantation.
Cell surface expression  of adh esion  m olecu les stab ilizes interactions 
b etw een  T -lym p h ocytes and target cells. CMV d i s e a s e  after liver 
transplantation is associated w ith enhanced surface expression of ICAM-1 
on hepatocytes (369). Sim ilarly, elevated surface expression of VCAM-1 
and ICAM-1 on  hepatic vascular and sinusoidal endothelium  has been  
associated w ith  active CMV infection  after liver transplantation (435). 
Craigen and Grundy 1996 (436) show ed that CMV upregulated ICAM-1 and 
LFA-3 levels in  vitro using fibroblasts; this is an important result because  
it could be argued that observations in v ivo  are due to early rejection  
events.
The exp ression  of lym phokines and adhesion  m olecules is enhanced  
during rejection  and therefore th ese  m arkers cannot be u sed  to 
discrim inate betw een CMV disease and rejection.
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U pregulation of adhesion m olecule and lym phokine expression by CMV 
m ay in itiate or increase the severity  of cellu lar im m une-m ed iated  
dam age after transplantation.
1 .9 .4 .1  T u m o u r  N e c r o s i s  F a c t o r - a  ( T N F - a ) ,  C M V  a n d  C h r o n i c
R e j e c t i o n  o f  L iv e r  G r a f t s
Tum our necrosis factor-a (TNF) is a cytokine that w as originally described  
by C arsw ell et al (1975) (393). Here, production  of m urine TNF w as  
stim ulated  by injection of bacterial endotoxin  and led to haem orragic  
necrosis of transplanted subcutaneous tumours; production of TNF w as  
predom inantly by m acrophages (394). In addition, TNF-a has been linked  
w ith  acute (395, 396) and chronic (397) rejection of liver grafts.
M oreover, there is ev idence to su ggest that active CMV infection  is 
induced  by TNF (398, 399). Docke et al (1994) (398) have sh ow n  that 
patients w ith  septic disease are more likely to have detectable levels of 
TNF in plasm a by im m unoassay (61% (27/44) versus 0% (0/44)) and active 
CMV infection by PCR of peripheral b lood m ononuclear cells (PBMC) 
(92% (23/25) versus 7% (3/44); p<0.001).
C onversely, active CMV infection m ay upregulate TNF production. Geist 
et al (1994) (402) found that the CMV proteins IE 1 and JE 2 upregulated the 
TNF prom oter (using a CAT reporter construct transfected into the 
m onocytic cell line THP-1). This effect w as also apparent after active CMV 
infection of differentiated THP-1 cells.
The quantity of TNF produced by an individual is partly governed by the 
genetics of tw o TNF promoter alleles. The TNF-2 prom oter allele differs 
from TNF-1 by a single base pair mutation in the promoter region of this
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gene (guanine (G) and alanine (A) residues are positioned at 308 bases 
upstream  of the transcription start site respectively). In vitro  studies using  
a CAT reporter construct have show n that the TNF-2 prom oter elicits 
higher basal and inducible expression com pared to the TNF-1 prom oter 
(405).
McGuire et al (1994) (403) analysed the frequencies of TNF-1 and TNF-2 
alleles in 918 patients w ith  malaria (475 cerebral malaria, 443 malarial 
anaemia) and 325 controls. The proportion of individuals w ith  the TNF-2 
allele w as significantly higher for the cerebral malaria group (compared to 
m alarial anaem ic patients and controls) and w as significantly elevated  
w ith in  the former group in those w ith  severe or fatal cerebral malaria. 
TNF-2 w as present in this Gambian population at a frequency of 0.16 and 
the authors suggest heterozygote advantage i.e. heterozygotes produce an 
optim al am ount of TNF w hich may be sufficient to reduce the incidence  
of infection but insufficient to elicit cerebral malaria.
1 .9 .5  C M V  I n f e c t i o n  M o d u l a t e s  A u t o a n t i b o d y  P r o d u c t i o n
1 .9 .5 .1  C M V  a n d  A u t o a n t i b o d y  P r o d u c t io n
Kantor et al 1970 (312) perform ed cardiopulm onary byp ass upon  39 
patients. Ten developed  active CMV infection; serum  w as collected and 
screen ed  im m u n o h isto ch em ica lly  aga in st fixed  p er ip h era l b lo o d  
lym phocytes. CMV infection w as associated w ith the production of auto­
antibodies w ith  activity against nuclear and erythrocyte antigens. One 
patient developed glom erulitis and it is suggested that CMV induces auto­
antibodies w ith  specificities towards renal antigens.
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This contention w as supported by A ndersen and A ndersen 1974 (313). 
Three groups w ere tested for auto-antibodies; healthy CMV antibody  
negative ind iv idu als (n=40), healthy CMV antibody positive ind ividuals  
and those w ith  active CMV infection (n=9). A greater prevalence of 
sm ooth m uscle antigen- (16% (10/63) versus 0% (0/40); p=0.005), nuclear 
antigen- (14% (9 /63) versus 2.5% (1/40; p=0.046) and glom erular antigen- 
(3% (2 /63) versus 0% (0/40)) specific auto-antibodies w ere found in CMV 
antibody positive individuals; 58% (5/9) and 44% (4 /9 ) of those w ith active 
CMV infection  had sm ooth  m uscle antigen- and glom erular antigen- 
sp e c if ic  a u to -a n tib o d ie s  r e sp ec tiv e ly . The im p ortan ce  of th ese  
autoantibodies after renal transplantation has been d iscussed  (see section
1.8.3.3.3).
It has been show n in vitro  that CMV infection of fibroblasts increases the 
cell surface expression of calreticulin (314) w hich is an autoantigen.
In addition, upregulation of class I surface expression by CMV infection  
m ay m ediate or enhance anti-HLA antibody production (see section 1.9.2).
1 .9 .5 .2  C M V  a n d  A u t o a n t i b o d y  P r o d u c t i o n  A f t e r  T r a n s p l a n t a t i o n
M iddleton et al 1981 (310) has show n that anti-smooth m uscle antigen IgM 
is found in significantly more patients after renal transplantation (76% 
(5 3 /7 0 )) com pared to pre-transplant patients on h aem od ia lysis  (14% 
(10 /70)) and norm al controls (5% (2/40)). A fourfold or greater increase in 
titre w as seen  in patients experiencing rejection a n d /o r  CMV infection  
and the authors propose a causal link.
E vidence m ay also be found in a murine m odel set up by Grundy and 
Shearer 1984 (257). Here, mCMV enhanced alloreactivity w as described
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(see sections 1.6.6.3, 1.6.6.4 and 1.9.3) and this coincided w ith an increase in 
auto-antibody production.
1.9.5.3 Cross-Reactive A ntibodies
Production of antibodies cross-reactive betw een HLA class I and the CMV 
H301 gene product has been demonstrated (60). The authors postulate that 
CMV infection could increase production of antibodies directed to graft 
HLA m otifs thus m odulating the rejection process.
1.9.6 R ejection m ay be M odulated by  A utoantibodies A ssociated
w ith  Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis (PBC) 
and A utoim m une H epatitis (AIH).
Som e authors su ggest that recurrence of autoim m unity fo llow ing  liver 
transplant can initiate or promote the rejection process (see section 1.8.2.5). 
The autoantigens associated w ith  PSC, PBC and AIH are sum m arised  
below ; this is integral to the Western blot results show n in Chapter 4.
1.9.6.1 Primary Sclerosing Cholangitis (PSC)
PSC is associated w ith  a number of autoantibodies that act as markers (316, 
317, 318). Snook et al (1989) (316) used im m unohistochem istry to find that 
84% of PSC patients harboured antibodies w ith  specificity to neutrophil 
n u cle i.
K lein et al (1993) (317) tested serum for anti-neutrophil nuclear antibody  
(A N C A ) after W estern blotting of sonicated neutrophils. Sera from PSC 
patients reacted w ith  a number of antigens w ith  m olecular w eights of 95, 
60, 55, 40, and 30 kD. The idiotype is almost exclusively IgG (319). Eighty 
per cent of PSC patients were scored positive using this m ethod compared  
to 9% ulcerative colitis, 10% Crohns disease, 11% PBC, 13% AIH and 0%
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norm al controls. N one of the 24 PSC patients contained antibodies to all 5 
antigens; 50% patients only had antibodies to the 60kD antigen.
A sim ilar W estern blotting protocol w as used by Lo et al (1993) (318) w ho  
identified 6 'PSC antigens' of 205, 116, 97, 68, 45 and 29 kD. H ow ever, 50% 
patients w ith out PSC and 50% normal controls harboured antibodies to 
these neutrophil antigens. The sensitivity of this test m ay be responsible  
for this d iscrepancy. This result is important; it su ggests that healthy  
ind ividuals harbour low  titres of the autoantibodies involved in PSC.
1 .9 .6 .2  P r i m a r y  B i l ia r y  C i r r h o s i s  (P B C )
PBC is characterised by circulating autoantibodies w ith  specificity  to 
m itochondrial proteins. Van de Water et al (1989) (320) found that serum  
from  93 patients w ith  PBC identified  three proteins w h en  app lied  to 
W estern blots of m itochondrial protein. These proteins are 74, 52 and 39 
kD in size. The 74 and 52 kD proteins are pyruvate d ehyd rogenase  
com plex-E2 com ponent and branched-chain a-keto acid dehydrogenase  
com plex-E 2 com p on en t resp ectively; the 39kD protein  m ay be a 
breakdow n product of the 74kD protein. Sera from 85% patients w ith  PBC 
reacted w ith the 74kD protein, 53% w ith the 52kD protein and 47% reacted 
w ith  both. Sera from normal controls (n=86) and patients w ith PSC (n=38) 
did not react.
1 .9 .6 .3  A u t o i m m u n e  H e p a t i t i s  (A IH )
Stechem esser et al (1993) (321) purified liver tissue for W estern blotting; 
63% (111/175) sera from patients w ith AIH identified the 'liver-pancreas' 
antigen w hich manifests as a doublet of 52 /4 8  kD. 'Liver-pancreas' antigen  
w as also recognized by 3% PSC and 9% PBC patients but not by normal 
controls.
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1.10 Human Herpesvirus 6 (HHV-6) and
Transplantation
1.10.1 D iscovery of a N ew  Herpesvirus
H um an herpesvirus 6 (HHV-6) w as discovered by Salahuddin et al (1986) 
in a group of patients w ith  lym phoproliferative disorders (323); B cells 
w ere readily infected in vitro g iving rise to cytom egaly and inclusions and 
the virus w as initially called hum an B-lymp ho tropic virus (HBLV).
This group show ed , in an accom panying paper (324), that HHV-6 has a 
d ou ble-stranded  D N A  genom e larger than 110 Kb in length; this is 
consistent w ith  herpesvirus classification. HHV-6 has a unique genom e  
and hybridisation work dem onstrated a 9 Kb region w ithout hom ology to 
the genom es of other herpesviruses (324). A m ino acid sequences w ere  
derived after D N A  sequencing by Lawrence et al 1990 (327); hom ology w ith  
CMV led to p-herpesvirus classification. The ultrastructure of HHV-6 also 
befits a herpesvirus (325, 326) (see section 1.2.1).
G enom ic polym orphism s separate HHV-6 variants A and B (333, 334, 335, 
356) w h ich  also have different grow th patterns, in v i tro  tropism  and 
antigens (im m unological distinction) (336).
1.10.2 B iology and V irology of HHV-6
C om pared to CMV, relatively little is know n about the b io logy  and 
virology of HHV-6.
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The prevalence of HHV-6 varies betw een 60-95% (328, 329) and infection  
has been  linked w ith  various clinical m anifestations. Primary infection  
w ith HHV-6 variant B causes exanthem subitum  in infants (326, 340, 341, 
342). T ransm ission m ay occur through saliva; salivary glands harbour 
virus and this may be a site of latency (337, 338).
H H V -6 m ay be in v o lv ed  in the progression  to acquired im m une  
d eficiency syndrom e (AIDS) in hum an im m unodeficiency virus (HIV)- 
p ositive  ind ividuals (342). CD4+ T-lym phocytes are the m ain carriers of 
both H H V-6 (339, 340, 334) and HIV and these cells die m ore rapidly in  
v i t ro  w hen  co-infected w ith both viruses (341). In addition, N icholas et al 
1994 (343) dem onstrated that several HHV-6 genes encode transactivators 
and som e upregulate the long terminal repeat (LTR) of HIV.
1.10.3 Interaction Betw een HHV-6 and CMV
C oncom itant rises of antibody titres to HHV-6 and CMV have been  
reported (344, 345, 346, 347, 348 ). Irving et al 1988 (347) reported  
sim ultaneous serological conversion to HHV-6 and CMV in renal and 
cardiac transplant recipients. This w as detected as an appearance of IgM or 
an eight-fold  increase in IgG titre. It w as not show n w hether CMV and 
HHV-6 co-infect or whether they generate cross-reactive antibodies.
This group subsequently (344) found that the incidence of seroconversion  
to H H V -6 am ong im m unocom petent patients w as significantly greater in 
patients w ith  primary CMV (15/25  (60%); p< 0.01) or EBV (17 /25  (68%); 
p<0.01) infections com pared to a control group (3 /3 7  (8%)) . Sera w as 
adsorbed w ith  CMV and EBV antigens before testing for HHV-6 specific 
antibodies; no difference in titre w as seen after absorption and it w as 
concluded that antibodies to HHV-6 do not cross-react w ith CMV or EBV.
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H ow ever, other reports have show n that antibodies generated against 
HHV-6 can cross-react w ith CMV (346, 348, 352). Sutherland et al 1991 (346) 
reported  on 30 liver transplant patients that w ere H H V -6 antibody  
n egative  pre-transplant. E ighteen patients generated antibodies against 
H H V -6 post-transplant; five such responses w ere w h o lly  cross-reactive  
w ith  CMV.
P rim a ry  in fe c t io n  w ith , or v a c c in a tio n  a g a in s t , CM V in  
im m unocom petent individuals also leads to the generation of antibodies 
w hich  cross-react w ith  HHV-6 (348); the authors W estern blotted CMV 
proteins and dem onstrated that antibodies generated against H H V-6  
recognised a 116-kD protein (gene product (gp) 116) and cross-reacted w ith  
CMV glycoprotein gB.
1 .1 0 .4  H H V - 6  I n f e c t io n  A f t e r  T r a n s p l a n t a t i o n
A ctive H H V-6 infection has been docum ented after bone m arrow (351, 
354, 358, 359, 361, 362, 363), renal (350, 355, 357, 364) and liver (349, 346) 
transplantation.
1 .1 0 .4 .1  H H V -6  a n d  L iv e r  T r a n s p l a n t a t i o n
There have been very few  reports of active HHV-6 infection after liver 
transplantation. The first case w as described by Ward et al 1989 (349); 
diagn osis w as m ade after electron m icroscopy, D N A  hybridisation and 
im m unohistochem istry studies.
The incidence of primary HHV-6 infection in 30 liver transplants w as 60% 
(1 8 /3 0 )  in a series d ocu m en ted  by Sutherland et al 1991 (346); 
seroconversion  occurred after 4-8 w eeks post-transplant. A ctive HHV-6
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infection w as m onitored by testing for HHV-6 specific antibodies. Clinical 
ob servation  of p atien ts experiencin g active H H V -6, but not CMV, 
in fection  sh o w ed  that HHV-6 m ay be in vo lved  w ith  hepatitis, lung  
dysfunction, pyrexia and neurological complications.
1.10.4.2 HHV-6 and Bone Marrow Transplantation
A num ber of reports have docum ented active HHV-6 infection after bone  
m arrow transplantation; the incidence of w hich varies betw een  38-60% 
(354, 358, 361). In one series (354), all patients w ith active infection (40% 
(12/25)) becam e viraemic between 14-22 days post-transplant.
The largest study to date (361) docum ents a 60% (36/60) incidence of active 
in fection  using PCR surveillance of huffy coat, urine and oral lavage  
w ashings. A greater proportion of patients w ith severe acute graft versus 
host disease (GVHD) tested PCR positive for HHV-6 (75% (6 /8 ) grade II-IV 
versus 25% (5 /25) grade 0-1; p=0.01); this finding has been supported (359) 
and parallels the link found betw een CMV and acute GVHD (see section
1.6.6.3). Restriction fragment length polym orphism  (RFLP) analysis of PCR 
products show ed that HHV-6 type B infection occurred in 89% of cases; the 
preponderance of type B isolates in this setting has been confirm ed (358, 
363).
Cone et al 1993 (359) propose a link betw een active HHV-6 infection and 
the developm ent of acute GVHD (see 361) and pneum onitis. Lung tissue  
from 15 bone m arrow transplant patients (all HHV-6 antibody positive) 
and 15 controls (14 HHV-6 antibody positive and one negative) w as  
subjected to a single round quantitative PCR. H igh levels of HHV-6 D N A  
(>20000 g e n o m e s / 10^ cells) correlated w ith a higher incidence of severe 
GVHD (p=0.023) and were found in sign ificantly  more patients w ith
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id iopath ic rather than attributable pneum onitis (63% (5 /8 ) versus 14% 
(1 /7 ); p=0.037); h igh levels also correlated w ith a reduced risk of death  
from pneum onitis (p=0.015) and the authors suggest that HHV-6 m ay be 
less pathogenic than CMV in this setting.
The in v o lv em en t of H H V -6 w ith  p n eu m on itis  w as su p p orted  by  
im m unohistochem istry of lung tissue (351, 360). Pitalia et al 1993 (360). 
sh o w ed  that H H V-6 antigens localize in pneum ocytes and infiltrating  
m acrophages. Pneum ocyte positiv ity  suggests that HHV-6 m ay initiate  
d am age rather than reactivate after the in filtration  of p erm issiv e  
lym phocytes.
HHV-6 has also been linked w ith the suppression of bone marrow growth  
in v itro  (358, 365) and in v ivo  (362). Carrigan and Knox 1994 (362) studied  
15 transplant patients that developed bone marrow suppression; HHV-6 
isolation from bone marrow occurred more frequently from patients w ith  
idiopathic rather than attributable bone marrow suppression (p<0.01).
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1 .1 1  O U T L I N E  O F  T H E S I S  A N D  H Y P O T H E S E S
1 .1 1 .1  O V E R A L L  H Y P O T H E S I S  F O R  T H E S I S
• H e r p e s v i r u s e s ,  C M V  a n d  H H V - 6  i n  p a r t i c u l a r ,  m a y  i n d u c e  o r  
e n h a n c e  c h r o n i c  r e j e c t i o n  o f  l i v e r  g r a f t s .
1 .1 1 .2  H Y P O T H E S E S  F O R  C H A P T E R S  2 A N D  3
•  D e t e c t i o n  o f  c y t o m e g a l o v i r u s  ( C M V )  D N A  i n  s e r u m  o r  u r i n e  i s  
m o r e  s e n s i t i v e  a n d  s p e c i f i c  t h a n  c o n v e n t i o n a l  t e s t s  ( C h a p t e r  2).
• D e t e c t i o n  o f  c y t o m e g a l o v i r u s  ( C M V )  D N A  i s  a s s o c i a t e d  w i t h  
d e v e l o p m e n t  o f  s y m p t o m a t i c  i n f e c t i o n  ( C h a p t e r  3).
The lack of an association of cytom egalovirus infection  w ith  chronic 
rejection, reported by som e, m ay be due to poor test sen sitiv ity . In 
addition, sym ptom s associated with episodes of acute rejection and active 
CMV infection are often similar. Therefore, testing the latter 2 hypotheses 
w as an important prerequisite for testing the overall hypothesis.
1 .1 1 .3  H Y P O T H E S E S  F O R  C H A P T E R  4
• C M V  i n f e c t i o n  c o n s t i t u t e s  a  r i s k  f o r  c h r o n i c  r e j e c t i o n  o f  l i v e r  g r a f t s .
M ism atched CMV serology (donor p o s itiv e / recipient negative) and active 
CMV infection (tested using the techniques validated in Chapters 2 and 3), 
persistent active CMV infection and viral load were assessed as risk factors 
for chronic rejection of liver grafts.
• T h e  t u m o u r  n e c r o s i s  f a c to r - 2  (T N F -2 )  p r o m o t e r  a l l e l e  is  a  r i s k  f a c t o r  
f o r  c h r o n i c  r e j e c t i o n .
• T h i s  r i s k  f a c t o r  s y n e r g i s e s  w i t h  a c t i v e  C M V  i n f e c t i o n .
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1.11.4 HYPOTHESES FOR CHAPTER 5
•  P r o d u c t i o n  o f  a n t i b o d i e s  t o  h e p a t i c  a r t e r y  a n d  b i l e  d u c t  t i s s u e
i n i t i a t e s  o r  e n h a n c e s  c h r o n i c  r e j e c t i o n .
•  A c t i v e  c y t o m e g a l o v i r u s  ( C M V )  i n f e c t i o n  o f  h e p a t i c  a r t e r y  o r  b i l e
d u c t  u p r e g u l a t e s  t h e  e x p r e s s i o n  o f  t a r g e t  a n t i g e n s .
• A c t i v e  C M V  i n f e c t i o n  o f  l i v e r  t r a n s p l a n t  r e c i p i e n t s  u p r e g u l a t e s  t h e  
p r o d u c t i o n  o f  a n t i b o d i e s  i n v o l v e d  i n  c h r o n i c  r e j e c t i o n .
1 .1 1 .5  H Y P O T H E S E S  F O R  C H A P T E R  6
• C y t o m e g a l o v i r u s  ( C M V )  a c t i v e l y  i n f e c t s  v a s c u l a r  e n d o t h e l i a l  a n d  
b i l e  d u c t  e p i t h e l i a l  c e l l s  a n d  d i r e c t l y  i n i t i a t e s  c h r o n i c  r e j e c t i o n  a t  t h e s e  
s i t e s .
• C M V  i n f e c t s  h e p a t o c y t e s  a n d  i n d i r e c t l y  i n i t i a t e s  o r  e n h a n c e s  
c h r o n i c  r e j e c t i o n .
T h e s e  2  h y p o t h e s e s  a r e  n o t  m u t u a l l y  e x c lu s iv e .
1 .1 1 .6  H Y P O T H E S I S  F O R  C H A P T E R  7
• H u m a n  h e r p e s  v i r u s  6 ( H H V - 6 )  i s  a n  i m p o r t a n t  p a t h o g e n  a f t e r  
l i v e r  t r a n s p l a n t a t i o n  a n d  a c t i v e  i n f e c t i o n  i n i t i a t e s  o r  e n h a n c e s  c h r o n i c  
r e j e c t i o n .
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CHAPTER 2
DEVELOPMENT OF A 
SENSITIVE AND SPECIFIC TEST 
FOR CYTOMEGALOVIRUS:
DOT-BLOT HYBRIDISATION AND THE 
POLYMERASE CHAIN REACTION
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2.1 Introduction
C ytom egalovirus (CMV) is a major cause of m ortality and m orbidity in 
organ transplant recipients (87, 92, 148; see sections 1.5 and 1.6). A  number 
of antiviral drugs are available. Prophylactic adm inistration of the drug 
gan cic lov ir  (a n u cleo sid e  an alogu e) e lim in ates CMV d isea se  after 
transplantation (see sections 1.5.4 and 1.6.5) but this regim e has som e  
disadvantages; ganciclovir has a number of adverse side effects including  
m yelotoxicity and treatment is costly. Furthermore, in a placebo controlled  
trial Boeckh M et al (1996) (437) show ed that ganciclovir prophylaxis was a 
risk factor for late onset CMV disease am ongst bone m arrow transplant 
recipients.
A com prom ise p o sitio n  m ay be clin ically  advantageous; early, pre­
em ptive treatment of patients w ith  active CMV infection w ith  ganciclovir 
(before the d evelop m en t of clin ical sym ptom s) has b een  sh o w n  to 
im prove patient survival and reduce CMV disease (107, 121). A reliable, 
specific, sen sitive  and rapid m ethod for the d iagn osis of active CMV 
infection is needed to allow early, targetted ganciclovir treatment.
This chapter reports developm ent of a dot blot hybridisation test for CMV 
D N A  in urine and polym erase chain reaction (PCR) tests for CMV D N A  
in urine and serum. Published m ethods were com pared and adapted to 
give optim al conditions. This chapter also reports the developm ent of 
quantitative and sem i-quantitative PCR tests for CMV D N A  in serum and 
urine. D evelopm ent of a sensitive and specific test for CMV w as a crucial 
prerequisite for testing the overall hypothesis of this thesis (see section  
1.11).
H ypothesis A ddressed in Chapter 2
• D etection of cytom egalovirus (CMV) D N A  in serum or urine, by  
hybridisation or PCR, w ould  be more sen sitive and specific than 
conventional tests.
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2.2 Materials and Methods
The recipes for som e com m ercially available buffers w ere not available; 
such buffers are indicated
2 .2 .1  D o t - b l o t  H y b r i d i s a t i o n
2 .2 .1 .1  P l a s m i d  G i f t s
A num ber of plasm ids containing hum an CMV D N A  w ere used  for dot 
blot hybridisation. The follow ing w ere used because they w ere available 
from  departm ents w ith in  Cambridge; initially, the sp ecificity  of these  
probes w as exam ined to determ ine their suitability for use in a dot-blot 
hybridisation test.
pSP64-gB com prised the 3.1 kb Xma III restriction fragment of CMV D N A  
(AD169 strain), encoding the glycoprotein B gene, cloned into plasm id  
pSP64 (Boehringer-M annheim ).
pGEM -IEl com prised the 1.8 kb H ind III- Eco R1 restriction fragm ent, 
en cod in g  im m ediate early genes 1 and 2, cloned into p lasm id  pGEM  
(Prom ega). Both pGEM -IEl and pSP64-gB w ere k in d ly  su p p lied  by 
Professor J G P Sissons (41, 48).
pAT153-H indIII contained the 22.81 kb H in d lll restriction fragm ent of 
CMV D N A  (AD169 strain) cloned into plasm id pAT153.
pRK19-UL75 contained the 2.55 kb Hind Ill/S m a I restriction fragment of 
CMV (AD169 strain) D N A , encoding the glycoprotein H gene, cloned into 
plasm id pRK19.
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pING-UL115 contained the 2.1 kb Bam HI restriction fragm ent of CMV  
D N A  (AD169 strain), en cod in g  the glycoprotein  L gene, cloned  into  
plasm id pING14.2. The latter three p lasm ids w ere kindly su pp lied  by  
Professor A M inson (58).
2.2.1.2 Construction of Plasm id pT7/T3-IE.PCR and pT7/T3-
IE.PCR.Del
I constructed the plasm ids designated as p.IE.PCR and p.IE.PCR.Del from  
PCR products. p.IE.PCR contained a 293bp fragm ent of IE gene D N A  
(AD169 strain). Plasm id pIE.PCR.Del w as used to perform  quantitative  
PCR (see section 2.2.2.4) and w as identical to the former except for a 50 bp 
deletion w ith in  the IE gene fragment. Recombinant PCR techniques (116) 
w ere used  to create the 50bp deleted insert; primer sequences rem ained  
intact. Both inserts w ere cloned into plasm id pT 7/T 3 alpha-18 (Life 
T echnologies).
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The I n s e r t  Sequence o f  pT7/T3-IE . P C R
The insert sequence was amplified from the lE l gene by PCR using Ipg  of 
pGEM lE l as target DNA. Primer sequences (41) for am plification of a 293 
bp region of CMV major im m ediate early gene 1, exon 4 are show n in 
figure 2.1.
F i g u r e  2 .1 : T a r g e t  D N A ,  P r i m e r s  a n d  O l i g o n u c l e o t i d e  S e q u e n c e  U s e d  to  
A m p l i f y  a  293  b p  R e g i o n  o f  t h e  C M V  I m m e d i a t e  E a r l y  G e n e  1
Sequence of CMV lE l gene, exon 4, target region for PCR (293 bp); primers and 
oligonucleotide probe, used to confirm specificity, are shown.
s e n s e
01
51
101
151
201
251
AAGTGAGTTC TGTCGGGTGC TGTGCTGCTA TGTCTTAGAG GAGACTAGTG
TGATGCTGGC CAAGCGGCCT CTGATAACCA AGCCTGAGTT TATCAGTGTA
_______ o l i g o n u c l e o t i d e  p r o b e _________________
ATGAAGCbcC GCATTGAGGA GATGTGCATG AAGGTctrTG CCCAGTACAT
TCTGGGGGCC GATCCTCTGA GAGTCTGCTO TCCTAGTGTG GATGACCTAC 
GGGCCATCGC CGAGGAGTCA GATGAGGAAG AGGCTATTGT AGGCTAGACT 
TTGGGGAGGG GTGGTGTGAG d TGGTGTGAT TGTGTGGTGT GAG
a n t i s e n s e
A m p lification  w as carried out w ith  reaction buffer™  (Perkin Elmer- 
Cetus), 2 mM M gC ll (Perkin Elmer-Cetus), 200 |iM each deoxynucleotide  
triphosphate (Pharmacia) and 1 pM each primer (Pharmacia). A thermal 
cycler (O m nigene, Hybaid) w as used to incubate this mixture at 94°C for 
five m inutes then 55°C for five m inutes. Tubes w ere then centrifuged  
briefly, to spin d ow n condensation, before the addition of 2.5 U  Am plitaq  
(Perkin Elmer-Cetus) and 1 pi of Perfect Match Enhancer (Stratagene) and 
overlaid  w ith  one drop of mineral oil (Sigma). Reaction m ixtures were
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then subjected to 30 therm al cycles (72°C for 90 seconds, 94°C for 30 
seconds, 55°C for 30 seconds) and finally 72°C for 10 minutes.
The Insert Sequence of pT7/T3-IE. PCR. DEL
The insert sequence of p.IE. PCR.Del w as constructed by a recombinant 
PCR procedure w hich is show n over the next five pages in figure 2.2.
72
w
T3
CfC
01
s0)
c/3
w
n
r4
W
D
O
Uh
cO)
S
’jh<U
:
uCh
Ol
>
C
3a
a
<u
c/3
3
kiOM-l
0/CJ
3o>
3
crO)
(/)
o>
£P
H
O)CL
O)JC
3O
'2O)
-3O)
O)
Q
d.
o
I D
(t
3_o
u
3
)-i
cr
3O
u
<vV
3<u
3cr<u
CD
n3
3
iCO)
kl34
O)u
S
O)
c/3
g
au
Oh
ea
Vh
c/3JhO)
?-i
CL
bO3
.3
c/3
3O)
fb
d:
TM
3O
X0»
s
3O
'bbO)
<vbO
j-ijb
U
P h
0»
O h
O)u3cu3cr0)
CD
-O0»
'oj
QJ
3o
'bbcu
tH
Cl-O
o
LO
<v
■£
cb
cr
%HO)
tH
O h
u
P h
3(b3
c/30)
s
CD
g
CD
i
I
II
Ü
i
CD
I
s
gI
g
i i
(= b
CD oj
I I
i s
5
CD
5
6  
Ü 
CD 
CD 
ÜI
Ü
CD
i
I
LO
I
OJ
HCD-^  03
8  
xy
I
o
CD
Ü
Ü
CD
Ü
CD
S
g
§
I
g
(3
5
R
0
R
R
(3
S
R
R
§
§
CD
1
lO
Ü
S
ë
«
i
CD
CD
i
I
R
CD
S
8
ÜI
CD
CD
CD
o
C\J
CO
Ü
S
II
1
-fe-
i
R
CD
g
CD
Üi
CD
;
lO
C\J
ra
in
TD(U
cb
1
(U
c/3
cr
O)
Vh
OJ
crT33O)
LO
35
U
Ph
QJ
O h
T30/
cr3
QJ
VH
(b
cr
?-i
Cl
3O•3
QJ
' qj
t3
3
cr
QJ
lb
3
CD
QJ
H
QJ
o
Z
3O
•3u
H
cr
3O
u
tj
373
2
P h
3O
QJ
' q j
D
<Homh
QJ
e
QJ
3u
CD
73
CO LO
OJJD
C
ê
OJ
Vhns
u
OVhOl,
y
T3
' §
g
?-l
_QJ
3
ooX5
' d
S
(3
OJÏ-I
(D
X »
so
'5b
O)V-l
O)
X
O h
03
CL
O
QJCO
OJ
Vh
O)
O
_ g
u
03dlk4
0
1
O)
;-i
O
t3
QJ
QJCJ
OVh
O h
CO
&
03
X
o
XJ
It
QJ
O
O
03
QJ
S
O
X
CO
CO
03
CO
Vh
I
g
3
oo
u
1t
X
CO
■ g
03Ut
QJ
X
H
IH
O h
QJ
CO
0
QJ
CO
0
03
QJ
Q
QJ
CO
o
QJ
CO
w
Co
V
n
QJ
O )  (D
Q .
ro
A
c
«
(/)
U J
lO  CO
QJ
Q
QJ
S
QJ
CO
'•O
0
03
W
ki
Ch
LÜ
A
O )
C
CO
( /)
0 )
a
lO CO
74
O)X
QJ
QJ
OCÛ
c
QJbOfC
a
uft
JCX
w
"qjbC
ft
5
ft
•sCOd
X5
QJ
ig
"0dCL
XSo
ft
X
QJ
QJ
"qjbO
QJ
COOVh
ft
bO
ft
C3^m
ft
c:o
o
dVh
QJV-l
QJ
UdXoVh
CL
C<
y
QJCO
QJ
eS
QJX
bOg
’bb
CO
QJ
d
0
6
CN
u
in
X
QJ
It
QJ
ft
Xc
ft
Î
g
in
U
k
X
QJ
J-H_g
ftc
QJX
c;
I
QJ
J-H
QJ
Ud
Xo
Cl
"qj
>
u
QJ
CL
CO
QJ
J-H
CLX
o
XC
ft
T—H
"qjX
0
X
CO
tJd
COcOu
<
z
Q
(3I--O
<o
g
o<
o<0
1CD
5
CD<
i
i
ÜCD
CD
CD
Üg0
1
CD
CD
ÜI
CDCD
I
CD
g
CD
CD
Ü
Ü
Ü
CDig
Ü
CD
Ü
Ü
gCD
CD
CD
I
t=
ICD
X
H
a
LO
2
U
k
CO
QJ
D<
uCL
CO
ft
oO
X
ft
g
QJ
COu
QJ
I
X
Xo
ft
QJ
CO
ftv-i
QJ
a
'o
CL
crft
H
bO
.a
COd
X
QJ
0
1
QJU
QJ
CO
XC
ft
QJ
CO
QJ
êS
LO
O H
"qjX
O
X
CO
tJd
X
Sou
<
z
o
QJ
:a
CO
QJ
>
'bb
goCD <  t— Ü CD Ü 
CD <II
Ü
CD
CL
X
OO
co
O)Vh
Jh
Jhet
U
CO
X
COJ
LO
X
Jh
CL
Co
2
ë
O)bO
B
bO
C
co
d
y
X
X
O)
CL
att
o
O
(/>ft
<z
Q
eS
<u
X
XfO
O)
Jhft
CO
Jhd)
X
a
dj
s
X
co
Jhd»a a
Jh
CL
d)
COd)
X
cod)u
Cdi
d
d>
co
E^
U
X
ft
O<u
■g
X
X
c
ft
t-H
ou
S
cod)
en
O
u
co
i
i
h
d>
co
COJ
(/)
dJ
co
cOJ
co
X
C
X
cft
C o '
d>
c
ft
u
d
Xo
Jh
CL
d>
CL
d»
X
co
bO
C
It
XdJ
cod>
Jh
X
CL
2
U
"qj
d)
JhdJ
CO
oT
co
ëft
co
u
d
Xo
Jh
CL
CLiu
p-
Xdl
"dj
X
Cdl
3crdl
co
X
den
I
dj
X
d
i
Xco
2
Sd
e ucoo
Jhft
bOft
CN|
ft
W)
do
2
00
o
dl
a
o
J hdl
X
Xft
Z
Û
ft
X
aft
76
e uc:
(t
hJ
u
OJ
X
O)v-t
Xft
-gJhCL
■g
ft
COe u
c
et
eu
co
eu
X
C
eu
co
eu
X.
g
"ft
Z
Q
<u
Cl
Jh
eu>
(U
o
CN
co
ëft
co
do
•Xeu
ft
eu
Jh
eo u
ft
z
X
eu
co
d
X  
eu 
u  
3  
X  
O
Jh
l 5
s - È
CO 4H
^  -tH
<  ^ 
§ 1
& °  
^  " j h
ft
X
eu
"Ôj
eu
>
O
Jh
Jh
f t
X
ë
Tj
X
C
ft
0 ^
o
u
w
X
c
ft
Xcs
X
X
B
u
’£
Jh
eu
d
Xo
Jh
Cl
eu
Cl
X
'o
s
eu
Jh
ft
eu
C
iü
X
eu
eu
co
ft
<z
û
eu
Q
B
H
D h
X
eu
HH «
eu C  
bO bO
Jh
jt
X
e u
dJ
"dj
X
X
H
coe u
X
co
et
a
co
ft
'Sh
<
Z
û
o
CN
C
g
co
Jh
eu>
eu
co
ft
C
dJ
dcr
euen
Xen
et
bO.a
co
d
X
eu
U
d
eu
dcr
eu
co
co
ft
<
Z
û
X
eu
X
C
ft
Jh
X  eua
Jh
%
O  
u
co 
ft
Z  
Q
u  
bO
Jh  
ft
X
U
bo 5  
in -S
V co 
bO ^
"  I
coc
u
X
do
X
co
u
>
Jh
ft
X
X
C
ft
X
û
co
;  H
O
Zr 
1 1
1 1
CL i
2 i.'
û- j2
I .S
u  
d  
u
u  en
<
77
R e s t r i c t i o n  D ig e s t io n  o f  D N A
l)ig  pT 7/T 3 D N A  or PCR product w as combined w ith Ig l Eco RI, Ifil H ind  
III (10 un its) and restriction buffer B™ (all reagents B oehringer- 
M annheim); reactions were incubated at 37°C for 1 hour.
D N A  'Insert'  F ra g m e n t  P u r i f ic a t io n /  A g a r o s e  G e l  E le c tr o p h o r e s is  
D N A  fragments underw ent agarose gel electrophoresis; 8g agarose (Sigma) 
w ere added  to 400m l TAE buffer (0.04M Tris-acetate, O.OOIM EDTA), 
d isso lved  after heating by m icrow ave, cooled  to 60°C (cool en ou gh  to 
hold; at this point ethidium  bromide (Sigma) w as added to 0 .5pg/m l) and 
set around a comb to form a 2% gel. The gel w as subm erged in TAE buffer 
w ith in  an electrophoresis tank and D N A  w as loaded w ith  gel loading  
buffer (gel load ing buffer (6X stock): 0.25% brom ophenol blue (Sigma), 
0.25% xylene cyanol FF (Sigma), 30% glycerol (Sigma) in water). D N A  w as 
separated by applying a potential difference of 5 V /cm .
D N A  fragm ents w ere visualised above ultraviolet light; linearised pT 7/T 3  
and PCR product fragm ents w ere cut out using  a scalpel. D N A  w as  
released using a Qiagel Extraction Kit (Qiagen) according to manufacturers 
instructions.
L ig a t io n
Ligation reactions betw een vector and 'insert' sequences w ere set up; 
lOOng p T 7/T 3 D N A  w as added to an equal num ber of copies of PCR 
product D N A  in 7.5|il water. This solution  w as w arm ed to 45°C for 5 
m inutes (to m elt cohesive termini) and cooled on ice before addition of 
Ip l T4 D N A  ligase buffer (lOX stock; Boehringer-M annheim ), Ig l 5mM  
ATP and 0.2|il T4 D N A  ligase (Boehringer-M annheim). This m ixture w as
78
overlayed w ith 1 drop mineral oil and incubated at 16°(2 overnight before 
transformation of Escherichia coli (E. coli).
T r a n s fo r m a t io n  o f  E. c o l i
E. coli strain X L l-blue allow s selection  of recom binant p lasm id s by- 
com plem entation of the Lac Z gene. This strain w as grow n overnight in 
2TY m edium  (1.6 % bacto-tryptone, 1% bacto-yeast extract, 0.5% NaCl; pH  
7.0) in a shaking incubator. A total of SOOjil w as used  to inoculate 30ml 
fresh 2TY w hich w as incubated as before for 2 hours (until optical density  
at 550nm  w as 0.4-0.5). Cells were centrifuged at 6000g for 10 m inutes at 4°C 
in a pre-cooled rotor and resuspended in 15ml ice-cold 50mM CaCl2. Cells 
w ere n o w  incubated on ice for 15 m inutes, centrifuged as before and 
resuspend ed  in 3m l ice-cold 50mM CaCl2- The contents of the ligation  
reaction (10 |il) were now  added to 300pl of these 'competent' cells and the 
m ixture incubated on ice for 30 m inutes before transfer to a 42°C water 
bath for 2 m inutes (heat shock) and brief incubation on ice. Transformed 
cells w ere n ow  incubated in 0.5 m l 2TY at 37°C for 1 hour to allow  
expression of antibiotic resistance genes. Finally, cells were spread on agar 
plates and cultured at 37°C.
S e le c t io n  o f  E. c o l i  T ra n sfo rm e d  w i t h  R e c o m b in a n t  P l a s m i d  
2TY-agar (1.6 % bacto-tryptone, 1% bacto-yeast extract, 0.5% NaCl, 1.5% 
bacto-agar) w as m ade. The mixture w as autoclaved and cooled . W hen  
co o l, 6 0 |ig /m l am p icillin  w as added; p lasm id  T 7 /T 3  contain ed  an 
am picillin  resistance gene enabling selection for transformed colonies.
Selection for recom binant plasm ids w as perform ed by com plem entation. 
pT 7/T 3 carried the gene Lac Z' (encoding the first 146 am ino acids of (3- 
ga lactosid ase) w h ich  com plem ented  a fragm ent produced  in E. coli
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( in c lu d in g  strain  X L l-b lu e) to form  a fu n ction a l en zy m e  u p on  
transformation. Enzyme activity was detected by spreading agar plates w ith  
50pl 2% X-gal (5-brom o-4-ch loro-3-indoly l-p-D -galactoside) and lOpl 
lOOmM IPTG (isopropyl-b-D -thiogalactopyranoside); blue co lon ies had  
enzym e activity. The restriction sites for D N A  insertion into pT 7/T 3 were  
p o sitio n ed  w ith in  Lac Z'; insertion of recom binant D N A  p reven ted  
produ ction  of functional Lac Z'. W hite colon ies (no enzym e activity) 
indicated successful recombination and were chosen.
2.2.1.3 Plasm id A m plification  and H arvesting
P r o p a g a t io n  o f E .c o l i  a n d  A lk a l in e  L y s is
A  total of 500m l of 2TY containing appropriate antibiotic (5 0 |ig /m l) w as  
inoculated  and incubated at 37°C overnight w ith  shaking. C ells w ere  
centrifuged at 6000g for 10 m inutes at 4°C and resuspended in 18ml 50mM  
g lu co se / 25mM  T ris/ lOmM EDTA (pH 8.0). Next, 40 ml 0.2M N a O H / 1% 
SDS w as added and the contents m ixed gently by inversion and incubated  
at room  tem perature for 10 m inutes before addition of 20 ml ice-cold 5M  
potassium  acetate/ 11.5% (v /v j  glacial acetic acid. The contents were m ixed  
and a w h ite  precipitate w as seen (this contained E.coli chrom osom al 
D N A ) and pelleted  by centrifugation (6000g, 15 m inutes, 4°C, no brake). 
The supernatant w as carefully rem oved, added to 0.6 volum e isopropanol 
and incubated  at room  tem perature for 15 m inutes. The precip itated  
plasm id D N A  w as pelleted (6000g, 15 m inutes, room temperature), dried, 
w ashed tw ice w ith 70% ethanol and dissolved in 3ml water.
P u r i f i c a t io n  o f  In se r te d  D N A
Probe D N A  w as released from p lasm id preparations by restriction of 
flan k in g  sites (described above) by appropriate restriction en zym es  
(Boehringer M annheim ). Probe and plasm id D N A  w ere separated by
80
agarose gel electrophoresis and probe D N A  w as purified from agarose 
u sin g  a Q IA quick  G el E xtraction Kit (Q iagen) accord in g to the  
m anufacturers' instructions.
S e q u e n c in g  o f  D o u b le  S tr a n d e d  D N A
A  total of 5pg plasm id w as denatured after addition of 0.1 volum e 2M 
N a O H / 2mM  EDTA and incubation at 37°C for 30 m inutes. N ext, 0.1 
volum e 3M sodium  acetate (pH 5.0) w as added to neutralise before D N A  
w as precipitated by addition of 2.5 volum e ethanol and incubation at -70°C 
for 30 m inutes. D N A  w as then centrifuged (13'000 rpm for 10 m inutes), 
w ash ed  tw ice in 70% ethanol and red issolved  in 7pl water. D N A  w as  
sequenced using the Sequenase Version 2.0 D N A  Sequencing Kit (USB) 
according to the manufacturers instructions.
2.2.1.3 A  983 base pair (bp) Probe D erived From PCR A m plification
P C R  P r im e r s
Primer sequences for amplification of a 983 bp region of CMV major and 
i m m e d i a t e  e a r l y  g e n e  1,  e x o n  4 w e r e  5 ' -  
G A G G A G A T G A A ' G T G T A T T G G G C - 3 '  ( s e n s e )  a n d  5' -  
GGCTCAGACTTGACAGACACAG-3' (anti sense).
P r o b e  C o n s tr u c t io n
The probe sequence (denoted lE l 983) was amplified from the lE l gene by  
PCR using Ip g  of pGEM lE l as target DNA. Am plification w as carried out 
as described earlier (section 2.2.1.2 ).
The PCR product w as 983 (bp) in length and underw ent agarose gel 
electrophoresis before purification using the W izard PCR Preps D N A  
Purification System  (Promega).
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2.2.1.5 Probe Labelling and Purification
Random  prim ed D N A  labelling (110) was used to label probes w ith  a-P^^ 
dCTP (Amersham) or DIG-11-dUTP (Boehringer M annheim ) according to 
M aniatis et al (1989) (111) and M usiani et al (1992) (112) respectively. P^  ^
labelled D N A  w as purified using a Sephadex G50-colum n (111) w hereas  
DIG labelled D N A  w as precipitated w ith ethanol, centrifuged (13,000 rpm, 
10 m inutes) and redissolved in 50 |il of water.
2.2.1.6 D ot blotting
D N A  (purified or crude extraction) w as blotted on to Zeta-Probe nylon  
m em brane (Bio Rad).
D o t  b l o t t i n g  u s in g  th e  v a c u u m  m a n ifo ld
D ot blotting w ith  use of a vacuum  m anifold w as carried out according to 
manufacturers instructions (Bio Rad); 500 pi of sam ple w as heat denatured  
at 100°C for 10 m in utes then chilled  on ice before b ein g  app lied  to 
prew etted (distilled water) Zeta-Probe membrane by vacuum  pressure. A  
total of 500 pi of 0.4 M NaO H  w as then applied sim ilarly before the 
membrane w as rinsed in 2X SSC (20X SSC stock; 3M NaCl, 0.3M trisodium  
citrate) and dried at 80°C for two hours (no vacuum).
D o t  b lo t t in g  b y  d ire c t  a p p l ic a t io n
D ot blotting directly on to Zeta-Probe w as achieved as fo llow s. 500 pi 
sam ple w as firstly reduced to 20-50 pi under vacuum  before being heat 
denatured at 100 °C for 10 minutes then chilled on ice. 20 pi of sam ple w as 
app lied  to the m em brane as tw o 10 pi aliquots (air drying betw een  
applications) before air drying, imm ersing in 0.4 M NaO H  for 10 m inutes, 
rinsing in 2X SSC and then drying at 80°C (no vacuum ) for 2 hours.
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2.2.1.7 Hybridisation
Pre-hybridisation and hybridisation solutions consisted of 150 p i/cm ^  
Im M  EDTA, 0.25 M N a2HP0 4  (pH7.2), 7% SDS and 100 p g /m l of sheared,
sonicated salm on sperm D N A  (Sigma) or 50 p g /m l sheared, sonicated calf 
th y m u s D N A  (S igm a) p lu s  50 p g / m l  sh eared , so n ica ted  E .coli 
chrom osom al D N A . M embranes w ere pre-hybridised and hybrid ised at 
60°C for one hour and 12 hours respectively. P^  ^ labelled probe D N A  w as  
denatured by addition of NaOH to 0.4M for 10 m inutes then neutralised  
w ith  HCl, w hereas DIG labelled probe w as heat denatured (100°C for 10 
m inutes) then chilled on ice. W ashes w ith  500 pi of w ash  buffer/cm ^  
w ere perform ed serially to 'low stringency' (2X SSC/0.1% SDS, 10 m inutes, 
20°C), 'high stringency' (O.IX SSC/0.1%  SDS, 10 m inutes, 25°C) or 'very 
high stringency' (O.IX SSC/0.1% SDS, 2 x 10 minutes, 60°C).
2.2.1.8 Visualisation of Hybridisation 
la b e l le d  p r o b e s
The extent of hybridisation w as visualised by exposure to an autom ated  
beta particle counter (Instant im ager, Packard) a n d /o r  to X-ray film  
(Kodak).
D I G  la b e l le d  p r o b e s
V isualisation w as achieved according to manufacturers' instructions w ith  
m odifications. M embranes were firstly equilibrated in buffer 1 (100 mM) 
m aleic acid, 150 mM NaCl (pH 7.5) twice and then blocked w ith  1% w / v  
blocking reagent, 5% marvel in buffer 1 for 12 hours. Anti DIG - alkaline 
p h osp h atase w as applied  at a w orking concentration o f 1:10,000 (75 
m U /m l)  in blocking solution for 30 m inutes before undergoing tw o 15 
m inute w ashes w ith buffer 1 and equilibration w ith buffer 3 (100 mM  Tris- 
HCl (pH  9.5), 100 mM NaCl, 50 mM M gCl2). L um inescent detection
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( e m p l o y i n g  l u m i g e n  as substrate)  w a s  c o m p l e t e d  f o l l o w i n g  
manufacturers' instructions (Boehringer-M annheim ).
2 .2 .1 .9  H u m a n  a n d  H e r p e s v i r u s  D N A  C o n t r o l s
D N A  w as extracted from fibroblasts infected w ith HSV-1, HSV-2, CMV 
and VZV (all contain ing 10^ pfu) generously supp lied  by Professor A  
M inson and from EBV transformed B-cells generously supplied  by Dr M 
Wills .
2 .2 .2  P o l y m e r a s e  C h a i n  R e a c t i o n  (P C R )
2 .2 .2 .1  U r i n e  S a m p l e  P r e p a r a t i o n
I n i t i a l  crude  s a m p le  p r e p a r a t io n
Urine sam ples were initially subjected to four rounds of freeze/th aw  cycles 
and cell debris w as rem oved by low  speed  centrifugation (3000 rpm  
,5m ins) before Ipl of supernatant, neat or diluted 1 / 20  w ith  water (161, 
113), w as subjected to PCR.
U l t r a f i l t r a t io n
U rine w as filtered using either Centricon-100 (Am icon) or ultrafree-MC  
filter units 100k (M illipore) system s follow ing protocols reported by Khan 
et al 1991 (114) and Miller 1994 (162). Both system s captured protein w ith  
m olecular w eight over 100 kD. A total of 50 pi of red issolved  retentate 
w as subjected to PCR w ithout further processing.
P E G  p r e c ip i ta t io n  o f  v i r a l  p a r t ic le s
The protocol reported by Yamaguchi et al 1992 (163) w as fo llow ed w ith  
m odifications. A  total of 1 ml of urine w as centrifuged at 6500 rpm for two 
m inutes to rem ove cellular debris. 750 pi of urine supernatant w as m ixed
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w ith 750 pi 20% PEG 6000 (Sigma) and 375 pi of 2mM NaCl and incubated  
on ice at 4°C for 12 to 16 hours, before being centrifuged at 13’000 rpm for 
30 m inutes. The resulting supernatant w as decanted and the tubes 
recentrifuged (6500 rpm, 2 m inutes) to rem ove supernatant further. The 
pellet w as re-suspended in 200 pi water and 50 pi w as subjected to PCR.
2.2.2.2 Serum  Sam ple Preparation 
'P r o te in a s e  K  M e th o d '
D N A  w as extracted from serum after W olf et al (115); 50pl of serum  w as 
m ixed w ith 50pl 2X Am plitaq buffer (lOX stock; Perkin-Elmer Cetus) before 
3 freeze /th a w  cycles, and incubation (60°C for 1 hour) w ith  120 p g /m l  
proteinase K (Boehringer-M annheim (20m g/m l stock)). This w as follow ed  
by heating  at 95°C for 10 m inutes and centrifugation (12'000 g for 5 
m in u tes) to rem ove debris. The supernatant w as u sed  for PCR 
am plification .
Q u ia g e n  M e th o d
D N A  w as also extracted from 200pl serum using the Qiamp Blood Kit 
(Qiagen). A total of 25 pi Q iagen protease (19.23 m g /m l) and 200 pi of 
buffer AL'^ '^  (Qiagen) were m ixed w ith 200pl serum before incubation at 
70°C for 10 m inutes and addition of 210 pi isopropanol. This mixture w as 
applied to a silicone resin (Qiamp spin column, Qiagen) by centrifugation, 
w ashed 3 tim es w ith  500pl buffer AW  (Qiagen). D N A  w as eluted into 
200pl preheated (70°C) water after incubation at 70°C for 10 m inutes. This 
elutant w as used for PCR amplification.
2.2.2.3 PCR A m plification of Sam ple D N A
50pl of prepared sam ple was added to 46 pi of reaction mixture in a 0.5 ml 
'am plitube' (Perkin-Elm er Cetus). PCR of a 293 bp region of CMV
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im m ediate early gene w as perform ed as described earlier (see section
2.2.1.2 and figure 2.1).
Subsequently, 30pl of each amplified product w as electrophoresed (60V) in 
a 2% agarose (Sigma) gel using TAB buffer. Gels were photographed over 
UV light after staining w ith ethidium  brom ide (10 p g /m l).
M easures w ere taken to prevent contamination; D N A  extraction, reaction 
m ix preparation (conducted in a positive pressure laminar flow  hood) and 
product electrophoresis were conducted in separate room s using separate 
pipettes, aerosol-resistant tips and reagents. Additionally, negative (water) 
and p ositive  (plasm id) controls w ere included in each experim ent. The 
plasm id control (p.IEl.PCR.DEL) contained a deleted version (50 bp) of the 
product (see figure 2.2) enabling possible tube-to-tube contam ination to be 
identified .
2.2.2.4 N on C om petitive Q uantitive PCR
P l a s m i d s  C o n ta in in g  W i ld  T y p e  an d  D e le te d  P C R  T a rg e ts
p.IE.PCR (w ild  type) and p.IE.PCR.Del (deleted) w ere constructed as
described earlier (section 2.2.1.2).
D e te c t io n  o f  W i ld  T y p e  a n d  D e le te d  T arge ts
D eleted and w ild  type products were distinguished by differential m obility 
upon gel electrophoresis.
A n autom ated fluorescence detection technique w as adapted from a recent 
report (117). PCR w as conducted as described above using a fluorescein  
labelled sense primer. Subsequently, 3 |il of each product w as loaded onto a 
6% non-denaturing polyacrylam ide gel and electrophoresed using an ABI
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373A autom atic D N A  sequencer (Genescan 1.1 softw are). The gel w as  
scanned w ith  a 40 mW argon ion laser at a fixed distance from the w ells  
and subsequent fluorescence was detected by a photom ultiplier tube. This 
data w as in tegrated  and the fluorescence in ten sity  w as p resen ted  
graphically for each lane loaded. The am ount of product (w ild  type or 
d e le ted ) w a s p rop ortion a l to the area under the co rresp on d in g  
fluorescence intensity peak.
A c c u r a te  N o n - C o m p e t i t i v e  Q u a n t i t a t i o n
For each sam ple, Ip g  of deleted target D N A  w as added to 50pl sam ple  
D N A  preparation before 5 doubling dilutions; for each sam ple 6 w ild  type: 
deleted  ratios w ere am plified. After am plification, the quantity of w ild  
type and deleted product in each tube was m easured (as described above) 
and w as plotted after regression analysis. Parallel curves indicated that 
am plification of deleted and w ild  type products had occurred w ith  equal 
efficiency and a gradient above zero indicated that the reaction w as at the 
exponential phase at the com pletion of cycling. The am ount of initial w ild  
type D N A  w as calculated from the ratio w ild  type: deleted w hich  w as  
derived from the curve.
S e m i - Q u a n t i t a t i o n
Sem i-quantitative PCR of a single sam ple w as perform ed in a single tube 
(w ithout the addition of deleted target molecules); w ild  type product w as 
m easured as described above. Exogenous controls, com prising doubling  
dilutions of w ild  type target D N A  from 5pg to 0.15pg, were run alongside  
sam ple tubes and w ere used to generate a standard curve from w hich  
initial w ild  type D N A  could be calculated.
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C o m p a r is o n  o f  A c c u r a te  Q u a n t i t a t i v e  P C R  w i t h  S e m i - Q u a n t i ta t i v e  P C R  
Sixteen serum  sam ples taken from 3 bone marrow patients, previously  
show n to be serum PCR positive, were tested by both accurate quantitative 
and sem i-quantitative PCR.
2.2.3 Detection of Early Antigen Fluorescent Foci (DEAFF)
MRC 5 fibroblasts w ere grow n to confluence in shell vials u sing  SOOfil 
m in im al essen tia l m ediu m  (MEM). Inoculation  w as perform ed  by  
replacem ent of m edia w ith SOOpl specim en and centrifugation (2500 g  for 
30 m in utes). The specim en w as then replaced w ith  500|il MEM and  
incubation at 37°C for 24 hours w as carried out in 5% CO2. The m onolayer  
w as then w ashed tw ice in PBS before being fixed in methanol. M onoclonal 
antibody to im m ediate early protein (raised in mouse; Dako) w as diluted 1 
in 500 w ith  PBS and 50pl applied to the m onolayer before incubation at 
37°C for 30 m inutes. The m onolayer w as then w ashed 3 tim es in PBS 
before d ilu tion  (1 in 50 w ith  PBS) and app lication  of flu orescein  
isoth iocyanate-conjugated  anti-m ouse antibody (raised in goat; Dako). 
Incubation w as carried out at 37°C for 30 minutes before w ash ing 3 tim es 
in PBS, w ash in g  once in d istilled  w ater, drying and observation  of 
fluorescent foci by microscopy.
2.2.4 Isolation of CMV by Cell Culture
CMV w as isolated in MRC 5 fibroblasts w hich were cultured in m inim al 
essen tia l m edium  (MEM; Gibco BRL) containing 2% foetal calf serum  
(ECS; Gibco BRL) in culture-flasks (75 cm^ surface area). A  total of lOOpl 
specim en  w as added to confluent fibroblasts in 1ml MEM. Flasks w ere  
incubated at 37°C for up to 3 weeks; MEM w as replaced every 7 days. 
Fibroblasts w ere m on itored  dai ly  for ev id en ce  of C M V -m ediated
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cytopathic effect; this was observed as focal formation of rounded, giant 
cells.
2.2.5 Collection and Processing of Clinical Samples 
D o t - b l o t  H y b r id is a t io n  an d  P C R
Serum and urine sam ples were collected. W hole blood (5ml) w as taken  
and a llow ed  to clot overnight at 4 “C; serum  w as collected from these  
blood tubes after centrifugation at 2500 g for 10 minutes and stored at -20°C 
before use. 10ml urine w as collected in a sterile 30 m l tube and stored at 
-20“C before use.
I s o la t io n  T hrough  Cell C u ltu re  a n d  DEAFF
W hole blood (10ml) w as added to preservative-free heparin (250 units) 
and stored at 4°C overnight. Buffy coat sam ples (at the interface betw een  
red b lood  cells and plasma) were then rem oved using a Pasteur pipette  
and tested im m ediately. 10ml urine w as collected in a sterile 30 m l tube 
and tested im m ediately.
2.2.6 Patients and Testing of Clinical Samples
Clinical sam ples w ere collected betw een January 1993 and January 1995 
from liver transplant (n=99) and non-autologous bone marrow transplant 
rec ip ien ts (n=35). 1 endeavered to collect these tw ice w eek ly  during  
hospitalisation then at each visit to clinic, until 6 m onths posttransplant.
Bone m arrow transplant patients w ere then selected from this pool for 
analysis according to the criteria that sam ples were successfully collected  
from them  for > 2 months and at a rate of > 1 sam ple (serum, w hole blood
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and urine) per week; 17 bone marrow allograft recipients w ere therefore 
included in this study.
Liver transplant recipients for in -depth  stud y w ere selected  in itia lly  
according to the criteria that all provided > 1 sam ple per w eek  (serum, 
w hole b lood and urine) for > 2 m onths. From this group, all patients that 
experienced chronic rejection w ere selected (n=14) and a control group  
(n=18) fo llow ed  for a comparable period but com prising patients that did  
not d eve lop  chronic rejection w as selected  seq uentia lly  (according to 
transplant date).
Samples w ere tested in parallel by PCR, DEAFF and culture.
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2.3 Results
2.3.1 O ptim ising Dot-blot Hybridisation
2.3.1.1 False Positives U sing a D igoxigenin (DIG) Labelled Probe
In the first instance pGEM-lEl was titrated from 3 ng to 0.7 pg using CMV 
negative urine and sterile distilled water as carriers. These sam ples, and 
negative controls containing no plasm id, were heat denatured and blotted  
onto Zgta Probe membrane (Biorad) before hybridisation w ith digoxigenin  
labelled lE l probe and colourimetric detection. W ith water as the carrier 
pG EM -lEl could  be detected w ith  a sensitiv ity  of 3 p g  and water alone 
appeared negative. H ow ever w hen urine w as used  as the carrier non­
specific reactions w ere observed (figure 2.3).
FIGURE 2.3 N on-Specific H ybridisation of a D igox igen in  Labelled
CM V D N A  Probe W ith Dot-Blotted Urine U sing Colourim etric detection
pGEM-IEl was titrated from 3ng to 0.7pg and applied to the filter using water ('dots' 1-8) or 
urine ('dots' 9-16) as carriers. Urine was obtained from a CMV antibody negative  
individual.
'Dots' 9-16 1-8
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Experim ents w ere undertaken to identify the factors m ediating this non­
specific  reaction. The experim ent described above w as repeated w hilst 
firstly om itting the DIG labelled probe (data not show n) and secondly  
om itting both DIG labelled probe and anti DIG fab fragments (figure 2.4); 
here b lotted  urine w as being bathed directly w ith  the colourim etric  
reagents NBT and X-PHOS. In both experim ents false positives occurred  
w h en  urine w as used as the carrier; dot-blotted urine interacted directly  
w ith  the colourimetric substrates NBT and X-PHOS.
F IG U R E  2.4 D o t - B l o t t e d  U r i n e  I n t e r a c t e d  D i r e c t l y  w i t h  t h e
C o l o u r i m e t r i c  S u b s t r a t e s  N B T  a n d  X -P H O S  b u t  n o t  w i t h  L u m ig e n
Water ('dot' 9-12) and urine ('dot' 13-16) were dot-blotted and bathed in colourimetric (a) 
and luminescent (b) detection substrates; a developed filter (a) and autoradiograph (b) are 
shown. Anti-digoxigenin antibody-alkaline phosphatase conjugate was blotted onto the 
membrane (omitting the heat dénaturation step) as a positive control ('dot' 1-8).
(a ) C o l o u r i m e t r i c  
'D o t '  1-8 9 -16
(b) L u m i n e s c e n t  
1 -8  9-16
t : '
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The lum inescent detection system  (LDS) (Boehringer-M annheim ) w as  
investigated. N o direct interaction w as seen betw een urine and the LDS 
substrate lum igen (figure 2.4). H ow ever, a small am ount of non specific  
interaction w as seen betw een urine and the anti DIG fab fragments w hen  
u sin g  the LDS. Therefore, d igox igen in  labelling and d etection  w as  
abandoned in favour of
Summary
• Digoxigen labelling was unsuitable for detection of nucleic acids in dot-blotted
urine.
2 .3 .1 .2  S p e c i f ic i ty  o f  ^ ^ P -L a b e lle d  C M V  D N A  P ro b e s
2 .3 .1 .2 .1  F a ls e  P o s i t iv e s  A f t e r  T e s t in g  C l in ic a l  S a m p le s
A num ber of DEAFF positive and DEAFF negative urines (the latter from  
both healthy CMV antibody negative and positive individuals) w ere tested  
using a ^^P-labelled lE l D N A  probe. Samples were processed fo llow ing a 
m ethod adapted from Kim pton et al 1991 (118). Virus particles w ere  
p elleted  by ultracentrifugation (40'000 rpm, overnight), d igested  w ith  
proteinase K (0.25 m g /m l, 3 hours, 56“C; Boehringer-M annheim ) and  
phenoLchloroform  extracted tw ice before subsequent heat dénaturation  
and blotting onto Zeta Probe membrane.
H ybrid isation  w as seen to both DEAFF positive and DEAFF negative  
urines (see figure 2.5). It was thought that false positives were caused by 
traces of E.coli chrom osom al and plasm id D N A  contam ination of the 
probe w hich  m ay have hybridised to E.coli D N A  present in the sam ples.
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FIGURE 2.5 ^^P-Labelled IE Gene D N A  Probe H ybridised w ith  Dot-Blotted  
D N A  from  CM V N egative Urine
Doubling dilutions of the following were blotted; 400pg pGEM.IEl (1-7, dot 8 is water), 
400pg linearised lambda DNA (Gibco) ( 9-15, dot 16 is water), CMV DEAFF negative urine 
preparations (17-24 and 25-32) and CMV DEAFF positive urine preparations (33-40, 41-48 
and 49-56); an autoradiograph is shown. The probe hybridised to blotted pGEM-IEl (1-7) 
positive control and to blotted DEAFF positive urine (33-56). However, the probe also 
hybridised to blotted DEAFF negative urine (dots 17 and 25) ie. non-specificity was 
observed.
'D ot' 01-08 09-16 17-24 25-32 33-40 41-48 49-56
2.3.1.2.2 Probe Contam ination w ith  E. coli N ucleic A cids Led to 
False-Positive Results
To further test specificity , four conventionally  prepared CMV probes  
(H in d lll, gL, gB, gH) w ere hybridised against CMV, hum an, E.coli and 
plasm id D N A . A utoradiography after h igh ly stringent w ash es show ed  
that all four probes hybridised to E.coli chrom osom al D N A  and to a lesser 
extent plasm id DNA; this is show n for the Hind 111 probe in figure 2.6.
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FIGURE 2.6 CM V H IN D  III D Fragm ent H yb rid ised  to H um an
D N A  and E. coli D N A  Under C onditions of Very H igh Stringency
Doubling dilutions of linearised E. coli chromosomal DNA (lOng- 80pg; 'dot' 1-8) and human
fibroblast DNA (16ng- 500pg; 'dot' 9-14) were applied to membranes; 'dot' 15 comprised 3 x
10^ plaque forming units (pfu) AD169/ 6ng human DNA and 'dot' 16 comprised 1 x 10^
32plaque forming units (pfu) AD169/ 2ng human DNA. Blots were probed with P labelled 
CMV HIND III D fragment (a) and human DNA (b), at very high stringency.
(a) HIND m  D  (b) H u m an
'D ot' 01-08 09-16 01-08 09-16
%
#
#
f
CMV H IND III D fragment clearly binds to DNA extracted from CMV infected fibroblasts 
(dots 15, 16), human D N A  (dots 9-14; sensitivity 4ng) and E. coli chromosomal DNA (dots 1- 
8; sensitivity 300pg). Human DNA binds to DNA extracted from human fibroblasts (dots 9- 
16; sensitivity 500pg) but does not bind E.coli DNA and, therefore, serves as a good control.
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CMV probes (Hind III, gH,gB,gL) were also generated from plasm ids using  
W izard preparations (Promega). U sing this m ethod, contam inating E.coli 
chrom osom al D N A  or RNA was not seen upon visualisation after agarose 
electrophoresis.
A lth ough  these probes contained less E. coli D N A  there still rem ained  
am ounts sufficient to produce a signal w hen hybridised, under stringent 
conditions, against E.coli chrom osom al and plasm id D NA.
Summary
• Probes cloned in E.coli contained contaminating E.coli nucleic acids that hybridised 
to E.coli DNA present in urine.
• Such probes mediated false positivity and were unsuitable for detection of nucleic 
acids in  dot-blotted urine.
2 .3 .1 .2 .3  C M V  D N A  H y b r i d i s e d  w i t h  H u m a n  G e n o m ic  D N A
In addition, probe HIND III-D hybridised to hum an D N A  (figure 2.6). An  
attem pt w as m ade to further localise the region of hum an h om ology  
present w ith in  the Hind D fragment. Restriction using Eco R1 generated  
four fragm ents (see figure 2.7) which were purified by gel electrophoresis. 
These fragm ents were eluted and labelled (^^P) before hybridising against 
CMV and hum an D N A . Filters w ere also probed w ith  labelled (32p) 
hum an D N A  as a control. U nder h igh  stringency all four Eco R1 
fragm ents of the H IND III D fragment hybridised to hum an D N A  (see 
figure 2.7). In addition the GL probe was also show n to hybridise to hum an  
D N A  under stringent conditions.
Summary
• Two CMV probes hybridised to human DNA at high stringency and were unsuitable 
for screening clinical samples
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2.3.1.2.4 B locking Experiments
The hyb rid isation  of W izard preparation (Prom ega) purified  probes 
against CM V,hum an and E.coli D N A  w as repeated but identical filters 
were prehybridised and hybridised in parallel in the presence of 100 p g /m l  
sonicated salm on sperm  DNA(Sigm a) or 50 p g /m l of calf thym us D N A  
(Sigma) plus 50 p g /m l E.coli chrom osom al D N A . The latter regim e w as 
u sed  in an attem pt to block the h yb rid isation  of traces of E .coli 
chrom osom al D N A , a n d /o r  hybridisation to hum an sequences by probe 
gL , by com petition w ith  excess am ounts of unlabelled D N A  (figure 2.8). 
The degree of hybridisation of probes gB, gH  and gL to E.coli chrom osom al 
D N A  and of gL to hum an D N A  w as lessened w hen the latter regim e w as 
u sed , w ith o u t a ltering  affin ity  to CMV D N A , but not e lim in ated  
com pletely. In addition, hybridisation of CMV D N A  probes to CMV D N A  
w as reduced w hen E .coli/calf thym us D N A  was used to prehybridise (see 
figure 2.8).
Summary
• The inclusion of unlabelled E.coli and mammalian DNA during hybridisation did 
not elim inate false positivity
• Therefore an attempt was made to produce probes without employing plasmid 
am plification through E.coli.
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Figure 2.8 In c lu sio n  o f E. co li and C alf T hym us D N A  in to
Prehybrid isation  and H ybrid isation  Solu tion s Reduced H ybrid isation  of 
CM V Probe gL to H um an and E. coli D N A
(a) sa lm on sperm  D N A  
Probe: CMV gL E. coli
1-8 9-16 17-24 1-8 9-16 17-24
(b) Calf thym us/ E.coli D N A
CMVgL E .coli
1-8 9-16 17-24 1-8 9-16 17-24
H alving dilutions of the following were blotted; DNA from CMV infected fibroblasts (10 
pfu A D 169/ lOng DNA - 1.25 x 10^ pfu A D 169/ 1.25ng DNA; 'dots' 1-4), CMV infected 
fibroblasts (10^ pfu- 10^ pfu AD169; 'dots' 5-8), E, coli DNA (10- 1.25ng; 'dots' 9-12), 
plasm id pSP64 (10-1.25 ng; 'dots' 13-16) and human fibroblast DNA (10-1.25 ng; 'dots' 17- 
20). Filters were processed in parallel and prehybridised/hybridised w ith lOOpg/ml 
salmon sperm DNA  (a) or 50 |ig /m l calf thymus D N A / 50 |ig /m l E.coli DNA (b). CMV probe 
gL w as investigated; E. coli DNA probe was used as a control. Labelled E. coli DNA  
hybridised specifically with dot-blotted E. coli D N A  and served as a good control; less 
h y b r id isa t io n  w a s seen  w h en  E. co li D N A  w a s in c lu d e d  in  the  
prehybridisation/hybridisation solution (b).
Under 'standard' hybridisation conditions (a) CMV DNA probe gL binds to CMV DNA  
('dots' 1-8), E.coli DNA ('dots' 9-12) and human DNA ('dots' 17-20). When E. co li/ calf 
thym us D N A  was included in the prehybridisation/ hybridisation solution (b) less 
hybridisation is seen to E. coli chromosomal ('dots' 9-12) and human D NA ('dots' 17-20). 
H owever, hybridisation to CMV DNA  ('dots' 1-8) is also reduced markedly.
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2 .3 .1 .2 .5  P C R  P ro b e s
A 983bp probe was produced by PCR amplification (lE l 983). In the first 
instance this probe w as investigated for specificity by hybridisation to 
CM V, hum an, E .coli chrom osom al and p lasm id  D N A  (figure 2.9). 
H y b rid isa tion  w as restricted  ex c lu siv e ly  to CMV D N A . Sim ilar  
experim ents show ed that this probe did not hybridise to HSV (types I and 
II), EBV, VZV or HHV-6 DNA).
F IG U R E  2.9 A  C M V  D N A  P r o b e  (IE 1 .9 8 3 ) t h a t  w a s  A m p l i f i e d  b y
P C R  d i d  N o t  H y b r i d i s e  to  H u m a n  o r  E . c o l i  D N A
'D o t '  01-08 09-16
Doubling dilutions of linearised E. coli chromosomal DNA (lOng- 80pg; 'dot' 1-8) and human 
fibroblast DNA (16ng- 500pg; 'dot' 9-14) were applied to membranes; 'dot' 15 comprised 3 x 
10^ plaque forming units (pfu) A D169/ 6ng human DNA and 'dot' 16 comprised 1 x 10  ^
plaque forming units (pfu) A D169/ 2ng human DNA. Blots were probed with P labelled 
CMV lE l gene PCR product (1E.983), at high stringency.
Summary
• A PCR derived probe from the IE gene hybridised specifically with CMV DNA
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2.3.1.3 Sensitivity
2.3.1.3.1 Detection of Naked DNA
Initial experim ents show ed that 10 pg of target D N A  (purified 983 bp PCR 
product) could be detected.
2.3.1.3.2 Liberation of CMV DNA from AD169 infected fibroblasts
A num ber of sam ple treatments were compared; each w as applied to 5 ml 
of CMV negative urine (healthy CMV antibody negative donor) spiked  
w ith  10  ^ pfu A D  169 before blotting a doubling dilution series. Each spiked  
urine underw ent four freeze/th aw  cycles then ultra centrifugation (36000 
rpm, 2 hours) before treatment. A com parison w as also m ade betw een  
direct application of liberated D N A  to the m em brane and the use of a 
vacuum  m anifold. After blotting, each membrane w as hybridised w ith  ^^ P 
labelled  PCR.IE1.293 and w ash ed  stringently  before autoradiography  
(figure 2.10).
D irect D N A  app lication  ach ieved  greater sen sitiv ity  than m an ifo ld  
application and w as m ost apparent w hen the phenohchloroform  step w as 
om itted (lanes 1-20; blots a and b). The low er sen sitiv ity  ach ieved  by  
m anifold  b lotting  w as likely to be due to com petition  for m em brane 
b in d in g  s ite s  b e tw e en  CMV D N A  and co n ta m in a tin g  p ro te in s . 
A dditionally , for sam ple treatments involv ing SDS, w ithout its rem oval 
by D N A  precipitation (lanes 5-8, 25-28; blots a and b), direct application  
allow ed the spread of this w etting agent therefore enhancing sensitivity. 
S im ila r ly , s e p a r a t io n  o f D N A  from  p r o te in  c o n ta m in a n ts  
(phenohchloroform  treatm ent) and SDS (D N A  precip itation) d id  not 
im prove sen sitiv ity  w hen direct application w as fo llow ed. After ultra­
centrifugation, proteinase K treatment w as more effective w hen  used  in 
conjunction w ith  SDS (lanes 9-12, 17-28; blots a and b). In situ proteinase
101
K /S D S  treatm ent (blot c), after M usiani et al (1991) (112), proved less 
sen sitive than treatment in vitro.
Table 2.1 Combinations of Treatments Compared in Order to O ptimise CMV D NA  
Preparation before Hybridisation (Results Shown in Figure 2.10)
TREATMENT
‘Dots’ / Filter 1 hour incubation Phenol:
chloroform
Ethanol
Proteinase k SDS
01-04 a NO NO NO NO D
05-08 a NO YES NO NO D
09-12 a YES YES NO NO D
13-16 a YES NO NO NO D
17-20 a YES YES NO YES D
21-24 a YES YES YES YES D
25-28 a YES YES YES NO D
01-04 b NO NO NO NO M
05-08 b NO YES NO NO M
09-12 b YES YES NO NO M
13-16 b YES NO NO NO M
17-20 b YES YES NO ■ YES M
21-24 b YES YES YES YES M
25-28 b YES YES YES NO M
01-04 c YES* YES* NO NO D
05-08 c YES* YES* NO NO M
* Performed in situ after blotting
Table 2.1 show s combinations of treatments used to generate Figure 2.10; 'dots' comprise 
AD169 virions that have been subject (YES) or not (NO) to various treatments and applied  
to the membrane by 'dotting' with a pipette (D) or by using a vacuum manifold (M).
102
0>_C
"C
D
<
Z
o
>
u
o
c
m
X
os
2,
o
Q
c(Us
O)
H
O)
'a.
e
(tCD
bO.s
CD
Dwo
<U
s
X
é
73
3
'S
-  g
73
'o
B
I
>
2"
73cu
o
2
o
Q
m m #
cn OJ
i  “i.i
"u J3
bJD o
zm?.mmm
mmm
«
0) .5 T-H>
■X3 V o g 2
bC
o>_> ■g 2
O) 03c o >
> e
U 1 1
s
B 04OJ _cu
£
to
=5
a .
03 1 33
103
In a further experim ent using CMV DEAFF positive urine it w as found  
that ultra centrifugation at 60'000 rpm for two hours or 36'000 rpm for two  
hours after PEG precipitation overnight w as more sen sitive than ultra 
centrifugation (36'000 rpm for tw o hours w ith  no PEG precipitation) used  
the preceding experim ent. It w as also show n that rem oval of debris by a 
3000 rpm centrifugation  before ultra centrifugation  greatly  reduced  
sensitivity even  after the sam ple had undergone four freeze thaw cycles.
Summary
• The optim al preparation m ethod for urine was shown to be four freeze/thaw cycles
and ultra centrifugation (60'000 rpm  for two hours) before in vitro  proteinase K/SDS 
treatm ent, phenohchloroform  extraction, heat dénaturation and direct application onto a 
nylon membrane.
2.3.2 Dot Blot H ybridisation of Clinical Urine Sam ples
2.3.2.1 Latent Virus Was N ot Detected by D ot Blot H ybridisation
A P^  ^ labelled PGR derived probe (lEl 983) w as hybridised against clinical 
sam ples prepared using the optim ised liberation protocol (above). Dot blot 
hybridisation of tw o DEAFF positive sam ples generated positive results 
but specim ens taken from healthy CMV antibody negative or positive  
individuals were negative; the latter result is important and suggested  that 
latent virus could not be detected w ith this protocol.
2.3.2.2 Com parison of Dot Blot H ybridisation w ith  Culture and
DEAFF Testing
Thirty tw o urine sam ples, taken from liver, bone marrow, heart or renal 
transplant recipients, were screened by dot blot hybridisation. The viral 
status of these sam ples was know n after testing by the 'gold standard' tests 
of culture and DEAFF; 20 samples were positive by CMV DEAFF or culture 
and 12 sam ples were negahve (Table 2.2).
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Table 2.2
D E A F F / C u l tu r e  +  D E A F F / C u l tu r e  
D o t  b l o t  + 9 5
D o t  b l o t  - 11 7
n = 3 2
Sam ples from 11 patients that were positive by DEAFF or culture w ere not 
p ositive  by dot-blot hybridisation. Therefore, the sensitiv ity  of dot blot 
hybridisation (compared to culture and DEAFF) w as only 45%.
H ow ever, dot-b lot hybrid isation m ay be a usefu l com plem entary test 
w hen  conventional tests fail. This w as suggested by the results from five  
patients w ho w ere positive by dot-blot hybridisation but were negative by 
culture and DEAFF.
Summary
• H ybridisation w ith a PCR derived probe (IE gene) detected CMV in urine from 
patients w ith  active CMV infection
• Dot-blot hybridisation has low sensitivity compared to isolation through culture 
and DEAFF but may serve as a useful complementary test
2.3.3 O p tim is in g  P olym erase C hain R eaction (PCR) A m p lifica tion  
o f C M V  D N A  in  Serum  and U rine
The p o lym erase  chain reaction (PCR) w as em p lo y ed  b ecau se  the 
sensitivity of dot-blot hybridisation w as disappointing. PCR w as optim ised  
and exam ined using a new  panel of control sam ples (the panel used for 
optim isation of dot-blot hybridisation had been exhausted).
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2.3.3.1 Sensitivity
A m plification of d ou blin g  d ilutions of target D N A  (pIEN, see M ethods 
and Materials), follow ed by gel electrophoresis gave a sensitivity of 0.078 fg 
which is equivalent to 561 genom e copies (figure 2.11).
FIGURE 2.11
Single Round PCR of CMV Target DNA Gave a Sensitivity of 561 copies
Lane 09 08 07 06 05 04 03 02 01
PCR Product
Plasmid DN A was titrated giving a target (insert) DNA titration of 10- 0.078pg (lanes 1- 
8); lane 10 is a 100 base pair DNA ladder (Gibco).
2.3.3.2 Specificity
Initially the im m ediate early (IE gene) PCR reaction w as tested for 
specificity. A m plification of a 293 base pair fragm ent w as seen  to be 
specific for CMV DNA; no am plification of HSV I and II, EBV, VZV, 
HHV6, hum an or E.coli chrom osom al D N A  w as seen. CMV specificity  
w as con firm ed  by  sou th ern  b lo ttin g  and h yb rid isa tion  w ith  an
106
oligonucleotide probe specific to the region of the IE gene am plified (figure 
2 .12).
Summary
• Single round PCR of a 293bp region of CMV DNA was sensitive and specific
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2.S.3.3 O ptim isation of Urine Sam ple Preparation
Six DEAFF positive urines and four DEAFF negative controls (collected  
from 2 CMV antibody-negative and two CMV antibody-positive healthy  
individuals) w ere collected for investigation. The DEAFF negative urines 
were PCR negative.
O nly one of six DEAFF positive sam ples was positive after PCR testing of 
neat, 'freeze-thawed' urine. This lack of sensitivity w as show n to be due 
to the presence of PCR inhibitors in urine. PCR am plification of 0.156 pg  
p.IEN w as inhibited by addition of 2 |il 'freeze-thawed' urine from 5 /6  
urines tested and in contrast, was unaffected by addition of 2jil of the urine 
sam ple that w as previously amplified successfully (data not show n).
A num ber of regim es were em ployed to try to separate CMV particles from  
PCR inhibitors (see Materials and M ethods). After ultra filtration through  
A m icon or M illipore filters before PCR of the retentate, tw o out of six 
sam ples were PCR positive. A method based on PEG precipitation of viral 
particles follow ing debris removal by a low  speed spin w as attempted; four 
out of six DEAFF positive urines were PCR positive w ith  this extraction 
technique. CMV specificity  w as confirm ed by southern b lotting  and  
hybridisation w ith  an oligonucleotide probe specific to the region of the IE 
gene am plified.
Summary
• Neat urine contained PCR Inhibitors
• Precipitation w ith PEG (on ice, overnight), after removal of debris by low speed 
centrifugation, was the optimal method for urine preparation before PCR
2.3.3.4 O ptim isation of Serum Sam ple Preparation
Serum  sam ples w ere collected  from three liver transplant patients  
experien cin g  active CMV infection and from healthy CMV antibody
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p o s it iv e  and n eg a tiv e  in d iv id u a ls  in order to o p tim ise  sam p le  
preparation.
Sam ples were subjected to proteinase K based extraction techniques and a 
silicone capture based kit, Qiamp kit (see M ethods and Materials), before 
PCR. CMV D N A  w as not am plified from serum  sam ples obtained from  
health y in d iv id u a ls  (CMV antibody negative and p ositive) but w as  
am plified from those experiencing acute CMV infection. The Qiam p kit 
successfu lly  extracted amplifiable D N A  from blood and serum (see figure 
2.13) w hereas the proteinase K based techniques were successful only w ith  
w hole blood.
F ig u r e  2 .13
T h e  Q i a m p  B lo o d  K i t  E n a b le d  E x tr a c t io n  o f  A m p l i f i a b l e  D N A  f r o m  S e r u m
L a n e 17  16 15 14 13 12 11 10 09 08 07  06  05 04  03 02 01
PCR product
Serum from 3 patients with active CMV infection were extracted using a proteinase K based 
technique (lanes 2-6) or the Qiamp Blood Kit (Qiagen; lanes 7-12). 50fil (lanes 3, 5, 6, 8, 10, 
12) or 25pl (lanes 2, 4, 7, 9, 11) of each preparation underwent PCR and products were 
electrophoresed on a 2% agarose gel alongside a lambda DNA ladder (123bp/ Gibco). 
Negative (water; lanes 13, 14) and positive (lOOpg, 50pg pT7/T3-IE.PCR; lanes 15, 16) 
controls were included and were PCR negative and positive respectively. Quiamp 
extraction (lanes 07-12) was more efficient than a proteinase K based method and enabled 
amplification of CMV DNA from all 3 patients.
Furthermore, CMV specificity w as confirm ed by southern b lotting and  
hybridisation w ith an oligonucleotide probe specific to the region of the IE 
gene am plified.
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Summary
• The Qiamp Blood Kit efficiently extracted DNA from sera.
• CMV DNA was am plified from serum samples from 3 patients w ith active CMV 
infection.
2.3.4 Com parison of PCR w ith  Culture and DEAFF Tests
2.3.4.1 Com parison of Urine PCR w ith  Culture and DEAFF T esting
Eighty nine urine sam ples collected from a m ixed population  of liver, 
bone m arrow, heart or renal transplant recipients, were tested for CMV by 
DEAFF, culture and the optim ised protocol for PCR am plification (sam ple 
preparation by PEG precipitation); (Table 2.3).
Table 2.3 Urine Testing for CMV by DEAFF or Culture was Com pared  
w ith  PCR
URINE
PCR vs DEAFF 
(n=64)
PCR vs culture 
(n=45)
DEAFF CULTURE
+ - ‘toxic’ + - ‘toxic’
PCR
+
5 2 0 5 2 0
PCR 5 45 7 1 22 15
Compared to DEAFF and culture, urine PCR has sensitivity 50% and 83%, specificity 96% and 
92% respectively; 11% and 33% of urine samples 'lost' to DEAFF and culture respectively.
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Summary
• PCR of CMV DNA from urine had high specificity but low sensitivity compared to 
isolation through cell culture or DEAFF
• A significant proportion of urine samples were toxic in conventional culture or 
DEAFF tests
2.3.3.4 Com parison of PCR of CM V D N A  from Serum w ith  Culture
and DEAFF Testing of Buffy Coat
89 serum  and buffy-coat sam ples w ere collected from liver and bone  
m arrow transplant recipients and tested for CMV by PCR and DEAFF; 76 
were tested by culture (Table 2.4).
Table 2.4 B u ffy  Coat T esting  for CM V b y  DEAFF or C ulture w as
Com pared w ith  PCR Testing of Serum
BLOOD
PCR vs DEAFF 
(n=89)
PCR vs culture 
(n=76)
DEAFF CULTURE
+ - ‘toxic’ + - ‘toxic’
PCR
+
0 9 3 0 6 2
PCR 0 65 12 0 31 37
Compared to DEAFF and culture, serum PCR has sensitivity 100% and 100%, 
specificity 93% and 84% respectively; 17% and 51% of buffy coat samples 'lost' 
to DEAFF and culture respectively.
112
Summary
• PCR of CMV DNA from serum had higher sensitivity than isolation through buffy 
coat cell culture and DEAFF
• A significant proportion of buffy coat samples were toxic in conventional culture and 
DEAFF tests
2.3.5 Q uantitative and Sem i-Q uantitative PCR
N o n -co m p etitiv e  quantitative PCR and sem i-qu antita tive PCR w ere  
com pared u sin g  sequential serum  sam ples from three bone m arrow  
transplant recipients that experienced CMV disease. The sam ples tested  
had previously  been show n to be positive by qualitative PCR; results are 
show n in figures 2.14 and 2.15.
Figure 2.14 Semi-Quantitative PCR for
CMV in 3 Bone Marrow Transplant Recipients
8  T CASE 1
CASE 2 E3
6 - -
4 --
O)
D)
1 201 008 06 04 02 00
Day Post- t ransp lan t
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Figure 2.15 Quantitative PCR for CMV in 3
Bone Marrow Transplant Recipients
CASE18 T
CASE 2
6 - - CASE 3
4 --
Ui 2 - ■
O)
4 0 6 0 8 0 1202 0 1 000
Day Post- transplant
Accurate quantitation allow ed discrim ination over 3.5 logs w hereas sem i­
quantitation discrim inated over on ly  2 logs; the latter test m ay have  
underestim ated the quantity of CMV present after becom ing saturated e.g. 
case 1 / sam ple 4. In contrast, non-com petitive quantitative PCR is not 
prone to such error because each sam ple is diluted several times.
H ow ever , the patterns generated by these tw o tests w ere essen tia lly  
similar. For both tests, the m axim um  viral load was deem ed to be highest 
in case 1 (CMV pneum onitis), fo llow ed  by case 2 (CMV retinitis) and 
low est in case 3 (pyrexia).
Summary
• Q uantitative and semi-quantitative PCR gave sim ilar results for sequential serum
sam ples taken from three patients with active CMV infection
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2.4 DISCUSSION
2.4.1 C onclusions
• The hypothesis that detection of CMV DN A in serum w ould be superior to 
conventional detection methods was upheld; serum PCR was more sensitive than culture and 
DEAFF
• The hypothesis that detection of CMV DN A in urine w ould be superior to 
conventional methods was not upheld
D ot-blot Hybridisation
• The digoxigen labelling system was unsuitable for detection of viral nucleic acids in 
dot-blotted urine because of the interaction between urine and colourimetric reagents and 
the anti-digoxigenin antibody.
• Conventional preparation of probes cloned after amplification in E.coli led to 
contamination with E.coli nucleic acids; these hybridised to E.coli DNA present in urine 
and m ediated false positivity.
• Two CMV probes (Hind III and gL) hybridised to human DNA at high stringency; 
these probes were unsuitable for detection of viral nucleic acids in clinical samples.
• A PCR derived probe from the immediate early gene of CMV detected dot-blotted 
CMV D N A  specifically.
• Optimal preparation of urine for detection of CMV DN A was as follows; four 
freeze/th aw  cycles and ultra centrifugation (60'000 rpm for two hours) before in vitro 
proteinase K /SDS treatment, phenohchloroform extraction, heat dénaturation and direct 
application onto a nylon membrane.
• However, dot-blot hybridisation was a poor test for CMV in urine; it had low  
sensitivity and specificity compared to isolation through culture and DEAFF.
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Polymerase Chain Reaction
• Single round PCR of a 293bp region of CMV DNA was sensitive and specific to CMV 
targets
• Neat urine contained PCR inhibitors that can be partly removed by using a PEG
precipitation method.
• The Qiamp Blood Kit efficiently extracted DNA from sera
• PCR of CMV D N A  from serum was more sensitive than isolation through cell
culture and DEAFF
• PCR of CMV DNA from urine was specific but was insensitive compared to
conventional culture and DEAFF
• A significant proportion of urine and buffy coat samples were toxic to conventional
culture and DEAFF tests
• Quantitative and semi-quantitative PCR yielded similar results
2 .4 .2  D ig o x i g e n i n  L a b e l l in g  a n d  D o t - b lo t  H y b r i d i s a t i o n  o f  U r in e
The digoxigen in  labelling and detection system  may not be suitable for the 
detection of D N A  in crude D N A  extractions from clinical material. Dot- 
blotted urine reacted directly w ith the colourimetric reagents NET and X- 
PHOS. C ells sloughed  into urine have endogenous alkaline phosphatase  
activity; how ever, enzym e activity should have been destroyed during  
D N A  dénaturation (95°C, 5 m inutes) and levam isole (inhibitor of hum an  
alkaline phosphatase) was not found to be preventative.
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False positivity w as also seen w hen lum igen w as used as substrate; again, 
com pon ents of the d igoxigen in  labelling and detection  system  w ere  
involved . It w as thought that non-specific interaction betw een dot-blotted  
proteins and anti-digoxigenin antibody w as responsible and a more robust 
blocking proceedure (5% Marvel, overnight) elim inated this problem.
2.4.3 C ontam ination of Probes w ith  E.coli N ucleic Acids
It w as show n, using labelled probes, that E.coli chrom osom al D N A  
contam ination  of p lasm id  derived probes consisten tly  m ediated  false  
p o sitiv e  reactions w h en  applied to crude D N A  extracted from  CMV  
negative urines. False positiv ity  w as reduced but not elim inated using  
preparations w ith  less chrom osom al contam ination (Wizard Preparations 
- Promega) and by including unlabelled E.coli chrom osom al D N A  in pre 
h yb rid isa tion  and hybrid isation  so lu tion s. Separation of the probe  
(p lasm id insert) by electrophoresis elim inates m ost contam ination but 
w ill not elim inate E.coli D N A  of a similar length.
A num ber of reports (157, 158, 159) su g g est that vector seq uence  
contam ination m ediates false positive reactions w hen probing crude D N A  
extractions from  clin ica l m aterial. A m binder et al (157) in clu d ed  
unlabelled plasm id D N A  in prehybridisation and hybridisation solutions  
and used  M13 and lambda bacteriophage vectors. H ow ever, this did not 
elim inate false positive  reactions w hich, in contrast, w as show n in this 
thesis to be m ediated by E.coli chromosomal DNA.
2.4.4 H ybridisation of CMV D N A  Probes w ith  H um an D N A
Further specificity  problem s were encountered. CMV D N A  fragm ents 
H IND 111 D (20 kB) and UL115 (gL gene) were both found to hybridise  
under stringent conditions to human DNA.
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Both H IN D  III D and E fragments (the latter contains UL115 w hich is the 
open reading frame for glycoprotein L (gL)) have been show n to contain  
reg ion s h om o lo g o u s to hum an D N A  (118, 173; see figure). In both  
previous papers, the Eco R1 U fragment (4.2 kb portion of Hind III D) did 
not hybridise w ith  hum an D N A  and I therefore isolated this fragment. In 
contrast, I found that this fragment did hybridise w ith hum an D N A , even  
under very stringent conditions and therefore sought an alternative.
2.4.5 Dot-blot Hybridisation Using a PCR Derived Probe
A  probe derived from PCR of the lE l gene (exon 4) show ed no hom ology  
w ith  hum an, EBV, HSV (I and II) or HHV6 DNA.
The sensitivity of hybridisation to naked target D N A  (10 pg) w as similar to 
sensitiv ities achieved by other workers (174, 175, 176, 177, 158, 159). A  
m ethod for the liberation of D N A  from AD169 particles w as optim ised; 
direct application of extracted D N A  on to the nylon m embrane precluded  
the need  for a D N A  precipitation step to separate D N A  from SDS and 
protein  contam inants. In m y hands, S D S /p rote in ase  K treatm ent of 
blotted sam ples perform ed in situ (follow ing M usiani et al 1992) (112) w as 
less sen sitive  than m ethods em ploying this step in v itro . The optim ised  
m ethod was similar to others reported (118, 157, 158).
D ot blot hybridisation was not a good candidate for routine surveillance of 
urine for CMV; sensitivity w as poor and the m ethods em ployed were time 
consum ing (each run took four days to perform), tedious and technically  
dem anding.
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2.4.6 O ptim isation of Polym erase Chain Reaction (PCR) A m plification  of 
CMV D N A  from Serum and Urine
Polym erase chain reaction (PCR) amplification of a 293 bp fragment of lE l 
gene exon 4 w as specific and sensitive; am plification did not occur w ith  
E.coli, hum an or other herpesvirus D N A  and 0.078fg (561 genom es) target 
cou ld  be detected  after PCR and agarose gel e lectroph oresis. This 
sensitivity w as comparable w ith other reports of single round PCR system s 
(163,169).
A m plification  param eters w ere optim ised by W eidem an JTW (41) w ith  
m odifications for this study; use of A m plitaq (Perkin Elmer) im proved  
sen sitiv ity ; this is a recom binant form of D N A  p olym erase  (from  
T h e r m u s  aquat icus  ) w ith  no 3'-5' exonuclease activity and is therefore 
high ly efficient. In addition, sensitivity w as increased by the use of Perfect 
M atch Enhancer (Stratagene); this ad d itive d estab ilizes m ism atched  
prim er-tem plate interactions and therefore increased reaction specificity. 
Therefore, primers and reagents are used alm ost exclusively  for specific 
am plification of target D N A  w hich leads to enhanced sensitivity.
Serum and sam ples were efficiently processed using the Qiamp Blood Kit 
w hich  perform ed better than a proteinase K based technique. The lack of 
se n sit iv ity  o f the proteinase K based technique is due to residual 
proteinase K activity during PCR according to Tysoe (178); h ow ever, I 
fou nd  th is an un likely  explanation  because proteinase K activ ity  is 
destroyed at 94°C. Instead, serum proteins m ay be acting as non-specific, 
non-enzym atic PCR inhibitors; they are not elim inated by the proteinase K 
based D N A  extraction technique but are eliminated after Qiamp extraction. 
A m p lifica tio n  w as seen  on ly  from  b lood  sam p les co llected  from  
in d iv id u a ls  experiencin g ep isod es of active CMV infection  and this
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specificity w as further substantiated w hen testing clinical sam ples. Other 
reports have also demonstrated the inability of single round PCR to detect 
CMV in healthy carriers (167, 183).
2.4.7 Com parison of PCR w ith  DEAFF and Culture Testing of CMV  
S e r u m
W hen serum  and buffy coat sam ples from transplant recipients w ere  
tested in parallel by PCR and culture a n d /o r  DEAFF respectively, it w as  
show n that PCR of serum w as more sensitive than DEAFF or culture. In 
fact, none of the serum  sam ples that w ere positive  by PCR w ere also  
positive by DEAFF or culture. The PCR test w as nevertheless show n to be 
specific after probing w ith a CMV-specific oligonucleotide and all sam ples 
that w ere PCR positive w ere taken from patients that were experiencing  
CMV disease (confirmed by DEAFF and culture testing of urine).
Previous reports have show n PCR testing of w hole  blood to be m ore 
sensitive than conventional cell culture (166, 167, 160, 168, 169, 170) and 
DEAFF (165 ,171,166,167, 160,172,170). Zipeto 1992 (167) found that a third 
of b lood  sam ples (n=293) taken from a m ixed population of transplant 
recipients, patients w ith AIDS and new borns tested positive by PCR but 
negative by DEAFF and culture.
M ost of the PCR positive serum sam ples (13/15) were taken from 2 bone 
marrow transplant recipients w ith severe CMV disease (see chapter 3) and 
it is surprising that sam ples rem ained DEAFF and culture negative. It is 
unlikely that these two patients harboured a strain of CMV w ith unusual 
in vitro  grow th characteristics (urine w as DEAFF and culture positive) or
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one w hich escaped antibody detection of the DEAFF test (im m ediate early 
proteins are h igh ly  conserved). It is more likely that obliteration of 
lym phocytes (cells tropic for CMV in buffy coat) prevented detection. In 
addition, a high proportion of sam ples were toxic to the fibroblasts used in 
the DEAFF test (17% toxic) and culture (51% toxic). A proportion of these 
'toxic sam ples' w ere taken from patients that were receiving ganciclovir  
treatment (33% and 31% respectively). Ganciclovir treatment m ay be partly 
responsible for the toxicity observed (it is possible that the drugs activity is 
not w h o lly  confined to viral D N A  polym erase and m ay affect cellular  
D N A  polym erase).
U r i n e
Establishing a reliable PCR test for urine proved difficult because of PCR 
inhibitors. The presence of PCR inhibitors in urine has been reported (171, 
160, 114, 179, 113, 163). Previous workers have attem pted to overcom e  
inhibition by ultra filtration (114), dilution (113, 161), nested PCR (113, 114, 
164, 184) or PEG precipitation m ethods (163). Published m ethods w ere  
com pared and adapted; PEG precipitation was the m ost useful. Khan 1991 
(114) show ed that urea concentrations of 100 mM inhibit PCR but I found  
that inhibition did not necessarily occur in sam ples w ith  the highest urea 
concentrations su ggestin g  that other inhibitors are present (data not 
show n). This phenom enon has been previously  reported (114) but the 
nature of this inhibition is unclear; ultra filtration and PEG precipitation  
elim inate aqueous inhibitors but retain protein and lipid w hich  m ay be 
responsible.
Urine sam ples from transplant recipients were tested in parallel by PCR, 
culture a n d /o r  DEAFF. The optim ised m ethod only attained sensitivities  
of 83% and 50% com pared to culture and DEAFF respectively. A lthough
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PEG precip itation  w as the m ost effective m ethod of separating virus  
particles from inhibitors, it is likely that this step does not lead to their 
com plete rem oval w hich  has a deleterious effect upon test sensitiv ity . 
H ow ever, a high proportion of urine sam ples were toxic to the fibroblasts 
used in DEAFF and culture testing. Therefore, despite poor sensitivity, 
PCR of CMV D N A  from  urine m ay be u sefu l w h en  perform ed in  
conjunction w ith DEAFF or culture.
2 .4 .8  Q u a n t i t a t i v e  a n d  S e m i - Q u a n t i t a t i v e  P C R
For accurate quantitative PCR, a control (flanked w ith  identical prim er 
binding sequences) m ust be included to com pensate for variations in PCR 
efficiency betw een  sam ples or reaction tubes. To differentiate betw een  
sam ple and control targets previous workers have created restriction sites 
by in vitro  m utagenesis (185), introduced single based perm utations and 
separated products by tem perature gradients gel electrophoresis (186), 
introduced heterologous D N A  and differentiated betw een  products by  
hybridisation (188, 182) or m ade size  differences and separated by gel 
electrophoresis (117, 187, 182).
In this study a 50 base bed deletion of the w ild  type sequence w as m ade  
u sin g  a recom binant PCR technique (116) that a llow s recom bination  
irrespective of restriction site position. Detection and results interpretation  
w as carried ou t w ith  ease and w ith ou t use of radioactive isotopes; 
fluorescein labelled PCR products were separated using an ABI Autom ated  
D N A  Sequencer.
It is im portant to am plify a dilution series of each spiked sample; single  
point analysis is inaccurate because am plification efficiencies m ay vary
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from tube to tube. A  dilution series also enables p lateau ing and or 
com petition betw een target D N A s to be identified and taken into account. 
A m plification profiles of w ild type (pT7/T3-IE) and recombinant (pT7/T3- 
lE.Del) targets mirrored each other. Am plification w as exponential after 30 
cycles and occurred w ith  equal efficiency; these are im portant pre­
requisites for accurate quantitation.
Accurate quantitation w as com pared w ith  sem i-quantitation for serum  
sam ples taken from three bone marrow transplant recipients. A  num ber 
of d iscrepancies arose because 'saturation' and variations in efficiency  
betw een  tubes cannot be m onitored w hen  perform ing sem i-quantitative  
PCR. H ow ever, both tests generated similar results and ranked these three 
patients identically (based upon m axim um viral load).
It w as decided  to adopt the sem i-quantitative technique for sam ple  
screening (see Chapter 4). This assay w as less tedious than the accurate 
quantitative assay w hich usually had to be repeated several tim es for each 
sam ple tested , u sin g  different series of deleted  target m olecu les, to 
generate parallel curves of positive gradient.
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CHAPTER 3
QUALITATIVE AND QUANTITATIVE 
POLYMERASE CHAIN REACTION (PCR) 
TESTING FOR CYTOMEGALOVIRUS DNA 
IN SERUM MAY ALLOW PREDICTION OF 
SYMPTOMATIC CMV INFECTION
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3.1 Introduction
An accurate and sensitive diagnosis of active CMV infection is a crucial 
prerequisite  for testing  the overall hyp oth esis that CMV initiates or 
enhances chronic rejection of liver grafts.
In add ition , to enable targetting of patients for pre-em ptive antiviral 
prophylaxis a accurate prediction of CMV disease m ust be made before the 
onset of sym ptom s.
The results presented in Chapter 2 show  clearly that PCR of CMV D N A  in 
serum  is m ore sensitive than buffy coat DEAFF. H ow ever, a num ber of 
reports show  that CMV PCR positivity does not necessarily correlate w ith  
sym ptom atic infection. This has been show n for heart (166), liver (160, 
168, 170), k id n ey  (167) and bone m arrow  (164, 169, 223) transplant 
recipients. Gerna 1991 (166) reported that, for 14 heart transplant recipients, 
w hole blood PCR positivity alone w as never associated w ith sym ptom s.
H y p o t h e s e s  T e s t e d  i n  C h a p te r  3
•  D e t e c t i o n  o f  c y to m e g a lo v i r u s  (C M V ) D N A  b y  q u a l i t a t i v e  P C R  o f  
s e r u m  o r  u r i n e  is  a s s o c ia te d  w i t h  d e v e l o p m e n t  o f  s y m p to m a t i c  i n f e c t io n
• D e t e c t i o n  o f  C M V  D N A  b y  q u a n t i t a t i v e  P C R  o f  s e r u m  o r  u r i n e  
e n a b l e s  a  t h r e s h o l d  to  b e  d r a w n  t h a t  d i s c r i m i n a t e s  b e t w e e n  s y m p t o m a t i c  
a n d  a s y m p t o m a t i c  C M V  i n f e c t io n
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3.2 Patients, Materials and Methods
3.2.1 Liver and Bone Marrow Transplant Recipients and C ollection of 
Clinical Sam ples
Thirty tw o liver and 17 bone marrow transplant recipients w ere studied. 
These patients were chosen according to the criteria described in Chapter 2 
(section 2.2.6); sam ples were successfully collected from these patients for 
> 2 m onths and at a rate of > 1 sam ple (serum, w hole blood and urine) per 
w eek. Sample collection, processing and storage w as carried out according 
to the m ethods described in Chapter 2 (section 2.2.5).
3.2.2 Laboratory Tests
3.2.2.1 Testing by PCR, DEAFF and Culture
Testing of clinical sam ples w as carried out using optim ised PCR tests (see 
sections 2.2.1.2 and 2.3.3), DEAFF (see section 2.2.3) and isolation through  
culture (2.2.4) as described in Chapter 2.
3.2.2.2 Serological Testing of Donor and R ecipient
CMV specific IgM w as detected using a p-capture ELISA kit (Eurogenetics, 
B elgium ); testin g  w as carried out according to the m anufacturers  
instructions. Briefly, serum sam ples were applied to microtitre plate w ells  
w hich had been coated in an anti-p chain polyclonal antibody. A ll sam ple 
IgM w as captured; CMV antigen (w hole virus proteins) w as then applied  
before application of CMV specific m onoclonal antibody (raised in m ouse) 
w hich w as conjugated to horse radish peroxidase. Colour w as developed  
after addition of substrate (H2O 2) and chrom ogen (tetram ethyl benzidine  
(TMB)) and read spectrophotometrically.
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CMV specific IgG w as detected using an indirect ELISA kit (D iam edix, 
USA); testing w as carried out according to the manufacturers instructions. 
Briefly, serum  sam ples were applied to microtitre plate w ells w hich had 
been coated w ith  CMV antigen (w hole virus proteins). A nti-hum an IgG 
antibody-alkaline phosphatase conjugate w as then applied. Colour w as 
developed after addition of substrate (p nitrophenyl phosphate (PNP)) and 
read spectrophotom etrically.
3 .2 .3  C l in ic a l  D a ta
Clinical w as collected by three other workers (Dr Jane Collier, Mr G iles 
Toogood and Mr A vi Soin); all blind to virological data.
The fo llow in g  sym ptom s w ere m onitored in liver transplant patients: 
pyrexia, hepatitis, abnormal liver function test results (LFT's), pneum onia, 
retinitis. These sym ptom s were only attributed to CMV after confirmation  
of CMV infection by laboratory testing. Furthermore, sym ptom s w ere not 
attributed to CMV if another infectious agent (e.g. bacteria) w as suspected  
or, in the case of pyrexia and LFT's, if rejection w as concom itant. The 
posttransplant courses of these patients were thus split into ep isodes of 
CMV disease and 'CMV disease-free' episodes; laboratory test results of 
sam ples taken during either episode were compared.
The fo llow in g  sym ptom s w ere investigated in bone marrow transplant 
patients: pyrexia, pneum onia, retinitis, leukopenia and throm bocytopenia.
3 .2 .4  A n a ly s i s  o f  R e s u l t s
Test results w ere compared w ith the incidence of disease by calculating the 
fo llo w in g  four statistics. Sensitivity w as m easured as the proportion of 
d isea se  ep isod es (or d iseased  patients) that tested  p o sitiv e  w hereas
127
specificity w as measured as the proportion of no-disease ep isod es/p atien ts  
that tested  negative. P ositive pred ictive value w as m easured as the 
proportion of 'test positive' ep iso d es/ patients that had disease w hereas  
n eg a tiv e  p red ictive  value w as m easured as the proportion  of 'test 
negative' ep isod es/p atien ts that were disease-free.
3.3 Results
3 .3 .1  C M V  D is e a s e  a f t e r  L iv e r  T r a n s p l a n t a t i o n
3 .3 .1 .1  T h e  S tu d y  G r o u p
In this study, 33 patients were investigated. These patients underw ent 57 
liver transplants, of w hich 44 were closely m onitored for CMV infection  
and d isease for more than 40 days a n d /o r  until the graft w as lost. This 
group had a m edian age of 49.5 years (17-63), received organs from donors 
w ith a m edian age 30.5 (12-56) and had a male: female ratio of 1.5 : 1.
A ctiv e  CM V in fection , detected  by PCR, DEAFF, cu ltu re a n d /o r  
serocon version , occurred in 48% (1 6 /3 3 ) patients and 59% (2 6 /4 4 )  
transplants. The overall incidence of CMV disease w as 33% of patients (ie 
11/33) and 46% transplants (ie 20/44).
The post-operative courses of 44 liver transplants were split into episodes  
of CM V disease (n=13) and CMV disease-free' ep isod es (n=36). Five 
patients experienced more than one episode of CMV disease; three patients 
experienced  tw o ep isodes during a single transplant and tw o patients  
experienced tw o episodes of CMV disease over two or more transplants.
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3.3.1.2 P red iction  of CM V In fectio n  and D isea se  from  CM V
A ntibody Status
The distribution of donor: recipient CMV antibody status in relation to 
post transplant active CMV infection and disease are show n in table 3.1 
and important points are described below.
Table 3.1 Incidence of active CMV Infection and D isease in  R elation to 
CM V A ntibody Status in  Liver Transplant Recipients
CMV antibodystatus Active CMV infection Proportion symptomatic
D+: R+ 77% (7 /9 ) 57% (4 /7 )
D+: R- 100% (9 /9 ) 78% (7 /9 )
D-: R+ 50% (3 /6 ) 67% (2 /3 )
D-: R- 0% (0 /4 ) NA
Table 3.1 shows the proportion of liver transplants (n=28) that involved active CMV infection in 
relation to CMV antibody status of donor (D) and recipient (R) and the proportion of active CMV 
infections that were symptomatic (proportion symptomatic). NA= not applicable.
M ism atching for CMV status (i.e. donor CMV antibody p o sitive  and  
recipient CMV antibody negative) w as associated w ith  a higher incidence  
of active in fection  com pared to that observed for other com binations  
(100% (9 /9) versus 53% (10/19); p=0.01).
H ow ever, the proportion of active CMV infections that were sym ptom atic  
w a s s im ila r  b e tw e en  'm ism atch  p o s it iv e ' and  'con tro l (o th er  
combinations)' groups (78% (7/9) versus 60% (6/10)).
Summary
• Identification of 'mismatched' donor/recipient combinations allowed retrospective
prediction of active CMV infection but not of the proportion of active infections that were 
symptomatic.
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3.3.1.3 Is Q ualitative Polym erase Chain Reaction (PCR) T estin g  of
CMV D N A  a C linically U seful Test ?
Sing le  R o u n d  P C R  and  P r e d ic t io n  o f  C M V  D is e a s e
Four patients w ere CMV antibody negative and received grafts from CMV 
antibody negative donors and were therefore not at risk of CMV infection  
since they also received CMV negative blood products. A ll sam ples taken 
from these patients, ie 39 serum and 26 urine taken over a m edian of 97 
days (range 69 to 129 days), were CMV negative by PCR.
The post-operative courses of 44 liver transplants w ere split into episodes  
of CMV disease (n=13) and CMV disease-free' episodes (n=36) as described  
earlier; the former were defined as episodes of pyrexia, hepatitis, abnormal 
liver function test results (LFT's), pneum onia or retinitis w hich correlated 
w ith  active CMV infection by laboratory testing. Correlation w as m ade 
betw een  p ositive  PCR a n d /o r  DEAFF results and CMV disease at each  
assessment; results are given in tables 3.2 and 3.3 and important points are 
described below.
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3ble 3.2
ORRELATION OF CLINICAL FINDINGS WITH QUALITATIVE PCR OF SERUM 
NO URINE AND WITH URINE DEAFF IN LIVER TRANSPLANT RECIPIENTS
SERUM PCR URINE PCR URINE DEAFF
POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE
CMV DISEASE 11 2 5 4 6 2
NO CMV DISEASE 2 30 6 2 6 5 2 4
Table 3.2 shows the distribution of qualitative serum and urine PCR and urine DEAFF results 
with episodes of CMV disease and ‘disease-free’ episodes. The sensitivity, specificity, positive 
predictive value and negative predictive value were calculated for each test from these figures 
and are given in table 3.3.
ABLE 3.3
ENSITIVITY, SPECIFICITY AND PREDICTIVE VALUE OF SERUM AND URINE 
CR AND URINE DEAFF IN RELATION TO EPISODES OF CMV DISEASE
SERUM PCR URINE PCR URINE DEAFF
SENSITIVITY 8 5 % 5 6% 7 5 %
SPECIFICITY 9 4 % 8 1% 8 3 %
'OSITIVE
'REDICTIVE VALUE 8 5 % 4 5% 5 5 %
lEGATIVE
'REDICTIVE VALUE 9 4 % 8 7% 9 2 %
tatistical parameters for qualitative PCR of serum and urine and for urine DEAFF in relation to CMV disease 
oisodes (data from table 3.2)
N ote that the total num ber of 'CMV disease' (n=13) and 'CMV disease- 
free' (n=36) episodes are not show n in table 3.2 because serum  and urine 
sam ples were not alw ays available.
Q ualitative PCR for the detection of CMV D N A  from serum  attained  
higher va lu es of sen sitiv ity , specificity , p ositive pred ictive value and  
negative predictive value w hen compared to urine PCR and urine DEAFF 
respectively (see table 3.3). A ll ep isodes of CMV disease w ere associated  
w ith  serum  a n d /o r  urine PCR positivity.
Tin t in g  o f  Q u a l i t a t i v e  P C R  P o s i t i v i t y
Serum  PCR w as a specific and sensitive indicator of CMV disease but 
unless CMV is detected before the onset of sym ptom s then pre-em ptive  
antiviral prophylaxis is im possible.
For the 44 liver transplants studied, initial serum PCR positivity occurred 
at a m edian of 38 days posttransplant (range 0-90 days) and initial urine 
PCR positivity also occurred at a m edian of 38 days posttransplant (range 3- 
114 days).
For each episode of CMV disease, the time of initial PCR positivity in days 
posttransplant was subtracted from the time of onset of sym ptom s in days 
posttransplant and expressed as days before or after the onset of sym ptom s.
D etection of CMV by qualitative PCR of serum occurred at a m edian of 3 
days before the onset of sym ptom s (range 12 days before to 14 days after) 
and before the onset of sym ptom s in 70% (7 /1 0 ) patients w ith  CMV 
disease. This suggests that qualitative PCR of serum  m ay be clinically  
usefu l.
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In contrast, urine PCR positivity occurred at a m edian time of 12.5 days 
after the onset of sym ptom s (range 11 days before to 20 days after) and 
preceded sym ptom s in 60% (3 /5 ) patients.
D u r a t i o n  o f  P C R  P o s i t i v i t y
The duration of serum and urine PCR positivity during episodes of CMV 
infection  w as correlated w ith  the occurrence of disease. There w as no  
difference betw een  the duration of PCR positiv ity  in sym ptom atic or 
asym ptom atic episodes.
The m ed ian  duration of serum  PCR p ositiv ity  w as 15 days during  
sym ptom atic infection (range 9-100) and 12 days (range 3-53) during  
asym ptom atic CMV infection; the patient w ith  serum  PCR p ositiv ity  of 
100 days is presented as a case study later (see case study 1).
U rine PCR p o sitiv ity  occurred for sim ilar length s of tim e du rin g  
sym ptom atic (m edian 11 days (range 7-37)) and asym ptom atic (m edian 25 
days (range 14-49)) CMV infection.
Summary
• Qualitative PCR of CMV DNA from serum had high sensitivity and specificity in 
relation to CMV disease and was more sensitive and specific than qualitative PCR or 
DEAFF testing of urine
• Serum and urine PCR positivity occurred before the onset of symptoms in 70% and 
60% of CMV diseased patients respectively
• Therefore, serum  PCR is a sensitive and specific test for CMV disease that may
predict the onset of CMV disease
• The duration of serum  or urine PCR positivity did not discrim inate betw een
asymptomatic and symptomatic CMV infection
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3.3.1.4 Is S em i-Q u an tita tive  P olym erase C hain R eaction  (PCR)
Testing of CM V D N A  a C linically U sefu l Test ?
Only sam ples that were positive by qualitative PCR were subject to sem i- 
qu antitative PCR; this w as perform ed a longsid e exogen ou s p lasm id  
controls (see section 2.2.2.4) w hich were used to plot a standard curve to 
enable copy number to be inferred for each sample tested.
P e a k  V ira l  L o a d  a n d  P r e d i c t i o n  o f  D i s e a s e  in P a t i e n t s  w i t h  a c t i v e  C M V  
I n f e c t i o n
The results generated w ere plotted for each patient a longside clinical 
details. After plotting sem i-quantitative serum  PCR results, I w as able to 
retrospectively, draw an arbitrary threshold of 2.55 x 10  ^ genom es w hich  
divided  perfectly the asymptom atic episodes of active CMV infection from  
the sym p tom atic . Such a threshold  could  not be draw n for sem i- 
quantitative urine PCR.
The d istribution  of ep isodes of asym ptom atic and sym ptom atic CMV  
infection using the arbitrary threshold is given in table 3.4.
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TABLE 3.4
CORRELATION OF VIRAL LOAD WITH THE PRESENCE OR 
ABSENCE OF CMV DISEASE DURING EPISODES OF ACTIVE 
CMV INFECTION
SERUM URINE
<2.55x105* >2.55x105* <2.55x105* >2.55x105*
EPISODES WITH 
DISEASE 0 11 4 3
EPISODES WITHOUT 
DISEASE 9 0 1 6
(p<0.000006) (N.S.)
The number of episodes with peak viral loads above or below the arbitrarily drawn 
threshold value are shown; episodes of active CMV infection are grouped according to 
presence or absence of symptoms. The sensitivity, specificity, positive predictive value and
negative predictive value for quantitative PCR of CMV DNA in serum, in relation to the 
occurrence of CMV disease during episodes of active CMV infection, were uniformly 100%; 
quantitative PCR of CMV DNA in urine gave statistic values of 43%, 14%, 33% and 20% 
respectively. The number of peaks plotted and analysed does not equal the number of 
episodes of active CMV infection; analysis was performed on each peak to allow vigorous 
examination of specificity.
V i r a l  L o a d  in  S e r u m  R e a c h e s  t h e  T h r e s h o l d  V a l u e  B e f o r e  o r  
S i m u l t a n e o u s l y  w i t h  the O n s e t  o f  C M V  D i s e a s e
Eleven ep isodes of sym ptom atic CMV infection w ere associated w ith a 
CMV load in serum that exceeded an arbitrary threshold; the time taken to 
exceed this threshold and the tim e of CMV disease w as com pared for 
seven of these episodes (clinical data regarding the t iming  of CMV disease 
w as insufficient for four episodes).
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Sem i-quantitative PCR may enable preem ptive antiviral prophylaxis; viral 
load in serum  reached the arbitrary threshold of 2.55 x 10  ^g e n o m e s /m l  
before or sim ultaneously w ith the onset of disease in 4 /7  and 3 /7  episodes 
respectively. The threshold w as exceeded before disease onset by a m edian  
of 4 days (range 0-10 days).
C M V  D i s e a s e  a n d  " C u m u l a t i v e  V ira l  L o a d "
M easuring the area under p lots of viral load w ith  tim e enabled  
calculation of the "cumulative viral load" for each ep isode of active CMV 
infection; this param eter takes into account viral load and duration of 
in fection .
After plotting "cumulative viral load" for serum PCR results, I w as able to 
draw an arbitrary threshold of 3.8 x 10  ^genom es w hich  d iv ided  perfectly  
the asym ptom atic episodes of active CMV infection from the sym ptom atic. 
Such a threshold could not be drawn for "cumulative viral load" for urine 
PCR.
The d istribution  of ep isod es of asym ptom atic and sym ptom atic CMV 
infection w ith this arbitrary threshold is given in table 3.5.
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TABLE 3.5
CORRELATION OF ‘CUMULATIVE’ VIRAL LOAD WITH THE 
PRESENCE OR ABSENCE OF CMV DISEASE DURING 
EPISODES OF ACTIVE CMV INFECTION IN LIVER 
TRANSPLANT RECIPIENTS
SERUM URINE
<3.8x106* >3.8x106* <3.8x106* >3.8x106*
EPISODES WITH 
DISEASE 0 11 2
2
EPISODES WITHOUl 
DISEASE
0 5 2
(p=0.00003) (N.S.)
The ‘cumulative’ viral load of each episode of active CMV infection was obtained after 
calculating the area under the plot of viral load against time.Table 3.5 shows the ‘cumulative’ 
viral load of each episode, in relation to the threshold value; episodes of active CMV infection 
are grouped according to presence or absence of CMV-related symptoms. The sensitivity, 
specificity, positive predictive value and negative predictive value of cumulative viral load of 
CMV DNA in serum, in relation to the occurance of CMV disease during episodes of active 
CMV infection, are uniformly 100%; cumulative viral load of CMV DNA in urine is not clinically 
useful (statistic values are 50%, 71%, 50% and 71% respectively).
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An arbitrary threshold am ount of "cumulative viral load" in serum (3.8 x 
10^ g en om es) w as able to d iscrim inate b etw een  sym p tom atic  and  
a sym p tom atic  e p iso d e s  of active CMV in fection . This param eter  
im proved the specificity of PCR of CMV D N A  in serum; specificity and 
positive predictive value were both 100%. In contrast, this w as not show n  
for "cumulative viral load" for urine PCR.
By definition, 'cum ulative viral load' cannot be calculated before the onset 
of sym ptom s and is therefore not usefu l for d iagnosis. H ow ever, this 
param eter is a m easure of the total am ount of CMV replication and here 
confirm ed that CMV replication caused the observed disease episodes.
Summary
• Sem iquantitative PCR enabled an arbitrary threshold to be draw n for peak viral
load values and "cum ulative viral load" in serum; all sym ptom atic episodes had peak 
values above this threshold and all asymptomatic episodes had peak values below it
• Such thresholds could not be drawn for urine PCR
• Furtherm ore, this threshold was exceeded before or sim ultaneously  w ith  the
appearance of symptoms for all symptomatic episodes analysed
3.3.2 CM V D isease After A llogeneic Bone Marrow Transplantation
3.3.2.1 The Study Group
In this study, 17 patients were investigated; 13 patients received marrow  
from  H L A -identical sib lings and four from H L A -identical unrelated  
donors. This group had a m edian age of 38 years (22-52) and had a male: 
fem ale ratio of 1.5: 1.
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3.S.2.2 CMV Infection and D isease
Three recipients were CMV antibody negative and received marrow from  
CMV antibody negative donors; these patients w ere not at risk of CMV 
infection and all samples (40 serum , 22 urine) tested negative by PCR.
CMV infection, positive by serum  PCR a n d /o r  urine PCR or DEAFF, 
occurred in 24% (4/17) patients, o f w hom  three developed CMV disease.
The relationship betw een donor and recipient CMV antibody status, active 
CMV infection, PCR positivity is show n in table 3.6. Two transplants were 
perform ed betw een donor and recipient w ith  unknow n CMV antibody  
status; neither hosted active CM V infection.
T a b l e  3 . 6
I n c i d e n c e  o f  C M V  I n f e c t i o n  a n d  D i s e a s e  i n  R e l a t i o n  t o  
C M V  S e r o l o g y  i n  B o n e  M a r r o w  T r a n s p l a n t  R e c i p i e n t s
C M V  S E R O L O G Y n
A C T IV E  C M V  
I N F E C T IO N
C M V
D I S E A S E
U R IN E
P O S IT IV E
S E R U M
P O S IT IV E
D + :  R + 2 0 0 0 0
D + : R - 4 1 0 1 0
D - : R + 6 3 3 3 3
D - : R - 3 0 0 0 0
Table 8 shows the number of transplants (n=17) involving active CMV infection (serum and/or 
urine positivity by PCR) and CMV disease. Two patients of unknown CMV antibody status 
did not host active CMV infection.
R=recipient, D=donor, n=number.
A ll three patients that d ev e lo p ed  CMV disease were CMV antibody  
p ositive pretransplant and received marrow from CMV antibody negative
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All three patients that developed CMV disease were CMV antibody 
positive pretransplant and received marrow from CMV antibody negative 
donors; all three tested positive by serum and urine PCR. All three 
patients received low  dose ganciclovir prophylaxis. A fourth patient 
(recipient negative and donor positive CMV serology, no ganciclovir 
prophylaxis) developed active CMV infection (urine positive only) but not 
CMV disease.
Timing of PCR positivity and disease and viral load in relation to disease 
is presented in the form of case studies (see cases 4 to 6; figures 3.4 to 3.6).
I
All of the patients with symptomatic infection (n=3) had serum viral loads 
above the arbitrary threshold of 2 x 10  ^ genomes/ml that was established 
using semi-quantitative data from liver transplant recipients. This is 
further evidence that this threshold may be clinically useful.
3.3.2 3 Active CMV Infection and Acute Graft Versus Host Disease
Thirteen patients developed acute graft versus host disease (GVHD); 4/13  
also developed active CMV infection. In contrast, none of the four patients 
that did not develop acute GVHD developed active CMV infection. The 
link between acute GVHD and CMV remains controversial and is 
discussed later.
Summary
• 24% (4/17) bone m arrow  transp lan t recipients developed active CM V in fection
• T h ree  of w h o m  w ere  re c ip ien t CM V an tib o d y  positive : d o n o r CM V  an tib o d y  
n eg a tiv e ; a ll th ree  d ev e lo p ed  CM V d isease . O ne p a tie n t (rec ip ien t CM V an tib o d y  
negative: donor CM V an tibody  positive) developed asym ptom atic CM V infection.
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3.3.3 Case studies
Case studies are shown and described in figures 3.1 to 3.6. Serum and urine 
samples were tested throughout the post-transplant course; qualitative and 
semiquantitative PCR results are shown. Note that semiquantitation of 
CMV is illustrated using either 1000 or lOOOOx genomes/ml as the y-axis 
scale, according to the peak load of the case.
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3.4 DISCUSSION
3.4.1 Conclusions
• The hypothesis that CMV detection by PCR was associated w ith the developm ent 
of symptomatic infection was upheld for serum PCR.
• The hypothesis that semi-quantitative PCR allowed an arbitrary threshold to be 
draw n that discrim inated between asymptomatic and symptomatic episodes of CMV was 
also upheld for serum  PCR.
• Neither hypothesis was upheld for urine PCR.
3.4.1.1 Liver Transplant Recipients 
Serology
• Pre-transplant serology for CMV identified patients a t risk of CMV disease and
m ay therefore be clinically useful.
Serum PCR of CMV DNA
• Qualitative PCR of CMV DNA from seriim m ay be clinically useful; it had  high 
sensitivity and specificity m relation to CMV disease and. positivity occurred before the 
onset of syn^tom s in 70% cases.
• The duration of serum  PCR positivity did  not discriminate between asymptomatic 
and symptomatic CMV infection.
• Sem iquantitative PCR of serum  m ay be clinically useful; arb itrarily  draw n 
thresholds for peaik viral load values and "cumulative viral load" discrim inated between 
symptomatic and asymptomatic infections.
Urine PCR of CMV DNA
• Qualitative and semiquantitative urine PCR and urine DEAFF were less clinically 
useful than serum PCR.
3.4.1.2 Bone Marrow Transplant Recipients
• CMV is an im portant pathogen after bone marrow transplantation.
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3.4.2 Incidence, of Active CMV Infection and Disease
The incidence of active CMV infection and disease after liver 
transplantation (48% and 33%) is consistent with that reported in other 
centres (93, 94, 43, 96, 97, 99). The incidence after bone marrow 
transplantation (24% and 18%) is lower than most reports (109, 110, 111). 
This may be due to the policy at Addenbrooke's NHS Trust to administer 
low-dose ganciclovir prophylaxis to all bone marrow transplant patients at 
risk of CMV disease (ie donor or recipient CMV antibody positive).
3.4.3 CMV Serology Identified Patients at Risk of Active CMV Infection
Mismatching for CMV serology (donor positive/ reciplent negative) is an 
important risk factor for active CMV infection after liver transplantation. 
Here, mismatched transplant recipients experienced significantly higher 
incidences of active CMV infection (100% versus 53%) compared to non­
mismatched controls. Similar results have been reported by other groups 
(43, 93, 94, 96, 98, 99, 227). The findings of Schmidt et al (1993) (227) mirror 
the results presented here; mismatching was associated with significantly 
increased active CMV infection (83% versus 48%).
In contrast, all 3 /17  bone marrow transplant recipients that developed
CMV disease were CMV antibody positive and received marrow from a
CMV antibody negative donor. In this scenario, recipient immune
responses to CMV are ablated before recipients acquire the donor immune
system which is naive to CMV. Similar results have been found by other
workers (141, 230, 241, 247). Transplantation of marrow from CMV
antibody positive donors into CMV antibody negative recipients results in
abortive CMV infection. De Cast (1992) (259) described four such patients;
whole blood PCR positivity and granulocyte pp65 antigen expression
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occurred transiently but buffy coat cultures were consistently negative and 
seroconversion did not occur. It is likely that case 6 of this study is an 
example of such an abortive CMV infection. \
I • .
After either liver (donor CMV antibody positive/recipient negative) or 
bone marrow transplantation (donor CMV antibody negative/recipient 
positive), recipients that harbour CMV but are immunologically naive are 
at high risk of active infection and disease. In addition, primary cellular 
immune responses to CMV are delayed due to immunosuppression. In 
contrast, CMV antibody positive recipients are primed to mount specific 
cellular and humoral immune responses to CMV and are able to do so 
despite immunosuppression.
The importance of such responses in combatting active CMV infection has 
been demonstrated (65, 260). Reusser et al (1991) (260) studied 20 recipients 
of marrow from CMV antibody positive donors; 10 recipients were able to 
mount cytotoxic lymphocyte (CD8 +) responses when challenged in vitro 
with CMV infected autologous fibroblasts. None of these 10 patients 
developed CMV pneumonitis whereas 6/10 patients that did not mount 
an in vitro response died from CMV pneumonitis. Indirect evidence was 
provided by Fox et al (1988) (98); recipient CMV antibody positivity was not 
protective w hen liver transplant recipients were subjected to heavy 
immunosuppression (cyclosporin-A and anti-thymocyte globulin).
liow ever, if mismatching was avoided then a large number of transplants 
would be excluded.
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3.4.4 Qualitative PCR and Prediction of CMV Disease 
The finding that all serum and urine samples taken from CMV antibody 
negative recipient and donor were PCR negative was an important 
indicator of specificity. This result is typical of reports made since the 
implementation of CMV-negative blood product use after transplantation 
(261).
Some reports have suggested that PCR of whole blood correlates relatively
j
poorly with disease (164, 166, 168, 169, 171, 180, 227); the work presented 
here shows that detection of CMV in serum and quantitation led to high 
specificity.
This study shows that PCR of CMV DNA from serum is a sensitive (88% 
(14/16)) and specific (96% (44/46)) indicator of CMV disease episodes in 
liver and bone marrow recipients. Two out of 16 episodes of CMV disease 
in liver transplant recipients did not test positive by serum PCR; it is 
possible that CMV infection was localised in the kidney (both episodes 
were associated with urine CMV positivity). It is also possible that serum 
positivity was transient and occurred when samples were not taken; CMV 
positivity of serum and urine often differs temporally (see below). 
Conversely, on two. occasions serum positivity was not associated with 
disease. In both cases, CMV positivity occurred very early (within 1 week) 
after re-transplantation for chronic rejection (see chapter 4).
151
transplant recipients by Patel et al (1994) (170) showed that serum PCR 
could detect active CMV infections with 92% sensitivity and 100% 
specificity; CMV disease was detected with 100% sensitivity but specificity 
was only 57%. Patel et al (1994) (170) do not quote sensitivity with respect 
to naked target DNA but their test is probably more sensitive than the test 
used in this study because they perform Southern hybridisation after 
amplification. In contrast, I report 88% sensitivity and 94% specificity; it is 
possible that there is a trade-off between sensitivity and specificity.
CMV is a cell-associated virus (see Introduction) and only enters serum 
after lytic infection; abortively infected cells are not detected. In addition, 
phagocytosed material is not detected by serum PCR.
3.4.5 Semi-Quantitative PCR and Prediction of CMV Disease
Semi-quantitation also improved the specificity and, positive predictive 
value of the test used in this study; all serum samples with viral loads 
greater than an arbitrarily drawn threshold were associated with  
symptomatic CMV infection.
This threshold was drawn after plotting of semi-quantitative results; the 
ability to draw such a threshold suggests that semi-quantitative PCR may 
be useful but this needs to be confirmed in a larger prospective study.
Quantitative PCR of CMV DNA has been attempted previously (181, 182, 
183, 271, 273) and successfully discriminated between asymptomatic and 
symptomatic CMV infection in renal (271) and liver (273) transplant 
recipients.
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Mutimer et al (1995) (273) have recently reported monitoring 32 liver 
transplant recipients by quantitative PCR of buffy coat. A 21b'p-deleted 
standard was included in each tube and the initial ratio wildtype: standard 
was calculated after measurement of PCR products using a rapid 
hybridisation technique. The results were presented as CMV genom es/1.5 
X 10  ^cells; peak load varied between 8.4 xlO  ^and 1.2 xlO  ^for three patients 
w ith symptom atic infection and between 950 and 2.8 xlO ^for  
asymptomatic patients. In contrast, the résulte presented in this thesis do 
not demonstrate overlap of viral loads between symptomatic and 
asymptomatic; this is possibly due to the specificity afforded through 
testing serum rather than buffy coat.
Schafer et al (271) used competitive nested PCR's to quantify the number 
of copies of CMV gB gene DNA per 10  ^ B-globin genes present in PBL; 
internal controls, each differing 3bp from w ild type (created by 
recombinant PCR), were generated for CMV and B-globin targets. Samples 
were spiked, in parallel, with 50 and 10^ copies respectively before 
amplification and products were quantified by temperature gradient gel 
electrophoresis (TGGE). For serial PBL samples, taken from 17 renal 
transplant recipients, quantitation discriminated between symptomatic 
and asymptomatic infection.
Rawal et al 1994 (183) compared two semi-quantitative nested-PCR tests;
endpoint titration, visualised after agarose gel electrophoresis, and a
method employing measurement of product by scintillation proximity
assay (SPA) with comparison to exogenous positive controls. These two
methods had comparable sensitivity and specificity. CMV DNA quantities
in whole blood samples taken from 6 bone marrow transplant recipients
experiencing active infection accurately mirrored infection and the effect
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of subsequent treatment but could not discriminate between asymptomatic 
and symptomatic infection. This lack of discrimination conflicts with the 
results presented here, by Schafer et al (1993) (271) and by Mutimer et al 
(1995) (273) and may be due to 'saturation' of nested PCR reactions, leading 
to an underestimate of viral load.
3.4.6 PCR Fositivity May Occur before the Onset of Symptoms .
The timing of PCR positivity is crucial. In this study, qualitative PCR 
positivity of serum occurred before disease in 75% (6/8) patients; the 
quantitation 'threshold' was exceeded before disease in 57% (4/7) patients 
(and was exceeded simultaneously with disease for 43% (3/7) patients). 
These results suggest that these PCR tests will only enable pre-emptive 
prophylactic treatment for a proportion of patients but will nevertheless, 
provide useful confirmation of CMV infection for all patients thus 
facilitating treatment. However, samples were only taken twice weekly in 
this study; accurate study of timing should be conducted in a further study 
by testing serum samples on a daily basis. Other reports have shown that 
whole blood PCR positivity occurs before CMV disease in liver transplants 
(160,227).
Finally, urine testing by PCR was not useful. Sensitivity, specificity and 
prediction of CMV disease episodes was poor (see also 160, 161, 162, 163, 
164 and Chapter 2).
3.4.7 Active CMV Infection and Bone Marrow Transplantation
A small number of bone marrow transplant patients were included in this 
study; results must therefore be interpreted with caution. However, some 
interesting observations could be made.
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All patients that developed symptomatic CMV infection were recipient 
CMV antibody positive/ donor negative combinations. Furthermore, all 
patients that developed active CMV infection also developed acute graft 
versus host disease.
Active cytomegalovirus infection and graft versus host disease have been 
linked (see section 1.6.6).
The Effect o f  CMV on GVHD ,
A number of papers have suggested that CMV infection may predispose 
patients to acute (131) or chronic GVHD (132, 133, 134, 135). Lonqvist 1984 
(132) studied 53 allograft recipients surviving more than three months; 
the incidence of chronic GVHD was 42% overall and was higher after 
CMV disease (56% (20/36) versus 12% (2/17); p<0.01). CMV disease 
occurred before GVHD by a median of 128 days (range 23-322 days). Other 
herpesviruses have also been implicated (136, 137).
Donor CMV antibody positivity and not active CMV infection was shown 
to be important by Jacobsen et al 1986 (134). Donor immunity to CMV is 
implicated and the authors suggest that CMV stimulation of lymphokines 
or MHC restricted presentation of CMV peptides mediates GVHD. CMV 
specific cytotoxic T-lymphocyte (CTL) activity of patients with active CMV 
infection is higher in those whose donor is CMV immune because it is the 
donor immune system that reconstitutes after allogeneic bone marrow 
transplantation (138).
Acute GVHD is also a risk factor for chronic GVHD; it is possible that
'i
epidemiological associations between chronic GVHD and CMV infection
result because CMV activation is a marker of acute GVHD.
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The Effect o f  GVHD upon A ctive CMV Infection and CMV Pneum onitis 
However, it is also possible that graft versus host disease predisposes to 
active CMV infection.
CMV has been found within skin and gut tissue during episodes of acute 
GVHD (139, 140). However, when Appleton et al 1995 analysed sequential 
rectal biopsies for acute GVHD and CMV infection it was found that 
GVHD preceded active CMV. Other authors also suggest that it is GVHD 
that initiates or amplifies active CMV infection (141, 142, 143, 139).
Meyers et al 1986 (141) studied 545 marrow recipients and found that the 
incidence of acute GVHD was not influenced by CMV serology and was 
39% am ongst CMV antibody negative recip ient/negative donor 
combinations. Conversely, the incidence of active CMV infection, detected 
by buffy coat culture, was higher in recipients developing severe (grade II- 
IV) acute GVHD (63.1% versus 42.1%; p=0.0001). CMV infection occurred 
after acute GVHD developed (median 19 days). In addition, severe acute 
GVHD was a risk factor for the development of CMV pneumonia 
(txO.0005). - , C ^
Bowden et al (1987) (144) suggested that recipient CMV reactivation was 
initiated after GVHD-induced obliteration of recipient lymphocytes; 
natural killer cell responses to CMV-infected and uninfected cells were 
significantly reduced during GVHD.
In addition, acute GVHD is a risk factor for the development of CMV
pneumonitis (141, 145, 148, 147, 143). It has been hypothesised that
alloreactive lymphocytes are involved and that CMV m odifies the
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In addition, acute GVHD is a risk factor for the development of CMV 
pneumonitis (141, 145, 148, 147, 143). It has been hypothesised that 
alloreactive lymphocytes are involved and that CMV m odifies the 
antigenic, status of lung interstitial cells; Zaia 1986 (148) showed that the 
amount of CMV DNA present in lung tissue does not predict the severity 
of pneumonitis.
This is difficult to reconcile with a relatively small number of reports that 
suggest that T-lymphocyte depletion prior to bone marrow transplantation 
increases the risk of developing CMV pneumonitis despite lowering the 
incidence of acute GVHD (150, 151, 152). CMV-spedfic ceUular responses 
are important after bone marrow transplantation (144, 153) and 
Hertenstein et al (1995) (150) suggest that T-cell depletion prevents an early 
and important cellular response to CMV thus allowing uncontrolled 
replication which predisposes to CMV pneumonitis which may, or may 
not, involve immune-mediated injury.
Murine M odels o f GVHD and CMV Pneum onitis
Grundy et al 1985 (154) injected immunocompetent (BIO x BIO.A) FI 
h yb rid  m ice w ith  parental sp leen  cells; G V H -induced  
immunosuppression of the recipient (FI hybrid) immune system was
measured by chromium release assay (CRA) after spleen ceU cytolysis of
>
allogeneic and trinitrophenol (TNP)-modified syngeneic target cells.
Twenty times less parental spleen ceUs were needed to ablate the recipient
immune system when murine cytomegalovirus (mCMV) was injected
concomitantly. Only mice injected with parental spleen cells and mCMV
died from CMV pneumonia; CMV was cultured from the lungs and
inflammation was seen. This group went on to show that 87% of the
infiltrating cells were donor specific (155). The authors suggest that the
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observed synergy between mCMV and induced GVH was mediated by the, 
previously observed, ability of mCMV to increase aUoreactivity (51; see 
section 1.9.3).
Ganciclovir significantly reduced the amount of mCMV isolated from the 
lurigs and the degree of interstitial inflammation but did not reduce the 
frequency of pneumonitis nor the degree of perivascular inflammation 
(156). This paper emphasised the immunopathology of CMV pneumonitis 
and suggests that an alloreactive, rather than a mCMV-specific, cellular 
response is important.
This proposal is supported indirectly-by the case reported in this thesis that 
died of CMV pneumonitis. Regular monitoring by serum and urine PCR 
showed that this case cleared CMV from both sites several days before 
death. Unfortunately, lung tissue from this patient, was not available.
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CHAPTER 4
RISK FACTORS FOR CHRONIC 
REJECTION OF LIVER GRAFTS
INCLUDING
CYTOMEGALOVIRUS
159
4.1 Introduction
A number of groups have attempted to elucidate the risk factors for 
chronic rejection after liver transplantation (204, 205, 210, 225, 283, 372); the 
importance of HLA m atching/ mismatching, primary disease and 
cytomegalovirus (CMV) remain controversial (see section 1.8.2). A 
summary of these findings for CMV is given in table 4.1 and important 
points are described below.
TABLE 4.1 Summary of Studies of CMV as a Risk Factor for Chronic Rejection of Liver 
Grafts
Group Reference CMV Risk ? CMV Risk ' 
Identified
Relative
Risk
Kings College O’Grady etal (1988) 
(283)
Yes Active CMV infection 7.5
Kings College Amold et al (1992) 
(284)
Yes Persistent graft infection
\
5.4
Pittsburgh Manez et al (1993) 
(225)
Yes CMV hepatitis 6
Birmingham Candinas et al (1995) 
(210)
Yes Serology mismatch 
(donor +/ recipient -)
3.5
Cambridge P.E. (1996) 
(THESIS)
Yes Active CMV infection 
for k 1 month
3.3
Mayo Clinic Paya (1992) 
(372)
No -----
These differences may have arisen because of different patient 
management regimes between centres such as the nature and degree of 
immunosuppression and the promptness of antiviral treatment.
Only one study (372) did not find a link between CMV and chronic 
rejection; here, all patients received acyclovir prophylaxis and were treated
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with ganciclovir after development of active CMV infection. However, 
CMV testing (by DEAFF and culture) was only performed when active 
CMV was suspected clinically; sub-clinical active infection was not 
analysed in this study and may have been important.
In this chapter, the involvement of CMV was analysed in detail; viral 
load and serum PCR positivity were shown to be important prognostic 
indicators of CMV disease in Chapter 3 and are now analysed in the 
context of chronic rejection. Other, previously published risk factors were 
also analysed for this group. ,
In addition, the role of the promoter allele TNF-2 was investigated in 
relation to chronic rejection and active CMV infection (see section 1.9.4); 
to my knowledge, this is the first study of its kind. This was undertaken 
because the TNF-2 promoter allele is associated with increased TNF 
expression (405) and elevated TNF levels have been described previously 
for chronically rejected livers (397). Furthermore, TNF expression and 
active CMV infection have been shown to positively up regulate each 
other (398,399,400,401,402; see section 1.9.4).
H ypotheses
• CMV infection may constitute a risk for chronic rejection of liver grafts.
• Class II MHC molecule matching may be a risk factor for chronic rejection.
• MHC molecule mismatching may be a risk factor for persistent active CMV 
infection.
• The tum our necrosis factor-2 (TNF-2) promoter allele, in liver transplant recipients, 
is a risk factor for chronic rejection and may interact w ith CMV.
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4.2 Patients, Materials and Methods
"  ' \  ■ ■ ■
4.2.1 Patients
Selection o f Chronic Rejection Study Group and Controls 
Initially, patients were selected according to the criteria that samples had 
been successfully collected post transplant for more than two months and 
at a rate of more than one sample (serum, whole blood and urine) per 
week (see section 2.2.6, see Appendix 1).
From this group, 33 patients were selected. All patients that were re­
transplanted were selected (18 patients were re-transplanted; 12 of whom  
lost grafts to chronic rejection). In addition, 15 patients that did not lose 
their graft were selected to serve as controls; these were chosen 
sequentially according to transplant date. All patients studied had been 
transplanted within the past 3 years.
,
The 33 patients chosen for study received 57 allografts which were split 
into two groups; those that were lost to chronic rejection (n=12) and 
controls (n=45). The latter group comprised 18 primary transplants,. 17 
secondary transplants and seven tertiary transplants that were retained 
and three primary transplants that were lost (to reasons other than chronic 
rejection).
All of these post transplant courses were monitored prospectiyely for 
active CMV infection by serum and urine PCR, buffy coat and urine 
DEAFF and culture and/or serological change.
162
Selection o f Patien ts fo r  TNF Allele Study
The criteria for selection for this study was the availability of a pre 
transplant whole blood sample; 123 liver transplant recipients (15 chronic 
rejectors and 108 controls) were tested for TNF allele status.
Data of active CMV infection was available for the majority of these 
patients (n=110). Of these, 33 patients were monitored by serumi and urine 
PCR, buffy coat and urine DEAFF and culture and/or serological change 
whereas 77 patients were only monitored as part of routine clinical
practice by buffy coat and urine DEAFF and culture and/or serological
1
change. The latter group were therefore monitored using techniques of 
lim ited sensitiv ity  and results from this group were gathered  
retrospectively.
4.2.2 Sample Collection
Sample collection, processing and storage was carried out according to the 
methods given in Chapter 2 (section 2.2.5).
4.2.3 Virological Data
Virological data (serology, DEAFF, serum PCR and urine PCR) was 
generated, without knowledge of clinical details, as described in Chapter 3.
4.2.4 Human Leukocyte Antigen (HLA) Allele Typing
FÎLA typing was performed by microcytotoxicity assay according to the 
method of Darke and Dyer (1992) (406) using a panel of sera with known 
HLA reactivity. Briefly, recipient and donor whole blood were collected in 
preservative free heparin before isolation of peripheral blood  
lymphocytes (PBL) on a Ficoll gradient. B-cells were enriched from a 
proportion of PBL after 'rosetting' of T-lymiphocytes with sheep red blood
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cells. PBL were used to determine HLA class I type and B cells to determine 
class n  type. For each assay, cells were then counted and concentration was 
adjusted to 10^/ml before Ijil cells was added to each well of a microtitre 
plate containing a test sera. The plate was now incubated at 22*C for 30 
minutes before 4|il of complement (rabbit serum) was added and a further 
incubation at 22"C for 30 minutes was performed. Staining was then 
carried out for five minutes using 2\l\ 5% aqueous eosin-Y before cells 
were fixed in formaldehyde. Plates were then centrifuged (200g/l minute) 
to recover cells and cells were visualised by microscopy. Positivity was 
scored when cell death exceeded 20% total. Matching and mismatching of 
specificities was scored for each donor/recipient pair,
4.2.5 Tumour Necrosis Factor (TNF) Promoter Allele Typing
This was performed by PCR of a 184 bp region of the TNF-a gene promoter 
using sequence specific primers (408). Sense primers for amplification of
TNF-1 or TNF-2 differed by a single, 3' terminal nucleotide at position -308
)
(if transcription start site is nucleotide +1); this single base mutation 
separates these 2 alleles. Two reactions were set up for each sample; PCR
a
for the TNF-1 allele (reaction 1) incorporated antisense primer (5'- 
TCTCGGTTTCTTCTCCATCG-3'; nucleotides -164 to -144) and sense 
primer (5 -ATAGGTTTTGAGGGGCATGG -3'; nucleotides -328 to -308). 
PCR. for the TNF^2 allele (reaction 2) incorporated identical antisense 
p r im e r  but  d i f f e r e n t ,  sp e c i f i c  s e n s e  p r im e r  (5'- 
ATAGGTTTTGAGGGGCATGA -3'; nucleotides -328 to -308).
Primers for human growth hormone were included in each reaction as a 
positive control for successful amplification (342 bp PCR product). These 
comprised sense (5'-GCCTTCCCAACCATTCCCTTA-3) and antisense (5- 
TCACGGATTTCTGTTGTGTTT-3 ) primers.
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yEach reaction was set up in a final volume of 13pl containing 75mM tris-
j
HCl (pH 9.0), 20mM (NH4)2 S04, 0.01% Tween, 2mM MgC12, 0.2ng 
template DNA, 200pM each dNTP, lOpmol each sequence specific primer, 
2pmol each control primer, 0.15 Units Taq Polymerase. Thermal cycling 
was performed as follows: 10 cycles (94"C, 20 seconds/ 65“C, 60 seconds) 
followed by 20 cycles (94"C, 20 seconds/ 61 “C, 50 seconds/ 72"C, 30 
seconds).
Reaction mixes were then loaded and electrophoresed upon a 1.5% agarose 
gel (75V, 3 hours), stained with ethidium bromide and viewed over 
ultraviolet light. TNF typing was then scored for reactions that had 
undergone successful PCR amplification (ie. positive control product 
identified).
4.2.6 Clinical Data
Clinical details were gathered by two independent workers (Dr Jane Collier 
and Mr Avi Soin) without knowledge of virological details. CMV disease 
was defined by the parameters given earlier in Chapter 3. Acute rejection 
was defined by parameters given by Snover et al (1984) (192; see section 
1.8.1.1) and chronic rejection was defined by the parameters set out by 
Wight D (1991) (95 ; also see section 1.8.1.2).
4.2.7 Results Analysis
Allografts were split into two groups; those lost to chronic rejection (n=12) 
and controls (n=45).
These two groups were analysed for CMV-related factors ie. serology, 
active infection, duration of active infection, time of initial positivity,
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viral load and 'cumulative viral load'. Duration and initial positivity time 
were plotted for each patient studied and an attempt was made to draw an 
arbitrary threshold to discriminate chronic rejectors from controls. In 
addition, the thresholds drawn in Chapter 3 for viral load and 
cumulative viral load' are drawn here. The results shown in table 4.2 
relate to these arbitrarily drawn thresholds.
In addition, factors that have previously been related to chronic rejection 
were analysed; ie. primary disease (PSC, PBC, hepatitis C and hepatitis B 
virus infection), recipient and donor age and sex, recipient and donor HLA 
status (matching ahd mismatching of DR and A and B loci), incidence, 
number, timing ^ d  grade of acute rejection episodes.
• ' .
Finally, the distribution of the TNF-2 allele among a larger group of 
consecutive liver transplant patients (15 chronic rejectors and 108 controls) 
was analysed.
Note that there is some variation in the number of grafts compared for 
different factors according to data availability.
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4.3 Results •
4.3.1 Cytomegalovirus as a Risk Factor for Chronic Rejection
43.1.1 CMV-Related Risk Factors for Chronic Rejection 
These are shown in table 4.2a.
TABLE 4 3  a C ytom egalovirus as a R isk  Factor fo r C hronic Rejection o f Liver G rafts
Factor CR group Controls  ^ Relative 95%  Confidence
(n=12) (n=45) Risk Interval
CYTOMEGALOVIRUS
Serology
Donor - : recipient - 
Donor - : recipient +
Donor + : recipient - 
Donor + ; recipient +
0%(0/10) 
50% (5/10) 
20% (2/10) 
30% (3/10)
26% (8/31) 
13% (4/31) 
26% (8/31) . 
36% (11/31)
3.87
0.78
0.84
p=0.08* 
1.28-11.70 
0.2- 3.07 
0.29- 2.44
Active Infection
Incidence 75% (6/8) 49% (20/41) 153 . 0.92-2.26
Duration > 30 days 83% (5/6) 25% (4/16) 3.33 1.32-8.37
Time initially positive > 25 days 83% (5/6) 63% (12/19) 2.35 0.33-16.97
Serum PCR +
Incidence 38% (3/8) 27% (11/41) 1.43 0.5-4.0
Duration ^ 30 days 67% (2/3) 20% (2/10) 4.5 056-36:44
Time initially positive ^ 25 days 100% (3/3) 73% (8/11) 1.36 0.26 - 456
Peak viral load > th re ^ o ld 50% (2/4) 83% (5/6) 0.43 0.10 -1.77
Cumulative viral load > threshold 50% (2/4) 83% (5/6) 0.43 0.10 -1.77
Urine P C R +
Incidence 75% (6/8) 39% (16/41) 1.92 1.14 - 3.43
Duration > 30 days 83% (5/6) 21% (3/14) 7.5 1.07-52.81
Time initially positive ^ 25 days 83% (5/6) 73% (11/15) 1.56 0.23-10.42
Symptomatic Infection
incidence ' 38% (3/8) 32% (12/40) 125 0.45-3.43
rim e initiaHy positive ^ 25 days 100% (6/6) . 93% (14/15) 0.7 0.23 - 2.26
Table 4.2 shows the results from analysis of 57 liver transplants; 15 were chronically rejected and 42
served as controls. The following factors were compared between these 2 groups; cytomegalovirus
(CMV) serology and active infection (incidence, onset, duration and load), serum and urine PCR
positivity (incidence, onset, duration and load) and the incidence of symptomatic infection).
* Fishers exact test
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4.3.1.2 Early Active CMV Infection after Retransplantation for 
Chronic Rejection
Indirect evidence that CMV persistence is associated with chronic rejection 
was sought by comparing the median time for the onset of active CMV 
infection after retransplantation between patients retransplanted for 
chronic rejection and controls. Results are given in table 4.2b, and 
important points are described below.
Table 4.2b Early Active CMV Infection Occurred after Retransplahtation 
for Chronic Rejection
Chronic Rejectors Controls
Initial
Transplant
Number of Transplants 8 17
Active CMV 63% 59%
Onset
(Median dav Dost transplant)
44  (24-61) 41 (32-68)
% onset < 25 days 20% (1 /5 ) a 0% (0 /1 0 ) b
Retransplant
Number of Transplants 9 6
Active CMV 78% — ' 67%
Onset
(Median dav Dost transplant) 10 (0-26) 36 (22-75)
% onset < 25 days 86% (6 /7 ) c 25% (1 /4 )  d
Table 4.2b show s th e  m ed ian  d ay  a fte r transplan ta tion  that active CMV infection occurred  
fo r in itia l tran sp lan ts  th a t  w ere  chronicsdly rejected, in itia l tran sp lan ts  th a t  w e re  n o t 
chroniccdly rq ec ted , re transp lan ts  fo r chronic rejection ctnd re transp lan ts fo r o th e r reasons. 
O f those  p a tien ts  th a t developed  ac tive CMV infection, a significantly  h ig h e r p ro p o rtio n  
of pa tien ts  tiia t w ere re transp lan ted  fo r chronic rejection h ad  onset of active CM V infection 
<25 d ay s  p o s ttran sp lan t w hen  co m p ared  to initiad transp lan ta tion  of these  p a tien ts  th a t 
d eveloped  chronic rejection (a versus c; p=0.06), îniticü transplan ta tion  o f the  con tro l g roup  
(b v ersu s  c; p=0.00004) o r re transp lan tation  of the control g roup  ie. grafts n o t lo st to chronic 
rq ec tio n  (c versus d; p=0.018). Significance w as calculated using  Fishers exact test.
Summaxy
D onor negative/ recip ien t po sitiv e  CMV an tibody  status m ay be  a risk  factor fo r 
chronic rejection.
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•  T he incidence o f ’prolonged’ (30 days o r m ore) active CM V infection or ’p ro longed’ 
u rin e  PCR positiv ity  w as sign ificantly  g reater fo r those  th a t su b seq u en tly  
developed chronic rejection.
•  ’Prolonged’ active CMV infection m ay b e  a risk  factor fo r chronic rejection.
Furtherm ore, the m edian onset of active CM V  infection  afte r chronic rejection was 
sign ifican tly  ea rlie r than th e  onset a fte r p rim ary  tran sp lan ta tio n  (irrespective of 
g raft outcome) o r retransplantation fo r reasons o ther th an  chronic rejection.
43.2  Human Leukocyte Antigen (HLA) Alleles and Chronic Rejection
43.2.1 The Effect of HLA Matching/ Mismatching upon Chronic 
Rejection
The distribution of matched and mismatched HLA alleles is shown in 
table 4.3.
Table 43  The Effect of HLA Matching/ Mismatching upon Chronic 
Rejection
HLA Status CR Group 
(n -1 1 )
Controls
(n -3 3 )
Relative
Risk
95% Confidenci 
In terval
Partial or complete match
HLA A Allele 45% (5/11) 55% (18/33) 0.83 '0.4 - 1.7
HLA B Allele 27% (3/11) 27% (9/33) 1.0 0.32 - 3.05
HLA DR Allele 55% (6/11) 45% (15/33) 1.2 0 .6-2 .3
Complete mismatch
HLA A Allele 55% (6/11) 45% (15/33) 1.2 0.6 - 2.3
HLA B Allele 73% (8/11) 73% (24/33) 1.0 0.66 - 1.52
HLA DR Allele 45% (5/11) 55% (18/33) 0.83 0.4 - 1.7
Table 4.3 shows the proportion of patients that developed chronic rejection (CR group) and 
those that d id  not develop chronic rejection (controls) that were partially or completely 
m atched or completely mismatched for HLA A, B and DR. The relative risk of developing 
chronic rejection is given with the 95% confidence interval.
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Summaiy
• The proportion of matched and mismatched HLA-A, -B or -DR alleles d id  not vary
between chronic rejectors and controls.
4.S.2.2 HLA Allele Combinations and Chronic Rejection 
The distribution of HLA DR partial or complete matches/ HLA A and B 
partial or complete matches and H IA  DR partial or complete m atches/ 
HLA A and B complete mismatches is shown in table 4.4.
Table 4.4 The Effect of HLA Adlele Combinations on the Incidence of;
Chronic rejection ^
DR status □ass 1 status CRgtXfj
(n=1Q
Oontnob
{ n ^
Relative
risk 95% a
Match (>1 aBele) HLA-A partial or complete msmatch 55% (6/11) 39% (13/33) . 1.38 0.7-2.7
Match (>1 allele) HLA-B partiaJ or complete mismatch 55% (6/11) 42% (14/33) 1.29 0.65-2.1
Match (^ 1 alele) HLA-AprB partrâl or complete msmatch 64% (7/11) 61% (20/33) 1.05 0.62-1.8
Match (>1 allele) H-AA complete manatch 36% (4/11) 21% (7/33) 1.70 C.6-4.8
Match (^ 1 âHele) l-LAB complete rrgmatch 45% (5/11) 30% (10/33) 1.50 0.7-3.4 X
Match (>T allele) l-LAAandB complete mismatch 45% (5/11) 36% (12/33) 125 . G.6-2.8
Table 4.4 shows the proportion of patients that developed chronic rejection (CR group) and 
those that d id  no t develop chronic rejection (controls) that were partially  or completely 
m atched or com pletely mismatched for HLA A, B and w ere partially  or com pletely 
m atched for HLA DR. The relative risk of developing chronic rejection/^is given w ith the 
95% confidence interval (Cl).
Summary
The distribu tion  of HLA DR partial or complete m atching/ HLA class I partial or 
complete matching combinations was similar for chronic rejectors and controls.
The d istribution of HLA DR partial or complete matching/ HLA class I complete 
mismatching combinations was similar for chronic rejectors and controls.
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4.3.3 The Effect of HLA Matching on the Duration of Active CMV 
Infection
The proportion of HLA class I and class II matched alleles were compared 
between patients hosting active CMV infection for 30 days or more and 
those actively infected for less than 30 days. This distribution is given in 
table 4.5.
Table 4.5
The Effect of HLA Allele Matching on the Duration of Active CMV Infection
HLA status Patients uiith Rctiue CMU infection P
Duration >38 days Duration <30 days
HLA-DR match (^ 1 allele) 44% (4/9) 54% (7/13) 0.31
HLA-A match (^ 1 allele) 22% (2/9) 46% (6/13) 0.19
' HLA-B match (^ 1 allele) 0% (0/9) 46% (6/13) 0.02
Class 1 match (^ 1 allele) 11% (2/9) 46% (12/26) 0.05
Table 4.4 shows the proportion of patients that developed active CMV infection for more 
than (>) 30 days or less than (<) 30 days in relation to partial or complete m atching for 
HLA A, B or DR. Fishers exact test was Used.
Summary
HLA class I m atching (HLA-A or HLA-B) was found in  a significantly higher 
proportion of patients w ith active CMV infection persisting for less than 30 days
This result was also significant for HLA-B matching alone; a sim ilar trend was seen 
for HLA-A matching alone b u t  th is  r e s u l t  w a s  n o t  s ig n if ic a n t .
43.4 Other Risk Factors for Chronic Rejection of Liver Grafts
Other, previously published risk factors were analysed; the distribution of
these factors is given in table 4.6.
TABLE 4.6 Other, P c^ ib le  Risk Factors for Chronic Rejection of Liver Grafts
Factor
CR group 
(n=12)
Controls
(n=45)
Relative
risk
95% Confiden< 
interval
Pretransplant disease 
Chrcmic rqection 8% (1/12) 20% (8/40) 0.4 5.8x10-2-3.0
Primmy sclerosing cholangitis (PSC) 
Prim ary biliary  cirrhosis (PBQ
8% (1/12) 
25% (3/12)
25%  (1/40) 
2.5% (1/40)
3.3
10
0.22-49
1.14-87.5
Hepatitis C | 
Hepatitis B
33% (4/12) 
8% (1/12)
125% (5/40) 
0% (0/40)
2.67
3.7
0 .8 -8  
p= 0.23 *
Age
Recipient > 30 years 
Recipient > 40 years 
Recipient > 50 years 
Recipient > 60 years
100% (11/11) 
73% (8/11) 
64% (7/11) 
9% (1/11)
. 95% (30/40) 
75% (30/40) 
55% (22/40) 
18% (7/40)
1.05
0.96
1.15
0.5
0.24-2.43
0 .6 -1 5
0.7-1.96
7x10-2-3.8
Donor > 30 years 
Donor > 40 years 
Donor > 50 years
40% (2/5) 
20% (1/5) 
14% (1/7)
65% (11/17) 
41% (7/17) 
18% (3/17)
0.6
0.41
0.81
0.2-1.9 
0.7x10-2-3.1 
0.1 65
Sex
Méde recipient 
Male donor
Méde recipient/ n\éde donor 
Male recipient/ female donor 
Feméde recipient^ male donor 
Female recipient/ female donor
58% (7/12) 
50% (6/12) 
50% (6/12) 
8% (1/12) 
0% (0/12) 
42% (5/12)
63% (26/41) 
44% (20/45) 
27% (12/44) 
34% (15/44) 
18% (8/44) 
20% (9/44)
0.9
125
1.8
0.24
0.43
2.0
0.54-1.56 
0.6-21 . 
0.9-3.9 
3.5x10-2-1.7 
p= 0 .13*
0.8-4.9
Acute Rejection
^ 1  episode 
^  episodes 
Highest grade ^
58% (7/12) 
42% (5/12) 
42% (5/12)
47% (21/45) 
2% (1/41) 
34% (14/41)
1.25
17
1.22
0.7-2.2 
2.2-132 
0.6-2.7
Fifty patients w ere re-transplanted at Addenbrooke’s NHS Trust over the past four years; 
38% of these w ere re-transplanted after chronic rejection (see section 15.5; figure 1.4).
• Fishers exact test
Sununaiy
• Two or more episodes of acute rejection conferred a significant risk for subsequent 
development of chronic rejection.
• Pre transplant diagnosis of prim ary biliary cirrhosis (PBC) conferred a significant 
risk for subsequent development of chronic rejection.
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4.3.5 Cytomegalovirus and the TNF-2 Allele: Risk Factors for Chronic 
Rejection ^
4.3.5.1 The TNF-2 Allele and Chronic Rejection ,
The distribution of INF genotypes with the incidence of chronic rejection 
is given in table 4.7.
Table 4.7 Distribution of TNF-1 and TNF-2 Promoter Allele Genotypes with the 
Incidence of Chronic Rejection in 123 Liver Graft Recipients
Chronic Rejectors 
(n= 15)
Controls 
(n= 108)
Relative Risk 95% Cl
TNF-1 Homozygote 53% (8/15) 75% (81/108) 0.437 0.172-1.112
TNF-l/TNF-2
Heterozygote
40% (6/15) 22% (24/108) 2.067 Ô.801-5.33
TNF-2 Homozygote 7% (1/15) 3% (3/108) 2.125 0363-12.45
TNF-2 Allele 
(homozygote or 
heterozygote)
47% (7/15) 25% (27/108) 2.29 0.9-5.831
TNF-2 promoter allele positivity (analysed as heterozygote genotype or 
allele p o s i t i v i t y )  in liver graft recipients was a risk factor for chronic 
rejection with borderline significance.
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4.3.S.2 Active CMV Infection and the TNF-2 Promoter A llele May 
Synergise as Risk Factors for Chronic Rejection
The relative risk of chronic rejection from TNF-2 positivity was elevated 
in patients with active CMV infection in their post transplant course (see 
table 4.8).
Table 4.8 Distribution of TNF-1 and TNF-2 Promoter Allele Genotypes and Active 
CMV Infection with Chronic Rejection for 110 Liver Graft Recipients
TNF Promoter 
Allele Status
CMV Status Chronic 
Rejectors (n=14)
Controls
(n=96)
Relative Risk a
TNF-2 allele 
positve
Active CMV 36% (5/14) 13% (12/96) 3.039 1.16-7.965
No Active CMV 7% (1/14) 9% (9/96) 0.769 0.112-5.288
TNF-1
homozygous
Active CMV 43% (6/14) 42% (40/96) 1.043 0388 - 2.804
No Active CMV 14% (2/14) 37% (35/96) 0329 0.078-1.394
Table 4.8 show s the proportion of liver graft recipients that developed chronic rejection 
(chronic rejectors) and  controls w ith the TNF-2 p rom oter allele (hom ozygotes and 
heterozygotes) and active CMV infection post transp lan t The relative risk of developing 
chronic rejection and the 95% confidence interval (Cl) are given.
Here, a greater proportion of patients that developed chronic rejection 
were positive for the TNF-2 promoter allele and active CMV infection 
when compared to controls. TNF-2 promoter allele positivity in 
combination with active CMV infection was a significant risk factor for 
chronic rejection.
174
• I
4.S.5.3 Active CMV Infection and the TNF-2 Allele
The distribution of TNF genotype with the mcidcnce of active CMV 
infection is given in table 4.9. TNF-2 positivity was distributed similarly
I • •
between these two groups.
Table 4.9 Distribution of TNF-1 and TNF-2 Promoter Allele Genotypes with the
Incidence of Active CMV Infection for 110 Liver Graft Recipients ^
Active ÇMV 
Infection (n= 64)
Controls. 
(n= 46)
Relative Risk 95% Cl
TNF-1 ffomozygote 73% (47/64) 78% (36/46) 0.899 0.637-1.27
TNF-l/TNF-2
Heterozygote
20% (13/64) 22% (10/46) 0.964 0.647 -1.438
TNF-2 Homozygote 6% (4/64) 0% (0/46) p= 0.138* .
TNF-2 Allele 
(homozygote or 
heterozygote)
27% (17/64) 22% (10/46) 1.112 / 0 .787-157
* Fishers exact test
No significant differences were seen for the distribution of the TNF-2 
allele between patients with active CMV infection and controls.
Summary
• TNF-2 prom oter allele positivity (heterozygote genotype or allele per se) was . 
found in  a significantly higher proportion of chronic rejectors compared to controls.
• Active CMV infection in  combination w ith TNF-2 prom oter allele positivity gave 
a h igher significant relative risk for chronic rejection than TNF-2 prom oter allele 
positivity alone. This suggested that these two factors act w ith  synergy.
TNF-2 prom oter allele positivity was distributed sim ilarly betw een patients w ith 
active CMV infection and controls.
4.4 DISCUSSION
Fifty six observations have been tested in this analysis of 33 liver 
transplant recipients (57 liver transplants) and it is possible that some 
observations have reached significance by chance. Therefore, the results of 
this broad analysis must be interpreted with caution. However, the results 
of interest set up hypotheses to be tested in a larger study.
Only three analyses of the TNF-2 allele were performed for over 100 liver 
transplant recipients and the results of this partly retrospective study may 
be interpreted more firmly.
4.4.1 Conclusions .
Cytom^galovirw
• Donor negative/ recipient positive CMV antibody status may be a risk factor for 
chronic rejection.
• Prolonged active CMV infection may be a risk factor for chronic rejection.
Hum an leukocyte antigens
• Matching or mismatching of HLA A, B or DR alleles are probably not risk factors 
for chronic rejection.
• HLA class II partial or complete matching in combination w ith HLA class I 
complete mismatching is probably not a risk factor for chronic rejection.
• HLA class I matching may be an important factor for prom pt clearance of active 
CMV infection and may therefore be indirectly linked to chronic rejection.
O th er R isk  Factors
• Two or more episodes of acute rejection may be a risk factor for chronic rejection.
• Pre transplant diagnosis of PBC may be a risk factor for chronic rejection.
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• Pre transplant diagnosis of PSC, hepatitis C or B or chronic rejection and 
redpient/donor age and sex are probably not risk factors for chronic rejection. 
However, a relatively small num ber of patients were analysed and a type II error 
may have occurred.
T um our Necrosis Factor Alleles
• TNF-2 promoter allele positivity may be a risk factor for chronic rejection.
• Active CMV infection m ay synergise w ith TNF-2 promoter allele positivity as a 
risk factor for chronic rejection.
>
• TNF-2 promoter allele positivity is probably not an influence upon the incidence of 
active CMV infection.
4.4.2 Prolonged Active CMV Infection may be a Risk Factor for Chronic 
Rejection
Patients that developed chronic rejection and controls who did not 
develop chronic rejection were distributed according to the duration of 
active CMV infection that was experienced. From this distribution, an 
arbitrary threshold of 30 days active CMV infection Was chosen; this 
threshold best separated these two groups (chronic rejectors and controls).
(
Active CMV infection for 30 or more days, diagnosed by serum PCR 
and/or urine PCR and/or urine DEAFF, constituted a risk for chronic 
rejection. This was seen when the duration of active CMV infection of 
urine was analysed separately but not after separate analysis of serum 
data. A similar trend was observed for the duration of active CMV 
infection in senim but this did not reach significance; this may be because 
low numbers were tested.
I
Active CMV infection and viral load of serum were shown to be 
important prognostic factors for acute symptomatic CMV infections (see
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chapter 3). Active CMV infections were initiated at similar times for 
discrete periods and the duration of infection was not a prognostic 
indicator. This contrasts with the nature of CMV infections that were 
shown to be associated with chronic rejection; duration was important 
whereas the appearance of recognised symptoms and viral load were not.
Active CMV infection per se did not correlate with the incidence of 
chronic rejection. This contrasts with the report by O'Grady et al (1988) 
(283). H owever, urine PCR positivity was associated w ith chronic 
rejection. It is possible that an association between serum PCR positivity 
and chronic rejection did not reach significance through lack of numbers.
Prolonged CMV infection (more than 30 days) occurred in 5 /6  actively 
infected chronic rejectors; of these, 3 /5  infections did not clear and 
persisted in serum until graft loss. The mechanism of such persistence is 
unclear because it is likely that an immune response is mounted; 2 /3  
persistent infections were temporarily symptomatic.
The association between persistent CMV infection and chronic rejection 
may explain the novel finding of very early active CMV infection after 
retransplantation for chronic rejection (median six days post transplant 
(range 0-24 days)); this was significantly earlier than infection after primary 
transplantation (irrespective of whether the graft was chronically rejected 
or not) and retransplantation for reasons other than chronic rejection.
Three chronic rejectors did not clear active CMV between initial and 
secondary transplantation and were therefore - positive on the day of 
retransplantation? (day 0); chronic rejectors that did apparently clear active 
CMV (ie. were negative by laboratory tests) were positive on days 4-24 after
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retransplantation. The 'incubation period’ for CMV after transplantation 
is remarkably constant (114,115) and it is likely that the latter cases did not 
clear but had persistent, sub-clinical CMV infection at an undetectable 
level (the sensitivity of the PGR test was 500 genomes/ml; see Chapter 2). 
It is possible that such a viral load, undetectable yet greater than that of 
latent infection, was able to replicate to detectable levels relatively quickly 
after the im m unosuppression  that w as adm in istered  after 
retransplantation.
These are novel findings but are supported by those of the Kings College 
group. Arnold et al (1992) (284) used in situ hybridisation to screen serial 
liver b iopsies taken from patients w ith chronic rejection or 
uncomplicated CMV hepatitis. CMV DNA was found in the hepatocytes of 
all patients with CMV hepatitis and 10/12 of those with chronic rejection. 
The latter group were persistently CMV positive until the graft was lost ' 
whereas the CMV hepatitis group cleared CMV from hepatocytes 
(p<0.0005). Importantly, the principal sites of damage (large bile ducts and 
hepatic arteries; see section 1.9.1 ) were not examined. However, CMV 
infection of hepatocytes may have indirectly caused or promoted damage 
of these tissues.by mediating local, clonal expansion of allospecific T- 
lymphocytes (see section 1.10.3) or, as suggested by the authors, by affecting 
the expression of inflammatory molecules (see section 1.10.4). The finding 
of persistence and the link with Arnold et al (1992) (284) inspired the in 
situ hybridisation work that is presented in Chapter 6.
Persistent CMV infection is an intriguing phenomenon but does not 
necessarily mediate or modify the process of chronic rejection (see section 
1-9.7). .Indeed, the rejection process may facilitate persistence. Sinclair and 
colleagues (48, 49) showed that monocytes are a site for latent CMV and
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that differentiation into macrophages renders these cells fully permissive 
to active CMV infection. Foam cells in arteries are macrophages and are 
characteristic of chronic rejection (see section 1.8.1.2 ); it is possible that 
these cells import latent CMV to the graft and then facilitate CMV 
replication after differentiation. During active infection, CMV is also 
tropic for neutrophils; these cells may also import CMV to the chronically 
rejected graft as they infiltrate.
CMV replication may also be facilitated by sm ooth m uscle cell 
proliferation after ischaemic injury; smooth muscle cells have been 
shown to be fully permissive to CMV in vitro. Finally, the increased 
surface expression of HLA molecules during chronic rejection may 
facilitate CMV entry, into rejection site cells, if the HLA molecule is a 
receptor for CMV, as postulated by McKeating et al (1987) (62).
4.4.3 CMV Antibody Status and Chronic Rejection
Recipient CMV antibody positivity in combination with donor CMV 
antibody negativity was shown to confer a significant risk for chronic 
rejection. This result is consistent with the proposal that persistent, low  
level replication of CMV was associated with chronic rejection.
It is possible that CMV antibody positive recipients that received grafts 
from CMV antibody negative donors were able to mount a cellular 
immune response to CMV. Such patients may therefore not develop 
symptomatic CMV infection and not be treated with antiviral drugs.
It is conceivable that such patients are able to mount an immune response 
that is sufficient to prevent symptomatic infection but is not sufficient to 
prevent asymptomatic, active CMV infection. Such patients may
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therefore host active CMV infection for a prolonged period of time (see 
above).
Conversely, CMV antibody negative recipients of liver grafts from CMV 
antibody positive donors are unable to mount a cellular immune response 
to CMV and are therefore more likely to develop symptomatic infection; 
the results presented in Chapter 3 show that active CMV was detected in 
all of the mismatched patients studied. Patients with mismatched CMV 
antibody status were therefore more likely to be treated with ganciclovir 
and therefore not host prolonged active CMV infection which may be an 
important risk factor for chronic rejection (see above).
4.4.4 The Effect of HLA Matching/ Mismatching upon the Incidence of 
Chronic Rejection
There was no overall correlation between matching or mismatching of 
class I or class II HLA molecules with the incidence of chronic rejection; in 
addition, the combination of class II partial or complete matching with 
class I complete mismatching (as reported by the Kings College group (243,
a
283)) was not shown to be a risk factor for chronic rejection.
However, complete mismatching of class I alleles was shown to be 
associated with active CMV infections of long duration (> 30 days) which 
in turn, was shown to be associated with the incidence of chronic 
rejection. One plausible hypothesis is that persistent CMV infection of the 
graft is a risk factor for chronic rejection and that complete mismatching of 
class I alleles prevents successful cellular immune surveillance therefore 
facilitating such persistence. This hypothesis predicts that class I 
mismatching will only be important when a recipient is at risk of active 
CMV infection apd may explain the lack of a direct association between
HLA class I mismatching and chronic rejection here and the positive 
association shown in larger studies (225, 243, 283). Certainly, the 
importance of class 1/ CD8+ T-lymphocyte surveillance in clearing active 
CMV infection has been shown after transplantation (65; see section 
1.4.1.1).
The Kings Group (243, 283) also showed that class II matching is important
J
and that this risk factor synergises with the risk contributed by active CMV 
infection; this has been supported by the Pittsburgh group (225) who show
I '
that DR matching is associated with the incidence of CMV hepatitis. Both 
groups suggest that class II presentation of CMV peptides is important.
HLA DR matching was not shown to be a risk factor for chronic rejection 
in this thesis but it is possible that this mechanism was not identified 
because of the low numbers studied.
Generally, class I alleles present peptides from endogenously produced 
proteins whereas class II present those from exogenously produced 
proteins (242). A  graft with class I complete mismatch/class II partial or 
complete match cannot present viral proteins produced endogenously, 
due to lack of MHC restriction, and so CMV transcription/translation and 
viral replication may occur undetected and lead to lytic infection. Only 
after reinfection of the graft with these progeny virions can cellular 
immune surveillance be performed successfully by class II presentation of 
exogenously derived CMV peptides; the immunopathological destruction 
suggested by the Kings College and Pittsburgh groups may now occur.
1Q0
Thus, mismatched class I may provide an important window in which 
CMV can replicate to numbers sufficient to cause graft damage upon 
subsequent class 11/ T-lymphocyte surveillance.
4.4.5 Recipients with the TNF-2 Promoter Allele May be at a Greater Risk 
of Developing Chronic Rejection
The link between TNF-2 promoter allele positivity and chronic rejection 
and its synergy with active CMV infection is intriguing.
I
1
The finding in this thesis of an association between recipient TNF-2 
promoter allele positivity and chronic rejection is supported by Hoffman 
et al (1993) (397) who showed an association between infiltration by TNF ' 
expressing cells and chronic rejection. Here, chronic rejection of liver 
grafts was accompanied by portal tract and central venous infiltration of 
T N F-expressing m acrophages and m onocytes (identified  by  
immunohistochemistry). Expression of the adhesion molecule ICAM-1
‘ I
was elevated in hepatocytes adjacent to TNF-expressing macrophages and 
monocytes and in vascular endothelial cells. The authors proposed that
a
infiltration of TNF-expressing cells led to further leukocyte infiltration 
after TNF-induced elevation of adhesion molecule expression upon  
vascular endothelial cells.
These results are intriguing because CMV persists latently in monocytes 
and reactivates upon their differentiation into macrophages (41, 48). 
Therefore, the data published by Hoffman et al (1993) (397) suggested that, 
for CMV antibody positive recipients, chronic rejection was associated 
with infiltration of actively infected cells.
U;.\- - i
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Furthermore, there is evidence to suggest that active CMV infection is 
induced by TNF (398, 399). Docke et al (1994) (398) studied 60 patients that 
were receiving intensive care for various reasons (18 after abdominal 
surgery, eight after cardiovascular surgery, six after surgery to remove 
tum ours (non-gastrointestinal), five after diagnosis of necrosing  
pancreatitis, three after diagnosis of liver cirrhosis and 20 for other 
reasons). Patients that developed sepsis were more likely to have 
detectable levels of TNF in plasma by immunoassay (61% versus 0%) and 
active CMV infection by PCR of peripheral blood mononuclear cells 
(PBMC) (92% versus 7%; p<0.001) compared to patients that did not 
develop sepsis.
I
This group (399) also studied liver and renal transplant recipients (n=190); 
episodes of acute rejection were significantly associated with elevated 
serum levels of TNF compared to non-rejecting controls (79% (60/76) 
versus 4% (1/25); p<0.01).- Furthermore, correlation 4vas found between 
elevated serum TNF and subsequent detection of CMV antigens in PBMC 
(88% >100pg/m l versus 16% <100pg/ml; p<0.001). The authors suggested 
that TNF enhanced CMV activity and also showed in vitro that TNF 
induced the CMV immediate-early prom oter/enhancer using a 
chloramphenicol acetyl transferase (CAT) reporter construct transfected 
into the monocytic cell line HL-60. This paper therefore provides evidence 
for the 'alternative hypothesis' that CMV is an opportunist that is 
favoured by the processes of chronic rejection.
However, the results presented in this thesis showed that recipients with 
the TNF-2 promoter allele were not at higher risk of active CMV infection. 
It is possible that CMV is retractile to 'TNF-2 promoter allele-enhanced 
levels' of TNF.
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In contrast, the clinical findings of the reports discussed may be due to 
induction or enhancement of TNF expression by CMV (400, 401, 402). Geist 
et al (1994) (402) found that active CMV infection upregulated TNF 
production by differentiated THP-1 cells (monocyte-derived macrophages); 
this in turn, was evidence that CMV may initiate or enhance the process 
of chronic rejection. „
The effect of TNF upon CMV activity and the converse are not mutually 
exclusive and it is possible that a 'vicious circle' exists during the 
involvement of CMV with chronic rejection of liver grafts.
Finally, an interesting analogy exists between the involvement of TNF
with chronie, rejection and its involvement with cerebral malaria (403).
Binding of the parasite Plasmodium falciparum to vascular endothelial
cell adhesion molecules is crucial to the pathogenesis of this disease.
Serum-TNF levels have been shown to correlate with the severity of
cerebral malaria (403) and TNF has been shown to upregulate adhesion 
% ^
O'
molecule expression (404). Binding of lymphocytes to vascular endothelial 
cells, before infiltration of liver grafts during chronic rejection, is 
analogous.
4.4.6 Recurrent Acute Rejection May be a Risk Factor for Chronic 
Rejection
The occurrence of two or more episodes of acute rejection was found to 
constitute a high risk for chronic rejection. This result is supported by 
previous findings (368, 285). Dousset et al (1993) (368) found that recurrent 
acute rejection and severity were risk factors for chronic rejection for 129 
liver transplant recipients and that the timing of the rejection episodes
I 1RS
was not important. In this thesis, the discrepant finding of a lack of 
association with acute rejection severity may be due to low numbers; only 
eight cases 'ot severe acute rejection Ç> grade 3) were present in this 
analysis. ^
Recently, the Birmingham group have reported that the occurrence of one 
or more episodes of acute rejection correlated with the incidence of 
chronic rejection. This report (210) may be misleading (Avi Soin; personal 
communicatipn) because single episodes of acute rejection (previously 
reported to bp unlinked to chronic rejection; 285, 368) were pooled with . 
recurrent episodes (previously reported to constitute a significant risk of 
chronic rejection; 285, 368).
Acute and chronic rejection have distinct pathologies (see section 1.8.1) 
and the former is not a prerequisite for the latter (8/15 patients in this 
analysis experienced chronic, but not acute, rejection); therefore, the 
mechanism accounting for this link is intriguing. Soin et al (1995) (285) 
suggest that clironic rejection can be split into two categories based on the 
presence or absence of cellular infiltrates and that ductopenic rejection is 
secondary to ischaemic injury (mediated by humoral immunity) in the 
latter condition. They suggest that the former condition, mediated by 
cellular infiltration, develops from acute rejection.
It is possible that acute rejection mediates a 'non-specific' inflammatory 
response i n v o l v i n g  u p r e g u l a t i o n  o f  HLA molecules, adhesion molecule 
and cytokines (369, 370, 371).
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4.4.7 Pretransplant Diagnosis of Primary Biliary Cirrhosis (PBC) may be a 
Risk Factor for Chronic Rejection
Primary diagnosis of PBC was shown to confer a significant risk for 
chronic rejection; this result is supported by the findings of others (200, 
201,202,210). .
V: '
PBC is an autoimmune diseases that is characterised by the presence of 
circulating autoantibodies (see section 1.9.5.3). H owever, a causal 
relationship has not been established.
Furthermore, a number of reports suggest that the humoral response is an 
important mediator of chronic rejection (293, 294, 286; see section 1.8.2.4) 
and it is possible that the antibodies associated with PBC are involved. 
These reports inspired an in-depth study of the effect of these and other 
antibodies upon chronic rejection which is presented in Chapter 5.
Markus et al (1988) (240) suggested an intriguing hypothesis linking HLA 
status and autoimmune disease. Here, 507 liver allograft recipients were 
studied and it was found that, although HLA-DR matching was associated 
with reduced graft survival (p=0.054), mismatching of this locus was 
associated with chronic rejection (p=0.007). The authors suggest that DR 
matching facilitates the recurrence of autoimmune diseases such as PBC 
and primary sclerosing cholangitis (PSC).
In contraist, although pre transplant diagnosis of PSC was shown to confer 
a relative risk for chronic rejection of 1.82, this result was not significant. . 
PSC is also an autoimmune diseases that is characterised by the presence of 
circulating autoantibodies (see section 1.9.5.3) but a causal relationship has 
not been established. The lack of a significant association between PSC and
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chronic rejection that is reported in this thesis may be due to the relatively 
low number of patients studied; larger studies have found significant 
associations of chronic rejection with pre transplant diagnosis of PSC (203, 
205,206,372).
4.4.8 Lack of/Correlation Between Chronic Rejection and Sex, Age or 
CMV Antibody Mismatch
Sex niismatch (male donor/ female recipient), CMV antibody mismatch 
(donor + /  recipient -) and recipient age < 30 years were positively 
associated with chronic rejection by the Birmingham group (210). These 
parameters were not shown to be important in this study, possibly because 
of low numbers (type II error).
4.4.9 Retransplantation was Not Shown to be a Risk Factor for Chronic 
Rejection
In this analysis, 24/57 liver transplants were retransplants; 12/24 were 
retransplanted for chronic rejection. Previous study at Addenbrooke's 
NHS Trust (Soin A; unpublished results) and other centres (315, 322, 353) 
showed that retransplantation for chronic rejection conferred a high risk 
for recurrence of this disease. Study of chronic rejection after 
retransplantation may introduce bias but this trend was not seen in the 
highly selected group that was studied in this thesis and may be reversed 
(7% chronic rejectors and 29% controls had previous chronic rejection).
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CHAPTER 5
THE RELATIONSHIP BETWEEN CHRONIC 
REJECTION OF LIVER QRAFTS, ACTIVE 
CYTOMEGALOVIRUS INFECTION AND 
HUMORAL IMMUNE RESPONSES TO 
BILE DUCT AND HEPATIC ARTERY
5.1 Introduction
Few studies have focussed on the role of humoral immunity during 
chroriic rejection of liver grafts; a number of groups have studied the effect 
of lymphocytotoxic antibodies in this setting but these findings are 
conflicting (see section 1.8.2.4).
This chapter presents aii analysis of antibodies to hepatic artery and bile 
duct and their relationship with chronic rejection of liver grafts; to my 
knowledge, such work has not been previously reported. However, a link 
between antibodies and chronic rejection of renal (305-311; see section 
1.8.3.3.3) and cardiac (309, 311; see section 1.8.3.3.3) grafts has beeri 
previously reported.
Active CMV infection is common after transplantation (see Chapter 3) and 
has been shown to be associated with chronic rejection (225, 283; see 
Chapter 4). A number of mechanisms have been proposed for this 
association including modulation of antibody production (see section 
1.9.5); active CMV infection has previously been shown to be associated 
with autoantibody production (257, 310, 312, 313, 314). In addition, it has 
been shown previously that CMV encodes a protein (H301 gene) with 
homology to HLA class I and that antibodies to this CMV protein are cross­
reactive with HLA class I (60). In this chapter, antibodies to hepatic artery 
and bile duct were analysed in relation to active CMV infection.
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are 
diseases that are characterised by the presence of a number of 
autoantibodies (317, 320; see section 1.9.6) and have also been associated
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with an increased risk of chronic rejection (197, 210, 203, 205, 206; see 
section 1.8.2.5). In this thesis, pretransplant diagnosis of PBC was also 
shown to be a risk factor for chronic rejection (see Chapter 4). In this 
c h a p te r ,  a n t ib o d ie s  t o  h e p a t i c  a r te r y  and bile duct were analysed in relation 
to pre-transplant diagnosis of PBC and PSC.
In this chapter, the presence of serum antibodies to bile duct and hepatic 
artery proteins was compared between chronic rejectors and controls, 
patients that developed active CMV infection and controls and patients 
with pretransplant diagnosis of autoimmune disease and controls.
I ,
H ypotheses ^
• Generation of antibodies to hepatic artery and bile duct tissue m ay initiate or 
enhance chronic rejection.
• Active cytomegalovirus (CMV) infection of hepatic artery or bile duct m ay 
upregulate the expression of target antigens.
I
• Active CMV infection may upregulate the production of antibodies involved in  
chronic rejection.
• Antibodies produced to CMV may cross react w ith cellular antigens involved in  
chronic rejection.
• A utoantibodies associated w ith  prim ary biliary cirrhosis (PBC) or prim ary 
sclerosing cholangitis (PSC) are present after transplantation and m ay be 
associated w ith  chronic rejection.
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5.2 Patients, Materials and Methods
This study was split into two phases; phase I involved screening of sera 
after Western blotting of a variety of tissues. This phase was labour 
intensive and so a small number of sera were screened. Trends identified 
in phase I were assessed further in phase II where further sera were 
screened after Western blotting a restricted panel of tissue; where putative 
target antigens had been identified, the results of phase I and phase II were 
combined for statistical analysis.
i
5.2.1 Selection of 38 Liver Transplant Recipients
Ninety nine patients were transplanted during the course of this thesis; 
patients were initially selected according to the criteria that appropriate 
serum was available for this study (pre-transplant and 3 months post- 
transplant). A highly selected group of 38 patients undergoing 43 liver 
transplants was chosen from this subgroup and tested during this study; aU 
re-transplanted patients were selected plus other patients of interest ie. 
those with active CMV infection and those with a pretransplant diagnosis 
of PBC or PSC (taken sequentially from sub-group according to date of 
transplant). This group is described briefly in table 5.1 (see also Appendix 
1).
Sera from 17 patients undergoing 20 liver transplants were screened 
during phase I with selection biased towards patients that developed 
chronic rejection and/or active CMV infection (see table 5.1 and Appendix 
1).
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Table 5.1 Patients Studied in Chapter 5
T ransp lan t
number
CR/ Redo
CR
CR
CR
CR
CR
CR
Redo
Redo
CR
CR
CR
Redo
Redo
Redo
CR
Active 
CMV (Y/N)
Y
Y
Y
Y
Y
Y
Y
Y 
N 
N
Y 
N 
N 
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y 
N 
N 
N 
N 
N 
N 
N 
N 
N
PBC/PSC
PBC
PBC
PSC
Serum used 
P re  P o s t
PBC
PBC
PBC
PBC
PBC
PBC
PSC
PBC
PSC
PSC
PSC
PSC
Fable 5.1 shows the patients (n=38) and transplants (n=43) studied in Chapter 5. In 
his table, CR= patients that lost the liver graft to chronic rejection, Redo= patients that 
ost the liver graft for reasons other than chronic rejection. This table also shows 
Datients that developed active CMV infection (Y= yes, N= no), those with pre transplant 
lliagnosis of primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC). 
jserum used' indicates which pre and post transplant sera were studied; transplants 
mown in bold indicate those studied in phase I of this chapter. These patients are 
described further in Appendix 1.
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5.2.2 Western Blotting
5.2.2.1 Protein Extraction and Quantitation
Tissue samples (1-5 g) were cut into fragments using a scalpel before 
suspension in 2 ml homogenisation buffer (0.25 M sucrose (Gibco), 15mM 
Tris (Gibco), O.lmM EDTA (Sigma); pH 6.8) and homogenisation using a 
mortar and pestle containing liquid Nitrogen. The sample was then 
transferred to a 2ml microfuge tube and stored at -20"C.
I '
Bovine serum albumin (BSA) was diluted to attain concentrations of 5, 10, 
15, 20, 25 p g /m l and used to generate a standard curve for protein 
quantitation. Extracted tissue samples and BSA standards' were pipetted 
into wells of a microtitre plate and adjusted to 80pl before addition of 20|xl 
BioRad Protein Assay Concentrate Solution and incubation at 37 "C for 1 
hour. Optical density (OD620nm) was read using a Flow Titertek 
Multiplate Washer (ICN-Flow) and a standard curve was produced 
enabling the concentration of test samples to be calculated.
5.2.2.2 SDS-Polyacrylamide Gel Electrophoresis and Blotting
SDS-polyacrylamide gels were formed using a BioRad Mini-Gel Apparatus. 
The 'resolving gel' (10% acrylamide (stock: 30% acrylamide, 0.3% bis- 
acrylamide; Sigma), 0.375M Tris (stock: 1.5M Tris (pH 8.8); Gibco), 0.1% SDS 
(Sigma), 0 ’1% ammonium persulphate (APS; Sigma), 0.1% (v /v ) Temed 
(added last; Sigma)) was formed before formation of 2cm of 'stacking gel' 
(6% acrylamide, 0.125M Tris (stock: 0.5M Tris (pH 6.8)), 0.1% SDS, 0.1% 
APS, 0.1% Temed)).
A total of 10 pg of protein was loaded onto each lane and electrophoresed
in 'running buffer' (2.8% glycine (Sigma), 0.6% Tris (Gibco), 0.1% SDS
>
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(Sigma)) at 75 V for 2 hours following Laemmli UK et al (1970) (376). 
Proteins were thus separated by charge. Transfer was made onto 
Immobilon P Membrane (Millipore) by semi-dry Western blotting at 18V 
for 4 hours in 'transfer buffer' (0.58% Tris (Gibco), 0.29% glycine (Sigma), 
0.04% SDS (Sigma), 20% (v/v) methanol (BDH)).
S.2.2.3 Detection of Serum Antibodies
Membranes were blocked (2.5% casein (Sigma), 0.9% NaCl (Gibco), 0.12% 
Tris (Gibco), 0.02% thiomersal (Sigma); pH 7.6) for 18 hours at room 
temperature w ith  mixing before application of sample sera at a 
concentration of 1% (v/v) in 'wash buffer' (0.9% NaCl (Gibco), 0.5% casein 
(Sigma), 0.12% Tris (Gibco), 0.02% thiomersal (Sigma); pH 7.6) and 
incubation, with mixing, at 4°C for 18 hours.
Non-specifically bound antibody was removed by washing (at room 
temperature); this was performed sequentially in 'wash buffer' for 5 
minutes, 'detergent buffer' ('wash buffer' with 0.5% Triton X-100 (Sigma), 
0.1% SDS (Sigma)) for 5 minutes then twice in 'wash buffer' for 10 
m inutes.
Secondary antibody was then applied in 'wash buffer' and incubated at 4°C 
for 18 hours with mixing. Anti-human IgG (Sigma), anti-human IgA 
(Sigma) and anti-goat IgG (A-4062, Sigma) were used; all were alkaline 
phosphatase conjugated and were added at a dilution of 1: 2000.
Non-specifically bound antibody was removed by 4 x 10 minute washes, at 
room temperature, with 'wash buffer' and then with tris buffered saline- 
tween (TBST; 1.17% NaCl (Gibco), 0.61% Tris (Gibco), 0.2% Tween-20 
(BDH)).
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Blots were then developed with 0.0165% NBT (stock: 50 m g/m l in 70% 
DMF; Sigma) and 0.033% BCIP (stock: 50 m g/m l in 100% DMF; Sigma) in 
'developing buffer' (O.IM NaCl (Gibco), 0.1 M Tris (Gibco), 5mM MgCl2  
(Gibco); pH 9.5).
S.2.2.4  ^ Investigation of Cross-Reactivity
In these experiments (see section 5.3.4.7), polyclonal antibodies to purified 
hexon protein from adenovirus type 2 (0151-9004; Biogenesis) or 
polyclonal antibodies to whole CMV virions (AD169 strain) (2470-5004; 
Biogenesis) were included in 'blocking buffer' during membrane blocking. 
All other steps were carried out as described above.
5.2.3 Phase I
Western blotting of a panel of various tissues was performed in Phase I of 
this study; this enabled a broad analysis to be carried out in an attempt to 
identify immunogenic tissues for study in phase 2 and to identify antigens 
that were upregulated by CMV infection and/or chronic rejection.
In addition, sera from patients of interest (see table 5.1) were screened in an 
attempt to identify antibodies to bile duct or hepatic artery tissue that were 
associated with chronic rejection, active CMV infection or pretransplant 
diagnosis of PBC.
Sera from two healthy individuals (CMV antibody positive and negative 
individuals) were tested against the panel of tissue as a further control.
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IgA A ntibodies to  Bile D uct Tissue
4
The reactivity of IgA antibodies in pre- and post-transplant sera from 17 
patients receiving 20 liver grafts (see table 5.1) to proteins of seven  
tissues/cells were investigated; these tissues/cells a ^  listed below:
1. Bile duct from an explanted, grafted liver that was not lost to chronic rejection and was 
not infected by CMV ('transplanted' bile duct).
2. Büe duct from an explanted, grafted liver that was lost to chronic rejection bu t was not 
infected by CMV ('chronically rejected' bile duct).
3. Bile duct from an explanted, grafted liver that was lost to chronic rejection and was 
infected by CMV ('chronically rejected, CMV infected' bile duct).
4. Büe duct from an expléinted liver from a patient that underw ent prim ary transplantation 
for PSC ('PSC-diseased' büe duct).
5. Liver from an explanted liver from a patient that underw ent prim ary transplantation for 
PBC ('PBG-diseased' liver).
6. CMV infected fibroblasts (containing 10^ pfu).
7. Uninfected fibroblasts.
Ideally, IgG, IgA and IgM antibodies would have been analysed. However, 
this work was labour intensive (bands were analysed for 440 Western blot 
lanes during phase 1 of this study) and therefore, only one isotype was 
investigated. I chose to investigate the presence of IgA antibodies against 
bile duct tissue because there is evidence to suggest that this isotype is 
predominantly produced when target antigens are expressed in bile 
duct/gut tissue (409,418,419,420,421).
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IgG Antibodies to  Hepatic Artery Tissue
Thé reactivity of IgG antibodies in pre- and post-transplant sera from 17 
patients receiving 20 liver grafts (see table 5.1) to proteins of 4 tissues/cells 
were investigated; these tissues/cells are listed below:
1. Hepatic artery from an explanted, grafted liver that was not lost to chronic rejection and 
was not infected by CMV ('transplanted' hepatic artery)
2. Hepatic artery from an explanted, grafted liver that was lost to chronic rejection bu t was
not infected by CMV ( chronically rejected' hepatic artery)
1
3. CMV infected fibroblasts (containing 10^ pfu)
4. Uninfected fibroblasts '
Unfortunately, hepatic artery from a CMV-infected liver graft was not 
available. Ideally, IgG, IgA and IgM antibodies would have been analysed 
but practical constraints prevented this (see above). I chose to investigate 
the presence of IgG antibodies against hepatic artery tissue because there is 
evidence to suggest that this isotype is predominantly produced when 
target antigens are expressed in vascular tissue (410, 422).
Phase I  Results Analysis
After Western blotting, the size of each band was identified and results for 
each serum /tissue combination were logged. A total of 280 and 160 lanes 
were analysed with respect to IgA antibodies and IgG antibodies 
respectively. Four rounds of univariate results analysis were performed to 
compare 'chronic rejection sera' (CR-sera), CMV sera, PBC-sera and PSC- 
sera with 'others'. The proportion of 'test sera' and 'other sera' that were 
positive for a particular band was plotted for each tissue tested; thus, 28 
and 16 such graphs were analysed and compared with respect to IgA and
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IgG antibodies respectively. An example graph is shown in figure 5.1; this 
plot shows the analysis of IgA antibodies in 'CR-sera' versus 'other sera' 
after Western blotting of 'chronically rejected, CMV infected bile duct'.
These analyses enabled investigation of the relation between chronic 
rejection, active CMV infection, PBC, PSC and antibody production pre- 
and post- transplant.
Furthermore, comparison of 44 such plots enabled investigation of the 
effect of chronic rejection and/or CMV infection on antigen expression; ie. 
comparison of 'chronically rejected, CMV infected', 'chronically rejected' 
and 'transplanted bile duct' and comparison of 'chronically rejected' and 
'transplanted' hepatic artery. Plots for uninfected fibroblasts were made to 
investigate whether these antigens were specific to bile duct or hepatic 
artery and comparison with the plot for CMV-infected fibroblasts was 
made to investigate CMV-mediated effects on antigen expression.
PBC liver' and 'PSC bile duct' were included as controls for PSC and PBC 
sera. It was thought that the reactivity of PBC- and PSC-associated 
antibodies may be pronounced in these tissues. In addition, these tissues 
were investigated for disease-specific antigens.
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5.2.4 Phase II 
Ig A  A n t i b o d i e s
The trends observed  in Phase I w ere stud ied  further in Phase II by  
screening for IgA antibodies to the follow ing tissue:
1. Bile duct from an explanted liver that was lost to chronic rejection and was infected by 
CMV ('chronically rejected, CMV infected' bUe duct; see phase I)
2. Bile duct taken from a 'cut down' donor liver ('normal' bile duct)
Ig G  A n t i b o d ie s
Screening for IgG antibodies to the follow ing tissue w as performed:
1. Hepatic artery from an explanted liver that was lost to chronic rejection but was not 
infected by CMV ('chronically rejected' hepatic artery; see phase 1)
2. Hepatic artery taken from a 'cut down' donor liver ('normal' hepatic artery)
Chronically rejected hepatic artery and chronically rejected, CMV infected  
bile duct tissue were used to screen sera from further patients. In addition, 
norm al hepatic artery and bile duct tissue were screened w ith  all sera as a 
further control. For statistical analysis the results generated during phases I 
and II w ere com bined. Therefore, the results presented in phase II were 
generated from screening all the sera show n in table 5.1; this sera w as 
taken from 38 patients undergoing 43 transplants (described in table 5.1). 
Statistical analysis of results w as carried out using Fishers exact test.
5.2.5 Crossreactivity B etw een A ntibodies Generated to CM V and Cellular 
Proteins
Finally, an experim ent w as carried out to test antibodies of interest for 
cross reactivity w ith  CMV.
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5.3 RESULTS
5 .3 .1  C o o m a s s ie  S t a i n  o f  W e s te m - b l o t t e d  T i s s u e
Various tissues were used in stage I of this study. Firstly, coomassie 
staining was performed on Western blotted protein extractions from these 
tissues. Figure 5.2 shows that bile duct, hepatic artery, liver and cultured 
fibroblasts had differing protein contents which was manifest as 
differences in band number, size and intensity. Protein separation under 
these conditions of electrophoresis was good and loading was similar.
Figure 5.2 Coomassie Stain of Western Blotted Proteins Extracted 
from Biie Duct, Hepatic Artery, Liver and Fibroblasts.
Lane
200 KD 
60 KD __
45KD —
1 2 3 4 5 6 7 8 9  10
I
Figure 5.2 is a Coomassie stain of a Western blot ot protein (5pg) extracted from 
various tissues (lanes 2-10) that are described fully above.
Lane 1= molecular weight marker (Gibco 2pl), lane 2= PSC bile duct, lane 3= PBC
CMV positive/ CR/ bile duct, lane 9= non-CR/ transplanted hepatic a y, 
hepatic artery.
2 0 2
5.3.2 Phase I: Analysis of Antibodies to a Panel of Various Tissues
Antigens identified by antisera were observed in a total of 440 lanes were 
analysed from four perspectives (see section 5.2.2) thus creating a mass of 
data; these data are summarised below.
5.3.2.1 Pretransplant and Posttransplant Sera Contained Num erous 
Antibodies to Bile Duct and Hepatic Artery Proteins
Pre- and post-transplant sera from liver transplant patients contained IgA 
which identified up to 18 antigens (36-175 kD) and IgG which identified up 
to 16 antigens (55-253 kD) in bile duct and hepatic artery respectively; 
example blots are shown in figures 5.3 (bile duc t/ anti-IgA) and 5.4 (hepatic 
a rte ry / anti-IgC). All antigens were also found after screening fibroblast 
proteins.
5.3.2.2 Reactive Antibodies and Liver Disease
A relatively small num ber of antigens were recognised by antibodies 
present in the sera of two norm al controls. Both sera contained IgA 
antibodies that reacted with antigens of 145, 134, 65 and 62 kD in all the bile 
duct tissues screened and IgG antibodies that reacted with antigens of 210, 
185, 78 and 75 kD in all the hepatic artery tissues screened.
The majority of IgA and IgG antibodies were associated with liver disease 
and were not found in healthy individuals; this m ay have been due to 
enhanced exposure of antigens during liver disease.
However, none of the antigens identified by IgA or IgG antibodies were 
exclusive to patients with chronic rejection, active CMV infection, PBC or 
PSC suggesting that reactive antibodies were not specific to these 
conditions.
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Figure 5.3 
Examples of Western Blots of Bile Duct Tissue after Application of Transplant 
Patient Sera
Patient 1
Pre
163
145
50
; 4 - i f  I f  I
163
80
65
-62
Patient 2
Pre Post
-1 4 5
I
Patient 3
Pre Post
— 163
Figure 5.3 shows 3 examples of Western blots of bile duct proteins (chronic rejector/ CMV positive). Patient 
1 hosted primary, active CMV infection after transplantation and retained the graft; IgA with affinity to 3 
protein bands appeared after transplantation. Patient 2 was retransplanted for reasons other than 
chronic rejection; IgA to 5 protein bands was seen pretransplant and to 10 bands posttransplant. Patient 3 
lost the graft to chronic rejection; IgA to 7 protein bands was seen pretransplant and to 12 bands 
posttransplant. Band sizes are shown in kD.
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Figure 5.4 
Examples of Western Blots of Hepatic Artery Tissue after Application of 
Transplant Patient Sera
Patient 1
Pre Post
Ki' 1 -
I .i
245- 
210  —  
185 —
140 —  
124—  IIS'-" 
109 —
7 5 ------
Patient 2
Pre Post
i=s P
^253 
245 
—  210 
' —  185
^140 
_  124 
116 
109
S i
245-^  
210 
185  —
140  —  
124  —  
116  —  
109  —  
78  —  
75 ------
Patient 3 
Pre Post
—  159
— 140
Figure 5.4 shows three examples of Western blots of hepatic artery proteins from a 
graft that was lost to chronic rejection. Patient 1 lost the graft to chronic rejection; IgG 
to eight protein bands was seen pre transplant but to only five bands post transplant. 
Patient 2 hosted active CMV infection after transplantation and retained the graft; IgG 
with affinity to eight protein bands was seen pre transplant and to ten bands post 
transplant. Patient 3 did not host active CMV infection and retained the graft; IgG to nine 
protein bands was seen pre transplant and to nine bands post transplant (however, one 
band appeared and one band disappeared post transplant). Band sizes are shown in 
kilodaltons (kD).
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S.3.2.3 IgA and Bile Duct Analysis
IgA Antibodies and Chronic Rejection
Two antigens were identified by antisera that discrim inated betw een 
patients that developed chronic rejection (n=7) and controls (n=13; all 
others).
A 94kD antigen was found in a greater proportion of pre-transplant sera 
from chronic rejectors compared to controls for all bile duct tissue tested. 
This difference was pronounced for 'chronically rejected, CMV infected' 
bile duct; reactivity to the 94 kD antigen disappeared post-transplant (see 
figure 5.5). It is possible that this antibody conferred a risk for chronic 
rejection and that a 94 kD antigen was upregulated in bile duct by CMV or 
chronic rejection.
Figure 5.5 The Proportion of Sera from Patients that Developed Chronic 
Rejection (CR) and controls (NON-CR) that Contained IgA Antibodies to a 
94kD Antigen in 'Chronically Rejected, CMV Infected Bile Duct'
6 0 - r
3 0 - -
94 kD
■  CR 
□  NON-CR
94 kD 
POST
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Similarly, a 39kD antigen was discriminatory in bile duct tissues but more 
so in 'chronically rejected, CMV infected' bile duct (see figure 5.6). In 
contrast, reactivity to this antigen did not disappear after transplantation.
F i g u r e  5 .6 P r o p o r t i o n  o f  S e r a  f r o m  P a t i e n t s  t h a t  D e v e l o p e d  C h r o n i c  
R e j e c t i o n  (C R )  a n d  c o n t r o l s  ( N O N - C R )  t h a t  C o n t a i n e d  I g A  A n t i b o d i e s  to  a  
3 9 k D  A n t i g e n  i n  ’C h r o n i c a l l y  R e j e c t e d ,  C M V  i n f e c t e d  B i le  D u c t '
□  NON-CR
39 kD39 kD
IgA  Antibodies and Active C M V  Infection
One antigen of 44 kD discriminated between patients that developed active 
CMV infection (n=14) and controls (n=6; all others). This was only 
observed for 'chronically rejected/CM V infected' bile duct screened with 
post-transplant sera (see figure 5.7). It is possible that active CMV infection 
stim ulated  an tibody  production  to a bile duct p ro tein  since this 
discrimination was not seen for CMV infected fibroblasts. However, a 44 
kD band was recognised in fibroblasts by serum IgA from chronic rejectors 
and controls indicating that this antigen was not bile duct specific.
F i g u r e  5 .7  P r o p o r t i o n  o f  S e r a  f r o m  P a t i e n t s  t h a t  D e v e l o p e d  A c t i v e  C M V  
I n f e c t i o n  ( C M V )  a n d  C o n t r o l s  t h a t  C o n t a i n e d  I g A  A n t i b o d i e s  t o  a  4 4 k D  
A n t i g e n  i n  'C h r o n i c a l l y  R e j e c t e d ,  C M V  i n f e c t e d  B i le  D u c t '
0)>
(/>
oQ.
CQ>U
0)Q.
6 0 - t-
4 0 - -
3 0 - -
L J  Controls2 0 - -
44 kD 44 kD 
POST
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IgA Antibodies and PBC and PSC
No notable differences were seen between the antibodies detected in sera 
taken from patients with pre transplant diagnosis of PBC or PSC sera and 
controls against any of the bile duct tissues used.
S.3.2.4 IgG and Hepatic Artery Analysis
IgG  Antibodies and Chronic Rejection
Two antigens w ere identified by antisera that discrim inated betw een 
patients that developed chronic rejection (n=7) and controls (n=13; all 
O th e r s ) .
A  160kD antigen was found in a greater proportion of post-transplant sera 
from chronic rejectors compared to controls for all hepatic artery tissues 
tested. This difference was pronounced for chronically rejected' hepatic 
artery (see figure 5.8). It is possible that this antibody conferred a risk for 
chronic rejection and that a 160 kD antigen was upregulated in hepatic 
artery by chronic rejection.
Figure 5.8 Proportion of Sera from Patients that D eveloped Chronic 
Rejection (CR) and controls (NON-CR) that Contained IgG Antibodies to a 
160 kD Antigen in 'Chronically Rejected Hepatic Artery'
'£ 60-j-
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An 85kD antigen  was discrim inatory in all hepatic artery  tissue; 
discrimination was not enhanced with 'chronically rejected' hepatic artery 
but this tissue is shown in figure 5.9.
Figure 5.9 Proportion of Sera from Patients that Developed Chronic 
Rejection (CR) and controls (NON-CR) that Contained IgG Antibodies to 
an 85 kD Antigen in 'Chronically Rejected Hepatic Artery'
□  NON-CR0) 2 0
85 kD 85 kD
IgG  Antibodies and Active C M V  Infection
No notable differences were seen between antibodies detected in sera taken 
from patients that developed active CMV infection and controls.
IgG  Antibodies and PBC and PSC
No notable differences were seen between the antibodies detected in sera 
taken from patients with pre transplant diagnosis of PBC or PSC sera and 
controls against any of the hepatic artery tissues used.
S.3.2.5 Summary for Phase I
Overall
• Sera from liver transplant patients contained antibodies to 18 bile duct antigens 
and 16 hepatic artery antigens.
• Sera from two normal subjects contained antibodies to four bile duct and four hepatic 
artery antigens suggesting that the majority of antibodies identified in liver 
transplant recipients were associated with liver disease.
IgA Reactivity w ith Bile Duct
• Antibody to two antigens (94 kD and 39 kD) discriminated between chronic rejectors
and others; this discrimination was more pronounced using 'chronically rejected, 
CMV infected' bile duct. Two normal sera did not contain antibodies to either 
antigen.
• Antibody to a 44 kD antigen discriminated between patients with active CMV
infection and others; this was only observed using 'chronically rejected, CMV 
infected' bile duct. Unfortunately, CMV infected bile duct tissue which was not 
chronically rejected was not available.
• No notable differences were observed between sera from patients with pre 
transplant diagnosis of PBC or PSC and controls for any of the tissue screened.
IgG Reactivity w ith Hepatic Artery
• Antibody to two antigens (160 kD and 85 kD) discriminated between chronic 
rejectors and others; for the 160 kD antigen, this was most pronounced using 
'chronically rejected' hepatic artery.
• No notable differences were observed between sera from patients with active CMV 
infection and others for any of the tissue screened.
• No notable differences were observed between sera from patients with pre 
transplant diagnosis of PBC or PSC and controls for any of the tissue screened.
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5.3.3 Phase II
Further sera were screened against a limited panel of tissues which are 
listed below and results from both phases were considered in the statistical 
approach. Therefore, the results presented here w ere generated from 
screening sera from 38 patients that underw ent 43 liver transplants (38 
pretransplant sera and 43 posttransplant sera; see table 5.1).
These results were subject to four rounds of statistical analysis separating 
sera from patien ts that developed chronic rejection (CR-sera), that 
developed active CMV infection (CMV sera) and patien ts w ith pre 
transplant diagnosis of PBC (PBC sera) or PSC (PSC sera). Differences 
betw een the test group and control group were analysed using Fishers 
exact test. Caution was used when interpretting these results because they 
were generated from a relatively small num ber of patients (type II error) 
and multiple testing was performed.
5.3.3.1 IgA Antibodies to Bile Duct Tissue
Tissue Panel
The following tissue was tested:
1. Bile duct from an explanted liver that was lost to chronic rejection and was infected by 
CMV ('chronically rejected, CMV infected' bile duct; see phase I)
2. Bile duct taken from a 'cut down' donor liver ('normal' bile duct)
IgA  Antibodies and Chronic Rejection
Comparison of patients that developed chronic rejection and controls for 
antibodies reactive w ith antigens from W estern b lotted  chronically
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rejected, CMV infected bile duct (CR/ CMV bile duct) and normal bile duct 
showed that antibodies antigens of 94kD and 39kD were discriminatory 
(see tables 5.2, 5.3, 5.4 and 5.5).
IgA Antibodies to a 94kD Bile Duct Antigen
Table 5.2 Distribution of Sera Containing IgA Antibodies to a 94kD 
Antigen Present in Chronically Rejected, CMV Infected Bile Duct (CR/ 
CMV bile duct) or Normal Bile Duct
CR/ CMV bile duct Normal bile duct
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
94 50% 11%
(p<0.03)
10% 12%
(p=0.42)
0% 39%
(p<0.02)
10% 21%
(p=0.29)
p values were calculated from the difference between CR sera and other sera using Fishers exact test.
Antibodies to a 94 kD antigen in 'chronically rejected, CMV infected' bile 
duct were also found significantly more often in pre-transplant sera from 
patients that developed chronic rejection (CR sera) compared to control 
(non-CR) sera w hen screening 'chronically rejected, CMV infected' bile 
duct (CR/ CMV). These antibodies were not detected in any chronic 
rejectors after transplantation. Interestingly, prior chronic rejection was 
not a risk factor for chronic rejection after retransplantation in this group 
of patients (see Chapter 4).
However, autoantibodies to a 94 kD antigen in normal bile duct were 
found in pre-transplant non-CR sera but not in CR sera.
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This result suggests that either the process of chronic rejection or CMV 
infection leads to upregulation of a 94kD antigen. These two effects may be 
distinguished by analysing closely the results generated in phases I and II 
w hen sera from six patients that developed chronic rejection were 
screened against a panel of bile duct tissues (see table 5.3).
Table 5.3 Presence (+) or Absence (-) of IgA Antibodies to a 94kD 
Antigen Present in Various Bile Duct Tissues (CR/CMV, CR, Tx or 
Normal) for Sera from Six Patients that Developed Chronic Rejection
Pre transplant Sera Post transplant Sera
Pati en (Number 
(see Append x l) CR/CMV CR Tx Normal CR/CMV CR Tx Normal
1 + + - - - - + -
2 + + - - - - - -
3 + - - - - - - -
5 + + - - - - - -
6 - - + - - - - -
1 3 - - - + - - - -
Table 5.3 shows results from screening four bile duct tissues which are defined as follows: CR/CMV= 
'chronically rejected/ CMV infected' bile duct, CR= 'chronically rejected' bile duct without CMV 
infection, Tx= 'transplanted' bile duct, Normal= 'normal' bile duct. Full descriptions of these tissues are 
given above (sections 5.2.3 and 5.2.4). The results of screening both pre and post transplant sera against 
these tissues are shown (+ indicates presence and - indicates absence of antigen identification by 
antisera) for six chronic rejectors (patient numbers 1, 2, 3, 5, 6 and 13) who are described in Appendix 1.
For pre transplant sera, 'chronically rejected' bile duct w ithout CMV 
infection had a similar immunogenicity with respect to a 94kD antigen 
when compared to 'chronically rejected/ CMV infected’ bile duct; both bile
ducts were more immunogenic with respect to a 94kD antigen compared 
to 'transplanted' bile duct or 'normal' bile duct. This result suggested that 
the process of chronic rejection upregulated expression of a 94kD antigen 
in bile duct tissue and that this upregulation was not m ediated or 
enhanced by CMV infection.
I g A  A n t i b o d i e s  t o  a  3 9 k D  B i le  D u c t  A n t i g e n
T a b l e  5.4 D i s t r i b u t i o n  o f  S e r a  C o n t a i n i n g  I g A  A n t i b o d i e s  t o  a  39  k D  
A n t i g e n  P r e s e n t  i n  'C h r o n i c a l l y  R e j e c t e d ,  C M V  I n f e c t e d '  B i l e  D u c t  ( C R /  
C M V  b i l e  d u c t )  o r  'N o r m a l '  B i le  D u c t
CR/ CMV bile duct Normal bile duct
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
39 80% 25%
(p=0.01)
90% 24%
(p<0.002)
50% 18%
(p<0.052)
10% 12%
(p=0.43)
p values were calculated from the difference between CR sera and other sera using Fishers exact test.
A ntibodies to the 39 kD antigen were found in a significantly larger 
proportion of pre transplant and post transplant CR sera compared to non- 
CR sera. Antibodies to a 39 kD antigen in 'chronically rejected, CMV 
infected' bile duct were highly prevalent among patients that developed 
chronic rejection (ie. harboured post transplant by 90% of chronic rejectors) 
and their detection may be potentially useful for diagnosis of chronic 
rejection.
A sim ilar trend was seen for pre transplant CR sera against norm al bile 
duct but significance was not reached.
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This result suggested that either the process of chronic rejection or CMV 
infection led to upregulation of a 39 kD antigen. These two effects may be 
distinguished by analysing closely the results generated in phases I and II 
w hen sera from six patients that developed chronic rejection were 
screened against a panel of bile duct tissues (see table 5.5).
Table 5.5 Presence (+) or Absence (-) of IgA Antibodies to a 39 kD  
Antigen Present in Various Bile Duct Tissues (CR/CMV, CR, Tx or 
Normal) for Sera from Six Patients that Developed Chronic Rejection
Pre transplant Sera Post transplant Sera
Pati a i  (Number 
(see Append x l ) CR/CMV CR Tx Normal CR/CMV CR Tx Normal
1 + 4- + + + + + +
2 + + - + + + - -
3 - + - - + + - -
5 + + - - + + - -
6 + + + - -F + + -
13 + + - - + + - -
Table 5.5 shows results from screening four bile duct tissues which are defined as follows: CR/CMV= 
'chronically rejected/ CMV infected' bile duct, CR= 'chronically rejected' bile duct without CMV 
infection, Tx= 'transplanted' bile duct, Normal= 'normal' bile duct. Full descriptions of these tissues are 
given above (sections 5.2.3 and 5.2.4). The results of screening both pre and post transplant sera against 
these tissues are shown (+ indicates presence and - indicates absence of antigen recognised by antisera) 
for six chronic rejectors (patient numbers 1, 2, 3, 5, 6 and 13) who are described in Appendix 1.
For both pre and post transplant sera, 'chronically rejected' bile duct had 
similar immunogenicity with respect to a 39 kD antigen when compared 
to 'chronically rejected/ CMV infected' bile duct. However, both bile ducts 
were more imm unogenic with respect to a 39 kD antigen compared to
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'transplanted' bile duct or 'normal' bile duct. This result suggests that the 
process of chronic rejection upregulated expression of a 39 kD antigen in 
bile duct tissue and that this upregulation was not mediated or enhanced 
by CMV infection.
IgA Antibodies to a 94kD or 39kD Bile Duct Antigen
When the results shown in tables 5.2 and 5.4 were combined for analysis of 
'chronically rejected / CMV infected' bile duct it was show n that all 
patients that developed chronic rejection contained antibodies to a 94kD 
antigen or to a 39kD antigen either pre or post transplant.
IgA  Antibodies and Active C M V  Infection
The presence of IgA antibodies was compared between patients with active 
CMV infection and controls after W estern blotting 'chronically rejected, 
CMV infected' bile duct and 'normal' bile duct (see table 5.6).
Table 5.6 Distribution of Sera Containing IgA Antibodies to a 44 kD 
Antigen Present in Chronically Rejected, CMV Infected Bile Duct (CR/ 
CMV bile duct) or Normal Bile Duct
CR/ CMV bile duct Normal bile duct
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD CMV
(n=27)
Others
(n = ll)
CMV
(n=29)
Others
(n=14)
CMV
(n=27)
Others
(n = ll)
CMV
(n=29)
Others
(n=14)
44 11% 10%
(p=0.435)
38% 14%
(p=0.056)
4% 0%
(P=0.71)
0% 0%
(p=1.000)
A 44 kD antigen was identified more often with post transplant sera from 
patients with active CMV infection compared to controls when sera were 
screened against 'chronically rejected, CMV infected' bile duct but this
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result was not significant. Only one serum sample contained antibodies 
that recognised a 44 kD antigen in 'normal' bile duct.
Furthermore, results generated in phase I of this study (see section 5.S.2.4 
and figure 5.7) showed that, for a proportion of the patients used for phase 
II statistical analysis, antibodies to a 44 kD antigen were discriminatory post 
transplantation  w hen sera was screened against 'chronically rejected, 
CMV infected' bile duct but that this trend was not evident when sera was 
screened  against 'chronically  rejected ' (uninfected) b ile duct or 
'transplanted ' bile duct (explanted, grafted liver that was not chronically 
rejected). This suggested that CMV infection of bile duct tissue was 
responsible for upregulation of a 44 kD antigen.
It is possible that the 44kD antigen was a CMV protein but this m ust be 
reconciled with the fact that phase I analysis showed that antibodies to a 44 
kD antigen in CMV-infected fibroblasts did not discrim inate between 
patients that developed active CMV infection and controls. Antigenic 
differences between the laboratory strain (AD169) used to infect fibroblasts 
in vitro and the clinical strain which infected bile duct tissue in vivo may 
account for this result.
Another possibility was that the 44kD antigen was a cellular protein that 
was upregulated by CMV infection and was specific to bile duct tissue.
However, identification of a 44kD antigen with antisera was not associated 
w ith the presence of chronic rejection (see above) and was therefore not 
investigated further.
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IgA  Antibodies and Pre-transplant Diagnosis of PSC
The presence of antibodies was compared betw een patients w ith pre 
transplant diagnosis of PSC (’PSC patients') and controls after W estern 
blotting chronically rejected, CMV infected bile duct or normal bile duct. 
Here, controls d id  not include those patients w ith a pre transp lan t 
diagnosis of PBC.
Antibodies directed to antigens of 145, 134 and 62 kD were most commonly 
(>40% sera) found in pre transplant sera from 'PSC patients'. However, 
only the 134 kD antigen was discriminatory (see table 5.7).
T a b l e  5.7 D i s t r i b u t i o n  o f  S e r a  C o n t a i n i n g  I g A  A n t i b o d i e s  to  a  1 3 4  k D  
A n t i g e n  P r e s e n t  i n  'C h r o n i c a l l y  R e j e c t e d ,  C M V  I n f e c t e d '  B i l e  D u c t  ( C R /  
C M V  b i l e  d u c t )  o r  'N o r m a l '  B i le  D u c t
CR/ CMV bile duct Normal bile duct
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD PSC
(n=6)
Others
(n=32)
PSC
(n=6)
Others
(n=37)
PSC
(n=6)
Others
(n=32)
PSC
(n=6)
Others
(n=37)
134 100% 53%
(p<0.05)
83% 35%
(p<0.05)
17% 47%.
(p=0.15)
33% 51%
(p=0.25)
A 134 kD antigen was identified by a significantly higher proportion of 
both pre and post transplant from 'PSC patients' when screened against 
'chronically rejected, CMV infected' bile duct; before transplantation, all 
'PSC patients' harboured antibody to the 134 kD antigen. However, this 
was not observed when sera was screened against 'normal' bile duct.
Useful analysis of a 134 kD antigen was not possible in phase 1 where only 
one PSC patien t (num ber 31) was studied. How ever, pre and post
transplant sera from this PSC patient was shown to contain antibodies to a 
134kD antigen of PSC bileduct' (ie. bile duct from a liver explanted after 
PSC).
Antibodies to a 134 kD antigen were not associated with chronic rejection 
(see above).
IgA  Antibodies and Pretransplant Diagnosis o f PBC
The presence of antibodies was compared betw een patients w ith pre­
transplant diagnosis of PBC ('PBC patients') and controls after W estern 
blotting 'chronically rejected, CMV infected' bile duct or 'norm al' bile 
duct. Here, controls did not include those patients w ith a pre transplant 
diagnosis of PSC.
Antibodies directed to antigens of 145, 134, 99 and 44 kD were most 
commonly (>40% sera) found in the pre transplant sera of 'PBC patients'. 
However, only the 44 kD antigen was discriminatory (see table 5.8).
Table 5.8 D istribution  of Sera Containing IgA A ntibodies to a 44 kD 
A ntigen Present in 'Chronically Rejected, CMV Infected' Bile Duct (CR/ 
CMV bile  duct) or 'Normal' Bile Duct
CR/ CMV bile duct Normal bile duct
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD PBC
(n=9)
Others
(n=29)
PBC
(n=9)
Others
(n=34)
PBC
(n=9)
Others
(n=29)
PBC
(n=9)
Others
(n=34)
44 56% 10%
(p=0.009)
44% 21%
(p=0.08)
0% 3%
(p=0.76)
0% 0%
(p=1.000)
Antibodies to a 44 kD antigen in 'chronically rejected, CMV infected' bile 
duct were detected in a significantly higher proportion of pre transplant 
sera from 'PBC patients' compared to controls. However, this was not 
observed  w hen  sera w ere screened against norm al b ile duct. 
Discrimination by identification of a 44 kD antigen with antisera was not 
apparent in phase I.
However, antibody to a 44kD antigen was not associated with the presence 
of chronic rejection (see above).
Sum m ary : IgA Antibodies Reactive to Bile Duct
Using Chronically Rejected, CMV Infected Bile Duct 
IgA Antibodies to Bile Duct Antigens and Chronic Rejection
• Antibody to a 94 kD antigen discriminated between pretransplant sera from chronic 
rejectors and 'others'; antibodies to this antigen were lost by all chronic rejectors 
after transplantation. Results from phase I suggested that a 94 kD bile duct antigen 
was upregulated by chronic rejection but not by CMV infection of bile duct.
• Antibody to a 39 kD antigen discriminated between sera from chronic rejectors and 
'others'; this was observed before and after transplantation. Antibodies to a 39 kD  
antigen of 'chronically rejected, CMV infected' bile duct were prevalent among 
patients that developed chronic rejection and may be useful for diagnosis of chronic 
rejection. Results from phase I suggested that a 39 kD bile duct antigen was 
upregulated by chronic rejection but not by CMV infection of bile duct.
IgA Antibodies to Bile Duct Antigens and Active CMV Infection
• The appearance of antibodies to a 44 kD antigen after transplantation 
discriminated between patients that had developed active CMV infection and 
others.
IgA Antibodies to Bile Duct Antigens and Pretransplant Diagnosis o f PBC
• Antibody to a 44 kD antigen also discriminated between pretransplant sera of PBC 
patients and others.
IgA Antibodies to Bile Duct Antigens and Pretransplant Diagnosis o f PSC 
• Antibody to a 134 kD antigen discriminated between sera from PSC patients and
others both before and after transplantation; all PSC patients harboured antibody 
to this antigen before transplantation.
Using Normal Bile Duct
• Screening sera against normal bile duct was never significantly discriminatory for
chronic rejection, active CMV infection or pre transplant diagnosis of PSC or PBC; 
normal bile duct was less immunogenic than chronically rejected bile duct.
S.3.3.2 I g G  A n t i b o d i e s  to  H e p a t i c  A r t e r y  T i s s u e
Tissue Panel
The following tissue was screened:
1. Hepatic artery from an explanted liver that was lost to chronic rejection but was not 
infected by CMV (’chronically rejected' hepatic artery; see phase I)
2. Hepatic artery taken from a 'cut down' donor liver ('normal' hepatic artery)
IgG  Antibodies and Chronic Rejection
The presence of antibodies was compared between chronic rejectors and 
controls after W estern blotting 'chronically rejected' and 'normal' hepatic 
artery. Identification of 160 kD and 85 kD antigens by antisera was 
discriminatory (see tables 5.9, 5.10, 5.11 and 5.12).
IgG Antibodies to a 160kD Antigen
Table 5.9 Distribution of Sera Containing IgG Antibodies to a 160 kD 
Antigen Present in 'Chronically Rejected' Hepatic Artery (CR Hepatic 
Artery) or 'Normal' Hepatic Artery
CR Hepatic Artery Normal Hepatic Artery
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
160 50% 21%
(p=0.08)
50% 21%
(p=0.07)
70% 36%
(p=0.055)
0% 46%
p=0.002)
Antibodies to a 160 kD antigen in 'chronically rejected' hepatic artery were 
found more often in pre transplant and post transplant sera from patients 
that developed chronic rejection (CR sera) compared to others. However, 
these differences were not significant.
Screening against 'norm al' hepatic artery show ed that pre transplant 
antibodies to a 160 kD antigen were present in a higher proportion of 
patien ts that developed chronic rejection com pared to others (this 
difference was not significant) but were lost from all chronic rejectors after 
transplantation.
The identification of a 160 kD antigen by antisera after W estern blot 
screening of various hepatic artery tissues was analysed to determ ine 
w hether the process of chronic rejection altered the immunogenicity of 
hepatic artery for a 160 kD antigen; results are shown for the six patients
that developed chronic rejection that were studied in phase I (see table 
5.10).
Table 5.10 Presence (+) or Absence (-) of IgG Antibodies to a 160kD 
Antigen Present in Various Hepatic Artery Tissues (CR, Tx or Normal) for 
Sera from Six Patients that Developed Chronic Rejection
Pre transplant Sera Post transplant Sera
Pati en (Number 
(see Append x l ) CR Tx Normal CR Tx Normal
1 - - + + - -
2 - - + 4- - -
3 - - - - - -
5 + + + + - -
6 + 4- + + - -
1 3 - - - - - -
Table 5.10 shows results from screening four hepatic artery tissues which are defined as follows: CR= 
'chronically rejected' hepatic artery, Tx= 'transplanted' hepatic artery, Normal= 'normal' hepatic artery. 
Full descriptions of these tissues are given above (sections 5.2.3 and 5.2.4). The results of screening both 
pre and post transplant sera against these tissues are shown (+ indicates presence and - indicates absence 
of antigen recognised by antisera) for six chronic rejectors (patient numbers 1, 2, 3, 5, 6 and 13) who are 
described in Appendix 1.
The results show n in table 5.10 for pre transplant sera suggested that the 
process of chronic 'rejection did not upregulate a 160 kD antigen. In 
contrast, post transp lan t sera identified a 160 kD antigen only in 
'chronically rejected' hepatic artery. These results may be consolidated if 
the 160 kD antigens identified in these tissues were not identical; here, post 
transplant upregulation of antibodies to a 160 kD antigen in 'chronically 
rejected' hepatic artery may occur simultaneously with downregulation of
antibodies to a 160 kD antigen present in 'transplanted' a n d /o r  'normal' 
hepatic artery.
IgG Antibodies to an 85 kD Antigen
Table 5.11 Distribution of Sera Containing IgG Antibodies to an 85 kD 
Antigen Present in 'Chronically Rejected' Hepatic Artery (CR Hepatic 
Artery) or 'Normal' Hepatic Artery
CR Hepatic Artery Normal Hepatic Artery
Pretransplant sera Post transplant sera Pretransplant sera Post transplantsera
Size kD CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
CR sera 
(n=10)
Others
(n=28)
CR sera 
(n=10)
Others
(n=33)
85 50% 11%
(p<0.04)
50% 21%
(p=0.07)
50% 25%
(p=0.11)
50% 9%
(p<0.04)
Antibodies to the 85 kD antigen were found in a larger proportion of pre 
transplant and post transplant sera from patients that developed chronic 
rejection (CR sera) compared to controls (non-CR sera). A sim ilar trend 
was seen after screening sera against normal bile duct but significance was 
not reached.
The identification of an 85 kD antigen by antisera after W estern blot 
screening of various hepatic artery tissues was analysed to determ ine 
w hether the process of chronic rejection altered the im m unogenicity of 
hepatic artery for an 85 kD antigen; results are shown for the six patients 
that developed chronic rejection that were studied in phase I (see table 
5.12).
Table 5.12 Presence (+) or Absence (-) of IgG Antibodies to an 85 kD 
Antigen Present in Various Hepatic Artery Tissues (CR, Tx or Normal) for 
Sera from Six Patients that Developed Chronic Rejection
Pre transplant Sera Post transplant Sera
Pati en (Number 
(see Append x l ) CR Tx Normal CR Tx Normal
1 + + - - - -
2 + + + + - +
3 + + 4- 4- + +
5 + - - 4- - -
6 - - - 4- + -
1 3 - - - - - -
Table 5.12 shows results from screening three hepatic artery tissues which are defined as follows: CR= 
'chronically rejected' hepatic artery, Tx= 'transplanted' hepatic artery, Normal= 'normal' hepatic artery. 
Full descriptions of these tissues are given above (sections 5.2.3 and 5.2.4). The results of screening both 
pre and post transplant sera against these tissues are shown (+ indicates presence and - indicates absence 
of antigen recognised by antisera) for six chronic rejectors (patient numbers 1, 2, 3, 5, 6 and 13) who are 
described in Appendix 1.
The results show n in table 5.12 suggested that the process of chronic 
rejection did not upregulate an 85 kD antigen; only one patient (patient 5) 
identified an 85kD antigen which was exclusive to 'chronically rejected' 
hepatic artery.
IgG Antibodies to a 160kD or 94kD Hepatic Artery Antigen
Comparison of tables 5.10 and 5.12 shows that, for patients that developed 
chronic rejection, the presence of antibodies to a 160kD antigen was 
usually associated with antibodies to an 85kD antigen. All patients (1, 2, 5
and 6) that harboured antibodies to a 160kD antigen in 'chronically 
rejected' hepatic artery also harboured antibodies to an 85kD antigen in 
this tissue.
Furtherm ore, only one patient that developed chronic rejection (patient 
13) did not harbour IgG antibodies to either a 160 kD or an 85 kD hepatic 
artery antigen.
IgG  Antibodies and Active C M V  Infection
The presence of antibodies was compared between sera from patients with 
active CMV infection and controls after W estern blotting 'chronically 
rejected' and 'normal' hepatic artery. None of the antigens identified were 
discrim inatory.
IgG  Antibodies and PSC
The presence of antibodies was compared between sera from patients with 
pre transp lan t diagnosis of PSC (PSC sera) and controls after W estern 
blotting 'chronically rejected' and 'normal' hepatic artery. Here, controls 
did not include those patients with a pre transplant diagnosis of PBC.
For both tissues screened, antibodies in PSC sera were most commonly 
directed to antigens of 210, 159, 109, 78 and 75 kD; identification of these 
antigens with antisera was not discriminatory.
IgG  Antibodies and PBC
The presence of autoantibodies was compared between sera from patients 
with pre-transplant diagnosis of PBC (PBC sera) and controls after Western 
blotting 'chronically rejected' and 'normal' hepatic artery. Here, controls 
did not include those patients with a pretransplant diagnosis of PSC.
For chronically rejected and normal hepatic artery, antibodies in PBC sera 
were most commonly directed to antigens of 210, 185, 140, 109, 78 and 75 
kD; identification of these antigens with antisera was not discriminatory.
Sum m ary: IgG Antibodies to Hepatic Artery
IgG Antibodies to Hepatic Artery Antigens and Chronic Rejection
• Screening against 'chronically rejected' hepatic artery show ed that a greater 
proportion of chronic rejectors harboured antibodies that identified a 160 kD  
antigen compared to controls; this was observed before and after transplantation. 
This trend did not reach significance.
• Similarly, screening against normal hepatic artery showed that identification of a
160 kD antigen was discriminatory pretransplant. However, antibody to this 160 
kD antigen was not detected in chronic rejectors after transplantation.
• Identification of a 85 kD antigen discriminated between sera from chronic rejectors 
and 'others' both pre- and post-transplant; this trend was observed after screening 
against chronically rejected and normal hepatic artery.
• Analysis of results from phase I suggested that the presence of antibodies to a 
160kD antigen was associated with the presence of antibodies to an 85 kD antigen in 
'chronically rejected' hepatic artery.
IgG Antibodies to Hepatic Artery Antigens and Active CMV Infection
• IgG antibodies to chronically rejected or normal hepatic artery did not discriminate
betw een sera from patients with active CMV and 'others'.
IgG Antibodies to Hepatic Artery Antigens and Pre transplant Diagnosis o f PBC
• IgG antibodies to chronically rejected or normal hepatic artery did not discriminate
betw een sera from 'PBC patients' and 'others'.
IgG Antibodies to Hepatic Artery Antigens and Pre transplant Diagnosis o f PSC
• IgG antibodies to chronically rejected or normal hepatic artery did not discriminate
betw een sera from 'PSC patients' and 'others'
5.3.4 Lack of Cross-Reactivity Between C ellular A ntigens and CMV- 
Specific Antibodies
Chronically rejected hepatic artery was blotted and polyclonal antibodies to 
CMV (raised in goat) were applied before application of sera containing 
antibodies of interest. This enabled blocking of endogenous antibody 
binding and binding of CMV specific antibodies to cellular proteins to be 
observed (see figure 5.10).
The banding pattern  obtained after incubation of blots w ith sera, which 
had previously been shown to contain autoantibodies to the 85 kD and 160 
kD hepatic artery antigens, was unaltered by prior incubation of the blots 
w ith polyclonal antibodies directed to CMV or adenovirus i.e. polyclonal 
antibodies to CMV did not block the binding of antibodies of interest to 
this tissue.
However, detection of goat IgG showed that interaction did take place 
between CMV polyclonal antibodies and 9 hepatic artery proteins of 253, 
245, 210, 185, 177, 167, 151, 145 and 78 kD molecular weight; 5 of which (253, 
245, 210, 185 and 78 kD) were previously shown to be targets for antibodies 
in vivo (see section 5.3.2). Interaction also took place between adenovirus 
polyclonal antibodies and autoantigens of 78 and 85 kD. However, these 
interactions were non-specific and occurred, w ith low avidity, only when 
antibodies were added at high titre (1:100); this interaction did not prevent 
binding of hum an antibodies. An identical experiment was perform ed to 
investigate possible cross-reactivity between antibodies to CMV and the 
bile duct antigens of interest (94 and 39 kD; results not shown). No such 
cross-reactivity was seen.
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Sum m ary
Hepatic artery antigens of interest (160 and 85 kD) did not cross react w ith 
antibodies raised against cytomegalovirus (AD169) proteins in goats.
Bile duct antigens of interest (94 and 39 kD) did not cross react w ith antibodies 
raised against cytomegalovirus (AD169) proteins in goats.
5.4 DISCUSSION
The results presented in this chapter underw ent 4 rounds of univariate  
analysis and each antigen that w as identified w ith antisera w as analysed  
separately. It is possible that some of the significant trends observed w ere  
due to random  events. Therefore, the findings of this chapter m ust be 
interpreted w ith  caution. H ow ever, these find ings set up in teresting  
hypotheses w hich should be tested in a larger study.
5.4.1 C onclusions
• The hypothesis that antibodies to bile duct or hepatic artery initiate or enhance 
chronic rejection was upheld. Two antibodies to chronically rejected, CMV infected 
bile duct (94 and 39 kD) and 2 antibodies to chronically rejected hepatic artery (160 
and 85 kD) discriminated between chronic rejectors and 'others'. It is of interest that 
these antibodies were often detected prior to transplant.
• Conflicting evidence was generated for the hypothesis that active cytomegalovirus 
(CMV) infection of hepatic artery or bile duct upregulates the expression of target 
antigens. Chronically rejected, CMV infected bile duct was more immunogenic than 
its chronically rejected (uninfected) (phase I) and normal (phase II) counterparts. 
However, CMV infected fibroblasts were not more immunogenic than uninfected 
fibroblasts (phase I).
• The hypothesis that active CMV infection upregulates the production of antibodies 
involved in chronic rejection was not upheld. IgA antibody to a 44kD bile duct 
antigen identified patients that developed active CMV infection but was not 
associated w ith chronic rejection.
• The hypothesis that antibodies produced to CMV are cross reactive w ith cellular 
antigens involved in chronic rejection was not upheld.
• The hypothesis that autoantibodies associated with primary biliary cirrhosis 
(PBC) or primary sclerosing cholangitis (PSC) are present after transplantation for 
these diseases and are associated with chronic rejection was not upheld. Antibodies 
to bile duct (44 and 134 kD) were shown to discriminate PBC sera and PSC sera from 
'other sera' respectively, but these antibodies were not associated with chronic 
rejection.
5.4.2 Humoral Immunity and Chronic Rejection
Four antibodies were found in a significantly higher proportion of chronic 
rejectors com pared to controls. A s far as 1 am aware, similar work has not 
been previously reported in the context of liver transplantation.
5.4.2.1 Two Antibodies to Bile Duct were Associated with Chronic 
Rejection
I g A  A n t i b o d i e s  to  a 39 k D  Bile  D u c t  A n t ig e n
Pre and post transplant sera from chronic rejectors w ere associated w ith  
IgA antibody to a 39 kD protein; this result w as only significant using  
chronically rejected, CMV infected' bile duct. A similar trend (but w ithout 
significance) w as seen after screening normal bile duct but less chronic 
rejectors w ere show n to harbour antibody.
It w as therefore proposed that the reactivity of a 39 kD protein  w as  
enhanced by CMV infection or by the process of chronic rejection.
Indeed, a number of cellular proteins (54, 55, 366, 214, 264, 265, 266, 267, 268; 
see sections 1.3.3.1, 1.9.2 and 1.9.3) and cellular antigens (312, 313, 314; see 
section 1.9.5) have been show n to be upregulated after CMV infection.
H ow ever, the hypothesis that CMV infection led to upregulation of a 39 
kD bile duct antigen w as not supported by results generated in phase 1. 
H ere, 'chronically  rejected' bile duct and 'chronically rejected, CMV 
infected' bile duct were sim ilarly im m unogenic w ith respect to the 39kD
antigen w hen im m unoblotted using sera from six patients that developed  
chronic rejection.
A nother p o ssib ility  considered  w as that chronic rejection m ay have  
enhanced the reactivity of a 39 kD bile duct antigen. Indeed, chronic 
rejection of liver grafts is associated w ith the increased surface expression  
of m any proteins w hich  may, or m ay not, be im m unogenic; these include  
HLA m olecu les (213, 287), adhesion m olecules (374) and lym phokines  
(373).
The hypothesis that chronic rejection w as associated w ith upregulation of 
a 39 kD bile duct antigen was supported by results generated in phase I of 
this study; both 'chronically rejected' bile duct and 'chronically rejected, 
CMV infected' bile duct were more im m unogenic than 'transplanted' or 
'normal' bile duct w ith  respect to a 39 kD antigen using sera from six  
patients that developed chronic rejection.
A 39 kD antigen identified in 'chronically rejected, CMV infected' bile duct 
w as not a CMV protein; identification of this antigen w as not exclusive to 
CMV infected tissue. H ow ever, it w as proposed that antibodies to the 39 
kD antigen w ere cross-reacting w ith CMV proteins but this possibility was 
excluded in a later experim ent (see section 5.3.4).
I g A  A n t i b o d i e s  to  a  94 k D  Bile  D u c t  A n t ig e n
Sim ilarly, pretransplant sera from chronic rejectors w as associated w ith  
IgA antibodies to a 94 kD antigen in 'chronically rejected, CMV infected' 
bile duct. R eactivity w as enhanced in this tissue com pared to 'normal' 
tissue and it w as proposed that the process of chronic rejection or CMV 
infection w as associated w ith upregulation of a 94 kD bile duct antigen.
This w as not supported  by results generated in phase I; 'chronically  
rejected' b ile duct and 'chronically rejected, CMV infected' bile duct were 
sim ilarly im m unogenic w ith respect to a 94 kD antigen using sera from six 
patients that developed chronic rejection.
Phase I results suggested  that chronic rejection led to upregulation of a 94 
kD bile duct antigen; both 'chronically rejected' bile duct and 'chronically 
rejected , CM V infected ' b ile  d u ct w ere  m ore im m u n ogen ic  than  
'transplanted' or 'normal' bile duct w ith  respect to a 94 kD antigen using  
sera from six patients that developed chronic rejection.
In tr ig u in g ly , p a tien ts  that d e v e lo p e d  chron ic rejection  b ecam e  
seronegative for antibodies to a 94 kD antigen in 'chronically rejected, 
CMV infected' b ile duct, after transplantation. One p ossib ility  is that 
im m unosuppresssion  follow ing transplantation led to dow nregulation of 
production of this antibody.
H ow ever, it is possib le  that this result w as due to dep osition  of this 
antibody in the grafted liver after transplantation. This does not account 
for the results observed after blotting normal bile duct w ith post transplant 
sera from patients w ho did not develop  chronic rejection and in w hom  
antibody w as detected. H ow ever, it is possible that the 94 kD antigens 
detected in these tw o bile duct tissues are distinct.
5.4.2.2 Tw o A ntibod ies to Hepatic Artery were A ssociated w ith  Chronic 
R ejection
Two IgC antibodies to hepatic artery w ere also associated w ith  chronic 
rejection.
Ig G  A n t ib o d ie s  to  an  85 k D  H e p a tic  A r te r y  A n t ig e n
Pre transplant IgG antibodies to an 85 kD antigen in 'chronically rejected' 
hepatic artery were significantly associated w ith rejection; a similar trend 
w as apparent post transplant but w ithout significance. Sim ilarly, IgG 
antibodies to an 85 kD antigen in 'normal' hepatic artery were associated  
w ith rejection (significance show n post transplant only).
C om parison of results from phases I and II using 'chronically rejected', 
'transplanted' or 'normal' hepatic artery against sera from six patients that 
d evelop ed  chronic rejection suggested  that an 85 kD antigen w as not 
upregulated by transplantation or by the process of chronic rejection.
Furtherm ore, phase I results show ed that an 85 kD antigen w as also 
present at h igh levels in fibroblasts but it is not know n whether the 85 kD 
antigen detected in fibroblasts was identical to that identified in hepatic 
artery. If the 85 kD antigens in bile duct and fibroblasts were identical, this 
w ou ld  not be necessarily  inconsistent w ith  an 'organ-specific' rejection  
process; it is p ossib le  that the surface express ion  of this protein w as 
enhanced in hepatic artery during the rejection process. Indeed, Latif et al 
(1995) (309) found antibodies to 'housekeeping' proteins (heat shock  
protein-60 and -70) that were associated w ith heart graft rejection (see 
section 1.8.3.3.3).
I g G  A n t i b o d i e s  t o  a 160 k D  H e p a t i c  A r t e r y  A n t i g e n
Posttransplant IgG antibody to a 160 kD antigen in 'chronically rejected' 
hepatic artery w as associated w ith rejection (this result did not reach 
sign ifican ce). H ow ever, post-transplant antibodies from patients that 
d evelop ed  chronic rejection did not bind 160 kD antigens present in 
'transplanted' or 'normal' hepatic artery w hereas antibodies from control
patients w ere show n to bind a 160 kD antigen from these tissues. H ow ever, 
it is possib le that the 160 kD antigens that were present in these tissues  
w ere antigenically distinct.
Results from phase I show ed that IgG antibodies to a 160 kD hepatic artery 
antigen w ere usually  associated w ith IgG antibodies to an 85 kD hepatic 
artery antigen.
5.4.2.3 Causality
A  causal relationship betw een these antibodies and chronic rejection has 
not been  estab lished . The association  b etw een  chronic rejection and  
antibodies after transplantation, as show n for IgG antibody to the 160 kD 
hepatic artery antigen, could be due to increased release of antigen after 
rejection m ediated  dam age. H ow ever, the link betw een  pre transplant 
antibodies, as show n for IgG antibody to the 85 kD hepatic artery antigen  
and IgA antibodies to 39 kD and 94 kD bile duct antigens, is m ore 
com pellin g .
Further work should  be directed at establishing the im portance of these  
antibodies; purification of a particular antibody could be carried out by  
absorbing-out all other antibodies (this could be conducted by incubating  
sera w ith  W estern blotted proteins w ith the antigen of interest rem oved). 
T he p u r if ie d  a n t ib o d ie s  c o u ld  th en  be u se d  to p er fo rm  
im m u noh istoch em istry  on sections of norm al and chronically rejected 
bile duct. Similar work for renal grafts has show n that antibodies localise 
at sites of rejection (305, 307; see section 1.8.3.3.3) including endothelial 
tissue (307; see also 308, 312) which is also a primary site of rejection for 
liver grafts (191, 193).
The antibodies identified  in this study w ere not associated w ith  active 
CMV infection (see sections 5.3.3.1 and 5.3.3.2) and were, therefore, not 
studied  further.
5.4.3 A ctive CM V Infection, Hum oral Im m unity and Chronic R ejection
N one of the antigens identified by antisera w ere confined exclusively  to 
CMV infected cells or tissue nor w ere any detected exclusively  w ith  sera 
from patients w ith  active CMV infection. Therefore it is unlikely that any 
of the W estern b lot bands represented CMV specific antibody bound to 
CMV protein; note that this does not exclude crossreactive antibody  
interactions, ie. CMV specific antibody bound to hum an antigen or visa  
versa.
CMV ind uced  autoantibodies have been reported p rev iou sly  in n on ­
transplant settings (312, 313); in this study, IgA antibody to a 44 kD bile duct 
antigen  identified patients that developed  active CMV infection but w as 
not associated w ith chronic rejection.
5.4.4 A ntibodies and Pretransplant D iagnosis of PBC or PSC
PBC is a disease that involves sm all bile ducts w hereas chronic rejection 
in volves m edium  to large sized bile ducts; therefore, antibodies associated  
w ith  PBC (320; see section 1.9.6) w ould not not necessarily be expected to be 
associated w ith  chronic rejection or detected w hen tested against large bile 
duct as performed in this study.
N evertheless, pretransplant diagnoses of PBC or PSC have been reported 
to be a risk factor for chronic rejection (200, 201, 203, 205) and this link was 
show n to be significant for patients w ith PBC in this study (see Chapter 4).
Several of the com m onest antigens detected by antibodies present in PBC 
(39, 53 and 75 kD) and PSC (210, 109 and 62 kD) sera, during this study, 
have previously been show n to be associated w ith PBC (320) or PSC (317, 
318) disease. H ow ever, in this study none of the antigens identified w ith  
antisera w ere confined exclusively  to PBC diseased liver tissue or PSC 
diseased bile duct (see Phase I) nor were any detected exclusively w ith  sera 
from patients PSC or PBC.
This lack of discrim ination may be due to 'masking' by other antigens of 
sim ilar size (a single Western blot band does not necessarily correspond to 
a single antigen). In addition, antigens that discriminate betw een PBC and 
non-PBC sera m ay be 'burnt out' in PBC-liver and PSC-bile duct by  
previous im m une activity or blocked by previous antigen binding in vivo.  
The latter phenom enon w as addressed in Phase II of this stu d y  w hen  
norm al tissue was screened.
A sim ilar lack of discrim ination w as seen after screening of normal tissue. 
The system  of detection used w as highly sensitive (alkaline phosphatase) 
w hich  m ay account for detection of antibodies w ith  specificity  to PBC 
antigens' and 'PSC antigens' in individuals w ithout either liver disease. A  
similar result has been reported previously for PSC (318).
Furtherm ore, the W estern blotting technique used w as perform ed under  
denaturing conditions in order to efficiently separate proteins by size; such  
conditions destroy secondary and tertiary structure. A ntibodies that react 
in v i v o  w ith  ep itop es w ith  com plex structure w ill therefore not be 
detected  in vi tro  using this technique. It is probable that such antibodies 
exist in v ivo  in association with PBC or PSC and were not detected in this 
study.
H ow ever, W estern blotting did identify IgA antibody to a 44 kD antigen in 
'chronically rejected, CMV infected'; this w as found in a sign ificantly  
higher proportion of PBC patients pretransplant and w as lost by all PBC 
patients post-transplant. Furtherm ore, this result w as m irrored, albeit 
w ith ou t significance, after blotting 'normal' bile duct tissue. The loss of 
antibody after transplantation m ay be due to rem oval of the antigen source 
(i.e. the d iseased liver). This antigen m ay be the 'liver-pancreas' antigen  
p r e v io u s ly  reported  to be 48-52 kD in s ize  and a ssoc ia ted  w ith  
autoim m une hepatitis, PBC and PSC (321).
IgG antibody to the 140 kD hepatic artery antigen is also associated w ith  
PBC and also  d isappears after transplant. This w as not seen  w h en  
chronically rejected tissue w as screened and it is possible that the antigen  
w as 'burnt out' or blocked in this tissue.
In contrast, PBC w as significantly associated w ith the presence of IgG to the 
78 kD hepatic artery antigen both before and after transplantation . 
H ow ever, none of the antibodies associated w ith PBC were associated w ith  
the incid en ce of chronic rejection (see section  5.4.1). A ntibody to an 
antigen of similar size (74 kD) w as found to be associated w ith PBC by Van 
de Water et al (1989) (320).
PSC w as significantly associated w ith IgA to the 134 kD bile duct antigen; 
this w as seen  for pre- and post-transplant sera but persistence of this 
antibody after transplantation w as not associated w ith the incidence of 
chronic rejection (see section 5.4.1).
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5.4.5 A ntigens of Interest did N ot Cross-React w ith  Polyclonal A ntibodies  
to CMV
Sera previously  show n to contain antibodies of interest to bile duct or 
hepatic artery proteins w as app lied  to tissue after incubation  w ith  
polyclonal antibodies to CMV or adenovirus. The latter antibodies were  
sh ow n  to b ind  a num ber of antigens but d id  not prevent b in din g of 
hum an antibodies. This suggests that b inding of CMV and adenovirus  
antibodies occurs through w eak, non-specific interactions that are readily  
displaced by stronger, specific binding of antibodies.
A ntigens did not cross react w ith  CMV antibodies. It is possible that the 
cross-reactive antibodies suggested by a previous study (60) were specific to 
a particular HLA m olecule w hich was not "inherited" by the donor of this 
tissue.
H um an CMV does not replicate in goats and therefore the goat polyclonal 
antibodies used  here w ill have specificities to structural proteins only. It 
w as not p ossib le  to test crossreactivity of hum an antibodies to non- 
structural CMV proteins using the techniques presented in this Chapter.
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CHAPTER 6
CYTOMEGALOVIRUS ACTIVELY 
INFECTS BILE DUCT EPITHELIAL 
CELLS AND VASCULAR 
ENDOTHELIAL CELLS OF LIVER 
GRAFTS LOST TO CHRONIC 
REJECTION
6.1 Introduction
A ctive cytom egalovirus (CMV) infection of graft tissue has been associated  
w ith  chronic rejection in a num ber of reports (225, 284). The Pittsburgh  
group found that HLA DR m atching facilitated CMV hepatitis w hich w as a 
risk factor for chronic rejection (225; see section 1.8.2.2).
The K ings C ollege group investigated  serial liver b iop sy  specim ens for 
active CMV infection by in s i tu  hybrid isation (ISH); p e r s i s t e n t  CMV 
infection  of liver grafts constituted a risk for chronic rejection (284; see 
section 1.8.2.3). In this report CMV infection of hepatocytes w as observed; 
in contrast, the primary sites of dam age during chronic rejection, ie. large 
bile ducts and hepatic artery (see section 1.8.1.2), w ere not studied . The 
authors su ggest that CMV i n d i r e c t l y  prom oted or initiated dam age of 
these latter tissues. H ow ever, screening of biopsy specim ens allow ed only  
lim ited analysis of the primary sites of chronic rejection because only  
sm all bile ducts and arterioles were present in these specim ens.
In contrast, this chapter reports the results of screening sections taken from  
explanted  livers that have been lost to chronic rejection. Sections that 
contained large or m edium  sized  bile duct a n d /o r  hepatic artery w ere  
selected for screening for active CMV infection by in s itu  hybrid isation  
(ISH) and im m unohistochem istry.
Four patients w ho lost grafts to hepatic artery throm bosis w ere also 
included in this study because the pathology of this disease is similar to the 
ischaem ic injury observed during early stages of chronic rejection of som e  
grafts (191,193; see section 1.8.1.2).
H ubscher 1991 (191) defined tw o criteria for the d iagn osis of chronic 
rejection (see section 1.8.1.2):
1. Vanishing bile duct syndrome (VBDS)
VBDS is a progressive disorder w hich cannot be treated and leads to graft 
loss.
2. Obliterative vasculopathy of small and medium sized arteries
Arteries are also involved; endothelial dam age leads to infiltration of the 
intim a by foam y macrophages and occlusion of the lum en.
A n exam ple of the h istopathological changes that are characteristic of 
chronic rejection is show n in figure 6.1 and important points are described  
below .
Figure 6.1 Cross-sections of Normal and Chronically Rejected Portal 
Tracts
a Normal portal tract
Chronically rejected portal tract
V*
HA
PV
• /  rt ' : .  I-
- ,  • >
FM
■VBD
Figure 6.1 show s a cross-section of a normal portal tract (a) comprising bile duct (BD), 
hepatic artery (HA) and portal vein  (PV). This is shown above a chronically rejected 
portal tract (b) which comprised 'vanished' bile duct (VBD), hepatic artery (HA) and 
portal vein (PV). Here, the 'vanished' bile duct can be identified by its position, adjacent to 
hepatic artery and portal vein, and shape; no bile duct epithelial cells remain. The 
hepatic artery is infiltrated by foamy macrophages (FM) which occlude the lumen.
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H ypothesis
• Cytom egalovirus (CMV) m ay actively infect vascular endothelial and b ile  duct 
epithelial cells and may initiate or enhance chronic rejection at these sites.
6.2 Patients, Materials and Methods
6.2.1 Patients
Patients were selected initially according to the criteria that all provided 
more than one sample (serum, whole blood and urine) per week for more 
than two months after transplant (see section 2.2.6). Samples were tested 
in parallel by PCR, DEAFF and culture (see Chapter 2).
From this sub-group, liver graft sections from 29, liver transplant recipients 
were examined. Fifteen explanted grafts, from which sections were 
available, were selected for this study; eight and four patients lost their 
graft to chronic rejection (CR) or hepatic artery thrombosis (HAT) 
respectively.
The control group comprised three patients that lost grafts to other 
diseases (see Appendix 3) and 14 patients that retained their grafts. This 
highly selected group was biased towards patients with evidence of active 
CMV infection and comprised ten patients that developed active CMV 
infection as detected by serum or urine PCR and /or DEAFF testing (see 
Chapters 2 and 3) and four patients that remained negative for CMV. The 
patients included in this control group were selected according to the 
availability of speciinens.
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AU sections studied were selected according to the presence of medium to 
large bile duct ^ d  hepatic artery tissue (the primary targets of chronic 
rejection).
The patients included in this study are described in Appendices 1 and 3.
All sections selected for study had been examined previously by an 
experienced pathologist; these reports were used throughout this study to 
define the histopathology of each section.
6.2.2 Preparation of Slides
Formalin fixed, paraffin embedded tissue sample slides were kindly 
provided by Dr Nick Coleman.
Formalin Fixation and Paraffin Embedding
Specimens were fixed by immersion in 10% formol saline for 24 hours. 
Tissue was then ertibedded using an automatic processor which immersed 
the specimen sequentiaUy in absolute ethanol for . 9 hours (changed after 2 
hours then hourly), xylene for 3 hours (changed after 1.5 hours), molten 
paraffin wax (56"C) for 2 hours before embedding into blocks and cooling 
to room temperature.
>
Preparation o f  Tissue Sections
Slides were washed in distiUed water ( 2 x 3  minutes), rinsed in industrial 
methylated spirits (IMS) and air dried. Slides were then soaked in 2% (v/v)  
aminopropyltri-ethoxysilane (APES) in dry acetone for 5 seconds and then 
in distilled water for 2 minutes before drying overnight at 37"C.
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Sections were cut (4-5p.m) using a new blade for each specimen and 
mounted onto the APES-coated slides before drying overnight at 37“C. 
This was performed the day before screening.
6.2.3 Immunohistochemistry 
A ntibodies
Four primary antibodies were used in this study; a monoclonal antibody 
against CMV delayed-early DNA binding protein p52 (raised in mouse; 
Dako), a monoclonal antibody raised against rubella which served as an 
irrelevant isotype-m atched control, a monoclonal raised against 
cytokeratin to identify epithelial cells (raised ill mouse; MNF116, Unipath) 
and a monoclonal antibody to identify endothelial cells (raised in mouse; 
Q. Bend 10, Unipath).
Goat-anti mouse (Dako) was used as secondary antibody; this was 
conjugated to biotin. Development was achieved by application of 
Streptavidin/biotin complex conjugated to horse radish peroxidase (HRP).
The anti-endothelial and anti-epithelial antibodies were used to confirm 
putative epithelial and endothelial positivity for CMV. The manufacturers 
claim specificity; antibody to CMV p52 protein does not cross react with 
any other herpesvirus.
A utom ated  Proceedure fo r  Im m unohistochem istry
This technique was performed using an automated system that was set up 
in the Histopathology Department, Addenbrooke's Hospital.
Slides were dewaxed in xylene for 5 minutes and washed in water for 5 
minutes before blocking of endogenous peroxidase activity (2.5% hydrogen 
peroxidase (v /v ) in methanol) for 10 minutes. Slides were washed again in 
water for 6 minutes before try^MKisation (0.1% trypsin, 0.1% CaCl (pH7.8))
water for 6 minutes before trypsinisation (0.1% trypsin, 0.1% CaCl (pH7.8)) 
at 37"C for 20 minutes, a further wash in water for 3 minutes to stop 
enzyme activity and equilibration in Tris-buffered saline (TBS) for 1 
minute. The primary antibody was then applied (diluted 1:500 in TBS) for 
30 minutes before removal of non-specifically bound antibody by 2 x 10 
minute washes in TBS. The secondary antibody-conjugate (diluted 1:1000 
in TBS) was then applied for 30 minutes before washes to remove antibody 
bound non-specifically (2 x 10 minutes with TBS) and application of 
tertiary solution (streptavidin/biotin complex conjugated to HRP (1:100 in 
TBS) ; Dako) for 30 minutes and further washes (2 x 10 miniites with TBS). 
Development was achieved by addition of substrate/chromagen (0.05M 
Tris, 0.04M HCl, 2.5% (v /v ) diaminobenzidine, 0.2% hydrogen peroxide) 
for 10 minutes. This reaction was stopped by washing in water for 10 
minutes and slides were then counterstained in Harris' Haematoxylin for 
15 seconds, rinsed in water, dried and mounted.
Immunohistochemistry was also performed without application of 
primary antibody for each slide processed; this served as a control for 
secondary antibodies and conjugate. A positive control (shown previously 
to be CMV infected) was also included in each run.
6.2.4 In Situ Hybridisation (ISH)
Probe fo r  CMV
A  digoxigenin-labelled 23kB probe was kindly supplied by Dr Fraser Lewis 
(University of Leeds, Leeds, UK); this comprised the Hind EQ F fragment 
from the genome of the CMV strain AD169. Labelling was performed by 
nick translation which generated labelled fragments of 300 - 500 base pairs. 
This probe showed minimal homology to cellular DNA (130, 173).
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Control Probe
A  control probe comprised mouse cellular DNA (balb/c strain) which was 
labelled with digoxigenin by nick translation according to manufacturers 
instructions (Boehringer Mannheim). Labelling was performed by nick 
translation which generated labelled fragments of 300 - 500 base pairs. All 
sections that were scored positive after in situ hybridisation with the CMV 
probe were also screened using the mouse DNA probe.
Prevention o f  KNA'se Contam ination
This was achieved by wearing disposable gloves at all times, using sterile 
plastic ware and/or baked glassware (180“C for 8 hours). Water was treated 
with diethyl pyrocarbonate (DEPC); 500pl DEPC was mixed with 500ml 
water, incubated at room temperature overnight and then autoclaved.
ISH M ethod
Wash and immersion steps were carried out in Hellendahl jars. Slides ' 
were de waxed in xylene (2 x 10 minutes) and rehydrated by serial 
immersion (for 2 minutes at room temperature) in 99%, 95%, 70% and 
50% ethanol followed by immersion in water for 5 minutes at room  
temperature and then 2 x SBC (20X SBC stock; 3M NaCl, 0.3M trisodium i 
citrate) for 10 minutes at 60"C.
Rehydrated slides were then processed using reagents from an IBH kit 
(R&D System s) fo llow in g the manufacturers instructions w ith  
modifications. Equilibration in 50mM Tris for 5 minutes was performed 
before lOOpI proteinase K solution (50|xg/ml in 50mM Tris) was pipetted 
onto each section which were then incubated in humidity chambers for 30 
minutes at 37“C. Slides were then rinsed in phosphate buffered saline
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(PBS), fixed (0.4% paraformaldehyde in PBS for 20 minutes at 4“C) and 
rinsed in water.
Dehydration was now carried out before hybridisation; slides were serially 
immersed (for 2 minutes at room temperature) in 50%, 70%, 95% and 99% 
ethanol and air dried.
Hybridisation was carried out as follows. Probe was added to hybridisation 
solution containing 30% formamide (R&D Systems) to a final 
concentration of 200ng/ml. A coverslip was placed and sealed with rubber 
cement (dried after application at 65"C for 10 minutes) before both probe 
and tissue DNA were denatured by heating the slide at 80“C for 10 
minutes. Slides were then placed in a 37“C incubator for 18 hours and 
hybridisation took place.
Coverslips and cement were then removed and probe bound non- 
specifically was removed by washing in 4 X SSC then 2 X SSC (both for 5 
minutes at room temperature) before equilibration in modified Tris 
buffered saline (TBS)/Triton (R&D Systems) for 15 minutes at room  
temperature.
Detection of digoxigenin was then carried out using a kit supplied by  
Boehringer Mannheim following the manufacturer's instructions (see 
section 2.2.8 for method and buffers). Briefly, sections were equilibrated in 
buffer 1 / 0.3% Tween for 5 minutes and blocked with buffer 2 before 
application of anti-digoxigenin Fab fragment-alkaline phosphatase 
conjugate (1:500 in buffer 2) for 30 minutes at room temperature. Antibody 
bound non-specifically was removed by 3 x 15 minute washes with buffer 
1 / 0.3% Tween at room temperature. Slides were then equilibrated in
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buffer 3 for 5 minutes before development. Developing buffer, comprised 
0.34 m g/m l nitroblue tétrazolium (NBT)/ 0.18 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) in buffer 3.
Incubation was carried out overnight, at room temperature. The reaction 
was stopped by washing in water for 3 minutes before counterstaining 
with haemotoxylin-eosin for 15 seconds. Sections were then air dried and 
mounted in glycerine.
ISH was also performed without addition of probe for each slide processed; 
this served as a control for the antibody-conjugate. A positive control 
(shown previously to be CMV infected by immunohistochemistry) was 
included in each run.
Sections were scored for the presence of a signal by a semiquantitative 
method ie. low, medium and high positivity, for each infected cell type. 
This was performed 'by eye' by myself and results were confirmed by an 
experienced pathologist (Dr Nick Coleman; Pathology, Addenbrookes NHS 
Trust).
6.2.5 CMV Antibody Status and Active CMV Infection
Each recipient/donor pair was tested for antibodies to CMV and each 
recipient was monitored regularly for active CMV infection by PCR> 
DEAFF and culture (these methods are described in Chapters 2 and 3).
6.2.6 HLA Typing
The HLA type of each recipient/donor pair was tested (methods are 
described in Chapter 4).
6.3 Results
6.3.1 Raw Data
The data analysed in this chapter are given fully for each patient studied in 
Appendix 3.
6.3.2 Cells Shown to Harbour Active CMV Infection
Active CMV infection was demonstrated in hepatocytes, infiltrating 
mononuclear cells, bile duct epithelial cells and endothelial cells of hepatic 
artery and portal vein.
6.3.3 In  Situ Hybridisation Detection of CMV Occurred via DNA: DNA  
Hybridisation
In situ hybridisation was repeated for specimens in which CMV had been 
detected by this technique. Two reactions were set up for two serial 
sections from each specimen; one in which the specimen DNA was 
denatured before hybridisation and. one in which this step was omitted. In 
situ hybridisation only occurred when specimen DNA was denatured 
before application of the probe. This showed that in situ hybridisation 
occurred by probe DNA: target DNA interaction (note that probe DNA: 
target RNA interaction does not require dénaturation of target DNA).
6.3.4 Specificity of In Situ Hybridisation to CMV DNA
No signal was detected in the absence of probe; the digoxigenin detection 
system did not mediate false positivity.
. Digoxigenin labelled mouse DNA was used against all specimens in which 
CMV had been detected by in situ hybridisation. This control probe did not 
hybridise to any of the sections tested (a positive control for this
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experiment (mouse lung section) was positive by in situ hybridisation.) 
These control experiments showed that the CMV probe hybridised 
specifically to CMV infected cells.
6.3.5 Distribution of CMV Positive Cells Amongst Liver Transplant 
Recipients According to CMV Antibody Status and Active CMV Infection
These data are summarised in table 6.1 and important points are described 
below.
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Table 6.1 Distribution of CMV Positive Cells Amongst 29 Liver Transplant
Recipients According to CMV Antibody Status and Active CMV Infection
CMV- POSITIVE GRAFT CELLS
CMV SURVEILLANCE Tissue positive 
(Immuno. or ISH)
Immunohistochemistry In Situ Hybridisation
CMV Ab status
H n n n r/recinient Active CMV
Hep. Mono Epi. End. Hep. Mono. Epi. End.
+ / - n-11
Yes n = ll 6 6 5 2 2 6 5 2 2
No n=0 0 0 0 0 0 0 0 0 0
+ /  + n=6
Yes n=2 0 0 0 0 0 0 0 0 0
No n=4 2 1 0 0 0 2 1 0 0
- / + n=4
Yes n= l 0 , 0 0 0 0 0 0 0 0
No n=3 0 0 0 0 0 0 . 0 0 0
- / - n -4
Yes n=0 0 0 0 . 0 0 0 0 0 0
No n=4 2 0 . 0 0 0 2 1 0 0
? /+ n=4
Yes n=2 1 0 0 0 0 0 0 1 0
No n=2 0 0 0 0 0 0 0 0 Q
Table 6.1 shows the num ber of patients that harboured active CMV in graft tissue by 
immunostaining or in situ hybridisation in relation to CMV antibody status and active CMV 
infection (Yes= active CMV infection post-transplant, No=. active CMV-free). The num ber 
of patients in each group that had  CMV detected in the graft, by immunostaining or in situ 
hybridisation, is given (Tissue positive (Immuno. or ISH)). The results generated by 
im m unostaining or in situ hybridisation are also shown separately; for both m ethods, the 
num ber of patients in w hom  CMV was show n to infect various cells is show n (Hep.= 
hepatocytes, Mono.= mononuclear cells, Epi.= epithelial cells and End.= endothelial cells) 
together w ith  the num ber of patients that had CMV detected in the graft irrespective of 
cell type (Tissue).
The results shown in table 6.1 show that most of the patients (6/11) that 
harboured active CMV in the graft were CMV antibody negative pre 
transplant and received a graft from a CMV antibody positive donor; all of 
the patients with this CMV antibody pattern were shown to develop active
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CMV infection by viral surveillance of serum and/or buffy coat and/or  
urine.
However, two CMV antibody positive recipients were shown to harbour 
active CMV in the graft without detection of active CMV by viral 
surveillance of serum and/or buffy coat and/or urine (patients 8 and 12).
Furthermore, two CMV antibody negative recipients that received grafts 
from CMV antibody negative donors and were consistently negative for 
active CMV after transplantation by viral surveillance of serum and/or  
buffy coat a n d /o r  urine, w ere shown to harbour active CMV in the graft 
(patients 11 and 15).
All of the sections and cell types for each section, that were shown to be 
positive for CMV by immunohistochemistry were also shown to be 
positive for CMV by in situ hybridisation but the converse was not true; in 
situ hybridisation was more sensitive than immunohistochemistry. With 
respect to the number of sections recorded as positive, the sensitivity of 
immunohistochemistry in relation to in situ hybridisation was 64% (7/11).
Summary
Liver graft vascular endothelial cells and bile duct epithelial cells were show n to 
harbour actively replicating CMV; this was a novel discovery.
CMV was detected in liver in  a high proportion of CMV antibody negative 
recipients that received grafts from CMV antibody positive donors; each of these 
also developed active CMV infection detected by viral surveillance of serum 
and/or buffy  coat and/or urine.
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Furthermore, CMV DNA in liver was detected for two recipients that were CMV 
antibody negative and received grafts from CMV antibody negative donors.
In  situ hybridisation was more sensitive than immunohistochemistry; aU sections 
(and cell types for each section) that were positive for active CMV infection by  
immunohistochemistry were also positive by in situ  hybridisation bu t the converse 
was not true.
6.3.6 Distribution of CMV Positive Cells Amongst Liver Transplant 
Recipients with the Development of Chronic Rejection
The results show n here were generated exclusively by in situ  
hybridisation; the results generated by immunohistochemistry are 
unhelpful because this technique lacks sensitivity (see above).
Overall, 41% (12/29) patients studied harboured active CMV in the liver 
graft; these patients comprised 50% (4/8) of patients that developed chronic 
rejection, 50% (2/4) of patients that developed hepatic artery thrombosis, 
100% (3/3) of patients with grafts lost to other diseases and 29% (4/14) of 
patients that retained grafts.
Active CMV infection was detected by in situ hybridisation (ISH) and 
immunohistochemistry in hepatocytes, mononuclear cells, bile duct 
epithelial cells and endothelial cells of hepatic artery and portal vein.
The distribution of CMV-positive cells amongst patients that developed
chronic rejection (CR) or hepatic artery thrombosis (HAT) and controls is
given in table 6.2. Note that the control population was biased towards
patients at risk of active CMV infection of the graft (see section 6.2.1) and
comprised 10 patients that developed active CMV infection (detected by
viral surveillance of serum and/or buffy coat and /or urine) after
transplantation and four patients that did not.
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Table 6.2 Distribution of CMV-Positive Cells Amongst Liver Graft Recipients
Group Number Total graft positive Hepatocyte
Mononuclear Epithelial Endotiielial
CR 8 50% (4/8) 
(0.31)
13% (1/8) 
(0.14)
13% (1/8) 
(0.24)
38% (3/8) 
(0.14)
0% (0/8) 
(0.45)
HAT 4 50% (2/4) 
(0.39) .
50% (2/4) 
(0.39)
25% (1/4) 
(0.45)
25% (1/4) 
(0.41)
25% (1/4) 
(0.41)
'Other loss' 3 100% (3/3) 100% (3/3) 67% (2/3) 33% (1/3) 33% (1/3)
'Retained' 14 29% (4/14) 29% (4/14) 21% (3/14) 7% (1/14) 7% (1/14)
Controls 17 41% (7/17) 41% (7/17) 29% (5/17) 12% (2/17) 12% (2/17)
Table 6.2 show s the distribution of CM V-positive hepatocytes, m ononuclear cells, 
epithelial cells zind endothelial cells am ongst patients that developed chronic rejection 
( CR ), patients that developed hepatic artery throm bosis ('HAT'), patients w ith  graft 
loss to other diseases ('other loss') and those who retained gréifts ( retained ). The total 
num ber of patients that harboured active CMV in the graft is shown for each group (Total 
grzdt positive). The proportion of CMV positive grafts (total graft positive) éind CMV 
positive cell types (columns) were compared between chronic rejectors (CR) and controls
Ï
( other loss' + retained') and between patients that developed HAT and controls ( other 
loss' + 'retained') using Fisher's exact test (p values given). !
CMV positive hepatocytes and mononuclear cells were found in 10 and 7 
recipients respectively and were equally prevalent amongst patients that 
developed chronic rejection, hepatic artery thrombosis or controls. In 
contrast, epithelial cell positivity was higher amongst patients that 
developed chronic rejection;-however this result was not significant. 
Endothelial cell positivity was a relatively rare event but was seen for four 
patients; none of these lost the graft to chronic rejection and two patients 
retained the graft.
257
Summaiy
• Overall, CMV was detected in  liver at sim ilar rates betw een patients w ith  chronic 
rejection (CR) or hepatic artery throm bosis (HAT) and a control population ('other 
loss' p lus 'retained') heavily biased towards patients w ith active CMV infection.
• Bile duct epithelial cell infection by CMV was higher amongst patients that lost 
the liver graft to chronic rejection. However, this result was not significant.
6.3.7 HLA Matching/ M ism atching. Between Recipient and Donor and 
Active CMV Infection of the Graft
Results presented in Chapter 4 suggested that HLA class I mismatching 
was a risk factor for persistent active CMV infection and it was suggested 
that this result reflected persistent infection of the graft; this was tested 
directly and results are given in table 6.3.
Table 6.3 Distribution of Mismatched HLA Alleles for Liver Transplant 
Recipients With or Without Active CMV Infection of the Graft as Detected 
by In Situ Hybridisation
Mismatches
Group HLA A HLA B HLA AorB HLA A and is HLA DR
CMV positive 50% 83% 83% 50% 42%
graft (n=12)
CMV negative 53% 59% 76% 35% 41%
graft (n=17)
p= 0.29 p=0.13 p=0.33 p=0.22 p=0.30
Table 6.3 shows the p roportion  of patients that were show n to develop active CMV 
infection of the graft (CMV positive graft) and those whose graft did not develop active 
CMV infection (CMV negative greift) according to mismatches for HLA alleles A, B and DR. 
Results were generated by in situ hybridisation and statistical analysis was perform ed 
using Fishers exact test.
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The data shown in table 6.3 were not conclusive. Detection of CMV DNA  
in liver was associated with an increased proportion of HLA B 
mismatched donor/ recipient pairs. This result supported the association 
between HLA B mismatching and prolonged active CMV infection as 
detected by viral surveillance of serum and/or buffy coat and/or urine (see 
Chapter 4); however, the numbers tested were small and this result was 
not significant.
Summary
• HLA B allele mismatching occurred in  a higher proportion of grafts that were
positive for active CMV infection bu t this result was not significant.
6.3.8 The Significance of Active CMV Infection of Liver Graft Epithelial^ 
or Endothelial Cells
Table 6.2 showed that epithelial cell positivity was higher amongst patients 
that developed chronic rejection and it is possible that active CMV 
infection of epithelial cells is particularly important in this setting.
In situ hybridisation results, infiltration and HLA typing data were 
compared for each patient that was shown tq harbour CMV in epithelial or 
endothelial tissue and are shown in table 6.4; these patients are numbered 
according to the system used in Appendix 1.
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Table 6.4 Patients Harbouring Active CMV in Epithelial and 
Endothelial Cells
Patient CMVAb.
D /R
Graft loss Active
CMV
CMV positive cells HLA matching Infiltrate
Loss
Y/N D isease Hep. Mono. Epi. End. A B DR
1 ?/+ Y CR + - - +(L) - 0 G G LD/MP
3 +/- Y CR + +(L) +(L) +(L) - 0 G 1 LD/LP
8 +/+ Y 'o th er loss ' - +(M) +(H) +(L) +(L) 1 G G LD/HP
12 +/+ Y CR ■- - - +(M) - 1 1 G LD
29 +/- Y HAT ■+ +(H) +(H) +(L) +(L) 0 0 1 LD/LP
26 +/- N ------- + +(H) +(H) +(L) +(L) G G G LD/LP
Table 6.4 shows features of 6 patients that harboured active CMV in endothelial a n d /o r  
epithelial cells. The CMV antibody status (CMV Ab.) of donor/ recipient (D/R) is show n 
alongside the occurrence of active CMV infection as detected by viral surveillance of serum  
a n d /o r  buffy coat a n d /o r  urine (Active CMV). CR= chronic rejection, HAT= hepatic artery 
thrombosis. Cells that héirboured active CMV are indicated as Hep.= hepatocyte, Mono.= 
m ononuclear cell, Epi.= epithelial cell and End.= endothelial cell and the quantity  of 
positive cells found is indicated as low (L), m oderate (M) or h igh (H). Infiltrating 
m ononuclear cells were defined as follows: LD= low diffuse ^ d  UP, MP and HP= low, 
m oderate and high aggregation around portal tracts respectively. Note that all chronic 
rejectors also had  infiltration of foam cells (macrophages) into the lum en of hepatic 
arteries.
Only one patient that retained the liver graft (patient 26) had active CMV 
infection of epithelial and endothelial cells; this patient died of CMV 
disease. One other control (patient 8) had active CMV infection of 
epithelial and endothelial cells; graft loss occurred through hepatitis C 
related cirrhosis.
A number of important points can be extracted from this data; these are 
summarised below.
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Summaiy
• Epithelial CMV infection was observed for two patients w ithout detection of active 
CMV by  viral surveillance of serum and/or buffy coat aiid/or urine.
• Epithelial and endothelial CMV infection was observed in  one graft that was 
retained (patient 26); th is patient died of CMV disease.
• Epithelial and endothelial CMV infection was observed in  one graft that was lost 
to hepatitis C related cirrhosis (patient 8).
• Epithelial CMV infection was associated w ith moderate to h igh m ononuclear cell 
infiltration of the portal tract for two patients (patients 1 and 8).
• In  contrast, endothelial CMV infection was observed only in grafts that contained 
h igh num bers of infected mononuclear cells and, in  2/3 cases, hepatocytes.
• However, there was no obvious relationship between graft loss to chronic rejection 
or hepatic artery throm bosis, active CMV infection of epithelial cells or 
endothelial cells and HLA allele m atching status.
6.3.2 Cases
Several cases are shown; fuller descriptions of each patient can be found in 
Appendix 1 (patient numbers given here). The data presented comprises 
my own observations of immunohistochemistry and in situ hybridisation 
results together with retrospective pathology reports of each section by Dr 
Nick Coleman and Dr Derek Wight.
In the figures show n, CMV in fected  cells d etected  by  
immunohistochemistry are brown in colour whereas those detected by in 
situ hybridisation are purple in colour; CMV infected cells are indicated by 
arrows. Structures are labelled as follows: PT= portal tract, BD= bile duct, 
VBD= 'vanished) bile duct, HA= hepatic artery, PV= portal vein, FM= 
foamy macrophages, H=hepatocyte, M= mononuclear cell, Epi= epithelial 
cell, Endo= endothelial cell.
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Patient 1
This patient developed active CMV infection post transplant before 
development of chronic rejection and subsequent loss of the liver graft; 
the section shown was taken from the explanted 'chronically rejected' 
liver (see also Appendixes 1 and 3).
The histopathology of the section studied was characteristic of chronic 
rejection. Bile ducts were absent from most portal tracts which contained 
moderate numbers of inflammatory mononuclear cells and pericellular 
fibrosis was observed around bile ducts. Furthermore, many medium and 
small sized arteries contained foam cells in the lumen.
Figure 6.2 shows a typical portal tract from this section which was stained, 
for CMV DNA by in szfw hybridisation. The lumen of the hepatic artery 
(HA) shown was occluded by foamy macrophages (FM) and the ghost of a 
bile duct could be identified by its position in the portal tract and the 
configuration of surrounding inflammatory cells. This photograph was 
also shown in figure 6.1 (see section 6.1) to contrast with the appearance of 
a normal portal tract.
Foamy macrophages (FM) and mononuclear cells (M) were not positive 
for CMV DNA. This result was consistent for all portal tracts examined in 
this case that displayed this histopathology and indeed was consistent for 
all cases of chronic rejection studied.
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Figure 6.2 Portal Tract S h o w in g  the Characteristic H istop ath o logy  o f  
Chronic Rejection: Stained for CM V D N A  by In Situ H ybridisation (Patient 
1).
. j»'
In figure 6.2 a portal tract (PT) is show n comprising Vanished' bile duct (VBD), hepatic 
artery (HA) with occlusion of the lumen by foamy macrophages (FM) and portal vein (PV). 
This photograph was taken at magnification x200. Active CMV infection was not observed.
In this case, CMV D N A  w as not detected in 'vanished' bile ducts or 
occluded hepatic arteries that d isp layed features characteristic of chronic 
rejection. H ow ever, epithelial cells of num erous sm all and m edium  sized  
bile ducts that did not display the characteristic histopathology of chronic 
rejection were positive for active CMV.
Figures 6.3 (m agnification x200) and 6.4 (m agnification x400) sh ow  a 
typical bile duct from this case that contained bile duct epithelial cells that 
were actively infected w ith  CMV which was detected predom inantly in the 
cytoplasm  of these cells.
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Figure 6.3 Active CMV Infection of Bile Duct Epithelial Cells Shown by
In Situ Hybridisation (Patient 1)
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Figure 6.3 shows bile ducts (arrows) w hich  have active CMV infection of epithelial cells 
(arrowheads). This pho tograph  was taken  at magnification x200.
Figure 6.4 Active CMV In fection  of B ile Duct Epithelial Cells Sh ow n by  
In Situ H ybridisation (Patient 1)
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Figure 6.4 also shows bile ducts (arrows) which have active CMV infection of epithelial 
cells (arrowheads) but at higher magnification (x400).
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M oderate num bers of m ononuclear cells were often observed to surround  
CMV infected epithelial cells (see figure 6.5; x 200 magnification).
Figure 6.5 Active CMV Infection of Bile Duct Epithelial Cells Shown by 
In Situ Hybridisation and Aggregation of Mononuclear cells (Patient 1)
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Figure 6.5 show s a b ile duct (BD) w ith  active CMV infection of epithelial cells 
(arrowheads); this bile duct was surrounded by infiltrating mononuclear cells (M). This 
photograph was taken at magnification x400.
Patient 8
This patient also developed active CMV infection post transplant before 
subsequent loss of the liver graft to hepatitis C related cirrhosis. The 
section show n w as taken from the explanted liver (see also A ppendixes 1 
and 3).
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Portal vein  endothelial cells and bile duct epithelial cells were show n to be 
actively infected w ith  CMV; hepatocytes and m ononuclear cells w ere also  
positive for active CMV.
Figure 6.6 sh ow s two m ed iu m  sized  portal veins; one contains a CMV- 
infected endothelial cell and the other is in close proxim ity to tw o CMV- 
infected m ononuclear cells. These are show n at higher m agnification in  
figures 6.7 and 6.8.
Figure 6.6 Active CMV Infection of Portal Vein Endothelial Cells and
Mononuclear Cells Shown by In Situ Hybridisation (Patient 8;)
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Figure 6.6 shows two portal veins (arrows); one contained a CMV-infected endothelial cell 
(arrowhead) and the other was in close proxim ity to two CMV-infected m ononuclear cells 
(arrowheads). This photograph was taken at magnification xlOO.
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Figure 6.7 Active CMV Infection  of a Portai V ein  Endothelial Cell
Shown by In Situ Hybridisation (Patient 8)
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Figure 6.7 show s a portal vein (arrow) that contained a CMV-infected endothelial cell 
(arrowhead) at magnification x200.
Figure 6.8 Active CMV Infection of Two Mononuclear Cells in Close 
Proximity to a Portal Vein Shown by In Situ Hybridisation (Patient 8)
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Figure 6.8 shows a portal vein (arrow) which was in close proximity to two CMV-infected 
mononuclear cells (arrowheads). This photograph was taken at magnification x200).
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Patient 12
This patient lost the liver graft to chronic rejection; the section show n w as  
taken from the explanted  'chronically rejected' liver. This patient w as  
CMV antibody positive before transplantation and received a graft from a 
CMV antibody positive donor. H ow ever, active CMV infection w as not 
detected post transplant by viral surveillance of serum a n d /o r  buffy coat 
a n d /o r  urine (see also A ppendixes 1 and 3).
The h istopathology of the section studied  w as characteristic of chronic 
rejection. Bile ducts w ere absent from num erous portal tracts and m any  
m edium  and sm all sized  arteries contained foam cells in the lum en. A  
low  level, diffuse infiltration of m ononuclear cells w as observed w ithout 
aggregation around portal tracts.
Figure 6.9 show s a m edium  sized  hepatic artery from this section w hich  
w as stained for CMV D N A  by in s i tu  hybridisation. The lum en of this 
hepatic artery (HA) w as occluded by foam y macrophages (FM) w hich w ere  
not positive for CMV D N A . This result w as consistent for all portal tracts 
exam ined  in this case that d isp layed  h istop athology  characteristic of 
chronic rejection.
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Figure 6.9 H epatic Artery O ccluded by Foamy Macrophages: Stained for 
CM V D N A  by In Situ H ybridisation (Patient 12).
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In figure 6.9 a hepatic artery (HA) with occlusion of the lumen by foamy macrophages (FM) 
is shown. This photograph was taken at magnification x200.
H ow ever, bile duct epithelial cells of other, apparently undiseased, portal 
tracts w ere show n to be actively infected w ith  CMV; hepatocytes and  
m ononuclear cells were also positive for active CMV.
Epithelial cells of one large bile duct and several sm all bile ducts w ere  
positive for active CMV in this case. These are show n in figure 6.10 and at 
higher m agnification in figure 6.11. M ost of the epithelial cells of these bile 
ducts w ere actively infected by CMV; positiv ity  w as observed for both  
cytoplasm  and nuclei of these cells. Very little inflam m ation w as observed.
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Figure 6.10 Active CMV Infection of Bile Duct Epithelial Cells Shown by
In Situ Hybridisation (Patient 12)
/
Figure 6.10 show s bile ducts (arrows) with active CMV infection of epithelial cells 
(arrowheads). This photograph was taken at magnification x200.
Figure 6.11 A ctive CMV Infection  of Bile Duct Epithelial Cells Show n by  
In Situ H ybridisation (Patient 12)
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Patient 29
This patient d ied  from  hepatic artery throm bosis on day 204 after 
transplantation; the section show n w as taken from a needle biopsy w hich  
w as perform ed on day 41 for suspected  CMV hepatitis w h ich  w as  
confirmed. Active CMV infection w as also detected from day 45 to day 155 
post transplant by viral surveillance of serum a n d /o r  buffy coat a n d /o r  
urine (see also A ppendixes 1 and 3).
The h istop athology  of the section  stud ied  w as characteristic of CMV 
hepatitis; there w as no evidence of rejection. Large num bers of CMV- 
in fec te d  h e p a to cy te s  and m o n o n u c lea r  ce lls  w ere  sh o w n  by  
im m unohistochem istry and in s itu hybridisation; in addition, active CMV 
infection of tw o bile duct epithelial cells (see figures 6.12 and 6.13) and one 
hepatic artery endothelial cell (see figure 6.14) w as show n. Little diffuse  
inflam m ation w as seen but there w as som e low  level aggregation  of 
m ononuclear cells around portal tracts.
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Figure 6.12 Active CMV Infection of Bile Duct Epithelium Shown by
Immunohistochemistry (Patient 29)
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Figure 6.12 shows active CMV infection of two bile duct epithelial cells (arrowheads); 
these cells were confirmed to be epithelial cells as shown in figure 6.13. This pho tograph  
was taken at magnification x200.
Figure 6.13 B ile  D uct E p ith e liu m  Show n by Im m u n oh istoch em istry  
(Patient 29)
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Figure 6.13 shows detection of epithelial cells (arrows) by im m unohis tochem istry  for 
cytokeratin. This pho tograph  w as taken at magnification x200. The slide s tained  was 
adjacent to that shown in figure 6.12 (stained for CMV) and confirmed active CMV infection 
of bile duct epithelial cells.
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Figure 6.14 Active CMV Infection of a Hepatic Artery Endothelial Cell
Shown by In Situ Hybridisation (Patient 29).
Figure 6.14 shows a hepatic artery (arrow) that contained a CMV-infected endothelial cell 
(arrowhead) at magnification x200.
Summary
• Active CMV infection was observed in  a graft lost to hepatitis C related cirrhosis.
• In patients that developed chronic rejection, active CMV infection of bile duct
epithelial cells or vascular endothelial cells was not demonstrated in portal 
tracts that displayed the histopathology of chronic rejection ie. absence of bile 
ducts and occlusion of hepatic artery lumen with foam cells.
• However, active CMV infection of bile duct epithelial cells or vascular 
endothelial cells was demonstrated in adjacent portal tracts of normal appearance.
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6.4 D iscussion
The results presented are based upon a small highly selected group of 
patients and m ust be interpretted w ith caution. H owever, these results are 
provocative and allow a number of hypotheses to be set up.
6.4.1 C onclusions
The Hypothesis Tested
• The hypothesis that CMV infection of bile duct epithelial and/or hepatic artery 
endothelial cells initiates or enhances chronic rejection was upheld but not proven.
Active CMV Infection of the Liver Graft and CMV Antibody Status
• CMV antibody negative recipients that receive grafts from CMV antibody positive  
donors and subsequently develop active CMV infection (detected by viral 
surveillance of serum and/or buffy coat and/or urine) may be at high risk of active 
CMV infection of the liver graft.
• However, active CMV infection of the liver graft may also occur without detection 
of active CMV infection by viral surveillance of serum and/or buffy coat and/or 
urine.
• Furthermore, active CMV infection of the liver graft may also occur in CMV
antibody negative recipients that receive grafts from CMV antibody negative 
donors.
Active CMV Infection of the Liver Graft and HLA Status
• Mismatching for the HLA B allele may be associated with an increased risk of
active CMV infection of the liver graft as predicted in Chapter 4; however, this 
result was not significant and a firm conclusion cannot be drawn.
Active CMV Infection o f the Liver Graft and Chronic Rejection
• Active CMV infection of b ile duct epithelial cells and hepatic artery endothelial 
cells occurs; these sites are the primary sites of damage for chronic rejection.
• Active CMV infection of bile duct epithelial cells may be associated w ith CR; only
two control patients had active CMV infection of epithelial cells and these
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patients died of CMV disease or were retransplanted for hepatitis C related 
cirrhosis respectively.
• In sections taken from liver grafts that were explanted after chronic rejection,
active CMV infection of bile duct epithelial cells or vascular endothelial cells was 
only demonstrated in portal tracts of normal appearance and was not demonstrated 
in adjacent portal tracts that were obviously damaged; it is possible that active 
CMV infection of these sites is an important event during the early stages of 
development of chronic rejection and that cells harbouring active CMV are 
destroyed.
6.4.2 In Situ H ybridisation was a Specific and Sensitive Technique
In situ hybrid isation using a probe com prising the Hind III F fragm ent 
from the genom e of the CMV strain A D I69 identified num erous cells that 
contained rep licating  CMV. H ybrid isation  occurred via D N A : D N A  
interaction; hybridisation did not occur w hen target nucleic acids w ere not 
heat denatured. In a series of similar experim ents, D N A  w as also show n to 
be the target nucleic acid by the Kings College group (423, 424).
The specificity of this probe w as confirm ed. Sections that w ere p ositive  
w ere also screened using digoxigenin labelled w hole genom ic m ouse D N A  
(a nonhom ologous control) and were also processed w ithout the addition  
of any probe; positive signal against the human sections of interest w as not 
generated by either control experim ent. The specificity  observed  w as  
expected because the H ind III F fragment h^^ previously been sh ow n  to 
share m inim al hom ology to cellular D N A  (130. 173). In situ hybridisation  
w as m ore sen sitive  than im m unohistochem istry; this w as also sh ow n  
previously by the Kings College group (Naoum ov et al (1988) (423)). Early 
antigen is produced throughout the replication cycle of CMV but it is 
possib le that D N A  replication exceeds early antigen production at late 
stages of this cycle.
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6.4.3 D etection  of A ctive CMV Infection  of the Graft, CM V A n tib od y  
Status and A ctive CM V Infection  as D etected  by Viral Surveillance o f  
Serum and/or B uffy Coat and/or Urine.
In situ hybrid isation  detected active CMV infection of grafts for four 
patien ts that v^ere con sisten tly  n ega tive  for active CMV by viral 
surveillance of serum  a n d /o r  buffy coat a n d /o r  urine. Furthermore, tw o  
of these patients w ere CMV antibody negative recipients of liver grafts 
from CMV antibody negative donors.
The latter result is consistent of the finding by Taylor-W eidem an et al 
(1991) (41) that CMV antibody negative ind ividuals m ay harbour latent 
CMV in m onocytes (also see Chapter 1).
These results have im portant im plications for clinical m anagem ent of 
liver transplant recipients. It is im portant to differentiate betw een acute 
rejection and active CMV infection after liver transplantation; these tw o  
conditions are associated w ith similar sym ptom s and accurate diagnosis of 
active CMV infection is important (see Chapters 2 and 3).
A cute rejection is treated by adm inistration of steroids a n d /o r  increasing  
im m u n o su p p ress io n  w h ereas active CMV in fection  is treated  by  
ad m in istra tion  of antiv ira ls and lo w erin g  of im m u n o su p p ressio n . 
M isdiagnosis o f acute rejection for a patient w ith  active CMV infection  
m ay therefore lead to adm inistration  of drugs that enhance CMV  
replication. Conversely, m isdiagnosis of active CMV infection for a patient 
w ith  a cu te  rejection  m ay th erefore  lead  to a red u c tio n  of 
im m u n osu p p ression .
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Patien t 11 d ev e lo p ed  an u n exp la in ed  h ep atitis  on d ay 98 after  
transplantation). This patient w as CMV antibody negative and received a 
graft from a CMV antibody negative donor and was consistently negative  
for active CMV by viral surveillance of serum a n d /o r  buffy coat a n d /o r  
urine. Furthermore, CMV w as not detected in a liver biopsy taken at day  
98 post transplant by either light m icroscopy or im m unohistochem istry. 
Therefore, this patient w as not treated w ith antivirals. The liver graft w as  
lost to chronic rejection on day 129 and CMV w as detected retrospectively  
in the explanted graft by in s i tu  hybridisation. It is likely that this patient 
had persistent active CMV infection w hich was localised to the liver graft.
S im ilarly, patient 12 d evelop ed  unexplained hepatitis on day 16 and  
pyrexia on day 30 after transplantation. This patient w as CMV antibody  
positive and received a graft from a CMV antibody positive donor but w as  
consisten tly  n egative for active CMV by viral surveillance of serum  
a n d /o r  buffy coat a n d /o r  urine. This patient w as treated w ith ganciclovir 
on day 32 for 14 days despite the lack of confirmation of active CMV by  
laboratory testing. The liver graft w as lost to chronic rejection on day 289 
and CMV w as detected retrospectively in the explanted graft by in s i tu  
hybridisation. It is likely that this patient also had persistent active CMV 
infection w hich was localised to the liver graft.
I therefore recom m end that all liver  graft b io p sie s  taken after  
transplantation are stained for CMV D N A  using in s i tu  hyb rid isation  
regardless of the CMV antibody status or 'active CMV status' of the 
patient. This p o licy  m ay enable d iagn osis of loca lised  active CMV  
infections of the liver graft w here the sensitivity of light m icroscopy or 
im m unohistochem istry are insufficient.
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Furtherm ore, if active CMV infection of the graft is im portant in the 
developm ent of chronic rejection then it is p ossib le  that the lack of 
association betw een active CMV infection as detected by viral surveillance 
of serum  a n d /o r  buffy coat a n d /o r  urine or CMV antibody status and 
chronic rejection as reported in this thesis (see Chapter 4) and by others 
(372, 225, 210) is because patients with localised active CMV infection of the 
graft (including those d on or/recip ien t pairs that are CMV antibody  
negative) are excluded from such analyses.
6.4.4 Active CMV Infection of the Liver Graft and Chronic Rejection
Tw o groups have show n that active CMV of the liver graft is associated  
w ith  chronic rejection (225, 284). H ow ever, liver graft recipients that 
develop  active CMV infection of the graft do not necessarily  develop  
chronic rejection and therefore other factors m ust be involved . The study  
presented in this chapter w as designed to compare patients that developed  
chronic rejection and those that developed active CMV infection of the 
graft but not chronic rejection; therefore, the control group w as biased  
towards patients in w hom  active CMV infection had been detected by viral 
surveillance of serum an d /o r  buffy coat an d /or  urine, ie. those at high risk 
of active CMV infection of the graft.
The study reported by Arnold et al (1992) (284) show ed that persistence of 
active CMV infection m ay be an im portant factor for develop m en t of 
chronic rejection. The results presented in this thesis suggest that the type  
of cells (ie. epithelial cells) that are actively infected w ith CMV m ay also be 
an important factor that discriminates betw een those that develop chronic 
rejection and those that do not.
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Interestingly, active CMV infection of the graft w as seen concom itantly  
w ith hepatitis C related cirrhosis for patient 8 w ho lost the graft to the 
latter disease. Pre transplant diagnosis of hepatitis C may be a risk factor for 
chronic rejection (see section 4.3.4, 427, 428). It is possible that in som e cases 
hepatitis C virus and CMV act in concert to elicit chronic rejection. 
A lternatively, hepatitis C virus m ay facilitate CMV infection w hich  in 
turn m ay elicit chronic rejection. This is supported by the find ings of 
Singh et al (1996) (429) w ho show ed a significantly higher rate of CMV 
disease in liver transplant patients w ith recurrent hepatitis C.
6.4.5 Persistence Active CMV Infection, Cellular Im m unity and Chronic 
Rejection
The Kings C ollege group (224, 284; see sections 1.8.2 and 1.9.1) suggested  
that com plete m ism atching of HLA class I alleles acted indirectly as a risk 
factor for chronic rejection by preventing im m une surveillance by CMV- 
specific T -lym phocytes and therefore facilitating persistent active CMV  
infection of the graft.
Furthermore, matching of HLA DR alleles w as shown to be a risk factor for 
chronic rejection and it w as h yp oth esised  that this facilitated  MHC  
restricted presentation of CMV peptides or 'foreign' MHC class I peptides  
and therefore facilitated cellular im m une m ediated lysis of graft cells.
6.4.5.1 Detection of Active CMV Infection in Bile Duct Epithelial
Cells and Hepatic Artery Endothelial Cells
The results presented in this thesis show ed that active CMV infection of 
bile duct epithelial cells and hepatic artery endothelial cells m ay occur 
after liver transplantation. In contrast, Arnold et al (1992) (284) observed  
CMV infection of hepatocytes but not of bile duct epithelial cells or hepatic 
artery en d oth elia l cells after screen ing b iop sy  specim en s by in s i tu
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hybrid isation . The apparent confinem ent of active CMV in fection  to 
hepatocytes suggested  that im m une m ediated lysis of bile duct or hepatic 
artery cells did not occur after presentation of CMV peptides by HLA DR  
(unless target cells w ere 'burnt out'). It w as therefore su ggested  that 
presentation of CMV peptides by hepatocytes m ay indirectly  lead to  
dam age of adjacent bile duct or hepatic artery tissue via local upregulation  
of cytokines a n d /o r  adhesion m olecules thus enhancing the activity of 
alloreactive T-lym phocytes (see sections 1.9.3 and 1.9.4).
H ow ever, the n ovel find ing presented  in this thesis of active CMV  
infection of vascular endothelium  and bile duct ep ith elium  p rov id es  
evidence that CMV may be directly involved w ith chronic rejection. One 
possibility  is that CMV is cytopathic. Another possibility is that HLA DR 
presentation of CMV peptides leads directly to im m une m ediated lysis of 
these cells. It is likely that CMV infection of the latter two cell types w as  
observed in this thesis, but not by Arnold et al (1992) (284), because sections 
of these tissues were selected from explanted organs in preference to b iopsy  
specim ens.
A ctive CMV infection of bile duct epithelial cells may be important; this 
w as found for 3 /8  patients that developed chronic rejection and for only  
2 /1 7  control patients. Patient 26 died from CMV disease and patient 8 lost 
the graft to hepatitis C related cirrhosis thus preventing long-term  fo llow  
up for chronic rejection.
These three chronic rejectors only harboured active CMV in apparently  
undam aged portal tracts; adjacent portal tracts displaying the characteristic 
histop athology of chronic rejection w ere CMV free. This su ggests  that 
CMV m ay be involved w ith the early stages of chronic rejection, possib ly
280
as an inducer. The process of chronic rejection leads to loss of CMV  
p erm issive tissue and CMV m ay be cleared from dam aged areas by  
phagocytes.
6.4.5.2 Persistence of Active CMV Infection in the G raft and 
Complete M ismatching of HLA Class I Alleles
The results presented in Chapter 4 of this thesis suggested that com plete  
m ism atching of class I alleles w as associated w ith active CMV infections of 
long duration (>30 days) and it was suggested that such infections w ere a 
marker for persistent active CMV infection of the graft.
The effect of com plete m ism atching of HLA class I upon active CMV 
infection of the graft w as exam ined here using in s itu  hybridisation. The 
results presented show ed that com plete m ism atching of HLA B alleles w as 
associated  w ith  a greater proportion of active C M V -positive grafts 
com pared w ith  partial or com plete m atching of HLA B alleles; how ever, 
this result w as not significant. This result suggests that, for at least som e  
liver graft recipients, com plete m ism atching for HLA B alleles w as a risk 
for persistent active CMV infection of the graft.
It can thus be env isaged  that CMV spread m ay occur unchecked in 
hepatocytes ,w hich predom inantly express HLA class I, but that subsequent 
infection of HLA D R -expressing endothelial a n d /o r  epithelial cells m ay  
trigger successful im m une surveillance w hich leads to destruction of bile  
ducts an d /or  hepatic arteries.
6.4.5.3 Persistence of Active CMV Infection in the Graft, Matching of
HLA DR Alleles and Chronic Rejection
Partial or com plete m atching of HLA DR alleles w as an im portant 
com ponent of the hypothesis put forward by the Kings College group. The 
results presented in this thesis show ed that m atching of HLA DR w as
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equally distributed betw een  chronic rejectors and controls. H ow ever, this 
lack of association m ay have been due to the relatively low  num bers of 
chronic rejectors studied . Furthermore, it is possible that there is more 
than one m echanism  responsible for chronic rejection.
Three patients stud ied  in  this chapter (num bers 3, 29 and 26) fit this 
hypothesis perfectly. A ll 3 had active CMV infection of endothelial and 
epithelial cells and zero m atched HLA class I. Patients 3 and 29 also  
received  H LA DR m atched grafts w h ich  they lost to CR and HAT  
respectively. In contrast, patient 26 received a zero HLA DR m atched graft 
w hich was retained.
HLA DR upregulation  has been show n during chronic rejection (191) 
which may enhance this process.
H ow ever, chronic rejection w as also observed in patients that received  
grafts that were HLA class I matched (patients 8 and 12) an d /or  HLA class II 
zero m atched (patients 1, 8 and 12). Therefore, other m echanism s m ust be 
operating in these grafts that do not involve the cellular im m une system; 
alternative hypotheses are g iven  below.
6.4.6 Active CMV Infection may Initiate Ischaemia
A n attractive alternative h y p oth esis  can be put forw ard w h ich  is 
analogous to accelerated atherosclerosis after cardiac transplantation (see 
section 1.8.3.3). A herpesvirus (Mareks disease virus) has been proven to 
mediate atherosclerosis in chickens (392) and there is evidence to suggest 
the involvem ent of CMV in the hum an form of the disease.
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Ischaem ic injury during the early stages of chronic rejection of hum an  
liver grafts has been  described  (191); these d iseased  arteries are 
h isto lo g ica lly  sim ilar to atherosclerotic tissue. Furtherm ore, chronic  
rejection is often observed w ith  little infiltration of m ononuclear cells  
(191, 193); this is supported by the findings herein (patients 3, 12, 26 and 29).
It is possible that a process similar to atherosclerosis initiates endothelial 
dam age w h ich  in turn in itiates the c lotting  cascade that leads to  
developm ent of hepatic artery thrombosis. It is also possible that CMV is 
involved w ith the developm ent of hepatic artery throm bosis.
It has been hypothesised (388) that CM V-mediated dam age to cardiac graft 
endothelial cells leads to dam age of exposed sm ooth cells. A repair process 
induces proliferation of sm ooth m uscle cells which leads to thickening of 
the intima and therefore occlusion of the lum en. A key piece of evidence  
for this hypothesis w as the discovery of active CMV infection of coronary  
artery endothelial cells (385).
CMV infection of hepatic artery endothelial cells was not show n for any of 
the chronic rejectors studied. H ow ever, the dem onstration of active CMV  
infection in hepatic artery endothelia l cells of liver grafts a llow s this 
hypothesis to be applied to chronic rejection of liver grafts.
E ndothelial cell p o sitiv ity  w as show n for patient 29 w h o  d evelop ed  
hepatic artery thrombosis w hich may be closely related to atherosclerosis.
Two control patients in this study (patients 8 and 26) hosted active CMV 
infection in hepatic artery endothelial cells. Patient 26 died from CMV 
disease and patient 8 lost the graft to hepatitis C related cirrhosis thus
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preventing long-term  fo llow  up for chronic rejection or hepatic artery 
throm bosis.
6.4.7 Lytic Infection of Endothelial or Epithelial Cells
It is possible that CM V-mediated lysis of epithelial an d /or  endothelial cells 
leads to the dam age of bile duct a n d /o r  hepatic artery; this also w ou ld  
explain the lack of HLA m atching and infiltration observed  in  som e  
chronically rejected grafts.
Epithelial cells have been show n to be fully perm issive to CMV in vi tro  
(251, 280; see section 1.8.2.3.2). This theory may explain the finding of 2 
patients (1 and 12) that only harboured active CMV in bile duct epithelial 
cells (and are not matched for HLA DR).
The lack of positive m ononuclear cells m ay be due to 'sam pling error' but 
it is also possib le that bile duct epithelial cells are a site of latency. 
Certainly, ep id em io log ica l ev idence suggests that liver grafts harbour 
latent CMV (43).
6.4.8 Chronically Rejected Liver Grafts may Facilitate Active CMV 
Infection
It is possible that upregulation of HLA expression facilitates CMV infection  
and that the observed association  betw een  active CMV infection  after 
transplantation and elevated  HLA levels are due to opportunism  of the 
virus during the in itial sub-cIinical stages of rejection. It has been  
suggested that the MHC m olecule is a receptor for CMV (61, 62; see section  
1.3.5).
Chronic rejection is associated w ith  infiltration of foam y m acrophages;
m onocyte-derived m acrophages have been show n to be fully perm issive
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to CMV in v i t ro  (41, 42, 48, 49; see sections 1.3.2 and 4.4.4). H ow ever, 
detection of active CMV infection of foam y m acrophages w as not show n  
in this thesis; it is possib le that these infiltrating cells w ere not fu lly  
perm issive to CMV as suggested by in vitro experim ents.
Furthermore, production of inflam m atory m olecules such as interleukins 
and tum our necrosis factor-a may have a stim ulatory effect upon CMV; 
T N F -a production and CMV replication have been show n to autoregulate 
each other positively (398-402; see Chapter 4).
A lternatively, CMV m ay lie latently in graft cells until the onset of 
chronic rejection; m urine CMV has recently been show n to infect liver  
endothelia l cells latently  (44; see section  1.3.2) but this has not been  
confirm ed for hum an CMV. A ctivation  of CMV in a graft rejected  
chronically m ay occur, for exam ple, after adm inistration of steroids or 
differentiation of cells infected latently (48; see section 1.3.2).
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CHAPTER 7
HUM AN HERPES VIRUS - 6 
(HHV-6) IS NOT AN  
IMPORTANT PATHOGEN AFTER 
LIVER TRANSPLANTATION
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7.1 Introduction
A num ber of reports document the importance of hum an herpes virus- 6 
(HHV-6) after bone m arrow (354, 358, 359, 361) or renal (350, 355, 357, 364) 
transplantation. Furthermore, there is evidence to suggest that HHV-6 is 
associated w ith  acute graft versus host disease after bone m arrow  
transplantation (359, 361; see section 1.10.4.2) and acute rejection of renal 
grafts (350, 364).
In a series of 21 renal transplant patients, Okuno et al 1990 (350) found that 
38% (8/21) developed active HHV-6 infection; all HHV-6-positive patients 
experienced severe acute rejection. Furthermore, HHV-6 antigens were 
detected by im m unohistochem istry in acutely rejected tissue; tubular 
epithelial cells and infiltrating lymphocytes stained positive. A study of 72 
renal transplant patients (364) found that a greater proportion of acutely 
rejected grafts contained HHV-6 antigens.
To my knowledge, only two reports have documented the incidence of 
active HHV-6 infection in liver transplant recipients (346, 423; see section
1.10.4.1).
H ypothesis
Hum an herpes virus 6 (HHV-6) may be an important pathogen after liver 
transplantation and active infection may initiate or enhance chronic rejection.
287
7.2 Patients, Materials and Methods
7 .2 .1  P a t i e n t s
Thirty three liver transplant and 17 bone m arrow transplant recipients 
were selected according to the criteria given in sections 2.2.6 and 4.2.1. 
Bone m arrow  transplant patients were included in this study  in an 
attem pt to validate the polym erase chain reaction (PCR) test used for 
HHV-6; the incidence of active HHV-6 infection after bone m arrow  
transplantation has been relatively well studied.
The bone m arrow transplant group was chosen sequentially according to 
transplant date (see Appendix 2) whereas the liver transplant group was 
highly selected (see Appendix 1 and section 4.2.1).
Of 17 bone m arrow transplant recipients, eight developed acute graft 
versus host disease; active CMV infection was present in 50% (4/8) of this 
group.
Of 33 liver transplant recipients, 11 lost the liver graft to chronic rejection 
and 22 patients comprised the control group; 73% and 46% of patients from 
these groups hosted active CMV infection respectively (see Chapter 4).
7 .2 .2  C l in i c a l  S p e c im e n s
7 .2 .2 .1  S e r u m  S a m p le s
A total of 687 serum samples were collected; 381 from liver transplant 
recipients (median samples per patient 9.5 (2-35)) and 306 from bone 
marrow transplant recipients (median 16.5 (5-29)). All serum samples were 
tested in parallel for CMV DNA or HHV-6 DNA by PCR.
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7 .1 .2.2 W h o le  B lo o d  S a m p le s
Whole blood samples (taken from a subset of the groups described above) 
were also available for study. These were collected from 23 liver and five 
bone m arrow transplant recipients (see Appendixes 1 and 2 respectively).
Of 23 liver transplant recipients, seven lost the liver graft to chronic 
rejection and 16 patients comprised the control group; 83% and 69% of 
patients from these groups hosted active CMV infection respectively. Of 5 
bone m arrow transplant recipients, none developed acute graft versus host 
disease or active CMV infection.
A total of 218 whole blood sam ples were collected; 181 from liver 
transplant recipients (median samples per patient 6.5 (2-18)) and 37 from 
bone m arrow transplant recipients (median 5 (4-15)). These samples were 
tested in parallel by PCR for hum an cellular DNA and HHV-6 DNA.
7 .2 .2 .3  T i s s u e  S a m p le s
Liver tissue samples were also available for study; these samples were also 
tested for active CMV and results were described in Chapter 6.
Selection of tissue samples was described in Chapter 6 (see section 6.2.1 and 
Appendix 1). Briefly, liver graft sections from 29 liver transplant recipients 
were exam ined. Fifteen explanted grafts, from which sections w ere 
available, were selected for this study; 8 and 4 patients lost their graft to 
chronic rejection (CR) and hepatic artery thrombosis (HAT) respectively.
The control group comprised 3 patients that lost the graft to other diseases 
and 14 patients that retained their grafts. This highly selected control group 
was biased towards patients with evidence of active CMV infection and
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comprised ten patients that developed active CMV infection (see Chapters 
2 and 3) and seven patients that remained negative for CMV.
These samples were tested in parallel by PCR for hum an cellular DNA 
and HHV-6 DNA.
7 .2 .2 .4  C o l le c t io n  a n d  S to r a g e  o f  S a m p le s
Collection and storage of sera was carried out as described in Chapter 2. 
Whole blood samples were taken into 5ml EDTA-blood tubes (Sarstedt) 
and stored at -20°C; these were taken in parallel with serum samples.
Form alin fixed, paraffin em bedded tissue sam ple slides were kindly 
provided by Dr Nick Coleman. Methods used to fix and paraffin embed 
tissue were given in section 6.2.2.
7 .2 .3  D N A  E x t r a c t io n  f r o m  C l in ic a l  S p e c im e n s
7 .2 .3 .1  S e r u m  a n d  W h o le  B lo o d
DNA extraction from 200jil serum or 200|il whole blood was perform ed 
using the Qiamp DNA Extraction Kit (Qiagen; see Chapter 2). Extracted 
DNA from serum was amplified for CMV DNA (see Chapter 2) and HHV- 
6 DNA in parallel. Furthermore, each DNA extraction from whole blood 
was amplified in parallel for cellular DNA (p-globin gene; see section 
7.2.4.2) and HHV-6 DNA.
7 .2 .3 .2  F o r m a l in  F ix e d ,  P a r a f f in  E m b e d d e d  T i s s u e
Formalin fixed, paraffin embedded tissue was cut into a 30pm section and 
placed in a 1.5 ml microfuge tube; blades were changed between each block 
to avoid contamination.
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Sections were de waxed by immersing in xylene (twice for 10 minutes each) 
before being washed in ethanol (twice for 10 minutes each) and air dried. 
Exposure of nucleic acids was achieved by digestion w ith 500pg/m l 
proteinase K (Boehringer Mannheim) in 50mM Tris (Sigma) for 12 hours 
at 37°C; proteinase K was then inactivated by heating the sample to 95°C 
for 10 m inutes. Debris was pelleted from the sample by centrifuging at 
13'000 rpm  for 10 minutes. A total of 5pl of supernatant was used for each 
PCR reaction. Each DNA extraction from liver tissue was amplified in 
parallel for cellular DNA (p-globin gene; see section 7.2.4.2) and HHV-6 
DNA.
7.2.4 Polymerase Chain Reaction (PCR)
7.2.4.1 PCR of HHV-6 DNA
Polymerase chain reaction (PCR) amplification of the major capsid gene of 
HHV-6 was carried out using sense (5'-TTAAGACTGTATGTAACGCAT- 
3') and antisense (5'-TTTCACCACGCCGATCGCCGT-3 ) prim ers (kindly 
supplied by Dr B Thompson). Successful amplification yielded a 287 bp 
product. The major capsid gene is not homologous to cellular DNA or 
DNA from other herpes viruses (356).
DNA extracted from 50|il of serum or 3|il whole blood (made up to 50pl 
w ith water) underw ent PCR. Sample DNA was added to 50pl of 'reaction 
m ixture' that comprised reaction buffer™ (Promega), 1.5 mM MgCl2 
(Promega), 250 pM each deoxynucleotide triphosphate (Pharmacia), 1 pM 
each prim er (Pharmacia) and 2.5 U Taq polym erase (Promega) and 
overlaid w ith one drop of mineral oil (Sigma). Reaction mixtures were
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then subjected to a denaturing step (94°C for 4 minutes) before 35 thermal 
cycles (94"C for 30 seconds, 55°C for 30 seconds, 72°C for 45 seconds).
7.2.4.2 PCR of CMV DNA
PCR amplification of a 293bp fragment of the imm ediate early gene of 
CMV was carried out as described in section 2.2.
7.2.4.3 PCR of Cellular DNA
Polymerase chain reaction (PCR) amplification of the hum an p-globin  
gene was carried out using primers which were kindly supplied by Dr B 
Thom pson.
PCR was carried out as described for PCR of HHV-6 DNA (see section
7.2.4.1).
7.2.5 Southern blotting
After PCR for HHV-6 DNA, each sample was Southern blotted and probed 
using  HHV-6 specific o ligonucleotides (kindly supp lied  by Dr B 
Thom pson).
Gel electrophoresis of 20pl PCR product was performed before Southern 
blotting onto nylon membrane as described earlier (see section 2.2.23 ). A 
cocktail of 2 oligonucleotides was end labelled with y-P32 and used to probe 
membranes (see section 2.3.3.2). Two oligonucleotides were used in order 
to detect both the A and B variants of HHV-6; these sequences were 
5 -CAGATGTTCCAGACAGGCAGCGC-3 (variant A) and 
5 -CAGATGCTCCAGACAGGCAGCAC-3' (variant B) respectively. These 
were kindly supplied by Dr B Thompson.
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7.3 Results
7.3.1 Sensitivity of the PCR Test for HHV-6 DNA
This PCR test was highly sensitive; serial dilution of HHV-6 virions 
showed that 120 genome copies could be detected by PCR followed by gel 
electrophoresis alone and that 30 genome copies could be detected by PCR 
follow ed by Southern b lo tting  and hybridisation of HHV-6 specific 
oligonucleotides (see figure 7.1).
Figure 7.1 D etection of 30 Copies of HHV-6 DNA A fter PCR and 
Southern Blotting
GENOME COPIES 120 60 30 120 60 30
PCR product
(i) Agarose gel (ii) Southern blot
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7.3.2 Serum Samples
7.5.2.2 PCR for CMV DNA (Control Reaction)
As shown in Chapter 3, 8.7% (60/687) serum samples were positive by 
PCR of CMV DNA; 48% (16/33) liver transplant and 24% (4/17) bone 
marrow transplant recipients were shown to develop active CMV 
infection post transplant.
7.3.2.1 PCR for HHV-6 DNA
None of 687 serum samples tested taken from 33 liver and 17 bone 
marrow transplant recipients were positive by PCR for HHV-6 DNA.
7.3.3 -Whole Blood Samples• ' •  ■»-  . . . . . . . .  «, .  . « * . . « . . . - • w - . .  MA» .  w . .. .. .
\
7.3.3.1 PCR for Cellular DNA (Control Reaction)
Initially, a random selection of 48 whole blood DNA samples underwent 
PCR for the human p-globin gene. DNA extracted from lOpl whole blood 
underwent PCR and P-globin DNA was amplified in 50% (24/48) samples.
It was suspected that PCR inhibitors were responsible for the lack of 
amplification of cellular DNA in half of the samples investigated. 
Therefore, PCR for the human p-globin gene was repeated using DNA  
from 3pl whole blood. Using this regime, all 218 samples were successfully 
amplified.
7.3.3.2 PCR for HHV-6 DNA
DNA from 3pl whole blood was amplified for HHV-6 DNA. None of 218 
whole blood samples tested taken from 23 liver and 5 bone marrow
transplant recipients were positive by PCR for HHV-6 DNA.
>
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7.3.4 Liver Tissue Samples
7.3.4.1 PCR for Cellular DNA (Control Reaction)
PCR for the human P-globin gene was performed using 3fxl extracted tissue 
D N A  ; using this regime a l l  29  s a m p le s  w e r e  s u c c e s s fu l ly  a m p l i f i e d .
7.3.4.2 PCR for HHV-6 DNA
None of 14 liver biopsy samples or 15 samples from explanted livers that 
were lost to chronic rejection or hepatic artery thrombosis tested positive 
by HHV-6 PCR.
7.3.5 Antiviral Treatment or Prophylaxis for Liver Transplant Recipients
The distribution of 33 liver transplant recipients according to antiviral 
treatment or prophylaxis is given in table 7.1 and important points , are 
described below.
Table 7.1 Distribution of Liver Transplant Recipients According to
CMV Antibody Status and Treatment with Ganciclovir
CMV Ab. status 
D/R
Number Active CMV GCV
+/- 9 9(100%) 7 (78%)
+/+ 9 7 (78%) 4 (44%)
-/+ 6 3 (50%) 2 (33%)
-/- 4 0(0%) 0(0%)
unknown 5 0(0%) 0(0%)
Total 33 19 (58%) 13 (39%)
Table 7.1 shows CMV antibody status (CMV Ab. status) of donor (D) and recipient (R) and active CMV 
infection status (Active CMV) for 33 liver transplant recipients. The number of patients of each group 
that were treated with ganciclovir is shown (GCV).
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The results presented in table 7.1 show that 39% of all liver transplant 
recipients studied were treated with ganciclovir for active CMV infection. 
Furthermore, 27% (9/33) patients were CMV antibody negative recipients 
of grafts from CMV antibody positive donors; these patients were treated 
prophylactically with oral acyclovir. Therefore, a total of 15 patients (46%) 
received antivirals.
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7.4 DISCUSSION
7.4.1 Conclusions
•' Human herpesvirus-6 (HHV-6) is not an important pathogen after
liver transplantation
• It is improbable that HHV-6 is involved in chronic rejection
7.4.2 Controls for HHV-6 PCR
Human herpes virus-6 (HHV-6) was absent in liver and bone marrow
transplant recipients; this result was not consistent with other reports.
\  "  ‘ ■ ■
It is possible that active HHV-6 infection did occur but that viral load in 
samples was below the sensitivity of the PCR test used; however, this PCR 
test was shown to be highly sensitive (< 30 genome copies). Furthermore, 
\ reports of HHV-6 detection in peripheral blood mononuclear cells and 
lung tissue have been made after using PCR tests of similar sensitivity 
(339,351).
A failure of DNA extraction from serum or in vitro degradation were 
excluded by the successful PCR for CMV DNA. Similarly, a failure of DNA  
extraction from w hole blood or liver tissue samples or in vitro  
degradation was excluded by successful PCR for p-globin DNA.
V
Therefore, if 30 copies or more of HHV-6 DNA were present in serum, 
whole blood or liver tissue it is likely that this DNA would have been 
extracted efficiently and amplified.
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It is also possible that sampling 'missed' episodes of active HHV-6 
infection. However, many samples were tested and this 'sampling 
protocol' was adequate for detection of active CMV infection. Whole blood 
samples were included because HHV-6 has been shown to be highly 'cell- 
associated'; Yoshikawa et al (1991) (354) detected HHV-6 in bone marrow 
transplant recipients after culture  of peripheral blood lym phocytes 
followed by immunohistochemistry but were unable to isolate HHV-6 
from plasma.
Therefore, it is likely that these results genuinely reflected the absence of 
active HHV-6 infection in the patients screened.
7.4.3 Antivirals and Active HHV-6 Infection
Antiviral drug administration may have prevented active HHV-6 
infection.
Bone M arrow Transplantation  
All bone marrow transplant patients studied in this thesis received
acyclovir prophylaxis from 3 days pretransplant. Furthermore, all patients
- 4 /
at risk of CMV disease (ie. donor or recipient CMV antibody positive) 
received ganciclovir prophylaxis (low dose) from 30 days posttransplant 
until day 100 posttransplant. Symptomatic CMV infection was treated with 
full dose ganciclovir. In this study, 3 patients were CMV antibody negative 
and received marrow from a CMV antibody negative donor and therefore, 
did not receive ganciclovir.
Prophylactic ganciclovir administration was. not performed during 
previous studies of HHV-6 reactivation after bone marrow transplantation 
in W isconsin (351, 358). This group administered only acyclovir
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prophylactically which has been shown to be less effective than ganciclovir 
for CMV (104, 105; see section 1.5.4) and HHV-6 (411,412).
Ganciclovir prophylaxis and treatment for CMV may have prevented 
active HHV-6 infection in patients studied in this thesis; ganciclovir 
inhibits HHV-6 replication in vitro (411, 412). Active CMV infection was 
observed in these patients (see Chapter 3) but it is possible that CMV is less 
susceptible to ganciclovir than HHV-6.
Liver Transplantation
All CMV antibody mismatched liver transplant patients (recipient CMV 
antibody negative/ donor CMV antibody positive) received oral acyclovir 
prophylaxis and symptomatic CMV infection was treated with full dose 
ganciclovir. Nearly half of the patients studied received antivirals (see 
table 7.1).
It is possible that HHV-6 would assume active infection at a later stage in a 
hypothetical population of liver transplant recipients that received no 
antiviral treatment. It is also possible that patients with latent CMV 
pretransplant (ie. those more likely to be given ganciclovir) were more 
likely to also harbour HHV-6. It follows that antiviral treatment for CMV 
may be pre emptive treatment for HHV-6.
One series of liver transplant recipients studied for active HHV-6 infection 
was reported by Sutherland et al (1991) (346). Here, ganciclovir was used as 
treatment for active CMV infection; details of any antiviral prophylaxis 
were riot published. This paper provided indirect evidence that active 
HHV-6 infection was prevented by ganciclovir. Serological changes 
accompanying active HHV-6 infection in 18 patients occurred between 3-5
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weeks post transplantation for 16/18 patients; serum was incubated with 
CMV before testing to remove antibodies cross-reactive between CMV and 
HHV-6. However, antibody rises occurred after 7 weeks posttransplant for 
2/18  patients; both patients with 'delayed active HHV-6 infection' had 
received ganciclovir treatment 3-4 weeks post transplant.
Furthermore, a recent study (425) supports the concept that prophylaxis or 
treatment for CMV may prevent active HHV-6 infection. Schmidt et al 
1996 (425) found no evidence for HHV-6 reactivation after liver 
transplantation for 46 patients. All of these patients received prophylaxis 
for CMV; 'high risk' patients received five lOg doses of anti-CMV 
hyperimmune globulin in the first four weeks after transplantation, 
whereas 'normal risk' patients received two lOg doses on days 1 and 14 
after transplantation. Details of any antiviral treatment administered were 
not given. It is possible that the anti^CMV hyperimmune globulin was 
reactive with HHV-6; cross-reactive antibodies between CMV and HHV-6 
have been demonstrated previously by Sutherland et al (1991) (346).
7.4.4 HHV-6 Was Not Found in Liver Grafts Lost to Chronic Rejection 
PCR testing of liver tissue from explanted grafts that had been lost to 
chronic rejection (and other liver graft samples) did not yield any positive 
results.
Therefore, it is unlikely that HHV-6 was associated with chronic rejection 
of liver grafts.
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CHAPTER 8
FINAL DISCUSSION
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8.1 Conclusions 
Overall Conclusion
The hypothesis that cytomegalovirus (CMV) may initiate or enhance 
chronic rejection of liver grafts was upheld.
Chapters 2 and 3
Diagnosis of Active CMV Infection in  Liver and Bone Marrow Transplant Recipients
' Detection of CMV DNA in serum  by PCR was shown to be more sensitive than huffy 
coat DEAFF or culture. ^
• Detection of CMV DNA in serum  by PCR aUows prediction of active CMV infection.
Semiquantitative PCR of CMV DNA in serum provides a threshold for prediction of 
active CMV infection.
Post transplant monitoring of patients for CMV DNA in serum  by qualitative a n d /o r  
sem iquantitative PCR facilitates pre-em ptive antiviral treatment.
Chapter 4 Risk Factors for Chronic Rejection of l iv e r  Grafts
Active CMV Infection
Prolonged active CMV infection after liver transplantation (30 days or more),
detected by serum  and/or urine PCR was a risk factor for chronic rejection.
The incidence of urine PCR positivity was a risk factor for chronic rejection.
CMV and Tumour Necrosis Factor (TNF)
Recipients that possess the TNF-2 prom oter allele, which is associated with 
e n h ^ c e d  expression of TNF, are at increased risk of developing chronic rejection.
Furthermore, active CMV infection may synergise with the TNF-2 promoter allele 
as a risk factor for chronic rejection.
CMV and Human Leukocyte Antigens (HLA)
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• Matching and mismatching of HLA alleles per se may not be an im portant risk 
factor for chronic rejection.
• However, HLA class I matching may be an important factor for clearance/control of 
active CMV which in turn may be a risk factor for chronic rejection.
Other Risk Factors
• Two or more episodes of acute rejection are a risk factor for chronic rqection.
• A  p re  tran sp lan t diagnosis of p rim ary  biliary cirrhosis (PBC) is a risk  factor for 
chronic rejection.
Chapter 5 Humoral Imm unity and Chronic Rejection of Liver Grafts
Antibodies to Bile Duct and Hepatic Artery
• Pre transplant IgG antibodies to 160 and 85 kD proteins of chronically rejected
hepatic artery m ay be associated w ith an increased risk of chronic rejection.
• Pre transplant IgA antibodies to 94 and 39 kD proteins of chronically rejected, CMV
infected bile duct are associated w ith an increased risk of chronic rejection.
Relationship w ith CMV
• An IgA antibody to a 44.kD protein of chronically rqected, CMV infected bile duct 
which developed post transplant was associated with development of active CMV 
infection but w as no t associated witii chronic rejection.
• Polyclonal antibodies raised against whole CMV were riot cross-reactive w ith 
hepatic artery or bile duct antigens.
Relationship w ith  Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis
(PSC)
• IgA antibodies to 44 and 34 kD proteins of chronically rejected, CMV infected bile 
duct were associated w ith a pre transplant diagnosis of PBC and PSC respectively 
bu t were not associated w ith chronic rejection.
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Chapter 6 Active CMV Infection of Liver Grafts
Tropism o f Active CMV in the Liver Graft
• • Replicating CMV was found in vascular endothelial cells, epithelial cells,
hepatocytes and mononuclear cells in liver grafts.
CMV Antibody Status and Active CMV Infection o f the Liver Graft
• CMV antibody negative recipients that received grafts from CMV antibody 
positive donois and subsequently developed active CMV infection (detected by 
viral surveillance of serum an d /o r buffy coat an d /o r urine) were at high risk of 
active CMV infection of the liver graft.
• However, active CMV infection of the liver graft occurred without detection of 
active CMV infection by viral surveillance of serum an d /o r buffy coat a n d /o r  urine.
• Furthermore, active CMV infection of the liver graft occurred in  CMV antibody 
negative recipients that received grafts from CMV antibody negative donors.
Active CMV Infection o f the Liver Graft and HLA Status
• Mismatching for the HLA B allele m ay be associated w ith an increased risk of 
active CMV infection of tiie liver graft as predicted in Chapter 4; however, this 
result was not significant and a firm conclusion cannot be drawn.
Active CMV Infection o f the Liver Graft and Chronic Rejection
• Active CMV infection of bile duct epithelial cells w as associated w ith CR . 
However, this result did not reach significance.
• In  sections taken from liver grafts that were explanted after chronic rejection, 
active CMV infection of bile duct epithelial cells or hepatic artery endothelial 
cells was only demonstrated in portal tracts of normal appearance and was not 
demonstrated in adjacent portal tracts that were obviously damaged; it is possible 
that active CMV infection of these sites is an im portant event during the early 
stages of development of chronic rejection and that cells harbouring active CMV 
become destroyed at a later stage.
Chapter 7 Human herpesvirus~6 (HHV-6) and Liver Transplantation
• HHV-6 is not an important pathogen after liver transplantation
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8.2 Diagnosis of Active CMV Infection
Liver and bone marrow transplant recipients at Addenbrooke's NHS Trust 
are currently monitored for active CMV infection by DEAFF and culture 
testing of buffy coat and urine samples and by serological change. In 
addition, immunostaining of liver biopsy specimens is carried out after 
clinical suspicion of CMV hepatitis.
8.2.1 Recommendations
■ !
However, on the basis of the work presented in Chapters 2 and 3 the 
following tests are suggested:
(1) Qualitative and sem i-quantitative. PCR of CMV DNA in serum 
performed weekly after transplantation
Qualitative and semiquantitative PCR were shown to be more sensitive 
than DEAFF, culture and CMV serology and to provide sensitive and 
specific prediction of CMV disease in liver and bone marrow transplant 
recipients.
Furthermore; PCR is suitable for routine use because it is rapid, reliable, 
and relatively cheap. ^
I
The PCR tests used in this thesis were completed after 12 hours for 
qualitative and 16 hours for semiquantitative PCR whereas DEAFF and
i
culture were completed after 48 hours and 2-21 days respectively. Over 100 
runs were performed during the course of this thesis and failure or 
contamination problems were only experienced four times; these
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problems were easily rectified by changing stock solutions. Finally, the cost 
per sample for PCR was approximately half that for culture or DEAFF.
The combination of rapid testing and high sensitivity may enable 
preemptive antiviral treatment.
(2) In situ  Hybridisation (ISH) and Immunostaining of Liver Biopsy 
Specimens for CMV
It is recommended that this is performed for all liver biopsies taken after 
transplantation. ISH w as show n to be more sen sitive  than  
immunostaining (see Chapter 6) and may allow preemptive antiviral
treatment before clinical signs of CMV hepatitis are apparent; these tests
<
should be compared in a large prospective study.
8.2.2 Recent Developments
Recent evidence suggests that semi-quantitative PCR of CMV DNA may 
facilitate preemptive antiviral therapy and therefore is in accord with the 
conclusions drawn from this thesis. Ljungmah et al (1996) (413) performed 
semi-quantitative PCR of CMV DNA in peripheral blood lymphocytes 
taken from 58 bone marrow transplant recipients and administered 
ganciclovir after two consecutive positive tests. Initiation of ganciclovir 
treatment was significantly earlier (mean equaled 10 days) when compared 
to 58 matched, historical controls and was shown to successfully clear 
active CMV for 28/36 treated episodes.
Transplant centres that adopt this technology should carefully validate 
their test. This is emphasised in a recent report of a quality control study 
set up by the European Group for Blood and Marrow Transplantation
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(414). Forty eight peripheral blood samples were taken from bone marrow 
transplant recipients and tested in parallel by three centres; 38/48 samples 
generated identical results (35 negative and three positive). However, of 12 
samples tested positive by one or more centres, only three were in 
agreement.
*
The Overall H ypothesis
Setting up sensitive PCR and in situ hybridisation tests for active CMV 
infection in serum and liver tissue was an important prerequisite for 
testing the overall hypothesis that CMV may be involved in chronic 
rejection.
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8.3 Cytomegalovirus and Chronic Rejection of Liver Grafts
8.3.1 Models
The conclusions of this thesis and other work allow several models to be 
set up to explain the interaction between CMV and chronic rejection of 
liver grafts. A link between mismatched CMV serology arid chronic 
rejection (210) suggests that CMV is causal but proposed links with active 
CMV infection can be interpreted ambiguously which is reflected here. It 
is important to realise that thé four proposed models are not mutually 
exclusive and that a vicious circle' may occur where CMV enhances the 
process of chronic rejection which in turn enhances CMV replication.
' '
Model 1 CMV Initiates or Augments Cellular Rejection
"niis model is shown diagramatically and possible interactions with CMV 
(numbered) are described below.
clonal
propogatii
clonal
propogatlon
activation
T-Cell
(Alloreactlve)
CMV infected (8)
ligand (3 ) ligandTCRTCRCMV _  
peptide
HLA
adhesion
molecule
adhesion
moleculeMHC II MHCII
^ E p i th é l i a  or 
endotheliaCMV infected CMV infected Uninfected
^  T-Cell
(CMV-peptide
reactive)
•TNFs (7)
Cytokines
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(1 ) Matched HLA DR presents CMV peptides to CMV-specific T-lymphocytes (224; see
section 1.9.1.1)
(2) Presenting cells (endothelial or epithelial cells) harbour replicating CMV; this was 
shown in Chapter 6 and permissivity has been demonstrated in vitro (249, 251, 271, 217; see
, section 1.8.2.3). Active CMV Infection activates CÜ4+ T cells which in turn leads to 
upregulation of HLA DR expression (431 ; see section 1.9.2) thus enhancing presentation of 
CMV or foreign peptides.
(3) Active CMV infection of endothelial or epithelial cells upregulates adhesion molecule 
expression (435, 436; see section 1.9.4) and thus augments presentation.
( 4 ) Other reports have suggested HLA restricted presentation of foreign HLA molecules 
(224; 243) or Y-chromosome specific antigens (210; see section 1 9 i)
(5) Active CMV infection enhances interleukin (iL) production (264, 266, 267; see 
section 1.9.4) thus enhancing T-iymphocyte activation.
(6 ) Active CMV infection also enhances interferon-a (IFN-a); Arnold et al (1993) (265)
found that IFN-a expression in bile duct epithelial cells was enhanced during episodes of 
active CMV infection.
(7) Tumour necrosis factor- a (TNF- a) is also an inflammatory molecule that activates T-
iymphocytes. Results presented in Chapter 4 of this thesis show that recipients that have the 
TNF-2 allele (associated with upregulated TNF expression) are more likely to develop chronic 
rejection and that active CMV infection synergises with this risk factor. This work is supported 
by reports that high serum TNF- a levels are associated with chronic rejectiorr of liver grafts 
(397) and that active CMV infection further upregulates TNF- a production (402).
(8) and (9) Active CMV infection may augment production of interleukins and TNF (see
(5) and (7)); this further a c t i v a t e s  T-lymphocytes directed to CMV peptides (8) and may also 
activate local alloreactlve T-lymphocytes (9).
This model applies to cellular responses to bile duct epithelium and 
hepatic artery endothelium. The latter layer, of chronically rejected liver 
grafts, contains endothelial cells and infiltrating macrophages ie. foam 
cells (191; see section 1.8.1.2); both of these ceUs may present peptides via 
MHC class n  (242).
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Finally, the hypothesis put forward by Arnold et al (1992) (284) that CMV 
infection of hepatocytes may enhance the activity of alloreactive T- 
lymphocytes directed to bile duct epithelial cells (by local upregulation of 
cytokines and adhesion molecules) is applicable to this model.
M odel 2 C ellu lar R ejection  In itia te s  or Augm ents O p p o rtu n is tic  
A ctive  CMV Infection
This model is shown diagramatically and possible interactions with CMV 
(numbered) are described below.
clonal 
propogati 
(5) Cytokines
TNFs (4)activation
te ro id s
T-Cell 
(CMV-peptide 
reactive)
CMV infected (2)
CMV (3)pwUde TCR
MHC II
CMV infected (1) CMV infected
Epithélia or 
endothelia
(1 ) The endothelium of chronically rejected liver grafts comprises endothelial cells and 
infiltrating foam cells (macrophages). Macrophages have been shown to harbour active CMV; 
these cells therefore import replicating CMV to areas of chronic rejection (397; see section 
4.4.4).
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Chapter 6 shows that endothelial cells may harbour replicating CMV. It is possible that this is a 
reactivation of latent virus (murine CMV is latent in liver endothelial cells (44)) initiated by a 
repair process; there is evidence to suggest that cell differentiation is crucial for CMV to switch 
from latent to lytic infection (48).
(2 )  T-lymphocytes have also been shown to be a site for CMV replication (272) and, in 
this model, also import CMV to sites of chronic rejection.
(3) Furthermore, CMV virions produced in lymphocytes may infect graft cells and vice 
versa. Graft cells and lymphocytes are intimate and MHC class I molecules have been 
suggested to be receptors for CMV (62).
(4) Activated T-lymphocytes.produce TNF-a which has been shown to upreguiate CMV 
activity in vitro (398,399; also see section 4.4.4).
(5) In the context of this model, clonal propagation of T-lymphocytes is seen as an 
amplification of viable sites for CMV replication.
(6) Finally, treatment of rejection with steroids may facilitate CMV replication; 
hydrocortisone has been shown to differentiate peripheral blood nrioriocytes into fully 
permissive macrophages (415).
M odel 3 CMV Infection m ay In itia te or Augment a Process Sim ilar to  
Atherosclerosis
This model is put forward because of the following observations:
1. Ischaemic injury has been documented during the early stages of
chronic rejection (191)
2. Hepatic arteries that are affected are histologically similar to
atherosclerotic arteries
3. Chronic rejected liver grafts do not often contain a large infiltrate of
mononuclear cells
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4. A herpesvirus has been shown to mediate atherosclerosis in an 
avian model (392)
Melnick et al (1995) (388) proposed a model for accelerated atherosclerosis 
after cardiac transplantation (see section 6.4.6). Here, damage to coronary 
artery endothelial cells leads to exposure and damage of smooth cells. A 
repair process induces proliferation of smooth muscle cells which leads to 
thickening of the intima and therefore occlusion of the lumen. The 
authors suggest that the initial injury to endothelial cells may be due to 
humoral responses or active CMV which has been shown to infect the 
coronary artery endothelium (385; see section 6.4.6).
This model is now proposed for damage to hepatic arteries observed 
during chronic rejection of liver grafts; further evidence for this model is 
summarised below.
(1 ) Chapter 6 of this thesis demonstrates CMV infection of endothelial cells. Endothelial 
cells are fully permissive to CMV (249, 251, 271) and therefore infection is likely to be 
associated with damage.
(2) Chapter 5 of this thesis describes antibodies to hepatic artery proteins of 85 and 160 
kD that were associated with chronic rejection. It is possible that these antibodies are directed 
to endothelial cells and therefore initiate an atherosclerosis-like process.
(3) There is also some evidence that CMV can transform smooth muscle cells (281); 
abnormal proliferation of these cells could further thicken the intima.
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M odel 4 . A  Process S im ilar to  Atherosclerosis m ay F acilita te A c tive  
CMV Infection
It is also possible that the link between active CMV infection and chronic 
rejection is due to CMV opportunism. In the context of this model, 
proliferation of smooth muscle cells observed during atherosclerosis is an 
amplification of sites permissive to CMV replication.
8.3.2 Recent Developments
A recent report provides further evidence for interaction between CMV 
and cellular immune responses important in chronic rejection of solid  
allografts, (model 1). Steinhoff G et al (1996) (416) studied a rat model of 
allogeneic lung transplantation and found that infection of recipients with 
rat cytomegalovirus was associated with s i^ ifican t elevation of the 
adhesion molecule ICAM-1 on pulmonary artery endothelium  and 
infiltration of CD11+ lymphocytes (CD4+).
Another recent report confirms the rationale used to propose that some 
cases of chronic rejection of liver grafts are due to a process similar to 
atherosclerosis. Radio S et al (1996) (417) has recently shown that coronary 
arteries involved w ith accelerated atherosclerosis after cardiac 
transplantation are similar histologically to medium sized and large 
arteries involved with chronic rejection of liver, pancreas and renal grafts.
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APPENDIX 1
Clinical Details of Liver Transpiant Recipients
Appendix 1 gives brief clinical information of the liver transplant patients 
in this study. All CMV cmtibody mismatched recipients (ie. donor positive 
/ recipient negative for CMV antibodies) received prophylactic acyclovir. 
Full dose ganciclovir treatment was given when symptomatic CMV 
disease was suspected.
Patients are ordered according to chronic rejector status (CR), 'non-CR' 
retransplantation status (Redo), active CMV status (by serum and/or urine 
PCR, buffy coat and/or urine DEAFF or culture), PBC status and then PSC 
status.
Numerals relate to the chapters in which a. particular patient was studied. 
Vn (a) marks patients studied by serum PCR, VH (b) marks patients studied 
by whole blood PCR and Vn (c) marks patients studied by liver tissue PCR 
in chapter VO.
CMV antibody status of donor/recipient is denoted D /R . The timing of 
clinical findings is given as days after transplantation. Liver function tests 
is abbreviated to LFT's.
P a tie n t 1 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This woman was 60 years old when she underwent her first liver transplant for primary biliary 
cirrhosis. CMV antibody status was D7/R+; a donor serum sample was not available. Active 
CMV infection was observed on day 45 by urine PCR without the appearance of symptoms. 
LFT's were raised on day 114 and ganciclovir treatment commenced on day 118; clearance
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was not proven. The graft was acutely rejected 3 times (days 7, 28,110) and this patient died 
of chronic rejection on day 161.
P a tie n t 2 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This woman was 41 years old when she unden/vent her first liver transplant for primary biliary 
cirrhosis. CMV antibody status was D+ /R-; active CMV infection was observed on day 26 by 
urine and serum PCR and lasted 38 days. Pyrexia and abnormal LFT's were observed on day 
38 and ganciclovir treatment commenced on day 40 and cleared by day 67. The graft was not 
acutely rejected but was lost to chronic rejection on day 132.
T ra n sp la n t 2
CMV antibody status was D7/R+; a donor serum sample was not available. Active CMV 
infection was observed on day 27 by urine PCR and lasted 28 days. Symptoms were not 
observed and antiviral treatment was not administered. The graft was neither acutely nor 
chronically rejected.
P a tie n t 3 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This man was 60 years old when he underwent his first liver transplant for primary sclerosing 
cholangitis. CMV antibody status was D+ /R-. Active CMV infection was observed 
intermittently from day 50 to 167 by serum and urine PCR. Furthermore, CMV hepatitis was 
diagnosed on day 40 and ganciclovir treatment commenced bn day 50; CMV appeared to 
clear from the graft. The graft was not acutely rejected but was lost to chronic rejection on day 
170.
T ra n sp la n t 2
CMV antibody status was D+ /R+. Active CMV infection was on day 0 by serum PCR and lasted 
14 days. The graft was lost on day 15.
T ra n sp la n t 3
CMV antibody status was D7 /R+; a donor serum sample was not available. Active CMV 
infection was observed on day 25 by serum and urine PCR but no symptoms were observed 
and anti virais were not administered. The graft was neither acutely nor chronically rejected. 
This patient died from multi organ failure.
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P a tie n t 4 II, III, IV, V, VII (a), VII (b)
T ra n sp la n t 1
This man was 47 years old when he uhdenvent his first liver transplant for hepatitis C cirrhosis. 
CMV antibody status was D- /R+, Active CMV infection did not occur. The graft was acutely 
rejected three times (days 2,12 and 362) and was lost on day 400 to chronic rejection.
T ra n sp la n t 2
CMV antibody status was D7/R+; donor serum was not available. Active CMV infection was not 
observed after testing blood or urine but CMV was observed in colon tissue on day 32. 
Furthermore, pyrexia, pneumonia and abnormal LFT's were observed on day 30; ganciclovir 
was administered on day 30. The graft was not acutely or chronically rejected. This patient 
died from multi organ failure.
P a tie n t 5 II, III, IV, V, VI, VII (a), VII (c)
T ra n sp la n t 1
This man was 33 years old when he underwent his first liver trarisplant for haemachromatosis/
and hepatitis C cirrhosis. CMV antibody status was D+/R+. Active CMV infection was observed 
on day 62 (by urine PCR) and did not clear; CMV related symptoms were not observed and 
antivirals were not administered. The graft was acutely rejected once (day 2) and lost to 
chronic rejection 110 days posttransplant.
T ra n sp la n t 2
The patient died in theatre.
P a tie n t 6 II, III, IV, V, VII (a)
T ra n sp la n t 1
This woman was 39 years old when she undenvent her first liver transplant for acute hepatic 
failure. CMV antibody status was D+/R+; further virological details are unknown. The graft was 
acutely rejected twice (days 3 and 33) and lost to chronic rejection 143 days posttransplant.
T ra n sp la n t 2
CMV antibody status was D- /R+; active CMV infection was observed on day 26 (by serum and 
urine PCR) and lasted for 33 days; no symptoms were observed and antivirals were not 
administered. The graft was not acutely rejected but was lost to chronic rejection 143 days 
posttransplant.
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T ra n sp la n t 3
CMV antibody status was D+ /R+; active CMV infection was observed on day 0 (by urine PCR) 
and lasted for 18 days; no symptoms were observed and antivirals were not administered. The 
graft was acutely rejected once (day 8). This patient died of a stroke.
P a tien t 7 II, III, IV, VII (a), VII (b)
T ra n sp la n t 1
This man was 58 years old when he underwent his first liver transplant for hepatitis C cirrhosis. 
CMV antibody status was D- /R+. Active CMV infection was not observed by laboratory testing 
but idiopathic abnormal LFT's were observed immediately after transplantation and worsened 
from day 38; antiviral treatment was not administered. The graft was not acutely rejected but 
was lost on day 53 to chronic rejection.
T ra n sp la n t 2
CMV antibody status was D- /R+. Active CMV infection was observed on day 4 by serum PCR 
and lasted 14 days. Symptoms (pyrexia) were observed on day 24 and ganciclovir treatment 
was initiated on day 25. Acute rejection occurred on day 26. The graft was lost on day 164 due 
to hepatic artery thrombosis and multi liver abcesses.
T ra n sp la n t 3
CMV antibody status was D- /R+. The posttransplant course was uncomplicated and this 
patient is well at 32 months post transplant.
P a tien t 8 II, III, IV, VI, VII (a), VII (c)
T ra n sp la n t 1 ,
This man was 45 years old when he undenA/ent his first liver transplant for cirrhosis of unknown 
causes. CMV antibody status was D+ /R+. Active CMV infection was not observed. The graft 
was not acutely rejected but was lost to pn day 19 to hepatic artery thrombosis.
T ra n sp la n t 2
CMV antibody status was D+ /R+. Data for active CMV infection status was not available. The 
graft was not acutely rejected (day 3) and but was lost to hepatitis C related cirrhosis On day 
705.
T ra n sp la n t 3
CMV antibody status was D? /R+; donor serum was not available. Active CMV infection was 
observed intermittently from day 59 to day 110 by serum PCR. CMV hepatitis was diagnosed 
on day 45 and ganciclovir treatment commenced on day 50. The graft was acutely rejected 
once (day 45).
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P a tie n t 9 il, III, IV, VI, VII (a), VII (c)
T ra n sp la n t 1
This woman was 59 years old when she underwent her first liver transplant for cirrhosis of 
unknown causes. CMV antibody status was D- /R+; further virological details are unknown. 
The graft was acutely rejected once (day 30) and was lost to chronic rejection on day 229.
T ra n sp la n t 2
CMV antibody status was D7/R+; a donor serum sample was not available. Active CMV 
infection was not observed by laboratory testing but idiopathic cholestatic LFT's were raised 
on day 67; antivirals were not administered. The graft was neither acutely nor chronically 
rejected.
P a tie n t 10 V, VI, VII (c)
T ra n sp la n t 1
This woman was 62 years old when she underwent liver transplantation for prirnary biliary 
cirrhosis. CMV antibody status was D7/R+; a donor serum sample was not available. 
Symptomatic CMV infection was observed clinically and confirmed by antibody status; CMV 
hepatitis was observed on liver biopsy at day 54. This patient was retransplanted for chronic 
rejection on day 135.
P a tie n t 11 II, III, IV, V, VI, VII (a), VII (c)
T ra n sp la n t 1
This woman was 22 years old when she underwent liver transplantation for subacute 
hepatitis. CMV antibody status was D- /R-; active CMV infection was not observed. However, 
idiopathic hepatitis and abnormal LFT's were observed on day 98. The graft was lost on day 
129 ; recurrent disease was thought to be responsible.
T ra n sp la n t 2
CMV antibody status was D- /R-; active CMV infection was not observed. The graft was acutely 
rejected on day 8 and lost on day 14.
T ra n sp la n t 3
CMV antibody status was D- /R-; active CMV infection was not observed. However, idiopathic 
abnormal LFTs were observed on day 34. The graft was acutely rejected on day 4 but this 
patient is well at 15 months post transplant.
P a tie n t 12 II, III, IV, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
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This woman was 53 years old when she undenvent her first liver transplant for hepatitis C 
cirrhosis. CMV antibody status was D+/R+; active CMV infection was not observed by serum or 
urine PCR or DEAFF. However, idiopathic symptoms prevailed ( LFT's were raised on day 16 
and pyrexia was obsen/ed on day 30) and ganciclovir was administered on day 32. The graft 
was acutely rejected once (day 7) and lost to chronic rejection on day 289.
T ra n sp la n t 2
CMV antibody status was D+/R+. Active CMV infection was observed on day 8; no symptoms 
were observed and antivirals were not administered. The graft was lost on day 20 to hepatic 
artery thrombosis.
T ra n sp la n t 3
CMV antibody status was D? /R+; a donor serum sample was not available. Active CMV 
infection was not followed. This patient died on day 3.
P a tie n t 13 II, III, IV, V, VI, VII (a), VII (b). VII (c)
T ra n sp la n t 1
This man was 54 years old when he underwent his first liver transplant for primary biliary 
cirrhosis. CMV antibody status was D? /R+; donor serum was not available. Active CMV 
infection was not observed. The graft was not acutely rejected but was lost to chronic rejectiori 
on day 132.
T ra n sp la n t 2
CMV antibody status was unknown. Active CMV infection was not observed. The graft was 
acutely rejected once (day 41). This patient remains well at 3 years post transplant.
P a tie n t 14 II, III, IV, V, VII (a).
T ra n sp la n t 1
This man was 31 years old when he underwent his first liver transplant for hepatitis B cirrhosis. 
CMV antibody status was D- /R+. Active CMV infection was not observed. The graft was 
acutely rejected three times (days 2, 7 and 62) and this patient died of chronic rejection.
P a tie n t 15 II, III, IV, VI, VII (a), VII (c)
T ra n sp la n t 1
This man was 39 years old when he underwent his first liver transplant for Budd Chiari 
syndrome. CMV antibody status was D- /R-. Active CMV infection was not observed. The graft 
was not acutely rejected but was lost to unspecified biliary tract disease.
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T ra n sp la n t 2
CMV antibody status was D+ /R-. Active CMV infection was not observed. The graft was 
acutely rejected (day 3) and was lost to hepatic artery thrombosis on day 12.
T ra n sp la n t 3
CMV antibody status was D+ /R-. Active CMV infection was observed on day 37 (by urine 
PCR) and cleared after 10 days. Symptoms were not observed and antivirals were not 
administered. The graft was acutely rejected once (day 7).
P a tie n t 16 V
T ra n sp la n t 1
This man was 66 years old when he underwent his first liver transplant for PBC. CMV antibody 
status was D+ /R+. The graft was lost to hepatic artery thrombosis on day 2.
T ra n sp la n t 2
CMV antibody status was D+ /R+. Active CMV infection was observed by CMV antibody 
surveillance on day 111; symptoms were not observed and antivirals were not administered. 
The graft was acutely rejected on day 69 but retained.
P a tie n t 17 _ li, lii, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp ia n t 1
This man was 45 years old when he underwent his first liver transplant for hepatitis C cirrhosis. 
CMV antibody status was D+ /R+. Active CMV infection was not observed. The graft was 
acutely rejected on day 7 and lost on day 12.
T ra n sp la n t 2
CMV antibody status was D+ /R+. Active CMV infection occurred on days 24 and 56 
diagnosed by urine and serum PCR respectively and lasting for 11 and 20 days respectively. 
Abnormal LFTs were observed on days 9 arid 25. Acute or chronic rejection did not occur.
P a tie n t 18 V
T ra n sp la n t 1
This woman was 49 years old when she undenA/ent liver transplantation for autoimmune 
cirrhosis. CMV antibody status was D- /R+; active CMV infection was not observed. The graft 
was lost on day 11 to non-thrombotic graft infarction
T ra n sp ia n t 2
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CMV antibody status was D+/ R+. Active CMV infection occurred; pyrexia was observed on 
day 29 and ganciclovir treatment was initiated on day 29. Serological changes confirmed CMV 
on day 32. Acute or chronic rejection did not occur.
P a tie n t 19 II, III, IV, VI, VII (a), VII (c)
T ra n sp la n t 1
This man was 55 years old when he underwent his first liver transplant for alcoholic cirrhosis. 
CMV antibody status was D- /R-. Active CMV infection was not observed. The graft was lost on 
day 9 to hepatic artery thrombosis.
T ra n sp ia n t 2
CMV antibody status was unknown. Active CMV infection was not observed. Again, the graft 
was lost to hepatic artery thrombosis on day 33.
T ra n sp la n t 3
CMV antibody status was unknown. This patient died on day 3 from pneumonia.
P a tie n t 20 II, III, IV, VI, VII (a), VII (c)
T ra n sp la n t 1
This woman was 61 years old when she underwent liver transplantation for subacute 
hepatitis. CMV antibody status was D? /R+; donor serum was not available. Active CMV 
infection was not observed. Symptomatic infection did not occur. The graft was lost to acute 
rejection on day 14.
T ra n sp la n t 2
CMV antibody status was D? /R+; donor serum was not available. Active CMV infection was 
not observed. Symptomatic infection did not occur. The graft was acutely rejected on day 
149.
P a tie n t 21 II, III, IV, V, VI, VII (a), VII (c)
T ra n sp la n t 1
This woman was 23 years old when she unden/vent liver transplantation for cryptogenic biliary 
cirrhosis. CMV antibody status was D+ /R+. Active CMV infection was observed on day 37 by 
serum and urine PCR; overall duration was 23 days. Symptoms (abnormal LFT's and pyrexia) 
were observed on day 38. The graft was acutely rejected on day 8.
P a tie n t 22 V
T ra n sp ia n t 1
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This woman was 47 years old when she underwent liver transplantation for primary biliary 
cirrhosis. CMV antibody status was D? /R+; a donor serum sample was not available. Active 
CMV infection of urine was observed on day 40 by culture and did not clear. Symptoms 
(abnormal LFT's and pyrexia) were observed on day 36. Acute or chronic rejection did not 
occur.
P a tie n t 23 V
T ra n sp la n t 1
This woman was 51 years old when she underwent liver transplantation for primary biliary 
cirrhosis. CMV antibody status was D? /R+; donor serum was not available. Active CMV 
infection was observed on day 43 by antibody status. Symptomatic infection did not occur and 
antivirals were not administered. Acute or chronic rejection did not occur..
P a tie n t 24 V
T ra n sp ia n t 1
This woman was 43 years old when she underwent liver transplantation for primary biliary 
cirrhosis. CMV antibody status was D+ /R-; active CMV infection was not observed. Acute 
rejection occurred on day 7.
P a tie n t 25 V
T ra n sp ia n t 1
This man was 54 years old when he underwent his first liver transplant for alcoholic cirrhosis. 
CMV antibody status was D? /R?; serum was not available. Active CMV infection was observed 
as DEÀFF positive urine (d68) without symptoms and antivirals were not administered. Acute 
or chronic rejection did not occur.
I ,  ■
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P a tie n t 26 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This woman was 63 years old when she undenvent liven-transplantation for hepatic carcinoid. 
CMV antibody status was D+ /R-. Active CMV infection was absented on day 39 by urine PCR 
and day 44 by serum PCR; overall duration was 32 days. Symptoms were observed; abnormal 
LFT's (day 15) and pyrexia (day 20). The graft was neither acutely nor chronically rejected. 
This patient died of CMV pneumonitis despite ganciclovir treatment which commenced on day 
42.
P a tie n t 27 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This man was 55 years old when he underwent liver transplantation for alcoholic cirrhosis. 
CMV antibody status was D+ /R-. Active CMV infection was observed on day 39 by serum
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PCR and day 74 by urine PCR. Overall duration was 70 days. Cholestatic LFTs were observed 
on day 113 and 1 episode of acute rejection was observed on day 114.
P a tie n t 28 II, III, IV, V, VII (a)
T ra n sp la n t 1
This man was 52 years old when he underwent liver transplantation tor cirrhosis of unknown 
causes. CMV antibody status was D- /R+. Active CMV infection was observed on day 43 by 
urine PCR and lasted 7 days. Pyrexia and abnormal LFT’s were observed on day 25. Acute 
rejection occurred on day 7.
P a tie n t 29 li. III, IV, V, VI, VII (a), VII (c)
T ra n sp ia n t 1
This man was 30 years old when he unden/vent liver transplantation for cirrhosis of unknown 
causes. CMV antibody status was D+ /R-. Active CMV infection was obsenred on day 46 by 
serum and urine PCR and lasted for over 100 days despite administration of ganciclovir on day
46. Abnormal LFTs were observed on day 26 and CMV hepatitis was diagnosed on day 46. 
Acute or chronic rejection did not occur.
P a tie n t 30 V, VI, VII (c)
T ra n sp la n t 1
This woman was 33 years old when she underwent liver transplantation for glycogen storage 
disease. CMV antibody status was D+ /R-; active CMV infection was observed and 
accompanied by abnormal LFT's and pyrexia . The graft was neither acutely nor chronically 
rejected.
P a tie n t 31 V, VI, VII (c)
T ra n sp la n t 1
This woman was 43 years old when she underwent liver transplantation for primary biliary 
cirrhosis. CMV antibody status was D? /R-; donor serum was not available. CMV-like symptoms 
(abnormal LFT's and pyrexia) were observed but CMV was not confirmed by laboratory 
testing. The graft was neither acutely nor chronically rejected.
P a tie n t 32 V, VI, VII (c)
T ra n sp la n t 1
This woman was 56 years old when she unden/vent liver transplantation. CMV antibody status 
was D? /R?; serum was not available. Active CMV infection was observed by DEAFF positive 
urine on day 67. This patient developed CMV retinitis, was transiently blind and is now partially 
sighted after administration of ganciclovir. The graft was neither acutely nor chronically 
rejected.
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P a tie n t 33 V, VI, VII (c)
This man was 59 years old when he underwent liver transplantation for hepatitis C cirrhosis. 
CMV antibody status was D+ /R-. Active CMV infection was observed on day 76 by antibody 
status. The graft was lost to chronic rejection at 180 days post-transplant. .
P a tie n t 34 II, III, IV, V, VI, VII (a), VII (c)
T ra n sp la n t 1
This woman was 32 years old when she underwent liver transplantation for Budd Chiari 
syndrome. CMV antibody status was D+ /R-; active CMV infection was observed on day 60 by 
serum PCR . Symptomatic infection did not occur and antivirals were not administered. The 
graft was neither acutely nor chronically rejected.
P a tie n t 35 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This man was 31 years old when he underwent liver transplantation for alcoholic cirrhosis. 
CMV antibody status was D+ /R-. Active CMV infection was observed on days 36 and 82 by 
serum PCR; lasting for 10 and 14 days respectively. CMV hepatitis was diagnosed on day 46 
and pyrexia was observed on days 40 and 90. Acute rejection occurred on day 22.
p a tie n t  36 II, III, IV, VI, VII (a), VII (c)
T ra n sp la n t 1
This man was 34 years old when he undenwent liver transplantation for cirrhosis of unknown 
causes. CMV antibody status was D+ /R-. Active CMV infection was observed on day 46 by 
urine PCR and lasted 8 days. Furthermore, unexplained hepatitis was observed on day 70. 
Neither acute nor chronic rejection were observed.
P a tie n t 37 II, III, IV, VII (a)
T ra n sp la n t 1
This woman was 51 years old when she underwent liver transplantation for fulminant hepatitis. 
CMV antibody status was D? /R+; donor serum was not available. Active CMV infection was 
observed on day 47 by urine PCR . Symptomatic infection did not occur and antivirals were 
not administered. The graft was acutely rejected on day 5.
P a tie n t 38 V
T ra n sp la n t 1 «
This woman was 54 years old when she unden/vent liver transplantation for PBC. CMV 
antibody status was D? /R+; donor serum was not available. Active CMV infection was hot 
observed. The graft was neither acutely nor chronically rejected.
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P a tie n t 39 V
T ra n sp la n t 1 '
This man was 33 years old when he underwent liver transplantation for PSC. CMV antibody 
status was D? /R+; donor serum was not available. Active CMV infection was not observed 
and neither acute nor chronic rejection were observed.
P a tie n t 40 V
T ra n sp la n t 1
This woman was 44 years old when she underwent liver transplantation for primary sclerosing 
cholangitis. CMV antibody status was D- /R+. Active CMV infection was observed on day 11 
but symptoms were not observed and antivirals were not administered. The graft was acutely 
rejected on day 6.
P a tie n t 41 V
T ran sp lan t. 1
This man was 49 years old when he unden/vent liver transplantation for PSC. CMV antibody 
status was D- /R-. Active CMV infection and acute or chronic rejection were not observed.
P a tie n t 42 V
T ra n sp la n t 1 ^
This woman was 57 years old when she unden/vent liver transplantation for PSC. CMV 
antibody status was D+ /R+; active CMV infection was not observed. The graft was acutely 
rejected on days 1 and 26.
P a tie n t 43 II, III, IV, V, VII (a), VII (b)
T ra n sp la n t 1
This woman was 62 years old when she unden/vent liver transplantation for acute hepatic 
failure. CMV antibody status was D+ /R+; active CMV infection was not observed. The graft 
was acutely rejected on day 9.
P a tie n t 44 II, III, IV, V, VII (a)
T ra n sp la n t 1
This woman was 17 years old when she unden/vent liver transplantation for adrenal and liver 
malignancies. CMV antibody status was D- /R-; active CMV infection was not observed. The 
graft was acutely rejected on day 7. This patient died of primary disease at 12 months after 
transplantation.
P a tie n t 45 II, III, IV, V, VI, VII (a), VII (c)
T ra n sp la n t 1
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This man was 51 years old when he undenvent liver transplantation for alcoholic cirrhosis. 
CMV antibody status was D- /R+. Active CMV infection was not observed. The graft was 
acutely rejected on day 12.
P a tie n t 46 II, III, IV, V, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This man was 55 years old when he unden/vent liver transplantation for alcoholic cirrhosis. 
CMV antibody status was D+ /R+. The course posttransplantion was uneventful.
P a tie n t 47 II, III, IV, VI, VII (a), VII (c)
This man was 52 years old when he undenvent liver transplantation for hepatitis C cirrhosis. 
CMV antibody status was D- /R-. Active CMV infection was not observed. Acute rejection was 
observed on day 9.
P a tie n t 48 II, III, IV, VI, VII (a), VII (b), VII (c)
T ra n sp la n t 1
This man was also 52 years old when he underwent liver transplantation for hepatitis C
cirrhosis. CMV antibody status was D- /R+. Active CMV infection was not observed. Acute or
chronic rejection was not observed.
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APPENDIX 2 
Clinical Details of Bone Marrow Transpiant Recipients
Appendix 2 gives brief clinical information of the bone marrow transplant 
patients in this study. All patients were given acyclovir prophylaxis prior 
to transplantation and all at risk of CMV disease (ie. all except donor 
negative / recipient negative CMV antibody status) received prophylactic, 
low dose ganciclovir from day 30. Full dose ganciclovir treatment was 
given when symptomatic CMV disease was suspected or laboratory results 
were positive.
Numerals relate to the chapter(s) in which a particular patient was studied, 
v n  (a) marks patients studied by serum PCR and VU (b) marks patients 
studied by whole blood PCR in chapter VII.
Patients are ordered according to acute and then chronic graft versus host 
status (AGVH, CGVH) and then by active CMV status (by serum and/or  
urine PCR, buffy coat and/or urine DEAFF or culture).
P a tie n t 1 II, ill, VII (a)
This 34 year old man undenwent allogeneic bone marrow transplantation for multiple myeloma. 
Acute graft versus host disease developed. CMV serology was donor negative/ recipient 
positive. Despite ganciclovir prophylaxis, active CMV infection commenced on day 67 and 
therefore occurred concomitantly with the onset of symptoms (pyrexia) but 25 days before 
diagnosis of CMV pneumonitis. Ganciclovir therapy was initiated on day 67 but this patient did 
not respond initially and died 126 days posttransplant; interestingly this patient apparently 
cleared CMV 19 days t)efore death.
See figure 3.4.
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P a tie n t 2 il, III, VII (a)
This 34 year old man undenvent 'volunteer unrelated (VUD)' bone marrow transplantation for 
multiple myeloma. Acute graft versus host disease developed. CMV serology was donor
negative/ recipient positive. Serum PCR for CMV was initially positive on day 45 which was 85
days before symptoms (day 130; CMV retinitis). This patient appeared to clear CMV but urine 
PCR and DEAFF posftivity was detected on day 100 until day 118 and CMV retinitis was 
diagnosed on day 130; CMV was subclinical until the diagnosis of CMV retinitis. This patient 
responded clinically to ganciclovir treatment (initiated on day 130) but died on day 309 from 
progressive multi focal leucoencephalopathy.
See figure 3.5.
P a tie n t 3 II, III, VII (a)
This 44 year old man underwent allogeneic bone marrow transpiantation for multiple myeloma. 
Acute graft versus host disease developed. CMV serology was donor negative/ recipient 
positive; serum was initially positive on day 65 which was 6 days after the onset of symptoms 
(pyrexia).This patient cleared CMV after ganciclovir treatment from day 59 to day 66. Urine was 
not positive by PCR. This patient made a full recovery but died 10 months after transplantation 
from recurrent initial disease.
See figure 3.6
P a tie n t 4 II, III, VII (a)
This 41 year old man underwent 'volunteer unrelated (VUD) bone marrow transplantation 
Acute graft versus host disease developed. CMV serology was donor positive/ recipient 
negative and actiVe CMV infection developed; urine positivity on day 102 was responded to 
initiation of full dose ganciclovir treatment the following day. CMV-symptoms were not 
observed. This patient died 9 months after transplantation from recurrent initial disease.
P a tien t 5 II, III, VII (a)
This 22 year old man underwent 'volunteer unrelated ' (VUD) bone marrow transplantation for 
acute lymphoblastic leukaemia. Acute graft versus host disease developed. CMV serology 
was donor negative/ recipient positive but active CMV infection did not develop. However, 
this patient died 3 months after transplantation from gastrointestinal,bleeding.
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P a tie n t 6 II, III, VII (a)
This 41 year old woman underwent allogeneic bone marrow transplantation for acute myeloid 
leukaemia. Acute graft versus host disease developed. CMV serology was donor negative/
recipient positive but active CMV Infection did not develop. This patient survives at 39
months after transplantation.
Patient 7 II, III, VII (a)
This 26 year old man underwent allogeneic bone marrow transplantation for acute 
lymphoblastic leukaemia. Acute graft versus host disease developed. CMV serology was 
donor positive/ recipient negative but active CMV Infection did not develop. This patient 
survives at 16 months after transplantation.
P a tie n t 8 II, ill, VII (a)
This 24 year old man underwent allogeneic bone marrow transplantation for acute 
lymphoblastic leukaemia. Acute graft versus host disease developed. CMV serology was 
donor negative/ recipient negative and active CMV Infection did not develop. This patient 
died 3 months after transplantation from Aspergillus pneumonia.
P a tie n t 9 II, III, VII (a), VII (b)
This 39 year old woman underwent allogeneic bone marrow transplantation for chronic 
rnyelogenous leukaemia. Acute and chronic graft versus host disease developed. CMV 
serology was donor negative/ recipient positive but active CMV Infection did not develop. 
This patient survives at 30 months after transplantation.
P a tie n t 10 II, III, VII (a)
This 48 year old man underwent allogeneic bone marrow transplantation for chronic 
myelogenous leukaemia. Acute and chronic graft versus host disease developed. CMV 
serology was donor positive/ recipient positive but active CMV Infection did not develop. This 
patient survives at 34 months after transplantation.
Patient 11 II, III, VII (a), Vil (b)
This 52 year old woman underwent allogeneic bone marrow transplantation for acute myeloid 
leukaemia. Acute and chronic graft versus host disease developed. CMV serology was donor 
positive/ recipient negative but active CMV Infection did not develop. This patient survives at 
32 months after transplantation.
Patient 12 II, III, VII (a)
This 41 year old man underwent allogeneic bone marrow transplantation for myelofibrosis. 
Acute and chronic graft versus host disease developed. ÇMV serology was donor positive/
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recipient negative but active CMV Infection did not develop. This patient survives at 40 
months after transplantation.
P a tie n t 13 II, III, Vil (a), VII (b)
This 53 year old woman undenvent allogeneic bone marrow transplantation for chronic
myelogenous leukaemia. Acute and chronic graft versus host disease developed. CMV 
serology was donor negative/ recipient negative and active CMV Infection did not develop. 
This patient survives at 44 months after transplantation.
P a tie n t 14 II, III, VII (a)
This 37 year old woman underwent Volunteer unrelated' (VUD) bone marrow transplantation 
for chronic myelogenous leukaemia. CMV serology was donor positive/ recipient positive but 
the post-transplant course was not complicated by active CMV Infection. This patient died 
after 3 months posttransplant from pulmonary haemorrhage.
P a tie n t 15 II, III, Vil (a), VII (b)
This 59 year old woman underwent allogeneic bone marrow transplantation chronic 
myelogenous leukaemia. CMV serology was donor positive/ recipient negative but the post­
transplant course was not complicated by active CMV Infection. This patient survives at 31 
months after transplantation.
P a tie n t 16 II, III, VII (a), VII (b)
This 39 year old man underwent allogeneic bone marrow transplantation for chronic 
myelogenous leukaemia. CMV serology was donor negative/ recipient negative and active 
CMV Infection did not develop. This patient survives at 33 months after transplantation.
P a tie n t  17 II, III, VII (a)
This 37 year old woman underwent allogeneic bone marrow transplantation for acute myeloid 
leukaemia. CMV serology was donor negative/ recipient negative and active CMV Infection 
did not develop. This patient survives at 42 months after transplantation.
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